0001040130-25-00001410-Q PETMED EXPRESS INC 20250210202502101714561714581714580 0001040130-25-000014 10-Q 56 20241231 20250210 20250210 PETMED EXPRESS INC 0001040130 5912 650680967 FL 0331 10-Q 34 001-42429 25606664 420 SOUTH CONGRESS AVENUE DELRAY BEACH FL 33445 (561) 426-4444 420 SOUTH CONGRESS AVENUE DELRAY BEACH FL 33445 10-Q 1 pets-20241231.htm 10-Q pets-202412310001040130--03-312025Q3falseP2DP3DP3YP3YP3YP3YP1YP1Y0.33330.33330.33330.33330.33330.33330.33330.33330.33330.33330.33330.3333xbrli:sharesiso4217:USDiso4217:USDxbrli:sharespets:reportingU 04-012024-12-310001040130us-gaap:CommonStockMember2024-04-012024-12-310001040130us-gaap:PreferredStockMember2024-04-012024-12-3100010401302025-02-1000010401302024-12-3100010401302024-03-3100010401302024-10-012024-12-3100010401302023-10-012023-12-3100010401302023-04-012023-12-3100010401302023-03-3100010401302023-12-310001040130srt:MinimumMember2024-04-012024-12-310001040130srt:MaximumMember2024-04-012024-12-310001040130pets:MembershipCustomersMember2024-12-310001040130pets:MembershipCustomersMember2024-10-012024-12-310001040130pets:MembershipCustomersMember2024-04-012024-12-310001040130pets:MembershipCustomersMember2024-03-310001040130pets:MembershipCustomersMember2024-04-012024-06-300001040130pets:MembershipCustomersMember2024-06-300001040130pets:MembershipCustomersMember2024-07-012024-09-300001040130pets:MembershipCustomersMember2024-09-300001040130pets:MembershipCustomersMemberpets:PartnerProgramMember2024-10-012024-12-310001040130pets:MembershipCustomersMemberpets:PartnerProgramMember2024-04-012024-12-310001040130pets:MembershipCustomersMemberpets:PartnerProgramMember2023-10-012023-12-310001040130pets:MembershipCustomersMemberpets:PartnerProgramMember2023-04-012023-12-310001040130pets:ReorderMember2024-10-012024-12-310001040130pets:ReorderMember2023-10-012023-12-310001040130pets:NewOrderMember2024-10-012024-12-310001040130pets:NewOrderMember2023-10-012023-12-310001040130pets:MembershipFeesMember2024-10-012024-12-310001040130pets:MembershipFeesMember2023-10-012023-12-310001040130pets:ReorderMember2024-04-012024-12-310001040130pets:ReorderMember2023-04-012023-12-310001040130pets:NewOrderMember2024-04-012024-12-310001040130pets:NewOrderMember2023-04-012023-12-310001040130pets:MembershipFeesMember2024-04-012024-12-310001040130pets:MembershipFeesMember2023-04-012023-12-310001040130pets:ReorderMembersrt:ScenarioPreviouslyReportedMember2023-10-012023-12-310001040130pets:NewOrderMembersrt:ScenarioPreviouslyReportedMember2023-10-012023-12-310001040130pets:ReorderMembersrt:ScenarioPreviouslyReportedMember2023-04-012023-12-310001040130pets:NewOrderMembersrt:ScenarioPreviouslyReportedMember2023-04-012023-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2024-10-012024-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2023-10-012023-12-310001040130us-gaap:ConvertiblePreferredStockMember2024-10-012024-12-310001040130us-gaap:ConvertiblePreferredStockMember2023-10-012023-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2024-04-012024-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2023-04-012023-12-310001040130us-gaap:ConvertiblePreferredStockMember2024-04-012024-12-310001040130us-gaap:ConvertiblePreferredStockMember2023-04-012023-12-310001040130us-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember2024-04-012024-12-310001040130us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember2024-04-012024-12-310001040130us-gaap:RestrictedStockMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2024-04-012024-12-310001040130us-gaap:PerformanceSharesMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2024-04-012024-12-310001040130pets:EmployeeAndDirectorEquityCompensationPlanMember2024-10-012024-12-310001040130pets:EmployeeAndDirectorEquityCompensationPlanMember2023-10-012023-12-310001040130pets:EmployeeAndDirectorEquityCompensationPlanMember2024-04-012024-12-310001040130pets:EmployeeAndDirectorEquityCompensationPlanMember2023-04-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:A2024OmnibusPlanMember2024-04-012024-12-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:A2024InducementPlanMember2024-04-012024-12-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMember2024-04-012024-12-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2024-04-012024-12-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockMembersrt:ChiefExecutiveOfficerMember2021-08-012021-08-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberpets:PerformanceRestrictedStockMembersrt:ChiefExecutiveOfficerMember2021-08-012021-08-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberpets:PerformanceRestrictedStockMembersrt:ChiefExecutiveOfficerMember2024-04-012024-04-300001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockMembersrt:ChiefExecutiveOfficerMember2024-04-012024-04-300001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:PerformanceSharesMembersrt:ChiefExecutiveOfficerMember2024-04-012024-04-300001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2024-04-012024-12-310001040130us-gaap:RestrictedStockMemberpets:The2022EmployeeEquityCompensationRestrictedStockPlanMember2024-04-292024-04-290001040130pets:IncentivePlan2024Memberus-gaap:RestrictedStockMembersrt:ChiefFinancialOfficerMember2024-04-292024-04-290001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockMemberpets:FormerChiefFinancialOfficerMember2022-08-012022-08-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberpets:PerformanceRestrictedStockMemberpets:FormerChiefFinancialOfficerMember2022-08-012022-08-310001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberpets:FormerChiefFinancialOfficerMember2023-06-012023-06-300001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberpets:FormerChiefFinancialOfficerMemberpets:FiscalYear2023Member2023-06-012023-06-300001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberpets:FormerChiefFinancialOfficerMemberpets:FiscalYear2024Member2023-06-012023-06-300001040130pets:A2022EmployeePlanMemberus-gaap:PerformanceSharesMemberpets:FormerChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:RestrictedStockUnitsRSUMemberpets:FormerChiefFinancialOfficerMember2024-05-162024-05-160001040130us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-06-302024-06-300001040130us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-08-312024-08-310001040130us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMembersrt:ScenarioForecastMember2025-08-312025-08-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:FormerChiefFinancialOfficerMember2024-04-012024-06-300001040130pets:A2024OmnibusIncentivePlanMember2024-08-080001040130pets:A2024InducementIncentivePlanMember2024-09-270001040130pets:IncentivePlan2024Memberus-gaap:RestrictedStockUnitsRSUMembersrt:ChiefFinancialOfficerMember2024-09-272024-09-270001040130us-gaap:RestrictedStockMembersrt:MinimumMember2024-04-012024-12-310001040130us-gaap:RestrictedStockMembersrt:MaximumMember2024-04-012024-12-310001040130us-gaap:RestrictedStockMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2024-03-310001040130us-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember2024-03-310001040130us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember2024-03-310001040130us-gaap:RestrictedStockMember2024-03-310001040130us-gaap:RestrictedStockMember2024-04-012024-12-310001040130us-gaap:RestrictedStockMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2024-12-310001040130us-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember2024-12-310001040130us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember2024-12-310001040130us-gaap:RestrictedStockMember2024-12-310001040130us-gaap:RestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember2024-12-310001040130us-gaap:RestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember2023-12-310001040130us-gaap:RestrictedStockMember2024-10-012024-12-310001040130us-gaap:RestrictedStockMember2023-10-012023-12-310001040130us-gaap:RestrictedStockMember2023-04-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-04-012024-12-310001040130us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-04-012024-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2024-03-310001040130us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2024-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2024-10-012024-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2023-10-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-12-310001040130us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-04-012024-12-310001040130us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-04-012024-12-310001040130us-gaap:PerformanceSharesMember2024-03-310001040130us-gaap:PerformanceSharesMember2024-04-012024-12-310001040130us-gaap:PerformanceSharesMember2024-12-310001040130us-gaap:PerformanceSharesMember2023-04-012023-12-310001040130us-gaap:PerformanceSharesMember2024-10-012024-12-310001040130us-gaap:PerformanceSharesMember2023-10-012023-12-310001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberpets:FormerChiefFinancialOfficerMember2023-06-012023-06-300001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberpets:FormerChiefFinancialOfficerMember2023-06-012023-06-300001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMemberpets:FormerChiefFinancialOfficerMember2023-06-012023-06-300001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMembersrt:ChiefFinancialOfficerMember2024-04-292024-04-290001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:ChiefFinancialOfficerMember2024-04-292024-04-290001040130pets:A2022EmployeePlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMembersrt:ChiefFinancialOfficerMember2024-04-292024-04-290001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberpets:FormerChiefFinancialOfficerMember2022-08-012022-08-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberpets:FormerChiefFinancialOfficerMember2022-08-012022-08-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMemberpets:FormerChiefFinancialOfficerMember2022-08-012022-08-310001040130pets:IncentivePlan2024Memberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMembersrt:ChiefFinancialOfficerMember2024-09-272024-09-270001040130pets:IncentivePlan2024Memberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:ChiefFinancialOfficerMember2024-09-272024-09-270001040130pets:IncentivePlan2024Memberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMembersrt:ChiefFinancialOfficerMember2024-09-272024-09-270001040130pets:TollFreeTelephoneNumberMember2024-12-310001040130us-gaap:InternetDomainNamesMember2024-12-310001040130us-gaap:TradeNamesMember2024-12-310001040130us-gaap:CustomerRelationshipsMember2024-12-310001040130us-gaap:CustomerRelationshipsMember2024-04-012024-12-310001040130us-gaap:DevelopedTechnologyRightsMember2024-12-310001040130us-gaap:DevelopedTechnologyRightsMember2024-04-012024-12-310001040130pets:PartnershipAgreementWithVetsterMember2024-12-310001040130pets:TollFreeTelephoneNumberMember2024-03-310001040130us-gaap:InternetDomainNamesMember2024-03-310001040130us-gaap:TradeNamesMember2024-03-310001040130us-gaap:CustomerRelationshipsMember2024-03-310001040130us-gaap:CustomerRelationshipsMember2023-04-012024-03-310001040130us-gaap:DevelopedTechnologyRightsMember2024-03-310001040130us-gaap:DevelopedTechnologyRightsMember2023-04-012024-03-310001040130pets:PartnershipAgreementWithVetsterMember2024-03-3100010401302022-04-192022-04-190001040130pets:VetsterIncMember2022-04-1900010401302023-10-032023-10-0300010401302023-10-030001040130pets:VetsterIncMember2023-10-030001040130us-gaap:CommonStockMember2024-03-310001040130us-gaap:AdditionalPaidInCapitalMember2024-03-310001040130us-gaap:RetainedEarningsMember2024-03-310001040130us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001040130us-gaap:RetainedEarningsMember2024-04-012024-06-300001040130us-gaap:CommonStockMember2024-06-300001040130us-gaap:AdditionalPaidInCapitalMember2024-06-300001040130us-gaap:RetainedEarningsMember2024-06-300001040130us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001040130us-gaap:RetainedEarningsMember2024-07-012024-09-300001040130us-gaap:CommonStockMember2024-09-300001040130us-gaap:AdditionalPaidInCapitalMember2024-09-300001040130us-gaap:RetainedEarningsMember2024-09-300001040130us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310001040130us-gaap:RetainedEarningsMember2024-10-012024-12-310001040130us-gaap:CommonStockMember2024-12-310001040130us-gaap:AdditionalPaidInCapitalMember2024-12-310001040130us-gaap:RetainedEarningsMember2024-12-310001040130us-gaap:CommonStockMember2023-03-310001040130us-gaap:AdditionalPaidInCapitalMember2023-03-310001040130us-gaap:RetainedEarningsMember2023-03-310001040130us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001040130us-gaap:RetainedEarningsMember2023-04-012023-06-300001040130us-gaap:CommonStockMember2023-06-300001040130us-gaap:AdditionalPaidInCapitalMember2023-06-300001040130us-gaap:RetainedEarningsMember2023-06-300001040130us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001040130us-gaap:RetainedEarningsMember2023-07-012023-09-300001040130us-gaap:CommonStockMember2023-09-300001040130us-gaap:AdditionalPaidInCapitalMember2023-09-300001040130us-gaap:RetainedEarningsMember2023-09-300001040130us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310001040130us-gaap:RetainedEarningsMember2023-10-012023-12-310001040130us-gaap:CommonStockMember2023-12-310001040130us-gaap:AdditionalPaidInCapitalMember2023-12-310001040130us-gaap:RetainedEarningsMember2023-12-3100010401302024-12-020001040130us-gaap:SeriesAPreferredStockMember2024-12-030001040130us-gaap:SeriesAPreferredStockMember2024-12-030001040130us-gaap:PerformanceSharesMembersrt:ChiefExecutiveOfficerMember2024-04-012024-12-310001040130pets:PetCareRxIncMember2023-04-030001040130pets:PetCareRxIncMember2023-04-030001040130us-gaap:RelatedPartyMember2024-09-292024-09-290001040130us-gaap:RelatedPartyMember2024-12-31UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington D.C. 20549FORM 10-Q(Mark One)x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934For the quarterly period ended December 31, 2024 oro TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934For the transition period from _____________ to _____________Commission file number: 000-28827_________________________PETMED EXPRESS, INC.(Exact name of registrant as specified in its charter)_________________________FLORIDA65-0680967(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)420 South Congress Avenue, Delray Beach, Florida 33445 (Address of principal executive offices, including zip code)(561) 526-4444(Registrantâ€™s telephone number, including area code)N/A(Former name, former address and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, par value $.001 per sharePETSNASDAQ Global Select MarketPreferred

Stock Purchase RightsN/ANASDAQ Global Select MarketIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes x No oIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filer oAccelerated Filer xNon-accelerated filer oSmaller reporting company oEmerging growth company oIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. oIndicate by check mark whether the registrant is a shell company (defined in Rule 12b-2 of the Exchange Act).Yes o No xIndicate the number of shares outstanding of each of the issuerâ€™s classes of common stock, as of the latest practicable date: 20,656,457 shares of Common Stock, $.001 par value per share, at FebruaryÂ 10, 2025.PART I - FINANCIAL INFORMATIONCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSIn addition to historical information, certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, our results of operations, financial position and our business outlook, business trends and other information, may be forward-looking statements. You can identify these forward-looking statements by the words "believes," "intends," "expects," â€œmight,â€ "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," â€œpotential,â€ "predicts," "estimates," "anticipates," â€œfuture,â€ â€œgoal,â€ and variations of such words or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, estimates and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that managementâ€™s expectations, beliefs, estimates and projections will result or be achieved, and actual future results may differ materially from what is expressed in or indicated by the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A, under the heading â€œRisk Factors,â€ in our Annual Report on Form 10-K for the year ended MarchÂ 31, 2024 (the â€œ2024 Form 10-Kâ€) filed with the Securities and Exchange Commission (â€œSECâ€) on June 14, 2024, and under â€œPart II, Item 1A., Risk Factorsâ€ in this Quarterly Report on Form 10-Q, if and as such risk factors may be updated from time to time in our periodic filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and a reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments. We caution you that the risks, uncertainties and other factors referenced above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factorsâ€™ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this Quarterly Report on Form 10-Q apply only as of the date of this Quarterly Report on Form 10-Q or as of the date they were made or as otherwise specified herein. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law. Investors and others should note that we use our websites (https://petmeds.com, https://petcarerx.com and https://www.investors.petmeds.com), as well as social media, press releases, SEC filings, public conference calls and webcasts, as channels of distribution of Company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, SEC filings, public conference calls and webcasts. The contents of our websites and social media posts, however, are not incorporated by reference into this Quarterly Report on Form 10-Q. Further, our references to website URLs in this filing are intended to be inactive textual references only.NOTE REGARDING COMPANY REFERENCESWhen used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, "PetMed Express," "PetMeds," "PetMed," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries, taken as a whole.1ITEM 1. FINANCIAL STATEMENTS.PETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except for share and per share amounts)December 31,2024March 31,2024(Unaudited)ASSETSCurrent assets:Cash and cash equivalents$50,101Â $55,296Â Accounts receivable, less allowance for credit losses of $88 and $273, respectively2,259Â 3,283Â Inventories, net11,795Â 28,556Â Prepaid expenses and other current assets3,888Â 6,325Â Prepaid income taxes340Â 188Â Total current assets68,383Â 93,648Â Noncurrent assets:Property and equipment, net28,425Â 26,657Â Intangible and other assets, net15,035Â 16,503Â Goodwill26,658Â 26,658Â Operating lease right-of-use assets1,077Â 1,432Â Deferred tax assets, net5,217Â 4,986Â Total noncurrent assets76,412Â 76,236Â Total assets$144,795Â $169,884Â LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable$10,945Â $37,024Â Sales tax payable24,483Â 25,012Â Accrued expenses and other current liabilities10,922Â 7,060Â Current operating lease liabilities453Â 459Â Deferred revenue1,156Â 2,603Â Total current liabilities47,959Â 72,158Â Operating lease liabilities, net of current lease liabilities652Â 995Â Total liabilities48,611Â 73,153Â Commitments and contingencies (Note 7)Â Â Shareholders' equity:Preferred stock, $.001 par value, 5,100,000 shares and 5,000,000 shares authorized respectively; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share9Â 9Â Common stock, $.001 par value, 40,000,000 shares authorized; 20,656,457 and 21,148,692 shares issued and outstanding, respectively21Â 21Â Additional paid-in capital17,967Â 25,146Â Retained earnings78,187Â 71,555Â Total shareholders' equity96,184Â 96,731Â Total liabilities and shareholders' equity$144,795Â $169,884Â See accompanying notes to unaudited condensed consolidated financial statements.2PETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except for share and per share amounts) (Unaudited)Three Months EndedDecember 31,Nine Months EndedDecember 31,2024202320242023Net sales$52,984Â $65,317Â $180,506Â $214,560Â Cost of sales38,075Â 47,434Â 130,315Â 154,089Â Gross profit14,909Â 17,883Â 50,191Â 60,471Â Operating expenses:General and administrative 10,786Â 13,425Â 26,153Â 41,098Â Advertising2,987Â 5,762Â 14,583Â 18,539Â Depreciation and amortization1,586Â 1,770Â 4,965Â 5,161Â Total operating expenses15,359Â 20,957Â 45,701Â 64,798Â (Loss) income from operations(450)(3,074)4,490Â (4,327)Other income:Interest income, net28Â 136Â 308Â 481Â Other, net180Â 293Â 597Â 1,053Â Total other income208Â 429Â 905Â 1,534Â (Loss) income before provision (benefit) for income taxes(242)(2,645)5,395Â (2,793)Provision (benefit) for income taxes465Â (618)22Â (345)Net (loss) income (707)(2,027)$5,373Â $(2,448)Net (loss) income per common share:Basic(0.03)(0.10)$0.26Â $(0.12)Diluted$(0.03)(0.10)0.26Â $(0.12)Weighted average number of common shares outstanding:Basic20,634,65120,425,28220,581,91320,380,262Diluted20,634,65120,425,28220,987,26020,380,262Cash dividends declared per common share$â€”Â $â€”Â $â€”Â $0.60Â See accompanying notes to unaudited condensed consolidated financial statements.3PETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands) (Unaudited)Nine Months EndedDecember 31,20242023Cash flows from operating activities:Net income (loss)$5,373Â $(2,448)Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization4,965Â 5,161Â Share based compensation(7,179)5,196Â Deferred income taxes(231)(436)Bad debt expense324Â 53Â (Increase) decrease in operating assets and increase (decrease) in operating liabilities:Accounts receivable700Â (119)Inventories, net16,761Â (12,438)Prepaid income taxes(152)65Â Prepaid expenses and other current assets2,437Â (2,664)Operating lease right-of-use assets, net355Â 594Â Accounts payable(26,078)7,929Â Sales tax payable(529)(1,942)Accrued expenses and other current liabilities2,756Â (1,258)Lease liabilities(349)(577)Deferred revenue(1,447)75Â Net cash used in operating activities(2,294)(2,808)Cash flows from investing activities:Purchase of minority interest investment in Vetsterâ€“Â (300)Acquisition of PetCareRx, net of cash acquiredâ€“Â (35,859)Purchases of property and equipment(2,725)(3,260)Net cash used in investing activities(2,725)(39,419)Cash flows from financing activities:Dividends paid(176)(12,419)Net cash used in financing activities(176)(12,419)Net decrease in cash and cash equivalents(5,195)(54,646)Cash and cash equivalents, at beginning of period55,296Â 104,086Â Cash and cash equivalents, at end of period$50,101Â $49,440Â Supplemental disclosure of cash flow information:Cash paid for income taxes$474Â $43Â Dividends payable in accrued expenses and other current liabilities$32Â $1,498Â Non-cash investing activity for PPE additions$2,539Â $â€“Â See accompanying notes to unaudited condensed consolidated financial statements.4PETMED EXPRESS, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)Note 1:Â Â Â Â Summary of Significant Accounting PoliciesOrganizationPetMed Express, Inc. and subsidiaries, d/b/a PetMedsÂ® and PetCareRx, Inc. d/b/a PetCareRxÂ® (collectively, the â€œCompanyâ€), is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses. The Company markets and sells directly to consumers through its websites, customer contact center, and mobile application. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.Founded in 1996, the Companyâ€™s executive headquarters offices are currently located in Delray Beach, Florida. The Companyâ€™s fiscal year end is MarchÂ 31, and references herein to fiscal 2025 or fiscal 2024 refer to the Company's fiscal years ending MarchÂ 31, 2025 and 2024, respectively.Basis of Presentation and ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at DecemberÂ 31, 2024, the Statements of Operations for the three and nine months ended DecemberÂ 31, 2024 and 2023, and Cash Flows for the nine months ended DecemberÂ 31, 2024 and 2023. The results of operations for the three and nine months ended DecemberÂ 31, 2024 are not necessarily indicative of the operating results expected for the fiscal year ending MarchÂ 31, 2025. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in our 2024 Form 10-K. The unaudited condensed consolidated financial statements include the accounts of PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Fair Value of Financial Instruments The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments. Deferred RevenueDeferred revenue is recorded when payments are received or due in advance of performing our service obligations and revenue is recognized over the service period. Deferred revenue represents prepayments of PetPlus memberships with PetCareRx, Inc. (â€œPetCareRxâ€). The total deferred revenue as of DecemberÂ 31, 2024 and MarchÂ 31, 2024 for these memberships was $1.2 million and $2.6 million, respectively. Memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The membership fee is an annual charge and automatically renews one year from the initial enrollment date. The Company generally recognizes the revenue ratably over the term of the membership.Long-lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset 5to the undiscounted cash flows expected to be generated from the asset. Management determined that no impairment of long-lived assets existed as of DecemberÂ 31, 2024.Goodwill and Intangible AssetsGoodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. The Company is required to assess goodwill and other indefinite-lived intangible assets for impairment annually, or more frequently if circumstances indicate impairment may have occurred. Goodwill was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that goodwill was impaired as of December 31, 2024. The Company performs its annual impairment assessment in the fourth fiscal quarter of each year. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.The Companyâ€™s other indefinite-lived intangible assets are primarily made up of a trade name which was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that the other indefinite-lived assets were impaired as of December 31, 2024.Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company's consolidated financial position, results of operations, or cash flows. In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Update 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". This Update applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in this Update revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in this Update do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Update should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this Update.In December 2023, the FASB issued Update 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This Update applies to all entities that are subject to Topic 740. The amendments in this Update revise income tax disclosures primarily related to the rate reconciliation and income taxes paid information as well as the effectiveness of certain other income tax disclosures. The Update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Update should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the impact of adopting this Update.Note 2:Â Â Â Â Revenue RecognitionIn accordance with ASC Topic 606 ("Revenue from Contracts with Customers"), the Company primarily generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, and supplies, from one of the Companyâ€™s two warehouses. Certain pet supplies offered on the Companyâ€™s websites are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product. Customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are based on historical patterns, however this is not considered a key judgment. Revenue is recognized when control transfers to the customer at the point in time at which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time when the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Additionally, the Company has external relationships for telehealth veterinary and insurance services. Virtually all the Companyâ€™s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. 6Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.Membership fees represent the amounts recognized from two membership models. The first is the PetPlus membership for PetCareRx customers, and the second is a partner membership, which allows employees in-network to join the PetPlus membership program through their employers. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews one year from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally one year. As shown in the following table, under the PetPlus program, the Company recognized $1.0 million and $3.7 million of previously deferred annual membership fees in the three and nine months ended DecemberÂ 31, 2024, and had $1.2 million of deferred revenue as of DecemberÂ 31, 2024.(amounts in millions)Deferred revenue, March 31, 2024$2.6Â Deferred memberships fees and others received1.1Â Deferred membership fee revenue and others recognized (1.5)Deferred revenue, June 30, 20242.1Â Deferred memberships fees and others received0.7Â Deferred membership fee revenue and others recognized (1.2)Deferred revenue, September 30, 20241.6Â Deferred memberships fees and others received0.5Â Deferred membership fee revenue and others recognized (1.0)Deferred revenue, December 31, 2024$1.2Â In addition to annual membership fees earned under the PetPlus program, the Company also earns membership fees on a month-to-month basis under its PetCareRx partner membership program. For the three and nine months ended DecemberÂ 31, 2024, membership fees earned under the partner program were $0.9 million and $2.8 million, respectively. For the three and nine months ended DecemberÂ 31, 2023, membership fees earned under the partner program were $0.7 million and $2.1 million, respectively. The Company has no material contract asset or liability balances at DecemberÂ 31, 2024 or MarchÂ 31, 2024, respectively. The Company disaggregates sales in the following categories: reorder sales vs new order sales vs membership fees. The following table illustrates sales in those categories:Three Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$ % Reorder sales$45,076Â 85.1Â %$54,067Â 82.8Â %$(8,991)(16.6)%New order sales6,075Â 11.5Â %8,803Â 13.5Â %(2,728)(31.0)%Membership fees1,833Â 3.5Â %2,447Â 3.7Â %(614)(25.1)%Total net sales$52,984Â 100.0Â %$65,317Â 100.0Â %$(12,333)(18.9)%7Nine Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$ % Reorder sales$149,367Â 82.7Â %$174,250Â 81.3Â %$(24,883)(14.3)%New order sales24,913Â 13.8Â %33,054Â 15.4Â %(8,141)(24.6)%Membership fees6,226Â 3.4Â %7,256Â 3.4Â %(1,030)(14.2)%Total net sales$180,506Â 100.0Â %$214,560Â 100.0Â %$(34,054)(15.9)%The Company changed the definition of a new order sale on July 1, 2024, to include sales from customers who have not previously ordered from the Company over the past twelve months compared to the prior definition which was thirty-six months. The reorder and new order sales amounts for the three and nine months ended DecemberÂ 31, 2024, and the reorder and new order sales amounts for the three and nine months ended DecemberÂ 31, 2023 reflect this new customer definition change. Under the previous definition of a new customer, reorder and new order sales were $57.7 million and $5.2 million, respectively, for the three months ended December 31, 2023. Under the previous definition of a new customer, reorder and new order sales were $188.1 million and $19.2 million, respectively, for the nine months ended December 31, 2023. Note 3:Â Â Â Â Net (Loss) Income Per ShareIn accordance with the provisions of ASC Topic 260 (â€œEarnings Per Shareâ€) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted and performance stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock and convertible preferred shares issued by the Company represent the only dilutive effect reflected in the diluted weighted average shares outstanding.8The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for share and per share amounts):Three Months Ended December 31,Nine Months EndedDecember 31,2024202320242023Net (loss) income (numerator):Â Â Net (loss) income(707)(2,027)$5,373Â $(2,448)Shares (denominator):Â Â Weighted average number of common shares outstanding used in basic computation20,634,651Â 20,425,282Â 20,581,913Â 20,380,262Â Common shares issuable upon vesting of restricted stockâ€"Â â€"Â 395,222Â â€"Â Common shares issuable upon conversion of preferred sharesâ€"Â â€"Â 10,125Â â€"Â Shares used in diluted computation20,634,651Â 20,425,282Â 20,987,260Â 20,380,262Â Net (loss) income per common share:Basic(0.03)(0.10)$0.26Â $(0.12)Diluted$(0.03)(0.10)0.26Â $(0.12)For the three months ended DecemberÂ 31, 2024 and 2023, 986,378 and 825,825 shares issuable upon vesting of restricted stock and 10,125 and 10,125 shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share.For the nine months ended DecemberÂ 31, 2024 and 2023, 519,852 and 837,084 shares issuable upon vesting of restricted stock and zero and 10,125 shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share. Note 4:Â Â Â Â Stock-Based CompensationThe Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (â€œCompensation - Stock Compensationâ€). The Company had 423,619 common shares issued, net of forfeitures, under the 2016 Employee Equity Compensation Restricted Stock Plan (the â€œ2016 Employee Planâ€) (which 2016 Employee Plan was succeeded by the 2022 Employee Plan in April 2023, and no further awards will be granted under the 2016 Employee Plan), 55,074 common shares issued, net of forfeitures, under the 2022 Employee Equity Compensation Plan (as amended) (the â€œ2022 Employee Planâ€), and 257,567 common shares issued, net of forfeitures, under the 2015 Outside Director Equity Compensation Plan (as amended) (the â€œ2015 Director Planâ€). At DecemberÂ 31, 2024, all outstanding shares under these plans were issued with service-based vesting conditions with the exception of 2,000 performance stock units which vested on July 1, 2024. The Company records stock-based compensation expense for these awards on a straight-line basis over the requisite service period. The Company reverses stock-based compensation expense previously recorded upon forfeiture of unvested awards except for the performance restricted shares with a market condition issued to the former Chief Executive Officer (â€œCEOâ€) and performance stock units (â€œPSUsâ€) with a market condition issued to the former Chief Financial Officer (â€œCFOâ€) as described in the following paragraphs. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to restricted stock awards of $0.5Â million and $1.7Â million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded a (reversal) of previously recorded stock-based compensation expense and stock-based compensation expense related to restricted stock awards of $(7.2)Â million and $5.2Â million, respectively. In June 2023, the Board of Directors amended and restated the 2015 Director Plan and the 2022 Employee Plan (collectively, the "Plans") to include the ability to grant restricted stock units ("RSUs") and performance stock units 9("PSUs") under the Plans. The amendments and restatement of the Plans did not increase the maximum number of shares of common stock that could be awarded under the Plans. At DecemberÂ 31, 2024, the Company had 83,500 RSUs outstanding under the 2024 Omnibus Incentive Plan (the â€œ2024 Omnibus Planâ€), 290,000 RSUs outstanding under the 2024 Inducement Incentive Plan (the â€œ2024 Inducement Planâ€), 569,365 RSUs outstanding under the 2022 Employee Plan and 22,316 RSUs outstanding under the 2015 Director Plan.In August 2021, the Company issued 90,000 shares of restricted stock and 510,000 performance restricted shares with a market condition to the Companyâ€™s former CEO, in accordance with the former CEOâ€™s employment agreement, under the 2016 Employee Plan. In April 2024, the Company and former CEO entered into a Transition and Separation Agreement pursuant to which the Company cancelled the 510,000 performance restricted shares and accelerated vesting on 30,000 remaining unvested restricted shares which otherwise would not have vested. Cancellation of the 510,000 shares resulted in an $8.8Â million reversal of compensation expense, partially offset by $0.1Â million of compensation expense from the accelerated vesting of the 30,000 shares in the nine months ended DecemberÂ 31, 2024. On April 29, 2024, the Company appointed a new CEO, and in conjunction with her new employment agreement, she received a grant of 483,092 RSUs under the Companyâ€™s 2022 Employee Equity Compensation Plan. Such RSUs will vest in one-third increments on each of the first three anniversaries of the date of grant so long as the CEO continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. In August 2022, the Company issued 13,000 restricted shares and 3,000 performance restricted shares to the Company's former CFO, in accordance with the CFO's employment agreement, under the 2016 Employee Plan. One-third of the restricted shares were scheduled to vest on each of the first three anniversaries of the date of grant, subject to the CFOâ€™s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company. The performance restricted shares were based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue. On June 8, 2023, the Company determined that the performance criteria were not attained over the applicable performance period and accordingly, the performance restricted shares were cancelled.In June 2023, the Company granted the Company's former CFO 11,750 RSUs under the 2022 Employee Plan, of which 3,750 RSUs were awarded in recognition of the CFOâ€™s contributions during fiscal year 2023 and the remaining 8,000 awarded as a part of the equity award cycle for fiscal year 2024. One-third of the RSUs were scheduled to vest on each of the first three anniversaries of the date of grant, subject to the CFOâ€™s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the former CFO ceasing to be an employee of the Company. Also in June 2023, the former CFO was awarded 8,000 PSUs with a market condition. On May 16, 2024, the Company granted the former CFO 74,850 RSUs of which 14,970 would vest on June 30, 2024, 22,455 would vest August 31, 2024 and 37,425 would vest on August 31, 2025. On May 31, 2024, the Company and the former CFO entered into a Transition and Separation Agreement pursuant to which the former CFO agreed to leave the Company following a transition period. Upon the completion of the transition period and contingent on the former CFOâ€™s complying with the terms of the Agreement, the Company accelerated the vesting of all unvested restricted shares and RSUs that were originally scheduled to vest on or before August 3, 2025. Under the Agreement, PSUs with a market condition were cancelled. Acceleration and cancellation of the former CFOâ€™s restricted shares, RSUs and PSUs resulted in net additional compensation expense of $0.2Â million in the three months ended June 30, 2024.On August 8, 2024, the Company adopted the 2024 Omnibus Plan pursuant to which the Company reserved 850,000 shares of common stock, par value $.001 per share, of the Companyâ€™s common stock for the issuance of equity awards granted.On September 27, 2024, the Company adopted the 2024 Inducement Plan pursuant to which the Company reserved 350,000 shares of common stock, par value $.001 per share, of the Companyâ€™s common stock (subject to the adjustment provisions of the Inducement Plan) for the issuance of equity awards granted under the Inducement Plan.On September 27, 2024, the Companyâ€™s new CFO received a grant of 250,000 RSUs under the Companyâ€™s 2024 Inducement Plan. Such RSUs will vest in one-third increments on each of the first three anniversaries of the date of grant so long as the CFO continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. All stock-based compensation expense is recognized as a payroll-related expense and is included within the general and administrative expenses line item within the Companyâ€™s unaudited Condensed Consolidated Statements of Operations, 10with the offset included in the additional paid-in capital line item of the Companyâ€™s unaudited Condensed Consolidated Balance Sheets. Restricted Stock AwardsThe fair value assigned to restricted stock awards (â€œRSAsâ€) is the market price of the Companyâ€™s stock at the grant date. The vesting period ranges from one to three years. Restricted stock award activity in the nine months ended December 31, 2024 was as follows:Â 2015 Director Plan Â 2016 Employee Plan Â 2022 Employee Plan Â Total Â Weighted-Average Grant Date Fair Value Non-vested restricted stock outstanding at March 31, 202423,707Â 605,343Â 74,076Â 703,126Â $19.39Â Granted and issuedâ€"Â â€"Â â€"Â â€"Â $â€"Â Vested(13,666)(60,540)(46,742)(120,948)$22.10Â Forfeitedâ€"Â (533,641)(27,334)(560,975)$18.71Â Balance at December 31, 202410,041Â 11,162Â â€"Â 21,203Â $21.96Â At DecemberÂ 31, 2024 and 2023, there were 21,203 and 728,446 RSAs subject to restriction and forfeiture outstanding, respectively. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSAs of $0.1Â million and $1.6Â million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded a (reversal) of previously recorded stock-based compensation expense and stock-based compensation expense related to RSAs of $(8.2)Â million and $5.0Â million, respectively. Restricted Stock UnitsThe Company first granted RSUs in the year ended March 31, 2024. The fair value assigned to RSUs is the market price of the Companyâ€™s stock on the grant date. The vesting period for employees and members of the Board of Directors generally ranges from one to three years. For the nine months ended DecemberÂ 31, 2024, RSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:RSUsWeighted-AverageÂ Grant DateÂ Fair Value Per RSUBalance at March 31, 202485,080$12.75Â Granted 1,037,258$4.04Â Vested and issued(66,739)$8.38Â Forfeited(90,418)$5.84Â Balance at December 31, 2024965,181$4.33Â The total grant-date fair value of RSUs granted during the three months ended DecemberÂ 31, 2024 and 2023 was $0.2 million and zero, respectively. The total grant-date fair value of RSUs granted during the nine months ended DecemberÂ 31, 2024 and 2023 was $4.2 million and $1.1 million, respectively. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $0.4 million and $0.1Â million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $1.1 million and $0.2Â million, respectively. Performance Stock Units The fair value assigned to PSUs is determined using the market price of the Companyâ€™s stock on the grant date for awards with a performance condition, and by using a Monte Carlo simulation for awards with a market condition. PSUs with a performance condition generally vest over one year. PSUs with a market condition generally vest over three years. Stock-based compensation expense associated with PSUs with a performance condition are re-assessed each reporting period based upon the estimated performance attainment on the reporting date until the performance conditions are met. 11The ultimate number of shares of common stock that are issued to an employee is the result of the actual performance of the Company or individual at the end of the performance period compared to the performance targets. For the nine months ended DecemberÂ 31, 2024, PSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:PSUsWeighted-AverageÂ Grant DateÂ Fair Value Per PSUBalance at March 31, 202412,000$10.48Â Granted â€"$â€"Â Vested and issued(2,000)$13.95Â Forfeited(10,000)$9.79Â Balance at December 31, 2024â€"$â€"Â In the nine months ended December 31, 2024, 10,000 PSUs were forfeited. The total grant-date fair value of PSUs granted during the nine months ended DecemberÂ 31, 2024 and 2023 was zero and $0.1Â million, respectively. There were no PSUâ€™s granted in the three months ended DecemberÂ 31, 2024 and 2023. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense, net of forfeitures, related to PSUs of zero and $20 thousand, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded stock-based compensation (benefit) expense, net of forfeitures, related to PSUs of $(36) thousand and $44 thousand, respectively. Note 5:Â Â Â Â Fair ValueThe Company carries cash and cash equivalents at fair value in the unaudited Condensed Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (â€œFair Value Measurementâ€) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.Level 3 - Unobservable inputs which are supported by little or no market activity.The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At DecemberÂ 31, 2024 and MarchÂ 31, 2024, the Company had invested the majority of its $50.1 million and $55.3 million cash and cash equivalents balance in money market funds which are classified within Level 1.12Note 6: Intangible and Other Assets, NetIntangible assets and other assets, net consisted of the following (in thousands):Useful LifeGross ValueAccumulated AmortizationNet Carrying ValueWeighted Average Remaining Useful Life (Years)December 31, 2024Intangible AssetsToll-free telephone numberIndefinite$375Â $â€"Â $375Â IndefiniteInternet domain namesIndefinite485Â â€"Â 485Â IndefiniteTrade Names - PetCareRxIndefinite2,600Â â€"Â 2,600Â IndefiniteCustomer Relationships -PetCareRx7 years6,700Â (1,675)5,025Â 5.25 yearsDeveloped Technology - PetCareRx3 years3,000Â (1,750)1,250Â 1.25 years$13,160Â $(3,425)$9,735Â Other AssetsMinority interest investment in VetsterN/A5,300Â â€"Â 5,300Â N/ABalance December 31, 2024$18,460Â $(3,425)$15,035Â March 31, 2024Intangible AssetsToll-free telephone numberIndefinite$375Â $â€"Â $375Â IndefiniteInternet domain namesIndefinite485Â â€"Â 485Â IndefiniteTrade Names - PetCareRxIndefinite2,600Â 2,600Â IndefiniteCustomer Relationships -PetCareRx7 years6,700Â (957)$5,743Â 6 yearsDeveloped Technology - PetCareRx3 years3,000Â (1,000)$2,000Â 2 years$13,160Â $(1,957)$11,203Â Other AssetsMinority interest investment in VetsterN/A5,300Â â€"Â 5,300Â N/ABalance March 31, 2024$18,460Â $(1,957)$16,503Â Amortization expense for intangible assets was $0.5 million for the three months ended DecemberÂ 31, 2024 and 2023. Amortization expense for intangible assets was $1.5 million for the nine months ended DecemberÂ 31, 2024 and 2023. The indefinite life intangibles are not being amortized and are subject to an annual review for impairment in accordance with the ASC Topic 350 (â€œGoodwill and Other Intangible Assetsâ€).On AprilÂ 19, 2022, the Company engaged in a three-year partnership agreement with Vetster Inc. (â€œVetsterâ€), a Canadian veterinary telehealth company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0 million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, Vetster became the exclusive provider of telehealth and telemedicine services to the Company. The minority interest investment is being valued on the cost basis and the investment will be evaluated periodically for any impairment. On October 3, 2023, the Company purchased additional shares in Vetster in the amount of $0.3Â million, which increased the minority interest investment to $5.3 million. Following this round, the Companyâ€™s minority ownership changed to approximately 4.8% of Vetsterâ€™s outstanding shares.Note 7:Â Â Â Commitments and ContingenciesLegal Matters and Routine ProceedingsOn April 18, 2024, Plaintiff Timothy Fitchett (â€œPlaintiffâ€) filed an action against the Company in the Court of Common Pleas of Allegheny County, Pennsylvania, on behalf of himself and purportedly on behalf of a class of others similarly situated. Plaintiff alleges that the Company violated Pennsylvaniaâ€™s Unfair Trade Practices and Consumer 13Protection Law by representing â€œreg.â€ prices for products which the Company allegedly never charged for those products. On May 13, 2024, the Company removed the matter to the U.S. District Court for the Western District of Pennsylvania in Pittsburgh. The company successfully opposed the Plaintiff's motion to remand the case back to the Court of Common Pleas. On the face of the Complaint, Plaintiff is seeking damages for himself in the amount of the allegedly illusory discounts he allegedly believed he was receiving when purchasing products from the Company or, in the alternative, a complete refund of amounts he paid to the Company, and he is also seeking a liability determination for members of the proposed class. The Company denies liability in this matter and intends to defend the action accordingly. The Company cannot determine materiality or estimate a range of potential liability, if any, at this time if the Company were determined to be liable.The Company may from time to time be involved in various other claims and lawsuits in the ordinary course of business, including claims related to products, product warranties, contracts, employment, intellectual property, consumer protection, pharmacy and other regulatory matters. The Company has settled complaints that had been filed with various statesâ€™ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company also intends to vigorously defend its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred. From time to time, the Company may be involved in and subject to disputes and legal proceedings, as well as demands, claims and threatened litigation that arise in the ordinary course of its business. These proceedings may include allegations involving business practices, infringement of intellectual property, employment or other matters. The ultimate outcome of any legal proceeding is often uncertain, there can be no assurance that the Company will be successful in any legal proceeding, and unfavorable outcomes could have a negative impact on our results of operations and financial condition. In accordance with ASC Topic 450-20 ("Loss Contingencies"), the Company records a liability in its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews the status of each significant matter each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the financial statements not misleading. If the loss is not probable and cannot be reasonably estimated, a liability is not recorded in the Companyâ€™s financial statements. Gain contingencies are not recorded until they are realized. Legal costs related to any legal matters are expensed as incurred.Note 8:Â Â Â Changes in Shareholdersâ€™ Equity:Changes in Shareholdersâ€™ Equity for the three and nine months ended DecemberÂ 31, 2024 is summarized below (in thousands):Common StockAdditionalPaid-InCapitalRetainedEarningsBeginning balance at March 31, 2024:$21Â $25,146Â $71,555Â Stock based compensation (reversal) â€”Â (8,204)â€”Â Dividends forfeitedâ€”Â â€”Â 1,250Â Net incomeâ€”Â â€”Â 3,754Â Ending balance at June 30, 2024:$21Â $16,942Â $76,559Â Stock based compensation expenseâ€”Â 573Â â€”Â Dividends forfeitedâ€”Â â€”Â 4Â Net incomeâ€”Â â€”Â 2,326Â Ending balance at September 30, 2024:$21Â $17,515Â $78,889Â Stock based compensation expenseâ€”Â 452Â â€”Â Dividends forfeitedâ€”Â â€”Â 5Â Net lossâ€”Â â€”Â (707)Ending balance at December 31, 2024:$21Â $17,967Â $78,187Â 14Changes in Shareholdersâ€™ Equity for the three and nine months ended DecemberÂ 31, 2023 is summarized below (in thousands):Common StockAdditionalPaid-InCapitalRetainedEarningsBeginning balance at March 31, 2023:$21Â $18,277Â $91,659Â Stock based compensation expenseâ€”Â 1,760Â â€”Â Dividends declaredâ€”Â â€”Â (6,346)Net lossâ€”Â â€”Â (1,136)Ending balance at June 30, 2023:$21Â $20,037Â $84,177Â Stock based compensation expenseâ€”Â 1,728Â â€”Â Dividends declaredâ€”Â â€”Â (6,308)Net incomeâ€”Â â€”Â 715Â Ending balance at September 30, 2023:$21Â $21,765Â $78,584Â Stock based compensation expenseâ€”Â 1,708Â â€”Â Net lossâ€”Â â€”Â (2,027)Ending balance at December 31, 2023:$21Â $23,473Â $76,557Â There were no shares of common stock that were purchased or retired in the nine months ended DecemberÂ 31, 2024 or 2023. On December 2, 2024, the Board of Directors (the â€œBoardâ€) of the Company adopted a rights agreement and declared a dividend of one right (a â€œRightâ€) for each outstanding share of Company common stock, to shareholders of record at the close of business on December 16, 2024 (the â€œRecord Dateâ€). The description and terms of the Rights are set forth in a rights agreement, dated as of December 3, 2024 (the â€œRights Agreementâ€), between the Company and Continental Stock Transfer & Trust Company, a federally chartered trust company, as rights agent. The Board adopted the Rights Agreement to protect the investment of shareholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of common stock by certain shareholders. The Rights Agreement is intended to enable shareholders to realize the long-term value of their investment in the Company by reducing the likelihood that any entity, person, or group is able to gain a control or control-like position in the Company through open market accumulation without paying all shareholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of all shareholders. In general terms, the Rights Agreement imposes significant dilution upon any person or group (other than the Company and certain other excluded persons and exempt persons), that is or becomes the beneficial owner of 12.5% or more of the common stock without the prior approval of the Board following the first public announcement by the Company of the adoption of the Rights Agreement. The term â€œbeneficial ownershipâ€ is defined in the Rights Agreement and includes, among other things, certain derivative arrangements. In general, each Right entitles its registered holder, subject to the terms of the Rights Agreement, to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (â€œPreferred Stockâ€), of the Company at an exercise price of $27.00 per Right, subject to adjustment under certain circumstances (the â€œPurchase Priceâ€). The Rights will become exercisable if (among other things) any person or group acquires 12.5% or more of the outstanding common stock, including through derivatives agreements, without the approval of the Board (an â€œAcquiring Personâ€). If a person or group becomes an Acquiring Person, all holders of Rights except the Acquiring Person or any associate or affiliate thereof may, upon exercise of a Right, purchase for the Purchase Price shares of Common Stock with a market value of two times the Purchase Price, based on the market price of the Common Stock prior to such acquisition. If the Company is acquired in a merger or similar transaction after an Acquiring Person becomes such, all holders of Rights except the Acquiring Person or any associate or affiliate thereof may, upon exercise of a Right, purchase for the Purchase Price shares of the acquiring company with a market value of two times the Purchase Price, 15based on the market price of the acquiring companyâ€™s stock prior to such transaction. Any Rights held by an Acquiring Person will be void and may not be exercised. The Rights will expire on the earliest to occur of (a) the close of business on December 2, 2025, (b) the time at which the Rights are redeemed by the Company (as provided in the Rights Agreement), or (c) the time at which the Rights are exchanged by the Company (as provided in the Rights Agreement). There was no impact to the Companyâ€™s current period financial statements from adopting this Rights Agreement. In connection with the adoption of the Rights Agreement, the Board adopted Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company (the â€œArticles of Amendmentâ€), which designates the rights, preferences, and privileges of 100,000 shares of a new series of the Companyâ€™s preferred stock, par value $0.001 per share, designated as Series A Junior Participating Preferred Stock. The Company filed the Articles of Amendment with the Secretary of State of the State of Florida on December 3, 2024.Note 9: Income Taxes For the three months ended DecemberÂ 31, 2024 and 2023, the Company recorded an income tax provision of approximately $0.5 million and an income tax benefit of approximately $0.6 million, respectively, and for the nine months ended DecemberÂ 31, 2024 and 2023, the Company recorded an income tax provision of $22 thousand and an income tax benefit of $0.3 million, respectively. The increase in the income tax provision for the nine months ended DecemberÂ 31, 2024 is related to the cancellation of the former CEOâ€™s performance stock units resulting in additional $8.7Â million of increased income during the year. The effective tax rate for the three months ended DecemberÂ 31, 2024 was approximately (192.1)%, compared to approximately 23.4% for the three months ended DecemberÂ 31, 2023, and the effective tax rate for the nine months ended DecemberÂ 31, 2024 was approximately 0.4%, compared to approximately 12.4% for the nine months ended DecemberÂ 31, 2023. The projected full-year effective tax rate used for purposes of the income tax provision for the three and nine months ended DecemberÂ 31, 2024 reflects the $1.8Â million impact of a favorable permanent difference associated with the cancellation of the former CEOâ€™s performance restricted shares. No tax benefit was recorded for the original compensation expense due to expected limitation under Internal Revenue Code Section 162 (m) and therefore, there is no tax benefit to reverse upon cancellation of the stock. The impact of this favorable permanent difference is partially offset by the impacts of stock-based compensation recognized for book and tax purposes.Under Internal Revenue Code Section 382, if a corporation undergoes an â€œownership changeâ€, the corporationâ€™s ability to use its pre-change net operating loss and tax credit carryforwards to offset its post-change income and tax liabilities may be limited. Generally, an ownership change occurs when the equity ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporationâ€™s stock increases its ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years). On AprilÂ 3, 2023, 100% of the issued and outstanding stock of PetCareRx was acquired by the Company. The merger triggered an ownership change of PetCareRx within the meaning of Section 382. As a result of the acquisition, the Company performed a Section 382 analysis to determine if the net operating losses carried forward would have a utilization limitation. Any limitation could result in the expiration of a portion of the federal net operating loss carryforward before utilization, which would reduce the Company's gross deferred tax assets. As of AprilÂ 3, 2023, and prior to the acquisition, PetCareRx had approximately $96.0Â million of net operating losses and $1.9Â million of disallowed interest expense. The results of the Section 382 analysis determined the net operating losses and disallowed interest expense in total, would be limited and reduced to approximately $14.5Â million.Note 10: Related Party TransactionOn September 29, 2024 the Company entered into a master services agreement with Fabric, Inc (â€œFabricâ€), a privately-held company. Under this agreement, Fabric will provide cloud-based product services to the Company with a one-year term with auto-renewal unless either party provides notice at least 90 days in advance. Per the terms of the agreement, the Company will pay Fabric $115,000 the first year and $100,000 for each potential year thereafter with potential changes in the amounts paid based on actual usage of Fabricâ€™s services. There was no expense related to this contract for the three and nine months ended DecemberÂ 31, 2024. There was no amount owed by the Company to Fabric as of December 31, 2024. Sandra Campos, Chief Executive Officer and President of the Company, is an equity-holder in Fabric and serves on the Board of Directors of Fabric. This transaction was reviewed and approved by the Companyâ€™s Audit Committee of the Board of Directors in accordance with the Companyâ€™s related party transaction policy.16ITEM 2.Â Â Â Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended DecemberÂ 31, 2024, and our 2024 Form 10-K.Certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of our 2024 Form 10-K under the heading â€œRisk Factors.â€ A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law. When used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, "PetMed Express," "PetMeds," "PetMed," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries, taken as a whole.Executive SummaryPetMed Express, Inc. and subsidiaries, d/b/a PetMedsÂ®, and PetCareRx, Inc. is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies and vet services for dogs, cats and horses. PetMeds markets and sells directly to consumers through its websites, toll-free numbers, and mobile application. We offer consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.Founded in 1996, our executive headquarters offices are currently located at 420 South Congress Avenue, Delray Beach, Florida 33445, and our telephone number is (561) 526-4444. We have a March 31 fiscal year end.Presently, our product line includes approximately 12,000 of the most popular pet medications, health products, food and supplies for dogs, cats, and horses. We market our products through national advertising campaigns which aim to increase the recognition of the â€œPetMedsÂ®â€ brand name, and "PetCareRx" brand name, increase traffic to our websites at www.petmeds.com and www.petcarerx.com, acquire new customers, and maximize repeat purchases. Our sales consist of products sold mainly to retail consumers. The average purchase was approximately $97 and $93 for the quarters ended DecemberÂ 31, 2024, and DecemberÂ 31, 2023, respectively.Critical Accounting PoliciesOur discussion and analysis of our financial condition and the results of our operations contained herein are based upon our condensed consolidated financial statements and the data used to prepare them. Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.There have been no material changes to our significant accounting policies as compared to the significant accounting policies described in our Annual Report on Form 10-K, filed on June 14, 2024, except as noted below:17Long-lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset. Management determined that no impairment of long-lived assets existed as of DecemberÂ 31, 2024.Goodwill and Intangible AssetsGoodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. The Company is required to assess goodwill and other indefinite-lived intangible assets for impairment annually, or more frequently if circumstances indicate impairment may have occurred. The Company performs its annual impairment assessment in the fourth quarter of each year. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.The Companyâ€™s other indefinite-lived intangible assets are primarily made up of a trade name which was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that the other indefinite-lived assets were impaired as of December 31, 2024.Economic Conditions, Challenges, and RiskMacroeconomic factors, including inflation, increased interest rates, significant capital market and supply chain volatility, and political, global economic and geopolitical developments, have direct and indirect impacts on our results of operations that are difficult to isolate and quantify. In addition, rising fuel, utility, and food costs, rising interest rates, and recessionary fears may impact customer demand and our ability to forecast consumer spending patterns. We also expect the current macroeconomic environment and enterprise customer cost optimization efforts to impact our revenue growth rates. We expect some or all of these factors to continue to impact our operations for the remainder of fiscal 2025.18Results of OperationsThe following should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in our unaudited Condensed Consolidated Statements of (Loss) Income:Three Months EndedDecember 31,Nine Months EndedDecember 31,2024202320242023Sales100.0Â %100.0Â %100.0Â %100.0Â %Cost of sales71.9Â 72.6Â 72.2Â 71.8Â Gross profit28.1Â 27.4Â 27.8Â 28.2Â Operating expenses:General and administrative20.4Â 20.6Â 14.5Â 19.2Â Advertising5.6Â 8.8Â 8.1Â 8.6Â Depreciation and amortization3.0Â 2.7Â 2.8Â 2.4Â Total operating expenses29.0Â 32.1Â 25.3Â 30.2Â (Loss) income from operations(0.9)(4.7)2.5Â (2.0)Total other income0.4Â 0.7Â 0.5Â 0.7Â (Loss) income before provision (benefit) for income taxes(0.5)(4.0)3.0Â (1.3)Provision (benefit) for income taxes0.9Â (0.9)â€”Â (0.2)Net (loss) income (1.4)%(3.1)%3.0Â %(1.1)%Non-GAAP Financial MeasuresAdjusted EBITDA To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense (benefit), depreciation and amortization, income tax provision, interest income (expense), and other non-operational expenses. We have provided reconciliations below of net income to adjusted EBITDA, the most directly comparable GAAP financial measures.We have included adjusted EBITDA herein because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.We believe it is useful to exclude non-cash charges, such as net stock-based compensation expense (benefit), depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe 19that it is useful to exclude other non-operational expenses, including acquisition costs related to PetCareRx, employee severance and estimated state sales tax accruals and settlements as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:â€¢Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;â€¢Adjusted EBITDA does not reflect net share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;â€¢Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;â€¢Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems; â€¢Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us; â€¢Adjusted EBITDA does not reflect certain non-operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers. â€¢Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measureâ€™s usefulness as comparative measures.Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.20The following tables present a reconciliation of net (loss) income , the most directly comparable GAAP measure, to adjusted EBITDA for each of the periods indicated:Three Months EndedIncrease (Decrease)($ in thousands, except percentages)December 31,2024December 31,2023$%Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:Net loss(707)(2,027)$1,320Â (65)%Add (subtract):Stock-based Compensation 452Â 1,708Â (1,256)(74)%Income Taxes465Â (618)1,083Â (175)%Depreciation and Amortization1,586Â 1,770Â (184)(10)%Interest Income, Net (1)(28)(136)108Â (79)%Acquisition/Partnership Transactions and Other Items25Â â€”Â 25Â n/mEmployee Severance209Â â€”Â 209Â n/mSales Tax Expenseâ€”Â 228Â (228)(100)%Adjusted EBITDA$2,002Â $925Â $1,077Â 116Â %(1) Included in interest income, net is $0.4 million of interest expense related to the sales tax liability and $0.5 million of interest income for the three months ended December 31, 2024. This compares to $0.4 million of interest expense related to the sales tax liability and $0.6 million of interest income for the three months ended December 31, 2023.21Nine Months EndedIncrease (Decrease)($ in thousands, except percentages)December 31,2024December 31,2023$%Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:Net income (loss)$5,373Â $(2,448)$7,821Â n/mAdd (subtract):Stock-based Compensation $(7,179)$5,196Â $(12,375)n/mIncome Taxes$22Â $(345)367Â n/mDepreciation and Amortization$4,965Â $5,161Â (196)(4)%Interest Income, Net (1)(308)(481)173Â (36)%Acquisition/Partnership Transactions and Other Items$205Â $1,294Â (1,089)(84)%Employee Severance$663Â $408Â 255Â 63Â %Sales Tax (Income)$(1,178)$(1,088)(90)8Â %Adjusted EBITDA$2,563Â $7,697Â $(5,134)(67)%(1) Included in interest income, net is $1.2 million of interest expense related to the sales tax liability and $1.5 million of interest income for the nine months ended December 31, 2024. This compares to $1.3 million of interest expense related to the sales tax liability and $1.7 million of interest income for the nine months ended December 31, 2023.Three Months Ended December 31, 2024 Compared With Three Months Ended December 31, 2023 and Nine Months Ended December 31, 2024 Compared With Nine Months Ended December 31, 2023Net SalesSales decreased by approximately $12.3 million, or 18.9%, to approximately $53.0 million for the quarter ended DecemberÂ 31, 2024, compared to approximately $65.3 million for the quarter ended DecemberÂ 31, 2023. Sales decreased by approximately $34.1 million, or 15.9%, to approximately $180.5 million for the nine months ended DecemberÂ 31, 2024, compared to approximately $214.6 million for the nine months ended DecemberÂ 31, 2023. The decrease in sales for the quarter ended DecemberÂ 31, 2024 was primarily driven by an strategic reduction in gross advertising as we reset our marketing foundation for sustainable profitability. The decrease in sales for the nine months ended DecemberÂ 31, 2024 reflects a strategic reduction in advertising, broader macroeconomic factors, and higher consumer promotional usage. Reorder sales decreased by approximately $9.0 million, or 16.6%, to approximately $45.1 million for the quarter ended DecemberÂ 31, 2024, compared to approximately $54.1 million for the quarter ended DecemberÂ 31, 2023. Reorder sales decreased by approximately $24.9 million, or 14.3%, to approximately $149.4 million for the nine months ended DecemberÂ 31, 2024, compared to approximately $174.3 million for the nine months ended DecemberÂ 31, 2023. The decrease in reorder sales for the three and nine months ended DecemberÂ 31, 2024 is primarily due to a decline in prescription medication sales. New order sales decreased by approximately $2.7Â million or 31.0%, to approximately $6.1Â million for the quarter ended DecemberÂ 31, 2024, compared to $8.8Â million for the quarter ended DecemberÂ 31, 2023. New order sales decreased by approximately $8.1Â million or 24.6%, to approximately $24.9Â million for the nine months ended DecemberÂ 31, 2024, compared to $33.1Â million for the nine months ended DecemberÂ 31, 2023. The decrease for the quarter ended DecemberÂ 31, 2024 in new order sales is primarily due to a strategic reduction in advertising.We acquired approximately 63,000 new customers for the quarter ended DecemberÂ 31, 2024 compared to approximately 97,000 new customers for the quarter ended DecemberÂ 31, 2023. We acquired approximately 260,000 new 22customers for the nine months ended DecemberÂ 31, 2024 compared to approximately 347,000 new customers for the nine months ended DecemberÂ 31, 2023. The following tables illustrates revenue by various revenue classifications:Three Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$ % Reorder sales$45,076Â 85.1Â %$54,067Â 82.8Â %$(8,991)(16.6)%New order sales6,075Â 11.5Â %8,80313.5Â %(2,728)(31.0)%Membership fees1,833Â 3.5Â %2,4473.7Â %(614)(25.1)%Total net sales$52,984Â 100.0Â %$65,317Â 100.0Â %$(12,333)(18.9)%Nine Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$%Reorder sales$149,367Â 82.7Â %$174,250Â 81.3Â %$(24,883)(14.3)%New order sales24,913Â 13.8Â %33,05415.4Â %(8,141)(24.6)%Membership fees6,226Â 3.4Â %7,2563.4Â %(1,030)(14.2)%Total net sales$180,506Â 100.0Â %$214,560Â 100.0Â %$(34,054)(15.9)%The Company changed the definition of a new order sale on July 1, 2024, to include sales from customers who have not previously ordered from the Company over the past twelve months compared to the prior definition which was thirty-six months. The reorder and new order sales amounts for the three and nine months ended DecemberÂ 31, 2024, and the reorder and new order sales amounts for the three and nine months ended DecemberÂ 31, 2023 reflect this new definition. Under the previous definition of a new customer, reorder and new order sales were $57.7 million and $5.2 million, respectively, for the three months ended December 31, 2023. Under the previous definition of a new customer, reorder and new order sales were $188.1 million and $19.2 million, respectively, for the nine months ended December 31, 2023. Recurring net sales, which includes AutoShip & Save subscriptions, and membership revenue, as a percentage of total gross sales was 56.2% for the most recent quarter ended DecemberÂ 31, 2024, up from 52.2% for the same period last year.Going forward, sales may be adversely affected due to increased competition and consumers giving more consideration to price. The changes in consumer behavior due to macroeconomic factors makes future sales somewhat challenging to predict. No guarantees can be made that sales will grow in the future.Cost of salesCost of sales decreased by approximately $9.4 million, or 19.7%, to approximately $38.1 million for the quarter ended DecemberÂ 31, 2024, from approximately $47.4 million for the quarter ended DecemberÂ 31, 2023. Cost of sales decreased by approximately $23.8 million, or 15.4%, to approximately $130.3 million for the nine months ended DecemberÂ 31, 2024, from approximately $154.1 million for the nine months ended DecemberÂ 31, 2023. Cost of sales, as a percentage of sales, was 71.9% for the quarter ended DecemberÂ 31, 2024, compared to 72.6% for the quarter ended DecemberÂ 31, 2023. Cost of sales, as a percentage of sales, was 72.2% for the nine months ended DecemberÂ 31, 2024, compared to 71.8% for the nine months ended DecemberÂ 31, 2023. The year over year decline for cost of sales, as a percentage of sales for the quarter ended DecemberÂ 31, 2024 compared to the quarter ended DecemberÂ 31, 2023 was primarily due to lower discount activity and favorable sales mix. The increase in cost of sales, as a percentage of sales, for the nine months ended DecemberÂ 31, 2024 compared to the nine months ended DecemberÂ 31, 2023 was primarily due to an increase in discount activity during the first six months of the fiscal year.23Gross profitGross profit decreased by approximately $3.0 million, or 16.6%, to approximately $14.9 million for the quarter ended DecemberÂ 31, 2024, from approximately $17.9 million for the quarter ended DecemberÂ 31, 2023. Gross profit decreased by approximately $10.3 million, or 17.0%, to approximately $50.2 million for the nine months ended DecemberÂ 31, 2024, from approximately $60.5 million for the nine months ended DecemberÂ 31, 2023. The gross profit decreases for the quarter and nine months ended DecemberÂ 31, 2024 compared to the quarter ended and nine months ended DecemberÂ 31, 2023 were primarily due to lower sales. The gross margin percentage increased by approximately 0.8%, to approximately 28.1% for the quarter ended DecemberÂ 31, 2024, from approximately 27.4% for the quarter ended DecemberÂ 31, 2023, primarily due to favorable sales mix and lower consumer promotional usage.General and administrative expenses General and administrative expenses decreased by approximately $2.6 million, or 19.7%, to approximately $10.8 million for the quarter ended DecemberÂ 31, 2024, from approximately $13.4 million for the quarter ended DecemberÂ 31, 2023. The decrease to general and administrative expenses for the quarter ended DecemberÂ 31, 2024 was due to a $1.3 million decrease in stock-based compensation expense, primarily related to reduced stock compensation associated with an executive departure, a $1.1 million decrease in payroll and payroll related expense, and a $0.4 million decrease in credit card processing fees driven by lower sales. General and administrative expenses decreased by approximately $14.9 million, or 36.4%, to approximately $26.2 million for the nine months ended DecemberÂ 31, 2024, from approximately $41.1 million for the nine months ended DecemberÂ 31, 2023. The decrease to general and administrative expenses for the nine months ended DecemberÂ 31, 2024 was due to a $12.4 million decrease in stock-based compensation expense, of which $8.7 million was from the stock compensation reversal associated with an executive departure, a $1.6 million decrease in payroll and payroll related expense, and a $0.9 million decrease in credit card processing fees which were driven by lower sales.Advertising expenses Advertising expenses decreased by approximately $2.8 million, or 48.2%, to approximately $3.0 million for the quarter ended DecemberÂ 31, 2024, from approximately $5.8 million for the quarter ended DecemberÂ 31, 2023. The decrease for the quarter can be mainly attributed to lower gross media spend and a higher proportion of spending funded by third party partners. We strategically reduced gross advertising as we reset our marketing foundation for sustainable profitability. As a percentage of sales, advertising expense was 5.6% and 8.8% for the quarters ended DecemberÂ 31, 2024 and 2023, respectively. The advertising percentage may fluctuate quarter to quarter due to seasonality and advertising availability.The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $47 for the quarter ended DecemberÂ 31, 2024 compared to $59 for the quarter ended DecemberÂ 31, 2023. The decrease to customer acquisition costs for the quarter ended DecemberÂ 31, 2024, was due to a more efficient variable marketing spend. The advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, spending, and price competition. Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future sales, whereas a less favorable advertising environment may negatively impact future sales. Advertising expenses decreased by approximately $4.0 million, or 21.3%, to approximately $14.6 million for the nine months ended DecemberÂ 31, 2024, from approximately $18.5 million for the nine months ended DecemberÂ 31, 2023. The decrease can be mainly attributed to lower gross media spend, partially offset by lower marketing funded by manufacturers and advertising partners. The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $56 for the nine months ended DecemberÂ 31, 2024 compared to $53 for the nine months ended DecemberÂ 31, 2023. As a percentage of sales, advertising expense was 8.1% and 8.6% for the nine months ended DecemberÂ 31, 2024 and 2023, respectively.Depreciation and amortizationDepreciation and amortization expense was $1.6 million and $1.8 million for the quarters ended DecemberÂ 31, 2024 and DecemberÂ 31, 2023, respectively. Depreciation and amortization expense was $5.0 million and $5.2 million for the nine months ended DecemberÂ 31, 2024 and DecemberÂ 31, 2023, respectively.24Other incomeOther income decreased to approximately $0.2 million for the quarter ended DecemberÂ 31, 2024 compared to approximately $0.4 million for the quarter ended DecemberÂ 31, 2023. Other income decreased to approximately $0.9 million for the nine months ended DecemberÂ 31, 2024 compared to approximately $1.5 million for the nine months ended DecemberÂ 31, 2023.The decrease to other income for the quarter and the nine months ended DecemberÂ 31, 2024 was due to slightly lower invested balances, and the loss of subleasing rental revenue. Interest income may decrease in the future based on several factors, including utilization of our cash balances on future investments or partnerships, or on our operating activities. Additionally, interest income could increase or decrease if the current interest rate environment changes.Provision for income taxesFor the quarters ended DecemberÂ 31, 2024 and 2023, the Company recorded an income tax provision of approximately $0.5Â million and a tax benefit of approximately $0.6Â million, respectively. For the nine months ended DecemberÂ 31, 2024 and 2023, the Company recorded an income tax provision of approximately $0.0Â million and a tax benefit of approximately $0.3Â million, respectively. The increase in the tax provision for the three and nine months ended DecemberÂ 31, 2024 is related to the cancellation of the former CEOâ€™s performance stock units resulting in additional $8.7Â million of income during the quarter. The effective tax rate for the quarter ended DecemberÂ 31, 2024 was approximately (192.1)%, compared to approximately 23.4% for the quarter ended DecemberÂ 31, 2023.Liquidity and Capital ResourcesOverviewWe believe that our cash and cash equivalents currently on hand and expected cash flows from future operations will be sufficient to continue operations for at least the next twelve months. We continue to monitor, evaluate, and manage our operating plans, forecasts, and liquidity considering the most recent developments driven by macroeconomic conditions, such as supply chain challenges, inflation, rising interest rates, and geopolitical events. We proactively seek opportunities to improve the efficiency of our operations, take steps to realize internal cost savings, including aligning our staffing needs, creating a more variable cost structure to better support our current and expected future levels of operations and process streamlining. Current Sources of LiquidityOur working capital at DecemberÂ 31, 2024 and MarchÂ 31, 2024 was $20.4 million and $21.5 million, respectively. The $1.1 million decrease in working capital was attributable to the $25.3 million decrease in current assets, primarily inventory and prepaid expenses, which were partially offset by the $24.2 million decrease in current liabilities, primarily accounts payable. The inventory decline was attributable to the Companyâ€™s strategy to operate with fewer weeks of supply on hand, and to a lesser extent, timing of inventory receipts moving into the fourth quarter..Net cash used in operating activities was $2.3 million for the nine months ended December 31, 2024, compared to cash used in operating activities of $2.8 million for the nine months ended December 31, 2023. The $0.5 million increase in cash provided by operating activities is due to the $7.8 million increase in net income reduced by $12.1 million of non-cash operating adjustments and partially offset by the $4.8 million increase in current liabilities net of current assets excluding cash. Net cash used in investing activities was $2.7 million for the nine months ended December 31, 2024, compared to $39.4 million used in investing activities for the nine months ended December 31, 2023. The change in net cash used in investing activities is primarily related to the PetCareRx acquisition and an additional investment in Vetster in the prior year. Net cash used in financing activities was $0.2 million and $12.4 million for the nine months ended December 31, 2024 and the nine months ended December 31, 2023, respectively, due to the payment of an aggregate $0.60 per share dividend for the nine months ended December 31, 2023. The Board of Directors reviews and discusses the capital allocation needs of the Company on a quarterly basis, and as part of that review, on October 26, 2023, our Board of Directors elected to suspend the quarterly dividend indefinitely. This action was intended to focus use of the Companyâ€™s existing cash and cash flow on growth initiatives and other, higher return initiatives. The declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors.As of DecemberÂ 31, 2024, we had $1.1 million in outstanding lease commitments assumed as part of the PetCareRx acquisition for the leases on two buildings. Other than the foregoing leases, we are not currently bound by any material long-term or short-term commitments for the purchase or lease of capital expenditures. Any material amounts expended for 25capital expenditures would be the result of an increase in the capacity needed to adequately provide for any future increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Our primary source of working capital is cash from operations. We presently have no alternative sources of working capital and have no commitments.ITEM 3.Â Â Â Â QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The book values of cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and cash equivalents. At DecemberÂ 31, 2024, we had $50.1 million in cash and cash equivalents, and the majority of our cash and cash equivalents generate interest income based on prevailing interest rates. A significant change in interest rates would impact the amount of interest income generated from our excess cash and cash equivalents. It would also impact the market value of our cash and cash equivalents. Our cash and cash equivalents are subject to market risk, primarily interest rate and credit risk. Our cash and cash equivalents are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by maintaining cash in federally-insured bank deposit accounts and restricting cash equivalents to highly-liquid investments with maturities of three months or less. We do not hold any derivative financial instruments that could expose us to significant market risk. At DecemberÂ 31, 2024, we had no debt obligations.ITEM 4.Â Â Â Â CONTROLS AND PROCEDURES.Evaluation of Disclosure Controls and ProceduresOur management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13aâ€'15(e) and 15d-15(e) promulgated under the Exchange Act) as of DecemberÂ 31, 2024, the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date, that our disclosure controls and procedures were not effective as of DecemberÂ 31, 2024, due to material weaknesses described below.Material WeaknessesA material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.As identified in our 2024 Form 10-K, we identified the following material weaknesses:1.A material weakness in the design of our controls over the review of appropriate application of GAAP relating to our sales tax liability as well as an additional tax error relating the misapplication of Internal Revenue Code Section162(m) which limits the deductibility of executive compensation in our consolidated financial statements. We also identified a material weakness in the design of our controls over accurate valuation of our deferred tax asset and goodwill relating to our acquisition of PetCareRx .2.A material weakness in internal controls relating to our information technology general controls (â€œITGCsâ€) in the areas of user access, change management, and service organizations over information technology (â€œITâ€) systems that support the Companyâ€™s financial reporting processes. This material weakness may impact revenue and other business process controls and automated controls reliant upon these ITGCs. We believe these control deficiencies have been influenced by insufficient documentation to support management's procedures. The individual deficiencies identified in preventative and detective controls resulted in an aggregate material weakness related to ITGCs. This material weakness did not result in any identified misstatements to the financial statements or any change in previously released financial results.Management is taking steps to remediate these material weaknesses (see â€œRemediation of Material Weaknessesâ€ for details).26Remediation of Material WeaknessesIn response to the material weakness due to the tax calculations, we have developed and are in the process of implementing a remediation plan. The key elements of the plan include:1.Enhancing the oversight and review of tax-related accounting estimates and calculations to ensure they are complete and accurate.2.Providing additional training to personnel involved in tax accounting and financial reporting to enhance their understanding of the relevant accounting standards and requirements.3.Enhancing the documentation of tax positions and related accounting judgments to ensure they are adequately supported and can withstand external scrutiny.While our remediation plan related to the material weakness in internal controls relating to our information technology general controls (â€œITGCsâ€) may evolve and expand, management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated such that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) developing and maintaining documentation underlying ITGCs; (ii) implementing an IT management review, bringing in new management and revising the testing plan to monitor ITGCs with a specific focus on systems supporting our financial reporting processes; and (iii) enhanced quarterly reporting on the remediation measures to the Audit Committee of the Board of Directors.We will need to allow the updated controls to operate for an adequate period of time, and we have commenced thorough testing to ensure the new and improved controls are operating effectively. We will continue to test and monitor the new and improved controls to ensure they are operating as intended. It's possible that we may find additional steps, including adding more resources, are needed to fully address the material weaknesses in our internal control over financial reporting. This could require more time for evaluation and implementation. Additionally, we might make adjustments to the remediation efforts as we proceed.Changes in Internal Control Over Financial ReportingOther than as described above, there were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.Inherent Limitations on Effectiveness of ControlsIn designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design and disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgement in evaluating the benefits of possible controls and procedures relative to the their cost. 27PART II - OTHER INFORMATIONITEM 1.Â Â Â Â LEGAL PROCEEDINGS.For a description of our legal proceedings, see â€œNote 7: Commitments and Contingencies â€” Legal Matters and Routine Proceedingsâ€ to our condensed consolidated financial statements, which is incorporated by reference.ITEM 1A.Â Â Â Â RISK FACTORS. Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations, and trading price of our common stock. Please refer to our 2024 Form 10-K for additional information concerning these and other uncertainties that could negatively impact the Company. There have been no material changes to the risk factors disclosed in our 2024 Form 10-K.ITEM 2.Â Â Â Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.None.ITEM 3.Â Â Â Â DEFAULTS UPON SENIOR SECURITIES.None.ITEM 4.Â Â Â Â MINE SAFETY DISCLOSURES.Not applicable.ITEM 5.Â Â Â Â OTHER INFORMATION.(a) and (b)Not applicable.(c)During the three months ended DecemberÂ 31, 2024, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted, modified, or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K.28ITEM 6.Â Â Â Â EXHIBITS.3.1Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).3.2Articles of Amendment to the Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.2 to our Form 10-K for the year ended March 31, 2015, filed May 22, 2015).3.3Articles of Amendment to the Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 of our Form 8-K/A filed December 18, 2024).3.4 *Third Amended and Restated Bylaws of PetMed Express, Inc. (incorporated by reference to Exhibit 3.3 to our Form 10-Q for the quarter ended September 30, 2024, filed November 7, 2024).4.1Rights Agreement, dated December 3, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent (incorporated by reference to Exhibit 4.1 to our Form 8-K/A filed December 18, 2024).31.1 *Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002).31.2 *Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002).32.1 **Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS*Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)101.SCH*Inline XBRL Taxonomy Extension Schema Document101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*Filed herewith. **Â Â Â Â Furnished herewith. 29SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.PETMED EXPRESS, INC.Date: FebruaryÂ 10, 2025By:Â /s/ Sandra Y. CamposSandra Y. CamposChief Executive Officer and President(Principal Executive Officer)By:Â /s/ Robyn Dâ€™EliaRobyn Dâ€™EliaChief Financial Officer(Principal Financial Officer)By:/s/ Douglas KrulikDouglas KrulikChief Accounting Officer(Principal Accounting Officer)30UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_________________________PETMED EXPRESS, INC_________________________FORM 10-Q FOR THE QUARTER ENDED:DECEMBERÂ 31, 2024_________________________EXHIBITS_________________________ EX-31.1 2 pets-20241231xexx311.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERPURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Sandra Y. Campos, certify that:1.I have reviewed this report on Form 10-Q for the quarter ended DecemberÂ 31, 2024 of PetMed Express, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officers and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.February 10, 2025By: /s/ Sandra Y. CamposSandra Y. CamposChief Executive Officer and President EX-31.2 3 pets-20241231xexx312.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION OF PRINCIPAL FINANCIAL OFFICERPURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Robyn D'Elia, certify that:1.I have reviewed this report on Form 10-Q for the quarter ended DecemberÂ 31, 2024 of PetMed Express, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officers and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.February 10, 2025By: /s/ Robyn D'EliaRobyn D'EliaChief Financial Officer and Treasurer EX-32.1 4 pets-20241231xexx321.htm EX-32.1 DocumentExhibit 32.1CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002I, Sandra Y. Campos, and I, Robyn D'Elia, each certify to the best of our knowledge, based upon a review of the report on Form 10-Q for the quarter ended DecemberÂ 31, 2024 (the â€œReportâ€) of the Registrant, that:(1)the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2)the information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Registrant.Date: FebruaryÂ 10, 2025By:Â /s/ Sandra Y. CamposSandra Y. CamposChief Executive Officer and PresidentBy: Â /s/ Robyn D'EliaRobyn D'EliaChief Financial Officer and Treasurer EX-101.SCH 5 pets-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952155 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Net (Loss) Income Per Share link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Intangible and Other Assets, Net link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Changes in Shareholdersâ€™ Equity link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Related Party Transaction link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Net (Loss) Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Intangible and Other Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Changes in Shareholdersâ€™ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Revenue Recognition - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Net (Loss) Income Per Share - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink

link:definitionLink 9955522 - Disclosure - Net (Loss) Income Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Stock-Based Compensation - Rollforward of Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Stock-Based Compensation - Rollforward of RSU and PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Intangible and Other Assets, Net - Schedule of Intangible Assets and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Intangible and Other Assets, Net - Schedule of Intangible Assets and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Intangible and Other Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Changes in Shareholdersâ€™ Equity - Schedule of Changes in Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Changes in Shareholdersâ€™ Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Related Party Transaction (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 pets-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 pets-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 pets-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental disclosure of cash flow information: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Number of performance obligations Revenue From Contract With Customer, Number Of Performance Obligations Revenue From Contract With Customer, Number Of Performance Obligations Fiscal Year 2023 Fiscal Year 2023 [Member] Fiscal Year 2023 Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Prepaid income taxes Prepaid Taxes Statistical Measurement [Domain] Statistical Measurement [Domain] Related Party Transaction Related Party Transactions Disclosure [Text Block] Cover [Abstract] Cover [Abstract] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Percentage of equity interests acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Cash paid for income taxes Income Taxes Paid, Net 2024 Inducement Incentive Plan 2024 Inducement Incentive Plan [Member] 2024 Inducement Incentive Plan Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Minority interest investment in Vetster Equity Method Investments Pay vs Performance Disclosure [Line Items] Intangibles and Other Assets Intangibles and Other Assets [Abstract] Intangibles and Other Assets Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable Income Tax Contingency [Table] Income Tax Contingency [Table] Related party, first year transaction amount Related Party Transaction, Annual Amounts Of Transaction, Year One Related Party Transaction, Annual Amounts Of Transaction, Year One Lease liabilities Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Sales tax payable Sales and Excise Tax Payable, Current Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Operating lease liabilities, net of current lease liabilities Operating Lease, Liability, Noncurrent Total noncurrent assets Assets, Noncurrent Revenue from Contract with Customer [Abstract] Deferred revenue Deferred revenue, beginning balance Deferred revenue, ending balance Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] Shares Issuable Upon Vesting of Restricted Stock Shares Issuable Upon Vesting Of Restricted Stock [Member] Shares Issuable Upon Vesting Of Restricted Stock Preferred stock, liquidation preference (in dollars per share) Preferred Stock, Liquidation Preference Per Share Entity Tax Identification Number Entity Tax Identification Number Finite-lived intangibles Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of PSU Activity Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Plan Name [Axis] Plan Name [Axis] Dividends payable in accrued expenses and other current liabilities Liabilities Assumed Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Trade Names - PetCareRx Trade Names [Member] Intangible, Gross Value Intangible And Other Assets, Gross Intangible And Other Assets, Gross 2024 Inducement Plan 2024 Inducement Plan [Member] 2024 Inducement Plan Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Developed Technology - PetCareRx Developed Technology Rights [Member] Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Award Date [Axis] Award Date [Axis] Number of warehouses Number Of Warehouses Number Of Warehouses Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Chief Executive Officer Chief Executive Officer [Member] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Goodwill Goodwill Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Total operating loss carryforward and disallowed interest expense Operating Loss Carryforward And Disallowed Interest Expense Operating Loss Carryforward And Disallowed Interest Expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Operating lease right-of-use assets, net Increase (Decrease) in Operating Lease Right Of Use Asset Increase (Decrease) in Operating Lease Right Of Use Asset Number of reporting units Number of Reporting Units Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Weighted Average Remaining Useful Life (Years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Other Assets Other Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Number of outstanding right shares (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Disallowed interest expense Deferred Tax Liability, Nondeductible Interest Deferred Tax Liability, Nondeductible Interest Current operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued 2024 Omnibus Incentive Plan 2024 Omnibus Incentive Plan [Member] 2024 Omnibus Incentive Plan Schedule of Restricted Stock Awards Nonvested Restricted Stock Shares Activity [Table Text Block] Entity [Domain] Entity [Domain] Related party, after year one annual transaction amount Related Party Transaction, Annual Amounts Of Transaction After Year One Related Party Transaction, Annual Amounts Of Transaction After Year One Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Toll-free telephone number Toll-free telephone number [Member] Toll-free telephone number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Acquisition of PetCareRx, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Diluted (in shares) Shares used in diluted computation (in shares) Weighted Average Number of Shares Outstanding, Diluted Percentage of common stock exercise threshold Class of Warrant or Right, Percent Of Common Stock, Exercise Threshold Class of Warrant or Right, Percent Of Common Stock, Exercise Threshold MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Prepaid income taxes Increase (Decrease) in Prepaid Taxes Total shareholders' equity Beginning balance Ending balance Equity, Attributable to Parent Related Party Related Party [Member] Deferred income taxes Deferred Income Tax Expense (Benefit) Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Accounts receivable, less allowance for credit losses of $88 and $273, respectively Accounts Receivable, after Allowance for Credit Loss, Current Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Common shares issuable upon vesting of restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Deferred Revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Indefinite-lived intangibles Indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization expense Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Finite-lived intangibles Finite-Lived Intangible Assets, Net Convertible Preferred Stock Convertible Preferred Stock [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Membership Customers Membership Customers [Member] Membership Customers Accounting Policies [Abstract] Accounting Policies [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Related party transaction, expenses Related Party Transaction, Amounts of Transaction Noncurrent assets: Assets, Noncurrent [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] (Loss) income before provision (benefit) for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Revenue recognition period membership Revenue From Contract With Customer, Number Of Membership Models Revenue From Contract With Customer, Number Of Membership Models Shares issued under stock compensation plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Vested and issued (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Schedule of Intangible Assets and Other Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Deferred tax assets, net Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Useful life Finite-Lived Intangible Asset, Useful Life Title of Individual [Axis] Title and Position [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] 2024 Incentive Plan Incentive Plan 2024 [Member] 2024 Incentive Plan Award Timing Predetermined Award Timing Predetermined [Flag] Reversal of stock based compensation Share-Based Payment Arrangement Expense (Reversal Of Expense), Noncash Share-Based Payment Arrangement Expense (Reversal Of Expense), Noncash Dividends paid Payments of Ordinary Dividends, Common Stock Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Customer Relationships -PetCareRx Customer Relationships [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Series A Preferred Stock Series A Preferred Stock [Member] Forecast Forecast [Member] Diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Title of Individual [Domain] Title and Position [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Deferred Revenue Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Initial grant percentage based on performance targets Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] The 2022 Employee Equity Compensation Restricted Stock Plan The 2022 Employee Equity Compensation Restricted Stock Plan [Member] The 2022 Employee Equity Compensation Restricted Stock Plan Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Share based compensation Share-Based Payment Arrangement, Noncash Expense Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Provision (benefit) for income taxes Income Tax Expense (Benefit) Other income: Nonoperating Income (Expense) [Abstract] Sales tax payable Increase (Decrease) in Property and Other Taxes Payable Net sales Membership fees earned Revenue from Contract with Customer, Excluding Assessed Tax Total other income Nonoperating Income (Expense) Fiscal Year 2024 Fiscal Year 2024 [Member] Fiscal Year 2024 Effective income tax rate, percent Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities (Loss) income from operations Operating Income (Loss) Total liabilities and shareholders' equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Chief Financial Officer Chief Financial Officer [Member] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income, net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Vested and issued (in shares) Share-Based Compensation

Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period Underlying Security Market Price Change Underlying Security Market Price Change, Percent Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] Partnership Agreement with Vetster Partnership Agreement with Vetster [Member] Represents partnership agreement with Vestster. Inventories, net Inventory, Net Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Related party transaction, number of notice period in advance Related Party Transaction, Number Of Notice Period In Advance Related Party Transaction, Number Of Notice Period In Advance Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of Changes in Shareholders' Equity Schedule of Stockholders Equity [Table Text Block] Operating expenses: Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Vesting [Domain] Vesting [Domain] Non-vested beginning balance (in dollars per share) Non-vested ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] 2024 Omnibus Plan 2024 Omnibus Plan [Member] 2024 Omnibus Plan Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Granted and issued (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period Partner Program Partner Program [Member] Partner Program Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Deferred memberships fees and others received Contract With Customer Liability, Increase For Deferred Fees Received Contract With Customer Liability, Increase For Deferred Fees Received Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Intangible and other assets, net Intangible And Other Noncurrent Assets, Net Excluding Goodwill Intangible And Other Noncurrent Assets, Net Excluding Goodwill Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Contract With Customer, Liability, Current [Roll Forward] Contract With Customer, Liability, Current [Roll Forward] Contract With Customer, Liability, Current Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Payments to acquire equity method investments Payments to Acquire Equity Method Investments Membership fees Membership Fees [Member] Membership Fees Exercise Price Award Exercise Price Net (Loss) Income Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Net operating loss carryforward Operating Loss Carryforwards Shareholders' equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Minority interest investment in Vetster Investments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Related party transaction, service period Related Party Transaction, Service Period Related Party Transaction, Service Period PEO PEO [Member] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other, net Other Nonoperating Income (Expense) Intangibles Intangible Assets, Net (Excluding Goodwill) Annual membership fees renewal period Contract With Customer, Renewal Period Contract With Customer, Renewal Period Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Beneficial ownership threshold percentage Beneficial Ownership, Threshold Percentage Beneficial Ownership, Threshold Percentage Share-Based Payment Arrangement, Tranche Three Share-Based Payment Arrangement, Tranche Three [Member] Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Internet domain names Internet Domain Names [Member] 2022 Employee Plan 2022 Employee Plan [Member] 2022 Employee Plan Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Intangibles Intangible Assets, Gross (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Purchase of minority interest investment in Vetster Payments to Acquire Interest in Subsidiaries and Affiliates Total operating expenses Operating Expenses Term of agreement Term Of Agreement Represents term of agreement. Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] (Increase) decrease in operating assets and increase (decrease) in operating liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount No Trading Symbol Flag No Trading Symbol Flag Deferred memberships fees revenue and others recognized Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Impairment of long lived assets Impairment, Long-Lived Asset, Held-for-Use Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Vetster Inc Vetster Inc [Member] Vetster Inc Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Changes in Shareholdersâ€™ Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Common shares issuable upon conversion of preferred shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock based compensation (reversal) expenses APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted Stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net Carrying Value Intangible Assets, Net (Excluding Goodwill) [Abstract] Title Trading Arrangement, Individual Title Revenue recognition period Contract With Customer, Revenue Recognition, Period Contract With Customer, Revenue Recognition, Period City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2016 Employee Plan and 2015 Director Plan Employee and Director Equity Compensation Plan [Member] Refers to information regarding employee and director plans. Revision of Prior Period [Domain] Revision of Prior Period [Domain] Preferred Stock Preferred Stock [Member] Document Information [Line Items] Document Information [Line Items] Dividends forfeited Dividends Forfeited Dividends Forfeited Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Income Taxes Income Tax Disclosure [Text Block] Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Net (loss) income per common share: Earnings Per Share [Abstract] Net (loss) income (numerator): Net Income (Loss) Attributable to Parent [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Accrued expenses and other current liabilities Accrued expenses and other current liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Shares repurchased and retired (in shares) Stock Repurchased and Retired During Period, Shares Class of Stock [Domain] Class of Stock [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories, net Increase (Decrease) in Inventories Accumulated Amortization Intangibles And Other Assets, Accumulated Amortization Intangibles And Other Assets, Accumulated Amortization General and administrative General and Administrative Expense Reorder sales Reorder Customer [Member] The disaggregate of revenue in reorder sales. Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Sales, variance, percentage Revenue From Contract With Customer Variance Percentage The percentage of changes in revenue in current period comparing to the same period in the previous year. Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount PSUs Performance Shares [Member] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Intangible and Other Assets, Net Intangible Assets Disclosure [Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Advertising Advertising Expense Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common stock, \$.001 par value, 40,000,000 shares authorized; 20,656,457 and 21,148,692 shares issued and outstanding, respectively Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, \$.001 par value, 5,100,000 shares and 5,000,000 shares authorized respectively; 2,500 convertible shares issued and outstanding with a liquidation preference of \$4 per share Preferred Stock, Value, Issued Gross Value Intangible Assets, Gross (Excluding Goodwill) [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Total grant-date fair value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Grant Date Fair Value Accounts payable Increase (Decrease) in Accounts Payable Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] PetCareRx PetCareRx, Inc. [Member] PetCareRx, Inc. Non-cash investing activity for PPE additions Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Cash settlement period Concentration Risk, Cash Settlement Period For Sales Concentration Risk, Cash Settlement Period For Sales Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Shares (denominator): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Previously Reported Previously Reported [Member] Total assets Assets Cost of sales Cost of Goods and Services Sold Issued shares (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment New order sales New Order Customer [Member] The disaggregate of revenue in new order sales. Intangible, Net Carrying Value Intangible And Other Assets Intangible And Other Assets Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 7) Commitments and Contingencies Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Sales, percentage Revenue From Contract With Customer Percentage Percentage of revenue from the specified category to the total revenue during the period. Compensation (benefit) expense Share-Based Payment Arrangement, Expense Net (loss) income Net income (loss) Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value Granted and issued (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period, Weighted Average Grant Date Fair value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period, Weighted Average Grant Date Fair value Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Performance Restricted Stock Performance Restricted Stock [Member] Represents performance restricted stock. Sales, variance Revenue From Contract With Customer Variance The amount of changes in revenue in current period comparing to the same period in the previous year. Entity File Number Entity File Number Basis of Presentation and Consolidation Basis Of Presentation and Consolidation [Policy Text Block] Disclosure of accounting policy for basis of accounting, or basis of presentation and , used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Also consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements. Revenue Recognition Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Dividends declared Dividends, Common Stock Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name Award Date [Domain] Award Date [Domain] Document Period End Date Document Period End Date Award Timing MNPI Considered Award Timing MNPI Considered [Flag] 2015 Director Plan 2015 Outside Director Equity Compensation Restricted Stock Plan ("2015 Director Plan") [Member] Refers to information regarding 2015 Outside Director Equity Compensation Restricted Stock Plan ("2015 Director Plan"). Non-vested restricted shares issued and outstanding (in shares) Non-vested beginning balance (in shares) Non-vested ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Deferred membership fee revenue and others recognized Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Former Chief Financial Officer Former Chief Financial Officer [Member] Former Chief Financial Officer Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Market value purchase price rate Class of Warrant or Right, Market Value Purchase Price

Rate Class of Warrant or Right, Market Value Purchase Price Rate Related Party [Axis] Related and Nonrelated Parties [Axis] Basic (in shares) Weighted average number of common shares outstanding used in basic computation (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Net (loss) income per common share: Net Income Per Common Share, Basic And Diluted [Abstract] Net Income Per Common Share, Basic And Diluted Document Information [Table] Document Information [Table] RSUs Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category 2016 Employee Plan The 2016 Employee Equity Compensation Restricted Stock Plan [Member] represents the 2016 Employee Equity Compensation Restricted Stock Plan. Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 pets-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1 Cover - shares 9 Months Ended Dec. 31, 2024 Feb. 10, 2025 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Dec. 31, 2024 Â Document Transition Report false Â Entity File Number 000-28827 Â Entity Registrant Name PETMED EXPRESS, INC. Â Entity Incorporation, State or Country Code FL Â Entity Tax Identification Number 65-0680967 Â Entity Address, Address Line One 420 South Congress Avenue Â Entity Address, City or Town Delray Beach Â Entity Address, State or Province FL Â Entity Address, Postal Zip Code 33445 Â City Area Code 561 Â Local Phone Number 526-4444 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 20,656,457 Entity Central Index Key 0001040130 Â Current Fiscal Year End Date --03-31 Â Document Fiscal Year Focus 2025 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â Common Stock Â Â Document Information [Line Items] Â Â Title of 12(b) Security Common Stock, par value $.001 per share Â Trading Symbol PETS Â Security Exchange Name NASDAQ Â Preferred Stock Â Â Document Information [Line Items] Â Â Title of 12(b) Security Preferred Stock Purchase Rights Â No Trading Symbol Flag true Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a security having no trading symbol. + ReferencesNo definition available. + Details Name: dei_NoTradingSymbolFlag Namespace Prefix: dei_ Data Type: dei:trueItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Current assets: Â Â Cash and cash equivalents $ 50,101 $ 55,296 Accounts receivable, less allowance for credit losses of $88 and $273, respectively 2,259 3,283 Inventories, net 11,795 28,556 Prepaid expenses and other current assets 3,888 6,325 Prepaid income taxes 340 188 Total current assets 68,383 93,648 Noncurrent assets: Â Â Property and equipment, net 28,425 26,657 Intangible and other assets, net 15,035 16,503 Goodwill 26,658 26,658 Operating lease right-of-use assets 1,077 1,432 Deferred tax assets, net 5,217 4,986 Total noncurrent assets 76,412 76,236 Total assets 144,795 169,884 Current liabilities: Â Â Accounts payable 10,945 37,024 Sales tax payable 24,483 25,012 Accrued expenses and other current liabilities 10,922 7,060 Current operating lease liabilities 453 459 Deferred revenue 1,156 2,603 Total current liabilities 47,959 72,158 Operating lease liabilities, net of current lease liabilities 652 995 Total liabilities 48,611 73,153 Commitments and contingencies (Note 7) Shareholders' equity: Â Â Preferred stock, $.001 par value, 5,100,000 shares and 5,000,000 shares authorized respectively; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share 9 9 Common stock, $.001 par value, 40,000,000 shares authorized; 20,656,457 and 21,148,692 shares issued and outstanding, respectively 21 21 Additional paid-in capital 17,967 25,146 Retained earnings 78,187 71,555 Total shareholders' equity 96,184 96,731 Total liabilities and shareholders' equity $ 144,795 $ 169,884 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: pets_AccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIntangible And Other Noncurrent Assets, Net Excluding Goodwill + ReferencesNo definition available. + Details Name: pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 +

Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SalesAndExciseTaxPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Current assets: Â Â Allowance for credit losses $ 88 $ 273 Shareholders' equity: Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 5,100,000 5,000,000 Preferred stock, shares issued (in shares) 2,500 2,500 Preferred stock, shares outstanding (in shares) 2,500 2,500 Preferred stock, liquidation preference (in dollars per share) $ 4 $ 4 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 40,000,000 40,000,000 Common stock, shares issued (in shares) 20,656,457 21,148,692 Common stock, shares outstanding (in shares) 20,656,457 21,148,692 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockLiquidationPreference Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Income Statement [Abstract] Â Â Â Â Net sales $ 52,984 $ 65,317 $ 180,506 $ 214,560 Cost of sales 38,075 47,434 130,315 154,089 Gross profit 14,909 17,883 50,191 60,471 Operating expenses: Â Â Â Â General and administrative 10,786 13,425 26,153 41,098 Advertising 2,987 5,762 14,583 18,539 Depreciation and amortization 1,586 1,770 4,965 5,161 Total operating expenses 15,359 20,957 45,701 64,798 (Loss) income from operations (450) (3,074) 4,490 (4,327) Other income: Â Â Â Â Interest income, net 28 136 308 481 Other, net 180 293 597 1,053 Total other income 208 429 905 1,534 (Loss) income before provision (benefit) for income taxes (242) (2,645) 5,395 (2,793) Provision (benefit) for income taxes 465 (618) 22 (345) Net (loss) income $ (707) $ (2,027) $ 5,373 $ (2,448) Net (loss) income per common share: Â Â Â Â Basic (in dollars per share) $ (0.03) $ (0.10) $ 0.26 $ (0.12) Diluted (in dollars per share) $ (0.03) $ (0.10) $ 0.26 $ (0.12) Weighted average number of common shares outstanding: Â Â Â Â Basic (in shares) 20,634,651 20,425,282 20,581,913 20,380,262 Diluted (in shares) 20,634,651 20,425,282 20,987,260 20,380,262 Cash dividends declared per common share (in dollars per share) $ 0 $ 0 $ 0 $ 0.60 X - DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-

2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Cash flows from operating activities: Â Â Net income (loss) $ 5,373 $ (2,448) Adjustments to reconcile net income (loss) to net cash used in operating activities: Â Â Depreciation and amortization 4,965 5,161 Share based compensation (7,179) 5,196 Deferred income taxes (231) (436) Bad debt expense 324 53 (Increase) decrease in operating assets and increase (decrease) in operating liabilities: Â Â Accounts receivable 700 (119) Inventories, net 16,761 (12,438) Prepaid income taxes (152) 65 Prepaid expenses and other current assets 2,437 (2,664) Operating lease right-of-use assets, net 355 594 Accounts payable (26,078) 7,929 Sales tax payable (529) (1,942) Accrued expenses and other current liabilities 2,756 (1,258) Lease liabilities (349) (577) Deferred revenue (1,447) 75 Net cash used in operating activities (2,294) (2,808) Cash flows from investing activities: Â Â Purchase of minority interest investment in Vetster 0 (300) Acquisition of PetCareRx, net of cash acquired 0 (35,859) Purchases of property and equipment (2,725) (3,260) Net cash used in investing activities (2,725) (39,419) Cash flows from financing activities: Â Â Dividends paid (176) (12,419) Net cash used in financing activities (176) (12,419) Net decrease in cash and cash equivalents (5,195) (54,646) Cash and cash equivalents, at beginning of period 55,296 104,086 Cash and cash equivalents, at end of period 50,101 49,440 Supplemental disclosure of cash flow information: Â Â Cash paid for income taxes 474 43 Dividends payable in accrued expenses and other current liabilities 32 1,498 Non-cash investing activity for PPE additions $ 2,539 $ 0 X - DefinitionIncrease (Decrease) in Operating Lease Right Of Use Asset + ReferencesNo definition available. + Details Name: pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of liabilities assumed in noncash investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_LiabilitiesAssumed1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1 Summary of Significant Accounting Policies 9 Months Ended Dec. 31, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Summary of Significant Accounting PoliciesOrganizationPetMed Express, Inc. and subsidiaries, d/b/a PetMedsÂ® and PetCareRx, Inc. d/b/a PetCareRxÂ® (collectively, the â€œCompanyâ€), is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses. The Company markets and sells directly to consumers through its websites, customer contact center, and mobile application. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.Founded in 1996, the Companyâ€™s executive headquarters offices are currently located in Delray Beach, Florida. The Companyâ€™s fiscal year end is MarchÂ 31, and references herein to fiscal 2025 or fiscal 2024 refer to the Company's fiscal years ending MarchÂ 31, 2025 and 2024, respectively.Basis of Presentation and ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at DecemberÂ 31, 2024, the Statements of Operations for the three and nine months ended DecemberÂ 31, 2024 and 2023, and Cash Flows for the nine months ended DecemberÂ 31, 2024 and 2023. The results of operations for the three and nine months ended DecemberÂ 31, 2024 are not necessarily indicative of the operating results expected for the fiscal year ending MarchÂ 31, 2025. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in our 2024 Form 10-K. The unaudited condensed consolidated financial statements include the accounts of PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Fair Value of Financial Instruments The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments. Deferred RevenueDeferred revenue is recorded when payments are received or due in advance of performing our service obligations and revenue is recognized over the service period. Deferred revenue represents prepayments of PetPlus memberships with PetCareRx, Inc. (â€œPetCareRxâ€). The total deferred revenue as of DecemberÂ 31, 2024 and MarchÂ 31, 2024 for these memberships was $1.2 million and $2.6 million, respectively. Memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The membership fee is an annual charge and automatically renews one year from the initial enrollment date. The Company generally recognizes the revenue ratably over the term of the membership.Long-lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset. Management determined that no impairment of long-lived assets existed as of DecemberÂ 31, 2024.Goodwill and Intangible AssetsGoodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. The Company is required to assess goodwill and other indefinite-lived intangible assets for impairment annually, or more frequently if circumstances indicate impairment may have occurred. Goodwill was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that goodwill was impaired as of December 31, 2024. The Company performs its annual impairment assessment in the fourth fiscal quarter of each year. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.The Companyâ€™s other indefinite-lived intangible assets are primarily made up of a trade name which was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that the other indefinite-lived assets were impaired as of December 31, 2024.Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company's consolidated financial position, results of operations, or cash flows. In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Update 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". This Update applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in this Update revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in this Update do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Update should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this Update.In December 2023, the FASB issued Update 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This Update applies to all entities that are subject to Topic 740. The amendments in this Update revise income tax disclosures primarily related to the rate reconciliation and income taxes paid information as well as the effectiveness of certain other income tax disclosures. The Update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Update should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the impact of adopting this Update. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition 9 Months Ended Dec. 31, 2024 Revenue from Contract with Customer [Abstract] Â Revenue Recognition Revenue RecognitionIn accordance with ASC Topic 606 ("Revenue from Contracts with Customers"), the Company primarily generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, and supplies, from one of the Companyâ€™s two warehouses. Certain pet supplies offered on the Companyâ€™s websites are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product. Customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are based on historical patterns, however this is not considered a key judgment. Revenue is recognized when control transfers to the customer at the point in time at which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time when the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Additionally, the Company has external relationships for telehealth veterinary and insurance services. Virtually all the Companyâ€™s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.Membership fees represent the amounts recognized from two membership models. The first is the PetPlus membership for PetCareRx customers, and the second is a partner membership, which allows employees in-network to join the PetPlus membership program through their employers. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews one year from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally one year. As shown in the following table, under the PetPlus program, the Company recognized $1.0 million and $3.7 million of previously deferred annual membership fees in the three and nine months ended DecemberÂ 31, 2024, and had $1.2 million of deferred revenue as of DecemberÂ 31, 2024.(amounts in millions)Deferred revenue, March 31, 2024$2.6Â Deferred memberships fees and others received1.1Â Deferred membership fee revenue and others recognized (1.5)Deferred revenue, June 30, 20242.1Â Deferred memberships fees and others received0.7Â Deferred membership fee revenue and others recognized (1.2)Deferred revenue, September 30, 20241.6Â Deferred memberships fees and others received0.5Â Deferred membership fee revenue and others recognized (1.0)Deferred revenue, December 31, 2024$1.2Â In addition to annual membership fees earned under the PetPlus program, the Company also earns membership fees on a month-to-month basis under its PetCareRx partner membership program. For the three and nine months ended DecemberÂ 31, 2024, membership fees earned under the partner program were $0.9 million and $2.8 million, respectively. For the three and nine months ended DecemberÂ 31, 2023, membership fees earned under the partner program were $0.7 million and $2.1 million, respectively. The Company has no material contract asset or liability balances at DecemberÂ 31, 2024 or MarchÂ 31, 2024, respectively. The Company disaggregates sales in the following categories: reorder sales vs new order sales vs membership fees. The following table illustrates sales in those categories:Three Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$ % Reorder sales$45,076Â 85.1Â %$54,067Â 82.8Â %$(8,991)(16.6)%New order sales6,075Â 11.5Â %8,803Â 13.5Â %(2,728)(31.0)%Membership fees1,833Â 3.5Â %2,447Â 3.7Â %(614)(25.1)%Total net sales$52,984Â 100.0Â %$65,317Â 100.0Â %$(12,333)(18.9)%Nine Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$ % Reorder sales$149,367Â 82.7Â %$174,250Â 81.3Â %$(24,883)(14.3)%New order sales24,913Â 13.8Â %33,054Â 15.4Â %(8,141)(24.6)%Membership fees6,226Â 3.4Â %7,256Â 3.4Â %(1,030)(14.2)%Total net sales$180,506Â 100.0Â %$214,560Â 100.0Â %$(34,054)(15.9)%The Company changed the definition of a new order sale on July 1, 2024, to include sales from customers who have not previously ordered from the Company over the past twelve months compared to the prior definition which was thirty-six months. The reorder and new order sales amounts for the three and nine months ended DecemberÂ 31, 2024, and the reorder and new order sales amounts for the three and nine months ended DecemberÂ 31, 2023 reflect this new customer definition change. Under the previous definition of a new customer, reorder and new order sales were $57.7 million and $5.2 million, respectively, for the three months ended December 31, 2023. Under the previous definition of a new customer, reorder and new order sales were $188.1 million and $19.2 million, respectively, for the nine months ended December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1 Net (Loss) Income Per Share 9 Months Ended Dec. 31, 2024 Earnings Per Share [Abstract] Â Net (Loss) Income Per Share Net (Loss) Income Per ShareIn accordance with the provisions of ASC Topic 260 (â€œEarnings Per Shareâ€) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted and performance stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock and convertible preferred shares issued by the Company represent the only dilutive effect reflected in the diluted weighted average shares outstanding.The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for share and per share amounts):Three Months Ended December 31,Nine Months EndedDecember 31,2024202320242023Net (loss) income (numerator):Â Â Net (loss) income(707)(2,027)$5,373Â $(2,448)Shares (denominator):Â Â Weighted average number of common shares outstanding used in basic computation20,634,651Â 20,425,282Â 20,581,913Â 20,380,262Â Common shares issuable upon vesting of restricted stockâ€"Â â€"Â 395,222Â â€"Â Common shares issuable upon conversion of preferred sharesâ€"Â â€"Â 10,125Â â€"Â Shares used in diluted computation20,634,651Â 20,425,282Â 20,987,260Â 20,380,262Â Net (loss) income per common share:Basic(0.03)(0.10)$0.26Â $(0.12)Diluted$(0.03)(0.10)0.26Â $(0.12)For the three months ended DecemberÂ 31, 2024 and 2023, 986,378 and 825,825 shares issuable upon vesting of restricted stock and 10,125 and 10,125 shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share.For the nine months ended DecemberÂ 31, 2024 and 2023, 519,852 and 837,084 shares issuable upon vesting of restricted stock and zero and 10,125 shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stock-Based Compensation 9 Months Ended Dec. 31, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation Stock-Based CompensationThe Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (â€œCompensation - Stock Compensationâ€). The Company had 423,619 common shares issued, net of forfeitures, under the 2016 Employee Equity Compensation Restricted Stock Plan (the â€œ2016 Employee Planâ€) (which 2016 Employee Plan was succeeded by the 2022 Employee Plan in April 2023, and no further awards will be granted under the 2016 Employee Plan), 55,074 common shares issued, net of forfeitures, under the 2022 Employee Equity Compensation Plan (as amended) (the â€œ2022 Employee Planâ€), and 257,567 common shares issued, net of forfeitures, under the 2015 Outside Director Equity Compensation Plan (as amended) (the â€œ2015 Director Planâ€). At DecemberÂ 31, 2024, all outstanding shares under these plans were issued with service-based vesting conditions with the exception of 2,000 performance stock units which vested on July 1, 2024. The Company records stock-based compensation expense for these awards on a straight-line basis over the requisite service period. The Company reverses stock-based compensation expense previously recorded upon forfeiture of unvested awards except for the performance restricted shares with a market condition issued to the former Chief Executive Officer (â€œCEOâ€) and performance stock units (â€œPSUsâ€) with a market condition issued to the former Chief Financial Officer (â€œCFOâ€) as described in the following paragraphs. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to restricted stock awards of $0.5Â million and $1.7Â million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded a (reversal) of previously recorded stock-based compensation expense and stock-based compensation expense related to restricted stock awards of $(7.2)Â million and $5.2Â million, respectively. In June 2023, the Board of Directors amended and restated the 2015 Director Plan and the 2022 Employee Plan (collectively, the "Plans") to include the ability to grant restricted stock units ("RSUs") and performance stock units ("PSUs") under the Plans. The amendments and restatement of the Plans did not increase the maximum number of shares of common stock that could be awarded under the Plans. At DecemberÂ 31, 2024, the Company had 83,500 RSUs outstanding under the 2024 Omnibus Incentive Plan (the â€œ2024 Omnibus Planâ€), 290,000 RSUs outstanding under the 2024 Inducement Incentive Plan (the â€œ2024 Inducement Planâ€), 569,365 RSUs outstanding under the 2022 Employee Plan and 22,316 RSUs outstanding under the 2015 Director Plan.In August 2021, the Company issued 90,000 shares of restricted stock and 510,000 performance restricted shares with a market condition to the Companyâ€™s former CEO, in accordance with the former CEOâ€™s employment agreement, under the 2016 Employee Plan. In April 2024, the Company and former CEO entered into a Transition and Separation Agreement pursuant to which the Company cancelled the 510,000 performance restricted shares and accelerated vesting on 30,000 remaining unvested restricted shares which otherwise would not have vested. Cancellation of the 510,000 shares resulted in an $8.8Â million reversal of compensation expense, partially offset by $0.1Â million of compensation expense from the accelerated vesting of the 30,000 shares in the nine months ended DecemberÂ 31, 2024. On April 29, 2024, the Company appointed a new CEO, and in conjunction with her new employment agreement, she received a grant of 483,092 RSUs under the Companyâ€™s 2022 Employee Equity Compensation Plan. Such RSUs will vest in one-third increments on each of the first three anniversaries of the date of grant so long as the CEO continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. In August 2022, the Company issued 13,000 restricted shares and 3,000 performance restricted shares to the Company's former CFO, in accordance with the CFO's employment agreement, under the 2016 Employee Plan. One-third of the restricted shares were scheduled to vest on each of the first three anniversaries of the date of grant, subject to the CFOâ€™s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company. The performance restricted shares were based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue. On June 8, 2023, the Company determined that the performance criteria were not attained over the applicable performance period and accordingly, the performance restricted shares were cancelled.In June 2023, the Company granted the Company's former CFO 11,750 RSUs under the 2022 Employee Plan, of which 3,750 RSUs were awarded in recognition of the CFOâ€™s contributions during fiscal year 2023 and the remaining 8,000 awarded as a part of the equity award cycle for fiscal year 2024. One-third of the RSUs were scheduled to vest on each of the first three anniversaries of the date of grant, subject to the CFOâ€™s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the former CFO ceasing to be an employee of the Company. Also in June 2023, the former CFO was awarded 8,000 PSUs with a market condition. On May 16, 2024, the Company granted the former CFO 74,850 RSUs of which 14,970 would vest on June 30, 2024, 22,455 would vest August 31, 2024 and 37,425 would vest on August 31, 2025. On May 31, 2024, the Company and the former CFO entered into a Transition and Separation Agreement pursuant to which the former CFO agreed to leave the Company following a transition period. Upon the completion of the transition period and contingent on the former CFOâ€™s complying with the terms of the Agreement, the Company accelerated the vesting of all unvested restricted shares and RSUs that were originally scheduled to vest on or before August 3, 2025. Under the Agreement, PSUs with a market condition were cancelled. Acceleration and cancellation of the former CFOâ€™s restricted shares, RSUs and PSUs resulted in net additional compensation expense of $0.2Â million in the three months ended June 30, 2024.On August 8, 2024, the Company adopted the 2024 Omnibus Plan pursuant to which the Company reserved 850,000 shares of common stock, par value $.001 per share, of the Companyâ€™s common stock for the issuance of equity awards granted.On September 27, 2024, the Company adopted the 2024 Inducement Plan pursuant to which the Company reserved 350,000 shares of common stock, par value $.001 per share, of the Companyâ€™s common stock (subject to the adjustment provisions of the Inducement Plan) for the issuance of equity awards granted under the Inducement Plan.On September 27, 2024, the Companyâ€™s new CFO received a grant of 250,000 RSUs under the Companyâ€™s 2024 Inducement Plan. Such RSUs will vest in one-third increments on each of the first three anniversaries of the date of grant so long as the CFO continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. All stock-based compensation expense is recognized as a payroll-related expense and is included within the general and administrative expenses line item within the Companyâ€™s unaudited Condensed Consolidated Statements of Operations, with the offset included in the additional paid-in capital line item of the Companyâ€™s unaudited Condensed Consolidated Balance Sheets. Restricted Stock AwardsThe fair value assigned to restricted stock awards (â€œRSAsâ€) is the market price of the Companyâ€™s stock at the grant date. The vesting period ranges from one to three years. Restricted stock award activity in the nine months ended December 31, 2024 was as follows:Â 2015 Director Plan Â 2016 Employee Plan Â 2022 Employee Plan Â Total Â Weighted-Average Grant Date Fair Value Non-vested restricted stock outstanding at March 31, 202423,707Â 605,343Â 74,076Â 703,126Â $19.39Â Granted and issuedâ€“Â â€“Â â€“Â â€“Â $â€“Â Vested(13,666)(60,540)(46,742)(120,948)$22.10Â Forfeitedâ€“Â (533,641)(27,334)(560,975)$18.71Â Balance at December 31, 202410,041Â 11,162Â â€“Â 21,203Â $21.96Â At DecemberÂ 31, 2024 and 2023, there were 21,203 and 728,446 RSAs subject to restriction and forfeiture outstanding, respectively. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSAs of $0.1Â million and $1.6Â million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded a (reversal) of previously recorded stock-based compensation expense and stock-based compensation expense related to RSAs of $(8.2)Â million and $5.0Â million, respectively. Restricted Stock UnitsThe Company first granted RSUs in the year ended March 31, 2024. The fair value assigned to RSUs is the market price of the Companyâ€™s stock on the grant date. The vesting period for employees and members of the Board of Directors generally ranges from one to three years. For the nine months ended DecemberÂ 31, 2024, RSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:RSUsWeighted-AverageÂ Grant DateÂ Fair Value Per RSUBalance at March 31, 202485,080$12.75Â Granted 1,037,258$4.04Â Vested and issued(66,739)$8.38Â Forfeited(90,418)$5.84Â Balance at December 31, 2024965,181$4.33Â The total grant-date fair value of RSUs granted during the three months ended DecemberÂ 31, 2024 and 2023 was $0.2 million and zero, respectively. The total grant-date fair value of RSUs granted during the nine months ended DecemberÂ 31, 2024 and 2023 was $4.2 million and $1.1 million, respectively. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $0.4 million and $0.1Â million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $1.1 million and $0.2Â million, respectively. Performance Stock Units The fair value assigned to PSUs is determined using the market price of the Companyâ€™s stock on the grant date for awards with a performance condition, and by using a Monte Carlo simulation for awards with a market condition. PSUs with a performance condition generally vest over one year. PSUs with a market condition generally vest over three years. Stock-based compensation expense associated with PSUs with a performance condition are re-assessed each reporting period based upon the estimated performance attainment on the reporting date until the performance conditions are met. The ultimate number of shares of common stock that are issued to an employee is the result of the actual performance of the Company or individual at the end of the performance period compared to the performance targets. For the nine months ended DecemberÂ 31, 2024, PSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:PSUsWeighted-AverageÂ Grant DateÂ Fair Value Per PSUBalance at March 31, 202412,000$10.48Â Granted â€“$â€“Â Vested and issued(2,000)$13.95Â Forfeited(10,000)$9.79Â Balance at December 31, 2024â€“$â€“Â In the nine months ended December 31, 2024, 10,000 PSUs were forfeited. The total grant-date fair value of PSUs granted during the nine months ended DecemberÂ 31, 2024 and 2023 was zero and $0.1Â million, respectively. There were no PSUâ€™s granted in the three months ended DecemberÂ 31, 2024 and 2023. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense, net of forfeitures, related to PSUs of zero and $20 thousand, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded stock-based compensation (benefit) expense, net of forfeitures, related to PSUs of $(36) thousand and $44 thousand, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value 9 Months Ended Dec. 31, 2024 Fair Value Disclosures [Abstract] Â Fair Value Fair ValueThe Company carries cash and cash equivalents at fair value in the unaudited Condensed Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (â€œFair Value Measurementâ€) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.Level 3 - Unobservable inputs which are supported by little or no market activity.The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At DecemberÂ 31, 2024 and MarchÂ 31, 2024, the Company had invested the majority of its $50.1 million and $55.3 million cash and cash equivalents balance in money market funds which are classified within Level 1. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1 Intangible and Other Assets, Net 9 Months Ended Dec. 31, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Intangible and Other Assets, Net Intangible and Other Assets, NetIntangible assets and other assets, net consisted of the following (in thousands):Useful LifeGross Carrying ValueAccumulated AmortizationNet Carrying ValueWeighted Average Remaining Useful Life (Years)December 31, 2024Intangible AssetsToll-free telephone numberIndefinite$375Â $â€“Â $375Â IndefiniteInternet domain namesIndefinite485Â â€“Â 485Â IndefiniteTrade Names - PetCareRxIndefinite2,600Â â€“Â 2,600Â IndefiniteCustomer Relationships -PetCareRx7 years6,700Â (1,675)5,025Â 5.25 yearsDeveloped Technology - PetCareRx3 years3,000Â (1,750)1,250Â 1.25 years$13,160Â $(3,425)$9,735Â Other AssetsMinority interest investment in VetsterN/A5,300Â â€"Â 5,300Â N/ABalance December 31, 2024$18,460Â $(3,425)$15,035Â March 31, 2024Intangible AssetsToll-free telephone numberIndefinite$375Â $â€"Â $375Â IndefiniteInternet domain namesIndefinite485Â â€"Â 485Â IndefiniteTrade Names - PetCareRxIndefinite2,600Â 2,600Â IndefiniteCustomer Relationships -PetCareRx7 years6,700Â (957)$5,743Â 6 yearsDeveloped Technology - PetCareRx3 years3,000Â (1,000)$2,000Â 2 years$13,160Â $(1,957)$11,203Â Other AssetsMinority interest investment in VetsterN/A5,300Â â€"Â 5,300Â N/ABalance March 31, 2024$18,460Â $(1,957)$16,503Â Amortization expense for intangible assets was $0.5 million for the three months ended DecemberÂ 31, 2024 and 2023. Amortization expense for intangible assets was $1.5 million for the nine months ended DecemberÂ 31, 2024 and 2023. The indefinite life intangibles are not being amortized and are subject to an annual review for impairment in accordance with the ASC Topic 350 (â€œGoodwill and Other Intangible Assetsâ€).On AprilÂ 19, 2022, the Company engaged in a three-year partnership agreement with Vetster Inc. (â€œVetsterâ€), a Canadian veterinary telehealth company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0 million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, Vetster became the exclusive provider of telehealth and telemedicine services to the Company. The minority interest investment is being valued on the cost basis and the investment will be evaluated periodically for any impairment. On October 3, 2023, the Company purchased additional shares in Vetster in the amount of $0.3Â million, which increased the minority interest investment to $5.3 million. Following this round, the Companyâ€™s minority ownership changed to approximately 4.8% of Vetsterâ€™s outstanding shares. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1 Commitments and Contingencies 9 Months Ended Dec. 31, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Commitments and ContingenciesLegal Matters and Routine ProceedingsOn April 18, 2024, Plaintiff Timothy Fitchett (â€œPlaintiffâ€) filed an action against the Company in the Court of Common Pleas of Allegheny County, Pennsylvania, on behalf of himself and purportedly on behalf of a class of others similarly situated. Plaintiff alleges that the Company violated Pennsylvaniaâ€™s Unfair Trade Practices and Consumer Protection Law by representing â€œreg.â€ prices for products which the Company allegedly never charged for those products. On May 13, 2024, the Company removed the matter to the U.S. District Court for the Western District of Pennsylvania in Pittsburgh. The company successfully opposed the Plaintiff's motion to remand the case back to the Court of Common Pleas. On the face of the Complaint, Plaintiff is seeking damages for himself in the amount of the allegedly illusory discounts he allegedly believed he was receiving when purchasing products from the Company or, in the alternative, a complete refund of amounts he paid to the Company, and he is also seeking a liability determination for members of the proposed class. The Company denies liability in this matter and intends to defend the action accordingly. The Company cannot determine materiality or estimate a range of potential liability, if any, at this time if the Company were determined to be liable.The Company may from time to time be involved in various other claims and lawsuits in the ordinary course of business, including claims related to products, product warranties, contracts, employment, intellectual property, consumer protection, pharmacy and other regulatory matters. The Company has settled complaints that had been filed with various statesâ€™ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company also intends to vigorously defend its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred. From time to time, the Company may be involved in and subject to disputes and legal proceedings, as well as demands, claims and threatened litigation that arise in the ordinary course of its business. These proceedings may include allegations involving business practices, infringement of intellectual property, employment or other matters. The ultimate outcome of any legal proceeding is often uncertain, there can be no assurance that the Company will be successful in any legal proceeding, and unfavorable outcomes could have a negative impact on our results of operations and financial condition. In accordance with ASC Topic 450-20 ("Loss Contingencies"), the Company records a liability in its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews the status of each significant matter each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the financial statements not misleading. If the loss is not probable and cannot be reasonably estimated, a liability is not recorded in the Companyâ€™s financial statements. Gain contingencies are not recorded until they are realized. Legal costs related to any legal matters are expensed as incurred. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1 Changes in Shareholdersâ€™ Equity 9 Months Ended Dec. 31, 2024 Equity [Abstract] Â Changes in Shareholdersâ€™ Equity Changes in Shareholdersâ€™ Equity:Changes in Shareholdersâ€™ Equity for the three and nine months ended DecemberÂ 31, 2024 is summarized below (in thousands):Common StockAdditionalPaid-InCapitalRetainedEarningsBeginning balance at March 31, 2024:$21Â $25,146Â $71,555Â Stock based compensation (reversal) â€"Â (8,204)â€"Â Dividends forfeitedâ€"Â â€"Â 1,250Â Net incomeâ€"Â â€"Â 3,754Â Ending balance at June 30, 2024:$21Â $16,942Â $76,559Â Stock based compensation expenseâ€"Â 573Â â€"Â Dividends forfeitedâ€"Â â€"Â 4Â Net incomeâ€"Â â€"Â 2,326Â Ending balance at September 30, 2024:$21Â $17,515Â $78,889Â Stock based compensation expenseâ€"Â 452Â â€"Â Dividends forfeitedâ€"Â â€"Â 5Â Net lossâ€"Â â€"Â (707)Ending balance at December 31, 2024:$21Â $17,967Â $78,187Â Changes in Shareholdersâ€™ Equity for the three and nine months ended DecemberÂ 31, 2023 is summarized below (in thousands):Common StockAdditionalPaid-InCapitalRetainedEarningsBeginning balance at March 31, 2023:$21Â $18,277Â $91,659Â Stock based compensation expenseâ€"Â 1,760Â â€"Â Dividends declaredâ€"Â â€"Â (6,346)Net lossâ€"Â â€"Â (1,136)Ending balance at June 30, 2023:$21Â $20,037Â $84,177Â Stock based compensation expenseâ€"Â 1,728Â â€"Â Dividends declaredâ€"Â â€"Â (6,308)Net incomeâ€"Â â€"Â 715Â Ending balance at September 30, 2023:$21Â $21,765Â $78,584Â Stock based compensation expenseâ€"Â 1,708Â â€"Â Net lossâ€"Â â€"Â (2,027)Ending balance at December 31, 2023:$21Â $23,473Â $76,557Â There were no shares of common stock that were purchased or retired in the nine months ended DecemberÂ 31, 2024 or 2023. On December 2, 2024, the Board of Directors (the â€œBoardâ€) of the Company adopted a rights agreement and declared a dividend of one right (a â€œRightâ€) for each outstanding share of Company common stock, to shareholders of record at the close of business on December 16, 2024 (the â€œRecord Dateâ€). The description and terms of the Rights are set forth in a rights agreement, dated as of December 3, 2024 (the â€œRights Agreementâ€), between the Company and Continental Stock Transfer & Trust Company, a federally chartered trust company, as rights agent. The Board adopted the Rights Agreement to protect the investment of shareholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of common stock by certain shareholders. The Rights Agreement is intended to enable shareholders to realize the long-term value of their investment in the Company by reducing the likelihood that any entity, person, or group is able to gain a control or control-like position in the Company through open market accumulation without paying all shareholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of all shareholders. In general terms, the Rights Agreement imposes significant dilution upon any person or group (other than the Company and certain other excluded persons and exempt persons), that is or becomes the beneficial owner of 12.5% or more of the common stock without the prior approval of the Board following the first public announcement by the Company of the adoption of the Rights Agreement. The term â€œbeneficial ownershipâ€ is defined in the Rights Agreement and includes, among other things, certain derivative arrangements. In general, each Right entitles its registered holder, subject to the terms of the Rights Agreement, to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (â€œPreferred Stockâ€), of the Company at an exercise price of $27.00 per Right, subject to adjustment under certain circumstances (the â€œPurchase Priceâ€). The Rights will become exercisable if (among other things) any person or group acquires 12.5% or more of the outstanding common stock, including through derivatives agreements, without the approval of the Board (an â€œAcquiring Personâ€). If a person or group becomes an Acquiring Person, all holders of Rights except the Acquiring Person or any associate or affiliate thereof may, upon exercise of a Right, purchase for the Purchase Price shares of Common Stock with a market value of two times the Purchase Price, based on the market price of the Common Stock prior to such acquisition. If the Company is acquired in a merger or similar transaction after an Acquiring Person becomes such, all holders of Rights except the Acquiring Person or any associate or affiliate thereof may, upon exercise of a Right, purchase for the Purchase Price shares of the acquiring company with a market value of two times the Purchase Price, based on the market price of the acquiring companyâ€™s stock prior to such transaction. Any Rights held by an Acquiring Person will be void and may not be exercised. The Rights will expire on the earliest to occur of (a) the close of business on December 2, 2025, (b) the time at which the Rights are redeemed by the Company (as provided in the Rights Agreement), or (c) the time at which the Rights are exchanged by the Company (as provided in the Rights Agreement). There was no impact to the Companyâ€™s current period financial statements from adopting this Rights Agreement. In connection with the adoption of the Rights Agreement, the Board adopted Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company (the â€œArticles of Amendmentâ€), which designates the rights, preferences, and privileges of 100,000 shares of a new series of the Companyâ€™s preferred stock, par value $0.001 per share, designated as Series A Junior Participating Preferred Stock. The Company filed the Articles of Amendment with the Secretary of State of the State of Florida on December 3, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1 Income Taxes 9 Months Ended Dec. 31, 2024 Income Tax Disclosure [Abstract] Â Income Taxes Income Taxes For the three months ended DecemberÂ 31, 2024 and 2023, the Company recorded an income tax provision of approximately $0.5 million and an income tax benefit of approximately $0.6 million, respectively, and for the nine months ended DecemberÂ 31, 2024 and 2023, the Company recorded an income tax provision of $22 thousand and an income tax benefit of $0.3 million, respectively. The increase in the income tax provision for the nine months ended DecemberÂ 31, 2024 is related to the cancellation of the former CEOâ€™s performance stock units resulting in additional $8.7Â million of increased income during the year. The effective tax rate for the three months ended DecemberÂ 31, 2024 was approximately (192.1)%, compared to approximately 23.4% for the three months ended DecemberÂ 31, 2023, and the effective tax rate for the nine months ended DecemberÂ 31, 2024 was approximately 0.4%, compared to approximately 12.4% for the nine months ended DecemberÂ 31, 2023. The projected full-year effective tax rate used for purposes of the income tax provision for the three and nine months ended DecemberÂ 31, 2024 reflects the $1.8Â million impact of a favorable permanent difference associated with the cancellation of the former CEOâ€™s performance restricted shares. No tax benefit was recorded for the original compensation expense due to expected limitation under Internal Revenue Code Section 162 (m) and therefore, there is no tax benefit to reverse upon cancellation of the stock. The impact of this favorable permanent difference is partially offset by the impacts of stock-based compensation recognized for book and tax purposes.Under Internal Revenue Code Section 382, if a corporation undergoes an â€œownership changeâ€, the corporationâ€™s ability to use its pre-change net operating loss and tax credit carryforwards to offset its post-change income and tax liabilities may be limited. Generally, an ownership change occurs when the equity ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporationâ€™s stock increases its ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years). On AprilÂ 3, 2023, 100% of the issued and outstanding stock of PetCareRx was acquired by the Company. The merger triggered an ownership change of PetCareRx within the meaning of Section 382. As a result of the acquisition, the Company performed a Section 382 analysis to determine if the net operating losses carried forward would have a utilization limitation. Any limitation could result in the expiration of a portion of the federal net operating loss carryforward before utilization, which would reduce the Company's gross deferred tax assets. As of AprilÂ 3, 2023, and prior to the acquisition, PetCareRx had approximately $96.0Â million of net operating losses and $1.9Â million of disallowed interest expense. The results of the Section 382 analysis determined the net operating losses and disallowed interest expense in total, would be limited and reduced to approximately $14.5Â million. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1 Related Party Transaction 9 Months Ended Dec. 31, 2024 Related Party Transactions [Abstract] Â Related Party Transaction Related Party TransactionOn September 29, 2024 the Company entered into a master services agreement with Fabric, Inc (â€œFabricâ€), a privately-held company. Under this agreement, Fabric will provide cloud-based product services to the Company with a one-year term with auto-renewal unless either party provides notice at least 90 days in advance. Per the terms of the agreement, the Company will pay Fabric $115,000 the first year and $100,000 for each potential year thereafter with potential changes in the amounts paid based on actual usage of Fabricâ€™s services. There was no expense related to this contract for the three and nine months ended DecemberÂ 31, 2024. There was no amount owed by the Company to Fabric as of December 31, 2024. Sandra Campos, Chief Executive Officer and President of the Company, is an equity-holder in Fabric and serves on the Board of Directors of Fabric. This transaction was reviewed and approved by the Companyâ€™s Audit Committee of the Board of Directors in accordance with the Companyâ€™s related party transaction policy. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (707) $ (2,027) $ 5,373 $ (2,448) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1 Insider Trading Arrangements 3 Months Ended Dec. 31, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag

Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1 Summary of Significant Accounting Policies (Policies) 9 Months Ended Dec. 31, 2024 Accounting Policies [Abstract] Â Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at DecemberÂ 31, 2024, the Statements of Operations for the three and nine months ended DecemberÂ 31, 2024 and 2023, and Cash Flows for the nine months ended DecemberÂ 31, 2024 and 2023. The results of operations for the three and nine months ended DecemberÂ 31, 2024 are not necessarily indicative of the operating results expected for the fiscal year ending MarchÂ 31, 2025. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in our 2024 Form 10-K. The unaudited condensed consolidated financial statements include the accounts of PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Fair Value of Financial Instruments The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments. Deferred Revenue Deferred revenue is recorded when payments are received or due in advance of performing our service obligations and revenue is recognized over the service period. Deferred revenue represents prepayments of PetPlus memberships with PetCareRx, Inc. (â€œPetCareRxâ€). The total deferred revenue as of DecemberÂ 31, 2024 and MarchÂ 31, 2024 for these memberships was $1.2 million and $2.6 million, respectively. Memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The membership fee is an annual charge and automatically renews one year from the initial enrollment date. The Company generally recognizes the revenue ratably over the term of the membership. Long-lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset. Goodwill Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. The Company is required to assess goodwill and other indefinite-lived intangible assets for impairment annually, or more frequently if circumstances indicate impairment may have occurred. Goodwill was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that goodwill was impaired as of December 31, 2024. The Company performs its annual impairment assessment in the fourth fiscal quarter of each year. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. Intangible Assets The Companyâ€™s other indefinite-lived intangible assets are primarily made up of a trade name which was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that the other indefinite-lived assets were impaired as of December 31, 2024. Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company's consolidated financial position, results of operations, or cash flows. In November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Update 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". This Update applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in this Update revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in this Update do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Update should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this Update.In December 2023, the FASB issued Update 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This Update applies to all entities that are subject to Topic 740. The amendments in this Update revise income tax disclosures primarily related to the rate reconciliation and income taxes paid information as well as the effectiveness of certain other income tax disclosures. The Update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Update should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the impact of adopting this Update. X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation and , used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Also consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements. + ReferencesNo definition available. + Details Name: pets_BasisOfPresentationAndConsolidationPolicyTextBlock Namespace Prefix: pets_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 + Details Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition (Tables) 9 Months Ended Dec. 31, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Deferred Revenue As shown in the following table, under the PetPlus program, the Company recognized $1.0 million and $3.7 million of previously deferred annual membership fees in the three and nine months ended DecemberÂ 31, 2024, and had $1.2 million of deferred revenue as of DecemberÂ 31, 2024. (amounts in millions)Deferred revenue, March 31, 2024$2.6Â Deferred memberships fees and others received1.1Â Deferred membership fee revenue and others recognized (1.5)Deferred revenue, June 30, 20242.1Â Deferred memberships fees and others received0.7Â Deferred membership fee revenue and others recognized (1.2)Deferred revenue, September 30, 20241.6Â Deferred memberships fees and others received0.5Â Deferred membership fee revenue and others recognized (1.0)Deferred revenue, December 31, 2024$1.2Â Schedule of Disaggregation of Revenue The following table illustrates sales in those categories:Three Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$ % Reorder sales$45,076Â 85.1Â %$54,067Â 82.8Â %$(8,991)(16.6)%New order sales6,075Â 11.5Â %8,803Â 13.5Â %(2,728)(31.0)%Membership fees1,833Â 3.5Â %2,447Â 3.7Â %(614)(25.1)%Total net sales$52,984Â 100.0Â %$65,317Â 100.0Â %$(12,333)(18.9)%Nine Months Ended December 31,Increase (Decrease)Net Sales (in thousands)2024%2023%$ % Reorder sales$149,367Â 82.7Â %$174,250Â 81.3Â %$(24,883)(14.3)%New order sales24,913Â 13.8Â %33,054Â 15.4Â %(8,141)(24.6)%Membership fees6,226Â 3.4Â %7,256Â 3.4Â %(1,030)(14.2)%Total net sales$180,506Â 100.0Â %$214,560Â 100.0Â %$(34,054)(15.9)% X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1 Net (Loss) Income Per Share (Tables) 9 Months Ended Dec. 31, 2024 Earnings Per Share [Abstract] Â Schedule of Earnings Per Share The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for share and per share amounts):Three Months Ended December 31,Nine Months EndedDecember 31,2024202320242023Net (loss) income (numerator):Â Â Net (loss) income(707)(2,027)$5,373Â $(2,448)Shares (denominator):Â Â Weighted average number of common shares outstanding used in basic computation20,634,651Â 20,425,282Â 20,581,913Â 20,380,262Â Common shares issuable upon vesting of restricted stockâ€"Â â€"Â 395,222Â â€"Â Common shares issuable upon conversion of preferred sharesâ€"Â â€"Â 10,125Â â€"Â Shares used in diluted computation20,634,651Â 20,425,282Â 20,987,260Â 20,380,262Â Net (loss) income per common share:Basic(0.03)(0.10)$0.26Â $(0.12)Diluted$(0.03)(0.10)0.26Â $(0.12) X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stock-Based Compensation (Tables) 9 Months Ended Dec. 31, 2024 Share-

Based Payment Arrangement [Abstract] Â Schedule of Restricted Stock Awards Restricted stock award activity in the nine months ended December 31, 2024 was as follows:Â 2015 Director Plan Â 2016 Employee Plan Â 2022 Employee Plan Â Total Â Weighted-Average Grant Date Fair Value Non-vested restricted stock outstanding at March 31, 202423,707Â 605,343Â 74,076Â 703,126Â $19.39Â Granted and issuedâ€"Â â€"Â â€"Â â€"Â $â€"Â Vested(13,666)(60,540)(46,742)(120,948)$22.10Â Forfeitedâ€"Â (533,641)(27,334)(560,975)$18.71Â Balance at December 31, 202410,041Â 11,162Â â€"Â 21,203Â $21.96Â Schedule of RSU Activity For the nine months ended DecemberÂ 31, 2024, RSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:RSUsWeighted-AverageÂ Grant DateÂ Fair Value Per RSUBalance at March 31, 202485,080$12.75Â Granted 1,037,258$4.04Â Vested and issued(66,739)$8.38Â Forfeited(90,418)$5.84Â Balance at December 31, 2024965,181$4.33Â Schedule of PSU Activity For the nine months ended DecemberÂ 31, 2024, PSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:PSUsWeighted-AverageÂ Grant DateÂ Fair Value Per PSUBalance at March 31, 202412,000$10.48Â Granted â€"$â€"Â Vested and issued(2,000)$13.95Â Forfeited(10,000)$9.79Â Balance at December 31, 2024â€"$â€"Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1 Intangible and Other Assets, Net (Tables) 9 Months Ended Dec. 31, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Intangible Assets and Other Assets Intangible assets and other assets, net consisted of the following (in thousands):Useful LifeGross ValueAccumulated AmortizationNet Carrying ValueWeighted Average Remaining Useful Life (Years)December 31, 2024Intangible AssetsToll-free telephone numberIndefinite$375Â $â€"Â $375Â IndefiniteInternet domain namesIndefinite485Â â€"Â 485Â IndefiniteTrade Names - PetCareRxIndefinite2,600Â â€"Â 2,600Â IndefiniteCustomer Relationships -PetCareRx7 years6,700Â (1,675)5,025Â 5.25 yearsDeveloped Technology - PetCareRx3 years3,000Â (1,750)1,250Â 1.25 years$13,160Â $(3,425)$9,735Â Other AssetsMinority interest investment in VetsterN/A5,300Â â€"Â 5,300Â N/ABalance December 31, 2024$18,460Â $(3,425)$15,035Â March 31, 2024Intangible AssetsToll-free telephone numberIndefinite$375Â $â€"Â $375Â IndefiniteInternet domain namesIndefinite485Â â€"Â 485Â IndefiniteTrade Names - PetCareRxIndefinite2,600Â 2,600Â IndefiniteCustomer Relationships -PetCareRx7 years6,700Â (957)$5,743Â 6 yearsDeveloped Technology - PetCareRx3 years3,000Â (1,000)$2,000Â 2 years$13,160Â $(1,957)$11,203Â Other AssetsMinority interest investment in VetsterN/A5,300Â â€"Â 5,300Â N/ABalance March 31, 2024$18,460Â $(1,957)$16,503Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1 Changes in Shareholdersâ€™ Equity (Tables) 9 Months Ended Dec. 31, 2024 Equity [Abstract] Â Schedule of Changes in Shareholders' Equity Changes in Shareholdersâ€™ Equity for the three and nine months ended DecemberÂ 31, 2024 is summarized below (in thousands):Common StockAdditionalPaid-InCapitalRetainedEarningsBeginning balance at March 31, 2024:$21Â $25,146Â $71,555Â Stock based compensation (reversal) â€"Â (8,204)â€"Â Dividends forfeitedâ€"Â â€"Â 1,250Â Net incomeâ€"Â â€"Â 3,754Â Ending balance at June 30, 2024:$21Â $16,942Â $76,559Â Stock based compensation expenseâ€"Â 573Â â€"Â Dividends forfeitedâ€"Â â€"Â 4Â Net incomeâ€"Â â€"Â 2,326Â Ending balance at September 30, 2024:$21Â $17,515Â $78,889Â Stock based compensation expenseâ€"Â 452Â â€"Â Dividends forfeitedâ€"Â â€"Â 5Â Net lossâ€"Â â€"Â (707)Ending balance at December 31, 2024:$21Â $17,967Â $78,187Â Changes in Shareholdersâ€™ Equity for the three and nine months ended DecemberÂ 31, 2023 is summarized below (in thousands):Common StockAdditionalPaid-InCapitalRetainedEarningsBeginning balance at March 31, 2023:$21Â $18,277Â $91,659Â Stock based compensation expenseâ€"Â 1,760Â â€"Â Dividends declaredâ€"Â â€"Â (6,346)Net lossâ€"Â â€"Â (1,136)Ending balance at June 30, 2023:$21Â $20,037Â $84,177Â Stock based compensation expenseâ€"Â 1,728Â â€"Â Dividends declaredâ€"Â â€"Â (6,308)Net incomeâ€"Â â€"Â 715Â Ending balance at September 30, 2023:$21Â $21,765Â $78,584Â Stock based compensation expenseâ€"Â 1,708Â â€"Â Net lossâ€"Â â€"Â (2,027)Ending balance at December 31, 2023:$21Â $23,473Â $76,557Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_ScheduleOfStockholdersEquityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1 Summary of Significant Accounting Policies (Details) 9 Months Ended Dec. 31, 2024 USD ($) reportingUnit Mar. 31, 2024 USD ($) Accounting Policies [Abstract] Â Â Deferred revenue $ 1,156,000 $ 2,603,000 Impairment of long lived assets $ 0 Â Number of reporting units | reportingUnit 1 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. + ReferencesNo definition available. + Details Name: us-gaap_NumberOfReportingUnits Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition - Narrative (Details) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 USD ($) performanceObligation model Dec. 31, 2023 USD ($) Dec. 31, 2024 USD ($) performanceObligation warehouse model Dec. 31, 2023 USD ($) Sep. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Number of warehouses | warehouse Â Â 2 Â Â Â Â Number of performance obligations | performanceObligation 1 Â 1 Â Â Â Â Revenue recognition period membership | model 2 Â 2 Â Â Â Â Deferred revenue $ 1,156 Â $ 1,156 Â Â Â $ 2,603 Membership fees earned $ 52,984 $ 65,317 $ 180,506 $ 214,560 Â Â Â Membership Customers Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Annual membership fees renewal period 1 year Â 1 year Â Â Â Â Revenue recognition period 1 year Â 1 year Â Â Â Â Deferred memberships fees revenue and others recognized $ 1,000 Â $ 3,700 Â Â Â Â Deferred revenue 1,200 Â 1,200 Â $ 1,600 $ 2,100 $ 2,600 Membership Customers | Partner Program Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Membership fees earned 900 700 2,800 2,100 Â Â Â Membership fees Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Membership fees earned 1,833 2,447 6,226 7,256 Â Â Â Reorder sales Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Membership fees earned 45,076 54,067 149,367 174,250 Â Â Â Reorder sales | Previously Reported Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Membership fees earned Â 57,700 Â 188,100 Â Â Â New order sales Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Membership fees earned $ 6,075 8,803 $ 24,913 33,054 Â Â Â New order sales | Previously Reported Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Membership fees earned Â $ 5,200 Â $ 19,200 Â Â Â Minimum Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Cash settlement period Â Â 2 days Â Â Â Â Maximum Â Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Â Cash settlement period Â Â 3 days Â Â Â Â X - DefinitionConcentration Risk, Cash Settlement Period For Sales + ReferencesNo definition available. + Details Name: pets_ConcentrationRiskCashSettlementPeriodForSales Namespace Prefix: pets_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionContract with Customer, Liability, Revenue Recognized, Excluding Opening Balance + ReferencesNo definition available. + Details Name: pets_ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContract With Customer, Renewal Period + ReferencesNo definition available. + Details Name: pets_ContractWithCustomerRenewalPeriod Namespace Prefix: pets_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionContract With Customer, Revenue Recognition, Period + ReferencesNo definition available. + Details Name: pets_ContractWithCustomerRevenueRecognitionPeriod Namespace Prefix: pets_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Warehouses + ReferencesNo definition available. + Details Name: pets_NumberOfWarehouses Namespace Prefix: pets_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRevenue From Contract With Customer, Number Of Membership Models + ReferencesNo definition available. + Details Name: pets_RevenueFromContractWithCustomerNumberOfMembershipModels Namespace Prefix: pets_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionRevenue From Contract With Customer, Number Of Performance Obligations + ReferencesNo definition available. + Details Name: pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations Namespace Prefix: pets_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_MajorCustomersAxis=pets_MembershipCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=pets_PartnerProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=pets_MembershipFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=pets_ReorderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=pets_NewOrderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition - Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands 3 Months Ended Dec. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 Contract With Customer, Liability, Current [Roll Forward] Â Â Â Deferred revenue, beginning balance Â Â $ 2,603 Deferred revenue, ending balance $ 1,156 Â Â Membership Customers Â Â Â Contract With Customer, Liability, Current [Roll Forward] Â Â Â Deferred revenue, beginning balance 1,600 $ 2,100 2,600 Deferred memberships fees and others received 500 700 1,100 Deferred membership fee revenue and others recognized (1,000) (1,200) (1,500) Deferred revenue, ending balance $ 1,200 $ 1,600 $ 2,100 X - DefinitionContract With Customer, Liability, Current + ReferencesNo definition available. + Details Name: pets_ContractWithCustomerLiabilityCurrentRollForward Namespace Prefix: pets_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContract With Customer Liability, Increase For Deferred Fees Received + ReferencesNo definition available. + Details Name: pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_MajorCustomersAxis=pets_MembershipCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Net sales $ 52,984 $ 65,317 $ 180,506 $ 214,560 Sales, percentage 100.00% 100.00% 100.00% 100.00% Sales, variance $ (12,333) Â $ (34,054) Â Sales, variance, percentage (18.90%) Â (15.90%) Â Reorder sales Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Net sales $ 45,076 $ 54,067 $ 149,367 $ 174,250 Sales, percentage 85.10% 82.80% 82.70% 81.30% Sales, variance $ (8,991) Â $ (24,883) Â Sales, variance, percentage (16.60%) Â (14.30%) Â New order sales Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Net sales $ 6,075 $ 8,803 $ 24,913 $ 33,054 Sales, percentage 11.50% 13.50% 13.80% 15.40% Sales, variance $ (2,728) Â $ (8,141) Â Sales, variance, percentage (31.00%) Â (24.60%) Â Membership fees Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Net sales $ 1,833 $ 2,447 $ 6,226 $ 7,256 Sales, percentage 3.50% 3.70% 3.40% 3.40% Sales, variance $ (614) Â $ (1,030) Â Sales, variance, percentage (25.10%) Â (14.20%) Â X - DefinitionPercentage of revenue from the specified category to the total revenue during the period. + ReferencesNo definition available. + Details Name: pets_RevenueFromContractWithCustomerPercentage Namespace Prefix: pets_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of changes in revenue in current period comparing to the same period in the previous year. + ReferencesNo definition available. + Details Name: pets_RevenueFromContractWithCustomerVariance Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage of changes in revenue in current period comparing to the same period in the previous year. + ReferencesNo definition available. + Details Name: pets_RevenueFromContractWithCustomerVariancePercentage Namespace Prefix: pets_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_MajorCustomersAxis=pets_ReorderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=pets_NewOrderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=pets_MembershipFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1 Net (Loss) Income Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Net (loss) income (numerator): Â Â Â Â Net income (loss) $ (707) $ (2,027) $ 5,373 $ (2,448) Shares (denominator): Â Â Â Â Weighted average number of common shares outstanding used in basic computation (in shares) 20,634,651 20,425,282 20,581,913 20,380,262 Common shares issuable upon vesting of restricted stock (in shares) 0 0 395,222 0 Common shares issuable upon conversion of preferred shares (in shares) 0 0 10,125 0 Shares used in diluted computation (in shares) 20,634,651 20,425,282 20,987,260 20,380,262 Net (loss) income per common share: Â Â Â Â Basic (in dollars per share) $ (0.03) $ (0.10) $ 0.26 $ (0.12) Diluted (in dollars per share) $ (0.03) $ (0.10) $ 0.26 $ (0.12) X - DefinitionNet Income Per Common Share, Basic And Diluted + ReferencesNo definition available. + Details Name: pets_NetIncomePerCommonShareBasicAndDilutedAbstract Namespace Prefix: pets_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1 Net (Loss) Income Per Share - Narrative (Details) - shares 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Shares Issuable Upon Vesting of Restricted Stock Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities (in shares) 986,378 825,825 519,852 837,084 Convertible Preferred Stock Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities (in shares) 10,125 10,125 0 10,125 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pets_SharesIssuableUponVestingOfRestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Aug. 31, 2025 Sep. 27, 2024 Aug. 31, 2024 Jun. 30, 2024 May 16, 2024 Apr. 29, 2024 Apr. 30, 2024 Jun. 30, 2023 Aug. 31, 2022 Aug. 31, 2021 Dec. 31, 2024 Jun. 30, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Aug. 08, 2024 Mar. 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share based compensation Â Â Â Â Â Â Â Â Â Â Â Â Â $ (7,179) $ 5,196 Â Â Common stock, par value (in dollars per share) Â Â Â Â Â Â Â Â Â Â $ 0.001 Â Â $ 0.001 Â Â $ 0.001 2016 Employee Plan and 2015 Director Plan Â Â Â Â Â Â Â Â Â Â

Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share based compensation Â Â Â Â Â Â Â Â Â Â $ 500 Â $ 1,700 $ (7,200) 5,200 Â Â 2024 Omnibus Incentive Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, capital shares reserved for future issuance (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 850,000 Â 2024 Inducement Incentive Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Common stock, capital shares reserved for future issuance (in shares) Â 350,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Forfeited (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 560,975 Â Â Vested (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 120,948 Â Â Non-vested restricted shares issued and outstanding (in shares) Â Â Â Â Â Â Â Â Â Â 21,203 Â Â 21,203 Â Â 703,126 Compensation (benefit) expense Â Â Â Â Â Â Â Â Â Â $ 100 Â $ 1,600 $ (8,200) $ 5,000 Â Â Restricted Stock | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3 years Â Â Â Restricted Stock | Minimum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 year Â Â Â Restricted Stock | 2016 Employee Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares issued under stock compensation plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 423,619 Â Â Forfeited (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 533,641 Â Â Vested (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 60,540 Â Â Non-vested restricted shares issued and outstanding (in shares) Â Â Â Â Â Â Â Â Â Â 11,162 Â Â 11,162 Â Â 605,343 Restricted Stock | 2016 Employee Plan | Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 90,000 Â Â Â Â Â Â Vested (in shares) Â Â Â Â Â Â 30,000 Â Â Â Â Â Â Â Â Â Â Restricted Stock | 2016 Employee Plan | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â 13,000 Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â Â 3 years Â Â Â Â Â Â Â Â Restricted Stock | 2022 Employee Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares issued under stock compensation plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 55,074 Â Â Forfeited (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 27,334 Â Â Vested (in shares) Â Â Â Â Â Â Â Â Â Â Â Â 46,742 Â Â Â Non-vested restricted shares issued and outstanding (in shares) Â Â Â Â Â Â Â Â Â Â 0 Â Â 0 Â Â 74,076 Restricted Stock | 2015 Director Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares issued under stock compensation plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 257,567 Â Â Â Forfeited (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Vested (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 13,666 Â Â Â Non-vested restricted shares issued and outstanding (in shares) Â Â Â Â Â Â Â Â Â Â 10,041 Â Â 10,041 Â Â 23,707 Restricted Stock | 2016 Employee Plan and 2015 Director Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Non-vested restricted shares issued and outstanding (in shares) Â Â Â Â Â Â Â Â Â Â 21,203 Â 728,446 21,203 728,446 Â Â Restricted Stock | The 2022 Employee Equity Compensation Restricted Stock Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Issued shares (in shares) Â Â Â Â Â 483,092 Â Â Â Â Â Â Â Â Â Â Â Restricted Stock | 2024 Incentive Plan | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â 3 years Â Â Â Â Â Â Â Â Â Â Â PSUs Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Forfeited (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 10,000 Â Â Â Compensation (benefit) expense Â Â Â Â Â Â Â Â Â Â $ 0 Â $ 20 $ (36) $ 44 Â Â Total grant-date fair value Â Â Â Â Â Â Â Â Â Â 0 Â 0 0 100 Â Â PSUs | Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share based compensation Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ (8,700) Â Â Â PSUs | Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 year Â Â Â PSUs | Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3 years Â Â Â PSUs | 2016 Employee Plan | Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Forfeited (in shares) Â Â Â Â Â Â 510,000 Â Â Â Â Â Â Â Â Â Â PSUs | 2022 Employee Plan | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â 8,000 Â Â Â Â Â Â Â Â Â Â PSUs | 2015 Director Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares issued under stock compensation plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2,000 Â Â Â RSUs Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,037,258 Â Â Â Forfeited (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 90,418 Â Â Â Compensation (benefit) expense Â Â Â Â Â Â Â Â Â Â 400 Â 100 $ 1,100 200 Â Â Total grant-date fair value Â Â Â Â Â Â Â Â Â Â $ 200 Â $ 0 $ 4,200 $ 1,100 Â Â RSUs | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share based compensation Â Â Â Â Â Â Â Â Â Â $ 200 Â Â Â Â Issued shares (in shares) Â Â Â Â 74,850 Â Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3 years Â Â Â RSUs | Minimum Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1 year Â Â Â RSUs | Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vested (in shares) Â Â Â 14,970 Â Â Â Â Â Â Â Â Â Â Â RSUs | Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vested (in shares) Â Â 22,455 Â Â Â Â Â Â Â Â Â Â Â Â RSUs | Share-Based Payment Arrangement, Tranche Three | Forecast Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vested (in shares) 37,425 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2016 Employee Plan | Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share based compensation Â Â Â Â Â Â Â Â Â Â $ 100 Â Â Reversal of stock based compensation Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 8,800 Â Â Â Vested (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â 30,000 Â Â Â RSUs | 2016 Employee Plan | Share-Based Payment Arrangement, Tranche One | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â RSUs | 2016 Employee Plan | Share-Based Payment Arrangement, Tranche Two | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â RSUs | 2016 Employee Plan | Share-Based Payment Arrangement, Tranche Three | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 569,365 Â Â Â RSUs | 2022 Employee Plan | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â 11,750 Â Â Â Â Â Â Â Â Â Â Vesting period Â Â Â Â Â Â Â Â 3 years Â Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Share-Based Payment Arrangement, Tranche One | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Share-Based Payment Arrangement, Tranche One | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Share-Based Payment Arrangement, Tranche Two | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Share-Based Payment Arrangement, Tranche Two | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Share-Based Payment Arrangement, Tranche Three | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Share-Based Payment Arrangement, Tranche Three | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â Â Â Â Â 33.33% Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Fiscal Year 2023 | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â 3,750 Â Â Â Â Â Â Â Â Â Â RSUs | 2022 Employee Plan | Fiscal Year 2024 | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 8,000 Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2015 Director Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 22,316 Â Â Â RSUs | 2024 Omnibus Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 83,500 Â Â Â RSUs | 2024 Inducement Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 290,000 Â Â Â RSUs | 2024 Incentive Plan | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â 250,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Vesting period Â 3 years Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2024 Incentive Plan | Share-Based Payment Arrangement, Tranche One | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â 33.33% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2024 Incentive Plan | Share-Based Payment Arrangement, Tranche Two | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â 33.33% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RSUs | 2024 Incentive Plan | Share-Based Payment Arrangement, Tranche Three | Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial grant percentage based on performance targets Â 33.33% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Performance Restricted Stock | 2016 Employee Plan | Chief Executive Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â Â 510,000 Â Â Â Â Â Â Â Forfeited (in shares) Â Â Â Â Â Â 510,000 Â Â Â Â Â Â Â Performance Restricted Stock | 2016 Employee Plan | Former Chief Financial Officer Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issued shares (in shares) Â Â Â Â Â Â Â Â 3,000 Â Â Â Â Â Â Â Â Â X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Grant Date Fair Value + ReferencesNo definition available. + Details Name: pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedGrantDateFairValue Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare-Based Payment Arrangement Expense (Reversal Of Expense), Noncash + ReferencesNo definition available. + Details Name: pets_ShareBasedPaymentArrangementExpenseReversalOfExpenseNoncash Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=pets_EmployeeAndDirectorEquityCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_A2024OmnibusIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_A2024InducementIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=pets_FormerChiefFinancialOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_IncentivePlan2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=pets_FiscalYear2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=pets_FiscalYear2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_A2024OmnibusPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_A2024InducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=pets_PerformanceRestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stock-Based Compensation - Rollforward of Restricted Stock Awards (Details) - Restricted Stock 9 Months Ended Dec. 31, 2024 $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Non-vested beginning balance (in shares) 703,126 Granted and issued (in shares) 0 Vested (in shares) (120,948) Forfeited (in shares) (560,975) Non-vested ending balance (in shares) 21,203 Weighted-Average Grant Date Fair Value Â Non-vested beginning balance (in dollars per share) | $ / shares $ 19.39 Granted and issued (in dollars per share) | $ / shares 0 Vested (in dollars per share) | $ / shares 22.10 Forfeited (in dollars per share) | $ / shares 18.71 Non-vested ending balance (in dollars per share) | $ / shares $ 21.96 2015 Director Plan Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Non-vested beginning balance (in shares) 23,707 Granted and issued (in shares) 0 Vested (in shares) (13,666) Forfeited (in shares) 0 Non-vested ending balance (in shares) 10,041 2016 Employee Plan Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Non-vested beginning balance (in shares) 605,343 Granted and issued (in shares) 0 Vested (in shares) (60,540) Forfeited (in shares) (533,641) Non-vested ending balance (in shares) 11,162 2022 Employee Plan Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Non-vested beginning balance (in shares) 74,076 Granted and issued (in shares) 0 Vested (in shares) (46,742) Forfeited (in shares) (27,334) Non-vested ending balance (in shares) 0 X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period + ReferencesNo definition available. + Details Name: pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAndIssuedInPeriod Namespace Prefix: pets_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period, Weighted Average Grant Date Fair value + ReferencesNo definition available. + Details Name: pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAndIssuedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: pets_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pets_A2022EmployeePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1 Stock-Based Compensation - Rollforward of RSU and PSU Activity (Details) - $ / shares 9 Months Ended Dec. 31, 2024 Mar. 31, 2024 RSUs Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Â Beginning balance (in shares) 965,181 85,080 Granted (in shares) 1,037,258 Â Vested and issued (in shares) (66,739) Â Forfeited (in shares) (90,418) Â Ending balance (in shares) 965,181 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Â Â Beginning Balance (in dollars per share) $ 12.75 Â Granted (in dollars per share) 4.04 Â Vested and issued (in dollars per share) 8.38 Â Forfeited (in dollars per share) 5.84 Â Ending Balance (in dollars per share) $ 4.33 Â PSUs Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Â Â Beginning balance (in shares) 0 12,000 Granted (in shares) 0 Â Vested and issued (in shares) (2,000) Â Forfeited (in shares) (10,000) Â Ending balance (in shares) 0 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Â Â Beginning Balance (in dollars per share) $ 10.48 Â Granted (in dollars per share) 0 Â Vested and issued (in dollars per share) 13.95 Â Forfeited (in dollars per share) 9.79 Â Ending Balance (in dollars per share) $ 0 Â X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value + ReferencesNo definition available. + Details Name: pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue Namespace Prefix: pets_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period + ReferencesNo definition available. + Details Name: pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod Namespace Prefix: pets_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value + ReferencesNo definition available. + Details Name: pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: pets_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value (Details) - USD ($) $ in Thousands Dec. 31, 2024 Mar. 31, 2024 Fair Value Disclosures [Abstract] Â Â Cash and cash equivalents $ 50,101 $ 55,296 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1 Intangible and Other Assets, Net - Schedule of Intangible Assets and Other Assets (Details) - USD ($) $ in Thousands 9 Months Ended 12 Months Ended Dec. 31, 2024 Mar. 31, 2024 Oct. 03, 2023 Gross Value Â Â Â Intangibles $ 13,160 $ 13,160 Â Accumulated Amortization (3,425) (1,957) Â Net Carrying Value Â Â Â Intangibles 9,735 11,203 Â Other Assets Â Â Â Minority interest investment in Vetster Â Â $ 5,300 Intangibles and Other Assets Â Â Â Intangible, Gross Value 18,460 18,460 Â Accumulated Amortization (3,425) (1,957) Â Intangible, Net Carrying Value 15,035 16,503 Â Partnership Agreement with Vetster Â Â Â Other Assets Â Â Â Minority interest investment in Vetster 5,300 5,300 Â Minority interest investment in Vetster $ 5,300 $ 5,300 Â Customer Relationships -PetCareRx Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Useful Life 7 years 7 years Â Gross Value Â Â Â Finite-lived intangibles $ 6,700 $ 6,700 Â Accumulated Amortization (1,675) (957) Â Net Carrying Value Â Â Â Finite-lived intangibles $ 5,025 $ 5,743 Â Weighted Average Remaining Useful Life (Years) 5 years 3 months 6 years Â Developed Technology - PetCareRx Â Â Â Finite-Lived Intangible Assets [Line Items] Â Â Â Useful Life 3 years 3 years Â Gross Value Â Â Â Finite-lived intangibles $ 3,000 $ 3,000 Â Accumulated Amortization (1,750) (1,000) Â Net Carrying Value Â Â Â Finite-lived intangibles $ 1,250 $ 2,000 Â Weighted Average Remaining Useful Life (Years) 1 year 3 months 2 years Â Toll-free telephone number Â Â Â Gross Value Â Â Â Indefinite-lived intangibles $ 375 $ 375 Â Net Carrying Value Â Â Â Indefinite-lived intangibles 375 375 Â Internet domain names Â Â Â Gross Value Â Â Â Indefinite-lived intangibles 485 485 Â Net Carrying Value Â Â Â Indefinite-lived intangibles 485 485 Â Trade Names - PetCareRx Â Â Â Gross Value Â Â Â Indefinite-lived intangibles 2,600 2,600 Â Net Carrying Value Â Â Â Indefinite-lived intangibles $ 2,600 $ 2,600 Â X - DefinitionIntangible And Other Assets + ReferencesNo definition available. + Details Name: pets_IntangibleAndOtherAssets Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIntangible And Other Assets, Gross + ReferencesNo definition available. + Details Name: pets_IntangibleAndOtherAssetsGross Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIntangibles and Other Assets + ReferencesNo definition available. + Details Name: pets_IntangiblesAndOtherAssetsAbstract Namespace Prefix: pets_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIntangibles And Other Assets, Accumulated Amortization + ReferencesNo definition available. + Details Name: pets_IntangiblesAndOtherAssetsAccumulatedAmortization Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=pets_PartnershipAgreementWithVetsterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pets_TollFreeTelephoneNumberMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1 Intangible and Other Assets, Net - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Oct. 03, 2023 Apr. 19, 2022 Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Acquired Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Â Amortization expense Â Â $ 0.5 $ 0.5 $ 1.5 $ 1.5 Term of agreement Â 3 years Â Â Â Â Payments to acquire equity method investments $ 0.3 $ 5.0 Â Â Â Â Minority interest investment in Vetster $ 5.3 Â Â Â Â Â Vetster Inc Â Â Â Â Â Â Acquired Finite-Lived Intangible Assets [Line Items] Â Â Â Â Â Â Equity method investment, ownership percentage 4.80% 5.00% Â Â Â Â X - DefinitionRepresents term of agreement. + ReferencesNo definition available. + Details Name: pets_TermOfAgreement Namespace Prefix: pets_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pets_VetsterIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1 Changes in Shareholdersâ€™ Equity - Schedule of Changes in Shareholders' Equity (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Dec. 31, 2024 Dec. 31, 2023 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance Â Â $ 96,731 Â Â Â $ 96,731 Â Net income (loss) $ (707) Â Â $ (2,027) Â Â 5,373 $ (2,448) Ending balance 96,184 Â Â Â Â Â 96,184 Â Common Stock Â Â Â Â Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance 21 $ 21 21 21 $ 21 $ 21 21 21 Ending balance 21 21 21 21 21 21 21 21 Additional Paid-In Capital Â Â Â Â Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance 17,515 16,942 25,146 21,765 20,037 18,277 25,146 18,277 Stock based compensation (reversal) expenses 452 573 (8,204) 1,708 1,728 1,760 Â Â Ending balance 17,967 17,515 16,942 23,473 21,765 20,037 17,967 23,473 Retained Earnings Â Â Â Â Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance 78,889 76,559 71,555 78,584 84,177 91,659 71,555 91,659 Dividends forfeited 5 4 1,250 Â Â Â Â Â Dividends declared Â Â Â Â (6,308) (6,346) Â Â Net income (loss) (707) 2,326 3,754 (2,027) 715 (1,136) Â Â Ending balance $ 78,187 $ 78,889 $ 76,559 $ 76,557 $ 78,584 $ 84,177 $ 78,187 $ 76,557 X - DefinitionDividends Forfeited + ReferencesNo definition available. + Details Name: pets_DividendsForfeited Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-

S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1 Changes in Shareholdersâ€™ Equity - Narrative (Details) - $ / shares 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 03, 2024 Dec. 02, 2024 Mar. 31, 2024 Class of Stock [Line Items] Â Â Â Â Â Shares repurchased and retired (in shares) 0 0 Â Â Â Number of outstanding right shares (in shares) Â Â Â 1 Â Beneficial ownership threshold percentage Â Â Â 12.50% Â Preferred stock, par value (in dollars per share) $ 0.001 Â Â Â $ 0.001 Preferred stock, shares authorized (in shares) 5,100,000 Â Â Â 5,000,000 Series A Preferred Stock Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Preferred stock, par value (in dollars per share) Â Â $ 0.001 Â Â Preferred stock, shares authorized (in shares) Â Â 100,000 Â Â Series A Preferred Stock Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Number of outstanding right shares (in shares) Â Â 0.001 Â Â Exercise price (in dollars per share) Â Â $ 27.00 Â Â Percentage of common stock exercise threshold Â Â 12.50% Â Â Market value purchase price rate Â Â 2 Â Â X - DefinitionBeneficial Ownership, Threshold Percentage + ReferencesNo definition available. + Details Name: pets_BeneficialOwnershipThresholdPercentage Namespace Prefix: pets_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionClass of Warrant or Right, Market Value Purchase Price Rate + ReferencesNo definition available. + Details Name: pets_ClassOfWarrantOrRightMarketValuePurchasePriceRate Namespace Prefix: pets_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionClass of Warrant or Right, Percent Of Common Stock, Exercise Threshold + ReferencesNo definition available. + Details Name: pets_ClassOfWarrantOrRightPercentOfCommonStockExerciseThreshold Namespace Prefix: pets_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1 Income Taxes (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Apr. 03, 2023 Income Tax Contingency [Line Items] Â Â Â Â Provision (benefit) for income taxes $ 465 $ (618) $ 22 $ (345) Â Share based compensation Â Â $ (7,179) $ 5,196 Â Effective income tax rate, percent (192.10%) 23.40% 0.40% 12.40% Â Effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount $ 1,800 Â $ 1,800 Â Â PetCareRx Â Â Â Â Â Income Tax Contingency [Line Items] Â Â Â Â Â Net operating loss carryforward Â Â Â Â $ 96,000 Disallowed interest expense Â Â Â Â 1,900 Total operating loss carryforward and disallowed interest expense Â Â Â Â $ 14,500 PetCareRx Â Â Â Â Â Income Tax Contingency [Line Items] Â Â Â Â Â Percentage of equity interests acquired Â Â Â Â 100.00% Chief Executive Officer | PSUs Â Â Â Â Â Income Tax Contingency [Line Items] Â Â Â Â Â Share based compensation Â Â $ (8,700) Â Â X - DefinitionDeferred Tax Liability, Nondeductible Interest + ReferencesNo definition available. + Details Name: pets_DeferredTaxLiabilityNondeductibleInterest Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOperating Loss Carryforward And Disallowed Interest Expense + ReferencesNo definition available. + Details Name: pets_OperatingLossCarryforwardAndDisallowedInterestExpense Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxContingencyLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: dei_LegalEntityAxis=pets_PetCareRxIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=pets_PetCareRxIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1 Related Party Transaction (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 29, 2024 Dec. 31, 2024 Dec. 31, 2024 Mar. 31, 2024 Related Party Transaction [Line Items] Â Â Â Â Related party transaction, service period 1 year Â Â Â Related party transaction, number of notice period in advance 90 days Â Â Â Related party, first year transaction amount $ 115,000 Â Â Â Related party, after year one annual transaction amount $ 100,000 Â Â Â Related party transaction, expenses Â $ 0 $ 0 Â Accounts payable Â 10,945,000 10,945,000 $ 37,024,000 Related Party Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Accounts payable Â $ 0 $ 0 Â X - DefinitionRelated Party Transaction, Annual Amounts Of Transaction After Year One + ReferencesNo definition available. + Details Name: pets_RelatedPartyTransactionAnnualAmountsOfTransactionAfterYearOne Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRelated Party Transaction, Annual Amounts Of Transaction, Year One + ReferencesNo definition available. + Details Name: pets_RelatedPartyTransactionAnnualAmountsOfTransactionYearOne Namespace Prefix: pets_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRelated Party Transaction, Number Of Notice Period In Advance + ReferencesNo definition available. + Details Name: pets_RelatedPartyTransactionNumberOfNoticePeriodInAdvance Namespace Prefix: pets_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRelated Party Transaction, Service Period + ReferencesNo definition available. + Details Name: pets_RelatedPartyTransactionServicePeriod Namespace Prefix: pets_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (-J)2EH'04UB@0 +$ 0 9&)C4')O<',O87!P+GAM M;$V./0L",![\IQO,1#&1&LD/)OCG!CVX>;QA&WPIG M*N*I#BV&5(C((!47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P4 M " #:B4I:+Z*+)N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7)$6_, B4S,7W2 &D-*+^O&IFX+0&FIO.EQ*RZ"$^&\ZSH'(S[*S&WK]S\&KLA?AI8X5C\%KS4O=PRVMZ`GX:` 8O9^P$0B%<Y"$S)R(T%=I[=C9'2^^Y'8P &+_(#FRE?;@ U6TH^*]BT+TM[DU(%Y,A:!.]=K\UB]`$V7GH5#DFUZP&G+'!$WAD%7:9L&+HH[UB&H*+\-1=BRXJVD!K_&RI4J24>YFTX#)8]9P#@>@`.SKU`[\!X1?J)N`V`D6#L9PRLHE`A02WV16$`]XUPZ%8A7 MJ\#-5J<.=Z^IW=?J4$%[F;G3(*M!/&9)8@(OZV$`8]EGAVNCCO-\4H8G6I` MSI2AIM=L%D3\G[<&>K!.KWW.*%Y#OA#&'[\5B\@\$R[EV/NH0G&EJKY+,2<&0KLQA<5L*V=98HW$&0GCP@KEI)#PW\Q<MU<B:P?W/\0"KAF+TB6Q6J`T)&22+(:/HPQ8P\W7:C8/I`Z8&I4'*!.L4MIX9)O%F.7L/LJQTQO9XL=5%.?Z.M'$W92C&47&IW1>TNP7&LX=JT7%X_5,3\'-T2:4P%D^*2GC.R/YGIJR1)K@L?I@HPV/D0]%\)%*J[)R3F&R2+>:P_^;@#1<@L>@7LLP4#T[,5LB%1[;L5*_H%-:^6Z^2#/2&-Z'\YDN^&72KXGC*PJI&2DH/HJ2_^H0ZNA5]Q19+B2ZLL?94CTJ='F+:WHA2-WZC^*/6M)FX1LDRU>E&BK&%*#FR&

@E@\=>E%-+[+2>^"29B?$+])#$[FM M!5<1U%&Q&W@#%..:8FQ-A7<\3XYGP_@UL^$K&>NXBYU&^9PC2P:*H4*^E M< MI<,-E"=R<$L>K'5WFT?Z>]($"P(_-$\.;NDT/I(U),V?
4DB&K0U93=0P9:RO M9-]Q-%RR=8(ZJCO#@:T _ M?BUK7:<;K<1VL:P+P U]4=6?T6%= [$3>]K$Z# W+%L'X[PT6HFMVC2=0^4L MRHUHXQCKRP'?B;=&U)DTL@>LMPP]%DA=QE3JZ[=
(!EA()\!$DT;NB%WN^A+= M8EO*GNKX:D].6ABZV@6^MI9U4!P/]":D441RBB(>XZ>+G!<%N-]S&V"AB_VA MM=%H(;%KX8ROUZE4)7"5*1*>J^BS/ &^Z/<[+AD*WQB)6PV;Y0(93T?^OZ&N
M\XW.$KO.SE>T8"N>+5@A?BN; ?EB/@UZ5:%]+6M=KQNA)7:AA:;YD+"$Y,GW M,3]L,X2*@(52O#5P\Z#[=RQ8OTGS+S-:@RM<7__V"#=0#;E +&7 VKO ->A*'K.<,0@2,XX\(.QYX=E M/
@>8R\:!S&Q!^OX"1,3>7A'JD\%HM431[D/'4H+X01 MCC2.!ACV_0']<)O"PK47%I5^"$.2,I+5BX>21RXE7Y>7*T:!M@+ [TL.2GBX45]@ZB]NTW\!4$L#!!0 (-J)2EI# M7R%T>P, ,(, 8 >&PO=V]R:W-
H965T&ULK5?;;MLX M$/T50EMT$Z ;72S?4EN 8WO1 MW4J-/M,R.-+2*4J)*4W>[7[U!2%"N1;VW\ M8)'BS.$Y0PXY&FV%?% Q@"8_$IZJL15KG5W;M@IC2*BZ$AFD.+(2,J$:NW)M MJTP"C0JGA-
N>X_3LA++4"D;%NX4,1B+7G*6PD$3E24+ESQO@8CNV7.OQQ1>V MCK5Y80>CC*YA"?IKMI#8LVN4B"60*B92(F$UMB;N]=3M&(?"XE\&6[73)D;* MO1 /IO,Q&EN.800<0FT@*#XV,
7.#1+R^%Z!6O6Q=Q3!5/! MO[%(QV-K8)$(5C3G^HO8?H!*4-?@A8*KXI]L2]O^T")AKK1(F=DD+"T?-(? M52!V'%Q_CX-7.7BG.G0JAR)R=LFLD#6CF@8C*;9$&FM$,XTB-H4WJF&I6<:E
MECC*T$\'T\^WL_GM@ M64CY)?F+?%W.R,6;2_*&L)3 5>9U\XD8Q*LJ$\!W*!N18) MSJE4) ,\C$UP+MNB44[1WUD)Y\IQW&?K=U#3'OP2;;R[E<;#F:7K8]P'IW
_8M3@/JRY#_CSAEF>D2+FSXK!L$<5*0_TW'(HB'"=9[N4N>@C*E($B3\&WE37 L<8^:-07L% /N&0+.3MP* M?7=O^([3EKJG6#8U/-W@[L%+LUW#:;E(3?VMM/K]OQN_SG_%DO7]0>]H;>'
M_].M[!Z^EEOYGY'$%?PI(EHLVT78.P6FJ>ZQ[%JS5!$.*W1UKOJ((QH MD14UY[W06,$6S1@_,D : QQ?":$?.Z:,K3];@O\!4$L#!!0 (-J)2EI. M'_;T?P8),? 8 >&PO=V]R:W-H965T&ULK5E=;]LV
M%/TKA%<,"=#$)/6=)0822]T"M$E0I^O#L ?%HF-ADNB)=)+MUX^2',LBK]2T MTTMBR><>ZEQ>7AZ9Y\^_$NL&9/H)<*<3%92[DYFT[% MYK%4E^7C5&Q*%B=U4)Y-*<;N-(_38C([K^_=E;-
SOI596K"[$HEMGL?E/ULF=Q\!E54AXX_ZNZN$XN)KAZ(I:QI:PH8O7OB?7]D_U.*5F(=8L#G/OJ:)?%]._E*V"K>9O(S?_Z-[00Y%=^29Z+^ MBYX;K&=-T'(K),]WP>H)\K1H_L.(#N J@>8/<$6+L
ZZTCV+L M^ZTC.+N 6OJTT5XG+HQE/#LO^3,J*[1BJS[4V:^C5;[2HBJ4A2S5MZF*D[/Y M[4T8W2RB$*E/B]N/U^'EO;I8W*M_GZ*;^P6Z_8!N[Z+/E_?7"H!.T)=%B([> M':-
W*"W0_9IO15PDXGPJU=-4G-/E;N2K9F3:,[*%/O%"K@6*BH0E0'PX'!\, MQ$]5%O:IH*^IN**#A"%;GB*+O$<44QMXGOG;PRU(SO\;/?KAT3O)L/9U8=5\ M5@_?=;'D.4,+&4NF^H)$?UP^"%FJ=?TG-
-4-F0V35*,@4NM"77KT&IO>)HY M-/!5'3T=)M9$N8Y%O"XJ-%'$QPYVN[#(A%%B.R[>PSHJG;U*9U#EG N)^*I? M:1/N' QK^=AS-*4FRO9L2\M':**(A2VBD44 S+&Q'\!*W;U2=U#IKR47 FU*
MODHE)-0U1[4#'&A" 93G^Y8FU$0YF 1$TVFB7&Q[!);I[65Z@XWD=L/*6*;% M(V(ORMT()LX@M=Z8#61,LG!,LF@DLLY,^/N9\(<+CA5]*C*DMFL4)\I+I%5# MKWP:-"&^65C8\[4F,
=0EDVU!12:*.H21RO2R$39! <^7'[!7G0P*/HR>6*E M3(4J0$AE8#Y9X&L-<6Z"',^EFD83I+JAOA C .4[5D\G(;@U<7A09U?SF7*G^M[X!6C,,]#1C=B&4YV%-.8"R U=OH@#*
(6Y/.5N,MZC@H%F9D?3 M65.^7GHFAEBN7G@FR,*^7GV>JH M3?6<0"C7UOT2 %,FP4@+1.8%?370VD0R[!/O?C0%@('3;< <)VXQ-<3 #A&
MJLL'F*R#5';5MWZ1#!O&ZC7[*#NH#%!J8+S\GGA8]XT0BF)J& D3YEB>[AQ! M,MON\1&TM8X4#^ZEAEZD7 12'W)5 &(=E_ .2P<-Z??NL*.RA:.R16.Q=>>G M-;ATV.!>Q2)=HJ.T0 G/LK@4]?
S4$W,,3DQ#YQ_6"3[%6CG-89AF7D, A4^I M_DM0#Q?M*)!V&&>!,%B8>Y^L2W'I<.>]RO]1&' M4A^K%]CXD:%BFS\H\7S569P"\:T44KWSJ;*6.ZH5'90M'98O&8NO.6.N% MZ; 7;E=J,S-
PA0)&&+N6VBB)7J00TJ8.]?6?"D"DXY. Z)L(B+1\3-V^>FW= M,1UVQX>+=4@_X(![]$-(6#^$#'R/NOH+"8@Q6*,D?4H35B0" M)6RI^I7*A[Z;?D\WOR-F< /=#3(/+L6DR.^5D5>LFN!Y'JY
MI.+IE!7\X7C@#YX??,OO%DH_&$V.5O2.5$9CZOKH6<#?::,GR)2MESDLDV/QX M<.(?3DFD!QB)'SE[D%O72)MRR_DO?7.1'0\\C8@5+%5:!86_>S9E1:$U 8[? MM=+!YIMZX/;UL_9/QG@PYI9*-
N7%SSQ3B^/!>(R-J?K0GWC#Y]9;5"H]:6\ MD.87/=2RW@"E:ZGXLAX,")9Y6?W3Q]H16P- CWT K@?@]H"@9P"I!Q!C:(7, MF'5&%9T<"?Z A)8&;?K"^,:,!FOR4H=QI@2\S6&2 MEID\&BE
HW6.TOK+I]67<<^7$_25EVHAT7F9L6QW_BLV)B"GTTYQ4Z%9RS] MB(C_6$/!Q8\TYH"HO[ZJIFZN< MR4.;VRJU@5VM3NM#N:(I.QY WDHF[ME@\N"#8>"!P:9]<
M0A7*RY0O&3HHN)3O;=96*B*C0M><^TE(8O#__;857:$A#H+Q1FH'7KB!%SH# M=)+]#?D%)4E)I#C4I)27:5XP5+9QZ]?Z8:I#NI8LTU/_Q?$,WS*>;Z1LQV'1
MQF&1,YYG#)2F.:WJ;YDANN1"Y?^8!S;+*W7A5MB") I;L>T*A7[DVT,;;Y#& M3J2S!17,E/<,01R!\V0OR+CS_6'LQTD+95X\\Y$\+,)C/9 M%'UDUD(Z[D+$Q&\AM @%I
=ALD&8.!&>T@PX\58AIJA]R&S@DLYWB2Z_.]BZ M,B&Q(_.]AK@\9_H>7)0I-"Z2O0>(U54K+:5DD-IZHN:U*#IX%GV_WUOD]#8O M^G.XQO)&2?Q6VG8]MT7YOC.J)VG*U[KJ03:S_)[>%M;
UEJVHQ9[7BNR%]&A M[R<]P<4-1.R$>%'>0UWF N+Q09=>*S[<^;0?Q5$[+RQB0Q\'I(<]_(;??2=Y M3JX%6]%\?_;6:G8!A+@-LRNU52IW(38$[+L9^!EBG;Y5,G"U8)Z2R@]I:JS MQ(H[Z"
"M\5MW%VI(8ZBH =Z0\Z^D\HF5TUNFLP5NA\?\OD0^+<&W3\SPFY- M"MN\8Q$*DS[8#47Z;H[/&XC[,K%">[+K88;_3WD2 N8 M"3!=G1@MM!CB-
BO:I/PDP#T0&V+TW_&*F[#Z(758J&A1KR'&M@4X'.]:0$\KI[%8K!QU3M$[WP MTH'] 94<7EA]TN7$=O]A$1F2K2YEUX"&.+&;.$_2W^M%LO&,F#543-U5KW-LKW*KT0#*;"YW1 M]]#1E?
8FGE@X//23=FY8Q8(HZ-D_(V/$S>/3_O ?D!4H5MVEY>ECH N5$SD MW#IQ2)>L0VA&VQ&PB/E>X(W[C&A(G;A7HVXCF.Y-G?"[*]#0\[WV0M4B%B1!
MT%-7R=8^M'LC>K9>K0JFBSXM4);+M.!R+=B&Q73E@GE5'0D!X=DWI=]V5_K_ MV)8F#;L3-[N;>)]%,1B]=_U.NC0=Q.U^TB;4L\5%&AXGA[?+JEFI:;3G_[G MM1&Q+(_;VQ$6&3](>MICTG
\V=NQ1YR@ MAZ2]:+)(M=-HM'5FMF3BSAPE2F16[]69T^;IYKCRQ!S2M9Z^H?3ZM"Q45.= M@7ZE LJ;1 6;@TKO8PS>%-6Q8G6C^,J&PO=V]R:W-H M965T&ULQ5K?G_0:&-G
MI\]E[,*?/G==K(VE"Z]"US3:;\^I=IL7LZ-9/_#.K*O(P>GSUN]IDN*']H+ MCZ>#04II&K+!.*L\K5[,SHZ>GI_P?)GPLZ%-F/Q6[,G2N8_\\+9\,3MD@ZBF
M(K($C3]7])+JF@7!C$]9YFQ0R0NGOWOI;\1W^++4@5ZZ^E^FC-6+V>.9*FFE MNSJ^S%31A>B:O!@6-,:FO_HZQV&RX/'A'0N. M\X)CL3LI$BM?Z:A/GWNW49YG0QK_$%=E-8PSEC?
E,GJ\-5@73R_39BBW4I=F M;-5!D66?)]G'=\A^HGYT-E9!O;8E ME;OK#V#G8.QQ;^SY\6<%OJ)BH1XW"%OCY?JWV?+ M$#V2Y3_['$[R3O;+XP)Z&EI=T(L9*B20OZ+9Z;??'U_^.PSUIX,UIY\3OH?
MW*H_2[;ZR:^U-;]J*:H+BC]2J5Y?L[]AKMY:[)"V)8I\&4QIM,>2N2H/E@>4P+XWFF?>0Y%+%5U1OYRI6I+[]YO'Q\>&SEZYI MM=W*T]&S[^;*!*55#7!BDZW8B'HB51H/ ?>CNU\X"P
BKUH@7EMI5':Q%6.< M1$6UWEUAB>=8L%>%-VT"$,RQSM[?&6RH1*CX)]Q<.5?.X7K;U@3@BB$_<-AX M]1549@/?[E"97S@<)"O8>+V3<4N_](,0D FM4A.U-O572J M=R<@+-YUZTH9S-
T0HA\Y\@E"X TF1F2U*F T^7:2N<4M3D])L8G)B5[5;K5CR MJ$,C"E&J WNA= U)'&3)9F_<,J(+<.0YMKTA-3"RY]]J/#;M/Y*UQW&!\=R0!?J#5(5.,-RCYX\^3XERB1#CAX]
M"XJNJ>C$X@I9\]G3/K)C\%0V!6D'R=XC2(AO[>! DOB*:J^WZIQT4\ED>6" M:A%C"2D+]B5F$WI>K,0[8P&^G33LP!YSYU5'A_?_R<;)CB(8SB,[2H=BC%A0
MU%W)N5BS/TE&XBJ]2\B]B*F(MJ=/G6'MRZUHS]"&?(/)J-F@UF3)0V:\IS9O M/DO]8,7M2_8]J'NS'\[.+F;?2=YS?&J*M-?Y!9!-!+@6M0&38&6C+0@/OTY) M^B>$6,J;@XHXZ/(7%$<&
(%YJ@O@)S98C4R,0G.0\!M6^TS4F6D)"!FX"B'N; M\D*MM/$,--74N=8!7+(KDY0$-*!,"FJ6R-:^2R<'+T=#L>:G%C%.6\SAXPD M+Z*$L(S!3>(-)/5\2V:?U@]2.;W4H>**W(SB?H^05,3P%SQ.S'-_V#R
".=F M'U&#"!J;T!"%D*.6U6 />MUTS27*.YS5WD"2VP4NMH?]B:="Y;H:N<[.:"BY/MOVRD@]CS->2B\U'$ZT5!BN\\GEOD[_EJ+Y=3GZU S3H\T/F\IQ";L-
FSEE(@MUAOH($X9CN!OFZE/H;#;HC#XC:*'] M@'GWG:"8(N1"?0BRHZ]18HU _N?8$[W1?*UX>!)C&4F;M-^,>CT*!8F,,(E MV^B/I&@P@P.B _IVF\&T0GEJ-
'3$)TK"M\ZS;MT,@<;\GFG41H,;H,RSJ!*I M6+O0>-'J+8\8;_/N M6HP3H$[4"/Y33Q8 1ZL%RR+R7#>O"B084:;%\ P^,^-\5V*Z#B00\PD!O:@ M7V-L4W$GU]N\09ZRJ26MG%DU>LIA;4#<0-
M#%VJPST"9:M*,* M-?HK2[RB!(;]LGXG;YF(S4Y=*Z3ZVPX-!P!R47?ZXE\\5 MDQ-(.EDD6(LN8K?+FXJU*-G?87;P^J1'=L1_QQ9(^+NSZ_NU!/$LE=1DI"\R M"?65H4UN$@;Y9+P@ &*
<:S8*'8;O*32J-$$),8778.R$M:9FQ$E4(BW,Q:E ML)46)LVCX#W@C%L@/_(#U_EV@AF&HZL9'Q*[$E($S TC3;BI(P^+@#YAP> ! M-/R:OD4GM&O#I9BW;'@]R44VCJZ9"?0>MQUR0@=*!YTQ
MPR---/6=HR0?1-%.B>UF%V;CR3,%F=: M'I1)ZZDA2?7GLF$:\PQR04A)BM).W$9#\X%B!2P$!&6.ET^BK(B/F,+Y=A4@ M8_;XQ*/.3CM=A^U,EPEX!;4@.Y0B ^7P1RUUW2/SX*^4GZ3-5
S.+C=*=\A. M1.TWDT?2GLH4DC&YY[)X# UH1;@!^ISGML<)X@U/%NJ82VG_R?N+DYJ!%,77 M)&[>:)#.KA6WF /BR>H&I]+*8"?^WSDI9X7]CF5O-F#F7Y"MP&ZZ<:?GG<7O M@D;JTEM:.@JY
]0&+27S1[SQ(H:K'>R2<"A?=E%F;GG'A6#"N/GT@,UP4&K/ M-T ,$[P9^);\XNSWN*D..A/K1">EGB_<-'JK<-WSCF+4"6IVE"\/J5KP;R'6:<^2B6K$7GNS1& M>91QVX%3%5+HPL+3I@EK&-
M!JG'PJ76&H_&Z9,^MS&![*CG4A2V'\TFKI>0/5NG1(L>FIK9?<<_[?LBU?%B5" MI"]W09I-8X5D+OG'2NXE.7.&PWE6Q<1\O?:TUNDPS">#?9.08\.>P"3@ LM/ MP,"W"&#D=2G[-= 347@[;-FI[
%\&6I+0&CG]F]):V/EYE6ON(L,U7_T<#ZY M*9'#KFDRA4X<&)'Z7:( )*^U[XM7DB:P0!Q2(_?RBUW*A \<=+U%$.K]:FW+UFY2;$S#+3W3Y3;6:]!7FYG>S[MV#Z;/I_NF5'U.?
(_S5)VB#\#]8G*GWU-2(UN)X.G7T[V*/@3LG/?9\.#R=?> MAOQ:OFG+58:-ZF;.TZGB&-0-:VP]'#QZ.%,^?0=.SU$ MU\]WXZ6+T37RD[^;D.<)>,]WZ_T#*QC^,\'I?P%02P,$% @ VHE*6C(5 M)+2J"0
&1H !@ !X;"]W,W)KD?3V/ASN RW1%AM9U))47-^OOV=(298= M-=OMX0YH8XOBS#SS/J2O=TH_FD((RSYOR\K<3 IKZ]>7ER8KQ):;4-6BPINU
MTEMN\:@WEZ;6@N>.:%M>)E$TO]QR64UNKJW:!WU[K1I;RDI\T,PTVRW7^[>B M5+N;23SI%N[EIK"T<'E[7?.->!#V[_4'C:?+GDLNMZ(R4E5,B_7-Y$W\^NV4 M]KL-OTFQ,X/OC#19*?
5(#^_RFTE$@$0I,DL<.#Z>Q)TH2V($&+^W/">]2"(< M?N^X_^QTARXK;L2=*O\A:[5CFG:#&WUQ MJCIJ@),5.>7!:KR5H+.W]^))5(U@]R)3FTJ2I:XO+1C3Z\NL9?+6,TF^P.2*
MO5>5+0S[2Y6+_]C^$H!Z5$F'ZFWR(L.?1!:R- Y8$B73%_BEO9:IXY?^@99K MK;;L#E@UH@&6M@6[B9L)4L,(_20F MMS]\%\^C'U] /^W13U_B_K4^>'I').,01SNP=I4JF=,ZK3'@;O7FX8Q]5+3,V
MC^;L?#)J3G-L3S-Y%3!;"+S?UKS:LUI+I+TL]VPC*]&Y%099[1FM]@R)"L@; M1N R+6N?LU7.*E5=""W6*%5;DM\@,B _=BK50+H,34=2E0.VB9F+@% M*?
#D,*M*,+4>POOANV42+WXTS.X4VW$M"M4884)V)[1%;7/,.RZ@70LMP"O:CA@NP9Q+OP<= ">U! MT?8.6,@Z_V:]:^D;68$,5POMF@&%AUJ5.>B1*75^\[$K8?" M0ZYE9)C.+TI;3P6UR-V6
WP'G7."BVAO:;:VN-L47G[.45XUH:"!";PXODG MB (W;AU)#D:$QO 24:LT(UMQ=.?5^82K+ M&A^2$#Q$Y%T#7=!\"[IV=0N74E49PPM7&DA"SZ'X508QFH!7IRU% <7UWQ/
MK3^\@(CJ_!E""\"RW-HW>I%LCLG-*7J1UJ$&D1LC=Y[BH? M+\M]\ RA^$Q^I!@4I0MT(C(NB"QFBT+P$E7OB2PD*XPU3I"L3*-=@E"A15#" MLK]);1N2P?!GM&SX**2(JKG,J2AFT!CYFCG4G:
(=NL9X=@@3@7SS-L^X*2#4 M6E_^G/5W9#(M!/M;8U<(\/S@/N)9X(\KO6O1BN>^!2 5O(N1)GMV&*0H.:B0 M5%G9H-^3C!:Z.2U&?[*D;:!'1;NAE*F)?"5+:??.W&WUU+]_DQ$H9\D'=?
M;;1V"SBX,H1 :LJU+$NG?@MTQ+[TIBM@B*7W8KORX>N=UB>>M^C65[%(.'7!= MCP)A>Z#<*A3JM@NMI3:^+^+X X;OLC'#O006RW? =?_YT,(.V6<@BP+?I337 M%MDUH.^K98E#
')J6Y=J3\!E=5$)2X,[6?23:F-B! $=#,$SD07IW6>S4+145>#(% MYIE'|J'@:(;9_GARP;#TV-2G=1'&,1!3MJ(OZ!BU_T)#=;6PU< ZW5:8F]9(
M#N^R,2\)W_TJUM3P..FK*A0)E@'CQG=U];W@NHV3@H(/ M-1&4HD(R^.BD)GH\L_0!YN.FF^8PVZ&K[GT*T0QJ'EW#&8'=#PY^,"1<'2!4 M9]1%M-"J*Q=K13%$*49"1,"0PJV8CG4;*L>U?)
,9W$8X2R%>;--S+,T7/0+ MKM>+)XGY#T!PP/,)WUIR>Y)Y+2I?7]VXBC:)U'+'(4"(8;#C"/J#S1!6W8= MDF0HN)?6F9*[9O6,0\C.NR0'@):!>86-Q_0!>\\U;-O1L3.6A//#MF&V^.H/ M8
H*:=.UE9S%83Q&X:*MQWE$UQGZ/ YG8Z!^:6"C-&HQ)>/\7T 4P5W?C"@9 M0_0@:MN:N(,5_VE#1>'LVV%%8[">.1X.I)"A,UH[M;A.-!Z;R!\:V;XR07AI
ME",Y+2E4'F@8IYB^L.K"?:&A%QGK>5/#/G2'Y^6_$QBRGY7^EGSY0\TZF5V MV&&V9F=1=5Y*6'LWJ,\[C8 MX/@CS&NP4IHLX+<^ ;38L9.E$].U@\AQ>6%>AE<.-^7 _\VL\?0J2+T=
M%VY+O)@&R2QBRSCT-.>(T^72(9R&Z9AEL>$]=M8D5Z1I$,V@RPDT7!+/"6W MH(/.QVP[#Y)D#GO2Y@4D=]_/XR!*(R\U&;=NO(R"630?6#.)I\%L'@WMFTX) M#O&9>?L>W0 5= [RXS0&
=G>QZ'_\Y/TH8+\ZX/1E]]=-('VN- "A_#;K]#U!+ P04 M" #:B4I:74(-B>D$ #I#0 & 'AL+W=OS7 M[XZ4%:5.O3:?!R06>;Q[[OU$G6VU^6HKSAVYKZ6RYU'E7',RG=JBXC6S$]UP
M!2=K;6KF8&ONIK8QG)5>J)93FB2+:Z=5(H?F.(;>N:F8=+ M+O7V/$JC'>&CN*L<$J;+LX;=\5ON/C6UY#WT>_:VC%YKPI=.KJS[I(>!'S#BPG)TIC0A,X.X&6]MYG'R[Z#]Y89 M)=2=?722_'FQLLY
OTD5R>L#8 M66_L[!#ZSZ;FQ6! @.8HM"F9*CC4GZN(JSAIC-X(;#Y+])IO\HI34],Q'U1^GI&+L%V!5H%D%E SS6\PA+@-*TCI=D]4!*L1$EP R9
MV88)R5:2$Z>1N88>]L*5EB4W%N70S*UO/,!A&VY@CA#5UBM0!#8/I^)UEG' ME-=3M@8?WDUNA"XGY(V0WIQO[!UB(%VV)6"A8(D",%((7Z]AQJ#"1CNNG& 2 MYA54E2B\7:I$)#] ,
<#0T\573T64(.Q#[*WI$0JMP"$__! 9AA4W!N""-S$I MF"Q:R5!#:W?..!C,MC4/G9*:NPI]^PQ0%CD'9CV:$30Y@;'^5@]DRK8A28A_ M!4ECZ@%P?,$KYZE:R8>]< 0CEZ0%>HQ7K#=2]A^?
B;D$PBLM81W!KH&Y<(M$ PMA!3,=4%!5,@VH#@-!8&^E%QI&).!T+&$.O2G@QR/I.^&O=(,=>EU6##! M#(K$DLYK@!AYKW1K 1>RP>\+WCC/'V"ZK.]VM6Z5L^,3<,QP_F1.$IARW)_D-%1A
M?2T9#6((6%]>TE^M#7D/H1^$%,R/%]DL7LQ37,[H/*8YQ>4\3^/C%)V,LSR) MZ8)BM0WPL1+]/&@;(&)!HR8P8Z^H<0*E]+1_9L>@A=)^?PCW<-OM0:=)G-)Y MO^U"N'-_5V_%
(#C_"C&V3H(P'X>OQU))^32AQBRF$R2;!P6:8*+9$(7W9Z. M^_GVWYSONJ)WOE3K4(M\OU1].6*=8TG&Y#A?0$'EGI*#6_#_\ZE#X2ZF@^4+ M,A4C=L]/I4\^Q#!UH VA2W%^EV1M=.U]'&8&4
X/B&'@8\+\:T"8\%;P=FQU M*TM20:? #TY^^'/BU[TWA?H)19,^'PI'PP^G8YX>Q_FZZ>#Z#3/XSG]DX 4'1GZXB?74_COF(ES?']G#1] '9NX$O'@VJ*#_NEO^"U!+ M P04 " #:B4I:W0R!7/(, ![+ &
'AL+W=O.G*X2LZQ.ULU:U>7[_=#8 "*4JV,]EYV(?$% GTA>ZO#_+U?5E]46LA:O9UDQ?JS6A= MU]N7Y^]/SC=<%J.+UW3O MNKIX739U+@MQ73'5;#:\>K@4>7G_9A2,[(V\G9=XXWSB]=;?
BMN1/UY>UW! MK_.62B8WHE"R+%@E5F]&B^#E98SK:<$O4MPKYYJA)LNR_((_?LK>C'P42.0B MK9$"AS]WXJW(,TO7E?E/:MP-5##"U*5=H-PLL!#N:DK>"IA7WUQ4Y?IE[-+ MT"MC;\L-
G+7B:*[7YS50QS7GJ:%TJ2F%!RC-V<]E4:\5>U]D(NON/P>I6M%" M*]IE>)3@.Y&.611X+/3#^ B]]%4U(GK1(577O!)&U6O^)Y5LT55\>)6T/6_M%TM55^ F_QE27M..AVECZ+Q46YZ*-R.
(#26J.S&Z^/&'8.*_.B)YW$H>'Z/^ MK$,Z2FE8SD/DV:>UH!N\>(3,LJ4RQU%XBO>"T85ZI,):^!P+VLU[8+"E3 M,*V0.),8?TB %ZG0:Q8W;]FG1-@CG*N(&%"@]
<,:E4(S*/%0!QY8H!D*V$K!MXY+$&?+5B-=) M_6#"WF^V>?D@!'O_>R/KAR[?CSNEM%37.2_8"6XVPG=IX&,K*SNY7\MTS?97 ML'NN !+35 @(&[9,-
*$86\=F'"QK62.SR*/\2)C1/XT_D9[N1(.V4N;![3C$%Z@VVG/5GT-K:VT;F$R M]9+)]%O/,F%73:UD)M@["·Y;E]4WR0ATVOVNC&.VJ!D E-@L@:<%*9 ~~.HQ)@>25K895$>669]26]4H\001 MKCM9-~~
~~BJW8J.C;V'ISAW0-$UA%#>":KM9!3HV<_%*GQA9FT.FK;Z J[7'8(^L M+HD&$@ EWZZE6+'W7T?8(W!KE8KT+)J0>WM^ZL6" "W#QV777]]\UFU&[Y! MD@^R J2Y_N2?' D45"^J+222R~~
~~#Z*+)Y%"FH>=M><4!1;9K 68?C,GJ=06Q MNM%IGN)E/P9T\!)$U7O^9?/!L=.M1$Z)!!3;2R/6Y5;LA3].H![*7Z*<@SYXJ,J(H_O98>3Z3@\[5HB M&8>'+/$38D A'~~
~~TO2R"%E"S.M5A(Q)"U%L/B:@HE"S2O,D$W>=+F2,VPVW*7/L.FP 9?830&#T21:-KO6B7$(BMAAM2#NL] MY>I"!2 8H5W,,HGYM48QH=E16DXHO.6FV;"B(:>!#08NX,HF*I*D7G.,U2,/~~
~~M,!O3<76RL1%H*(FPKN=A73.+O 10'G7O9)=. H[9U::0RT,!(:>@#@+10(7B MK.LFW7#N4RYYC,M/1=:DVF"/,7*6=GDED[D739)'>/4=BD(S]"(H9(YN[#LI MN?VBN85N"LD&70,;'#7:[\YS/^B ?~~
~~1+X>PGWZ?("J5 M5@(7W@A,#_1S87FS;5.I!H,7=NC"PZ6?HD* !QHNGF9'9 76@!:^(@RR51&P MC?3^2N#@03N R?8#QT"'E%@GWTN(Y'N*2PSN-0??U?O&[*V6D-O2RI734()_MT.WK=~~
~~D.^6(VGK70:]."P8(]0/Q+DA# M%@3>-/'[Q[Z/_!RU5$<[7:0]#:URH+JK]M"NN%KREWR'O!5T'79Z&XJ:RH_MGI54*83L@^~~
~~5*=#6,SM@F=$Q6C[8*E(@6Q9"NR$]9*E#FNL6J4^D9WS(H3!2NOEOY:!\-@5B(^)E#7S@9"G_W$!T>T]B;V8-H#R>(MO?G4-_AJ]2 Y 9T,;8BD.$G<-2;(.A5X-/7B,.E1ZBY,6L%W[7<_H?6$_FY)~~
~~MS:%)P4<'EPO,)JX(NVZ*LWK'S':_G[%GQ?4(^KEP'7=O 4F(+@S4J%8M>H(X M?@[$'I!IBQB@]499THL=6G3,Y:06O.^D%QQJ$FO*!GY 16]Y-!E)6^A!\54 M-^C;$"!+~~
~~;*+]DSMD7YN8<"1\YC[:H9M=0$UM57$GFLZD-<*[+:GF*>U0A(D M@)O\"/9B[/L!>]%>Z[78VLO.G?[#EDP3U+V@DTN4BJ+ M*Z0M1%ZMJY)P*B2>XW%4Y6._K=*GZAF^1NT'3:K\^PW.$0-~~
~~(U5Y)Q5E'D.I MI\+ITTWFI,H>D:<8LQ6=:CD L*&"+$R*7O!H0;9W%M^M_%K WD>')%+9M/_' M+CD_5("[9W9^X@Y=I+)C!SUU-2$)B J D>M^(]M WL=Y)C6V9K=B_B48%EW M8]\@3<$;~~
~~5ZCP)6*_0;E4*5N_;,%.H%.93":G[&3B>TGLPT4\:9Q"!=!Z'OS>'8*N\)P M'/@X+L4QNL/G)(E@?QS :@"5*(KA(@%*\VF"VX+9>!JT3L2'AEK81\Q:V#'!? M#NQ.Y="H^*\>=9/TNF((^G/MR?~~
~~_K7+M5^F0V,,3V#ZF]ATZ?:>[KODS2B<0F M3$I&!D>I(]-&ZD;C^!BZ:0K/12U3I#^"6ICXA8$?76YNZ.S:4F%@1&\R%IY. M#_(TCWDP)!^->/A?]?CU6?+5;%76'] MQX7]#ECU3;(&?5SU#~~
~~[\ENW9F=GV$.0 0UP8@,H'-ML2[C;)N\"<0@]"A_;B# M.F!WHMBVP7HDNWPP7#E]C 5<>)673,E-8_K??7+[\R"WW1YDYL"/[NCQ33^"~~
~~M#X+K^'B[/K15.S!NAMKSYM$LT_O8Z'%QH8.#$SZ#C4(A66HY*K$M*Q>'->(;1;[[M- 0G6$6;-VQNTC,*ZV,\K1OL%QQ!NMZ'@Q@)DMW)#!>:*AO"TJYSMQHSX9GP M:O?E@;NDYM4M 1#/B'8:~~
~~[^BO,['7/3X'WJ_HO8$9B,&/_3D!34:5F#T(V ,\'/7G%: =ZIOPUM[[9?UB[T!Z6[Y?JS7+# K02WS<4*MOI0(XQ8 MI3]UU3_J&PO=V]R:W-H965T~~
~~MK]\94G84Q'5?,%YFSIRY4I:U=0^^0@SP5&OCIUD50G.6Y[ZLL!;^Q#9HZ&9A M72T";=TR]XU#(:-2K? B,/B8UT*9;#:)9W=N-K%MT,K@G0/?UK5PFTO4=CW-~~
~~MAMGVX(M:5H$/\MFD$4N\Q_"MN7.TRWY M\'AE]=]*AFJ:G68@<2%:';[8]2?L_/G->*75/O[".LF.QAF4K0^V[I2)0:U, M^A=/71QZ"]>#GR@4G4(1>2=#D>6U"&(V<78-CJ4)C1?1U:A-Y)3AI-P'1[>*~~
~~M],+L1B@'WX5N<9('PN/3O.QT+Y N\1/=W^'6FE!Y^, (E"_U<<^*Q(U-LR5P6 M!P&OL3R!T? (BD$Q/H WVCDWBGBC7SH'U\J7VOK6H8=_+N8^.*J'? ?YG"#' M^R&Y1\Y(TJ<9M0$'MT*L]G;~~
~~\./@_,#A,<[PN-#Z+_(QD'=_$^3RSIHA(H7E%CC%^A @%9BKK0* M&^9/LM9)=']31$2:"G,;T1#+>4>"*@1+JA249"8_H6G85561R]"0>0[Z6,> M!Q]]%%Q7*DZPK[:,I88T-71Z21K(^.V,MBX3^)~~
~~[3'<^MSZ&GH/$@>F[V_.. M>-Y?P5?;J!).BP&\>_OFM"@&Y]!+_FV/8[P>GK\'|$',M:+AP3Z%RB$>!T6A MZ[E;T5ZXLMH8S#8VNYS&+5>'A']2A_T(Q$ M^1[H?0(EN81*H5.=?~~
~~G&YU/R(VF1MRBCPC]F[&O?&(\$L!973?-HUU[-I\0XQ#("$R9.RV M.*+MF&MNXWWY :&J!4!1#_,XP:C6%#M!P9Y4C5E+#4Q%95=P&LZ/->H5E]) MMGNIX_YD4C$&H#F.]9RBN)WE$?N6>>Z.CJ*)~~
~~[4"J!%?/"CF771A_<)EMF(B M@_N&:]Y[]FITR_BXTU#CT9%>P-WI[OOA(CV;S^+IXX.X+14UI,8%J0Y.?ON0 M@4L/>MH$V\1'=&X#/&UL~~
~~MW5=M;]LV$/XK!S0>2=.T"K&V0IBV&81]HZ6QQE4B5I.QDOWYW ME"TKK9NA+?9E0!"3XMWQN;N'Q^/)4IM/MD!T<%>5RIX."N?JH]'(9@56P@YU MC8I69MI4PM'4S$>V-~~
~~BARKU25HS@,]T>5D&IP=N*_79NS$]VX4BJ\-F";JA+F M_@)+O3P=1(/UAQLY+QQ_&)V=U&*.[]"]KZ\-S4:=E5Q6]*S4"@S.3@?CT='% MF.6]P->)2]L;-WLRU?~~
~~H33Z[RTT'(@+#$S+$%03\+O,2R9$,$X_/*YJ#;DA7[-MX[7UE]YW\F4J+%[J\J/,77$Z.!A CC/1E.Y+#-ES3\IV\MT:?U_6+:R:3* MK+%.5RME0E!)U?Z*NU4<>@H'X3<4XI5"~~
~~[&W&WF4+X039R=&+\&P-%GC@725 M:Q,XJ3@I[YRA54EZ[NQ*.:'F@@7-KT=D WJ-[&3G:A65'V0[R('S7X K,A)%$-<1B/'[&7="XG~~
~~MWE[R#7NOM,Z7LBR]PSW-6Z_AA;19J6UC$/XXGUIGB#A_;@M#N\MX^RY\F(YL M+3(\'=!IL6@6.#A[]B3:#X\?\6'<^3!^S/H/I>WG+/8C)=I(L9SVC/'0LNT% 9@1OD6L0"??.[OZ,P M=@^(3%A-"?~~
~~*:4%L8<$N G\\,(CBJ'G6A%8]JO-85<7I&UAW"#B23E/X_>W(0 M1]'Q:MX3(_H_"*Y9D2@1(6V+S_^2#MM'O>6;HW($=YXC>=PC8Z\QIN[OD@<~~
~~M[(=AI]_.>LN7OG80Y!LL??!L(6LRMK$U@7N.">P'$U+=C8+]2;H'.1#&*:1# M^MZ:(GR+6:%TJ>?W#S E*\$D"%L[DS3<@RB(TQ"BC9T=B)* Z$^#~~
~~MW208Q[37#AP&DR1]0#9X+94VTMV#Y/BA=318T_=!#R$#R1$"_!F=$Y@DUX, MVAE_OQ"E4!ENR3:A. C&7Z"(R&F"\5J8K/B_$./G"7&83C@X:3 9)[#_PVR@ M'S83^WF\A0Q1L-~~
~~HI(LZ$R7_'AB_RVZ?"!L-^D!*&!U4'[Z@%LES(#,/XH@HN M!;D3#E.ZGQDB7X9;^,@UE,)\+NWC+9L267O.W:\)0VY M(4C)=7*S&=5WN@*5=C!%KJ:BQ4,_?7=*AJF4&"16+74Y='![#@QNZI3X-~~
~~X2/+M6==!AVJ><0&4HR];8Y$<,8H2@X M"Z1YY+)]$G!STUK?6TT@&4AZ3!P&ITD31"SK 4\RH/OE5O,O*QA(VJ(U>2+; >IL0,7R>5IC+C G+ MG9+,B'V$J)?%-H;;XK2I!G;%U 4W!M1^M"+-~~
~~(E1XR[;AL5YTG=*GF93-LI* MON$@_Z4F,*(L[]LX4M(V5/9T>YLY[0^5YUORD&^]W&XR8 L*MT\X>$P6:=U MG1^I,GIJL2WW,^Y3O(@8G84AO.SZ+E>0\X;VR1\@]95R2%JRMV=I!~~
~~<04D3&PX.GC+9W&KP->O!9.J(Y[]W>?.?M4V&ULI5AKC]LV%OTKA MT6\!K M>SR3-IO,##"9;'8#)-A!'NV'HA]HZYJN(\U45)?&NOBU:Q.J7VQ7.;BID;'A6_)X4GE0Z,3;L-V&=M MNI1#C5VN5ZL?~~
~~EHTV,G9]*6MWX?K2=\D:1W=!Q:YI=#B\(NOW5[.SV;#PP6SK MQ O+Z\M6;^DCI<_M7<#=-'_/ V_+]]F*#2)+16()&G\[NB5K61#,^+V7.1M5\L'3ZT'Z&_$=OFQTI%MO M?S9EJ]]FSV>JI$IW-~~

~~GWP^W]2[\\SEE=X&^57[?/>9^N9*KJ8?.,?A@6-O+X/-24-Y1:5=J6Z]2\9MR16&XN4R005O7!.]N%=9W/HKXOZFWD-'=7? M74GE]/P2IHWVK0?[JV?%/B:BH4Z/YNK]6I]\82\\]'?~~
~~5<"*]B*TNZ&J&3(D4=C2[_O:;LQ]6+Y]PX6)T MX>(IZ?][R/Z$./6.MMJJ]SHE"OGY!Z0V1*B[X NB$ENC^I=3-VTP5IT]SY&: MJSN+BI!,5:E/IO&I/J@W)J&DI*2^^_;Y^OUZN6X1>~~
~~[/7GZO*F.IA!9)5L[9 M+7;$I%)-L*MIM3LHX_K;+B3E*UYOL/7.DHY\?V,M;6O"3FQQZ0!3R+EXL#OM MC)XK[-U0K6W%FVO3H$)4XEC,A=:'1*4]3#=I55@=13@<81RB:8S5 1NC29W&~~
~~MF<6)PYHM-':IUE/3=\9;WCRQB)T_^_%E5)]=I4U0GX(N&5V&H* Q)JB:%!CT MU->S=WJO-@<41J&8Q$SUP ;:+GI,%<+"4E"^<=>G+KD"8]4IZHEEV63VW-$. M>HI:!]S+L53[2./A!0?~~
~~[O3ZHL_,AU*>" C5^AX.\U@AK5/)R]WGQ<<$)EF!0 MZL.7Q9/ZF2)VNN-C0'V*$0?]SJ04-UW8U@OU"6>*7F/L"C@8J\YRW-H6QF;U M8T#^$A48R)C!%!C(B/*& M4<);VX'TQ\E%/B,#^MD-#\~~
~~<'!7Q)\2W8 81/<< MB%(W>MO#/G"L)ZYNF):#H"/PQMHN^G!0)8H0;XEJ\GQ#UA!#B]4]J!ZH(+-C M97NPG=F+H$6^'^_^*<&@H32R'NIY7K!_(DRLCVX963'U@A^I1%#YP@;*]>1".^?~~
~~3:)TPE8+1 MH@5&@HV&E^!+T"B%;&V+Q$.84Q0'@X E5PZ&(F7+<(QX\13S/:&;C*H$Q@V) M$$M3LQID50X9W&X^1^;C=MYRZ$' CL=C.]BKD0,&]@E4%B]CYU!O/H B^N8~~
~~MLQ#:+D3Q8=.!'\@5)D%A.X9FD! H5R9H'>@S'ZY MP-<$J(QAS0G;1&7!,KX M W>.N03"\JC5 2&.*@4&J!@*5SL6+HA%<6ET<1"SLQ^H6!T,8/KGZ#[@ I@- M@J7$[:$8/O4GUB%),\"KV)?:H>.~~
~~U*$>D6AV3J M<$[CR M*^<5^-C!:RZ>#5=DT96MS5*AR5K%1&*+FS9)R/0]#>VAYV%\JHU57<*T,756 MTNF$V3NS]0'>V,_<@YSDCX!MO)\@1H/*S'(/^'"?_R;\>L~~
~~02*5A#GW!6P3GN6;4BRX$;IEO'I)]VDLX'QZPGQD3 MN\UOL$]RWL2V2WV3MK)0=>QQ+YJQM#UKR?REUGPE\3)E4XST&,$,V\MELC(O.;4QWK#M5V*]F.1YT;0F(B1D?DNKH\0F?QX$N=^"/FJ~~
~~M/Q/&Y?.9C+D2GK@[OD$\9M="_0-9+6W[R'(NR1.!S 3+,@_R#!99\V]FV5>]-M_#'%_[#*/_;&NSSY8('I8"N?9:02N)2_78RKXY>?F_S!X[@]?S9ZCQ<5-%=8 M4^'H:O'CLYD*^5-,ODF^E<\?X%~~
~~[RC5S6B!$%WH#GE4>[ZV]8P?@][/H_4$L# M!!0 (_J)2EIJ]%18T0D (\< 9 >&PO=V]R:W H965T!6;K:6'HPNSPN^$7?"_JVXT;@;_5(2F8G<~~
~~M2)4S+=87@ZOQI^LIK7<+_B[%SG2N&5FR4NJ>;KXF%X.0 (E4Q)8D M_[2,QHLS]O/OI;1/YR,+5;1A%=BK[W8Z!FQ']DWE=NM83_GB4CZ^T> V.", M:IS7T8L"OXCXE$W&~~
~~8O";/J"O$EC]\3)FSPCSQO&_GFU,E8C-/YUS$8O8GI< M!*7+)U/P6%P,D]&Z GKT <-H G+XD_<<<=\T-B65-N)-8]]0Q% M@=FMP(\6@O$\83GTL8-%4-D/_&^Q45!C:$(KM5I8$0 M\>B,?V:!>/I'!>+~~
~~<3";S2JIE,P)BU6& F>XJQ%#+1Y@)4]//"'1&1LN@RB< MMO=?Y(.,8)DAX]="6LBHW]5_QT$T"]E?4%)E#OGB8,$D6,RFE!M[^/]<@KU) MN =_/ \^3B."/P?\C\_#%X]TW:J;+29OPCU]"7,43*+Y$$;~~
~~E\%R^0;@TUGT)N S!SQ5QAR\&B["Q<4HBXA2D'/ID. \FT_G)"YX9!^/)_)AO MNFG00H_"(]P0].4T&,.&MT"/EF^%'BY/7LJ&!>+Z%;G004\$5KDP6T[?A#YL MT3_/9A2$T:LBO8-~~
~~I$DQ1(JK"LF"_;846;$>_TC-XA7OJ>/S&>J()J!6>:)C/#^ :9B7G2NNQLG,]94D4$ M25" [=:S(:_5N$FU44.)+CAR"R.NL=S3[;BB_;7V+F6PI6*S[K98"'L4;.7 M!#J&3]W^56G '/RK.IR@ 7C&NL;?~~
~~>@&8^D2-[90\",M,K&7AAUY8987.3,W. M;<4%T!J$$HRQ6_+9(4L!2[CCS^UMO7<,BM]Z56^M\02H:'8G1-YW##!]1F3 MSMRBCOE,^$WSW*RAX#W/BC/<8O:MMP2~~
~~MQ9@CJS9\" 7!T*&@04O>*;2R"##W7N8/PECW!H;W_).4FKS-62&T5"[8=UN)6)"6 MBK?$]& Z>=.U.E'(*4OGF+151/D&-0\\+46]H8T #;$&V9YO/I /V08C)+Q5 M "K8XVG@]EC\CBLR^ M?X ?~~
~~R@#E)7='Z_:+(N>K5/0IPV,<%E/T V=<:TW7.*F[K,M^O 2G%W& M9*43(>]!]5:IQ-H0+5]/F) N8;#I(O"HD":ECF-&; CX_<4.W0@!^W?RV1# MK!F?Z_2.Q]ZWGATM:HM6(~~
~~CY"^%IG>OWL9ZRKSE#[E"F^;H1'$\9F8$NBO5. M8"4R+1TA9>$JSU/EC=890T7Q2;@.*T(==7Z)>(S3DJ+*B_#&B4>1%;9^=!)X M Z7+E)6@-FTJ.W-~~
~~!W,$&M8,M9.DX.IW]B19F2C>IUHO\VHWT J["4N>U!Y*R M[CAFK5),:;6SUE*#U*)^ I(@XS#+$)9W+8NV&U&V $GM7,(P#D Z=_DB!H M.,V\+JZZ,1'XSN>4^)Q+:3"&0HT9U/BJ[&,I0~~
~~2OOKM2I_Q@?*0-7;7-AHIP M-4^PM599GSQT9?Q\J,=B5$&*WK;MW@$[D%S1Z$BNNT&+ &<%S(&]-ZBZ0A.V M.]^/"ZZK^O,N/ W#,<54)6Q8T;ZWIVUI^V,&44RAJ6-I7.3$#M&[: ')3K-S~~
~~MML<'3[Z75;$K43QUXX 8:E06&BMBT9]U;FIR;DA#O^ 7;.XDTMDG0@W(U3ZY MQC!SX/B3HRG*8QQGJ'T=39CNR .?<'R(^:SP];(-I\Y0@7#KYMGQ#!N"T,KJ M*P?'^=~~
~~!;>W^NO9MN(>^K@(0L+\S<,6N,X!5I*'28&AWVO>WD%SG8F-4[&HW M/4!93MV-Z[40E'$T'E?SFBAPP5FYO8WJZH38]V1G7.@=](@F"*D:3MLL=\@F~~
~~M65>ZOJB@.DXH7PJJK4U$5E';JO!5CF;3$DGM/.];H&.W&^3417U@)'Y8S(3>-M4&%%ULA,8I#&+(;YC5?_:ETCV8\YH7$0:?P_\(B+T09#-6C^0:XYT%/]@\%4 M_:GOK0[=I^P*H"KRMB)-~~
~~J/4<([^J#^Q!R<3U!?#DAM)54R]$)_W_-BRW+A?'1[0-MMU'FJ:^CIEI?'GWK\T."JZ7(O,,1 0T94V1>?=APX?B:V:)[IJX/1%?4)U,? M[5=8E-~~
~~0G(I=^F1_M*59NA4/9W_$UQQD4PRGOJFT(['2OHVK:GNH]@PD%XR24 M^ SR9[F !N4UG9-B \"C+A0:9BX\6-PS (T6G;K.4L%SL<;]U(T ?5^*)H MVKOY;R-!T~~
~~)SI^$WS1H^G6I*4*BJ0^AQWAM7WHE8"\NUFQOOK*MTWI#FYI=4 M:9GP7H95A_/38]\?1IV/1*Y\TZ&PO=V]R:W-H965TH#(ME8B&!!@ M*S\^KX%*$JV%=GI3 ^)2!"~~
~~[>/OV[0+PR=S8+ZX@\N*V*K4[[17> MUZ\' Y<55$F7F)HTODR K:3'JYT-7&U)YL&H*@?I<'@PJ*32O;.3,'9ESTY, MXTNEZNU:SP/# X.ZGEC#Z2_UQ?6;P .B^YJD@[M9;2P-~~
~~#WMG8]>7^SQ_##A#T5SM_8L.)*),5_XY5U^VALR("HI\^Q!XN>&+JDL MV1%@?&U]]KHEV7#]>>G]EQ [8IE(1Y>F_%/EOCCM'?9$3E/9E/I:S!^C-IY] M]I>9TH7_Q3S.'8][(FN<-U5K#~~
~~25TO%7WK8\K!D<#K]CD+8&:< =%PHHWT@O MSTZLF0O+L^&-'T*HP1K@E.:D?/067Q7L_-D[G9F*Q"=Y2^YDX.&1QP=9:WT1 MK=/O6!^)]T;[PHFW.J?\KOT~~
~~2#HXZ1+.1;K5X1O*C>]44Z3/>V^!MWX8V# MO_&CX8DWRF6E<8TE\=?YQ'D+0?R]*>3H<6^S1RZ2UZZ6&9WV4 6.[WUSI[] M-#H8'F_!N]?AW=OF_=%T/-~~
~~U:0+3"%X1_EDA4,4_$>1)@F:H)V8YI(77.#^^ M,+DT52WU D67&J#RH78&2;[D&E9AHK3 M]RTGI&FJ_$:[@Z5='^NZFD*YEHM^<#-M@]&(^/^+92=-86,:%Y%O00^\X\UX M$_$)]\~~
~~(*+=+Q0T"Q<<4?"4HYK%*"K%QX$ZPRJ3,T,^E;\#S&31I6EV_//OI M,!V].G:B)AM:-R8+=)/LBVBT\NS-H7$I/6.(,L\5^Y&EV#E,7G49A-ME)/DR MAKRQ;,7++4C:&"]-IY& $*~~
~~(%SBZZ)^EO+MT]13P?'.7)Z,5N7V2<01L#OSLG M'2=[NS^RT#BJR6]'_)1\/ 0\!)9M8$?I.MC'UQA'9N'B'P#%A&E3EB^9\DW8~~
~~M&\X0.Z\,6QN'^F\EL55YD3*FY"DQ8[_DS=0%TYU1=$?:BUP!L276H'3.9"H(>:Y\\5^E#/EZJP(OK@#A+A&_FSM5RAGJBGX9 ML+%JIECFG"~~
~~<<+>*2=,O/+&WBO/%K\%RJ2ODXI0$G5KS3GBR;7],-Z8:[2T[B M8WO"&!VDXGGU8BDQT&4L]>,C%["^"Q K6;BQ6+BI8;Z)A5"Q;4OI./8%G#U" M,V9 AU[)$M(STZG#^6ZRB(H(CH)~~
~~@ON7DU#>=QAAXF9:?6NIXU-5#(MEU"HL M$9^?0,KX,.T+Q<) *FI 7M$Y,Y I6BPG.!T>F[D&&86J159(/:,P/#J.;7S-MN-.#G*A2^043V7"K14S8DE]&:Z$1,G%G3U*O,+;_,"\^$*-7)9JU%_N[~~
~~ML1@WT19W@65?=R'<%0*()"SM@5CL#UE=&;2%-SHX49KG0K.;7EFP.D<=KEFO MS>9M17A\9OHQKDPNGOMN*K;*@R=AZN)VY%XGXH,5Y,54IQLL^/1H.=[L>YEQ# M<4?&O<)Y/+#3&~~
~~CF7)&-1-^XOHUM.0.KW()O;5TDL9'[_Q'ETD-S7#SH; M.6;_V.F.UB?FRD'!4#X?B9 HKH!V!XD:BW1V._#&+',Z]*4I3(?)J_V>L/&J'%^\J&ULG5;;;ALW$/V5P:8(6D#6KM9VXHLDP'82-_]!~~
~~M!#MI'XH^4-Q9+1$NN2&YDO7WG2%7LMPJ!M(7>WF9,^?,A:/IQKIOOD$,\-AJ MXV=9$T)WE>=>-M@*/[8=&CJIK6M%H*5,Y;YS**IHU.J\+(HW>2N4R>;3N+=P~~
~~M\ZGM@U8&%PY\W[;";6]1V\TLFV2[C7NU:@)OY/-I)U;X@.%KMW"TRO&4-*QGVY=L>/B]0-\0M9.6I?!X9_6?J@K-++O(H,):]#K@J-3179A?H].!*Q@(5S8PAU>OCK9NF#H]7?QW0GV+/CL-~~
~~PV5[X3$F<9]85'M\9L_OK5Y$UQ_0+I MLSWILY?0?RY!_Q,*/AMXP"Y@NT0'Y66*.(0&XJ0I#:]M4)MV7%>U4OPQ,I8GHH M(3(38-V>;%$0/KIVV.R#/7%H<",T]$:C]X!T0"2Z&*O!G0=C~~
~~T&#"*"10@"7 M!51BZRDL(*JU,!+'L(C<,>)[L'5<'.AXSHG%B.U.W"^3R?FH*(IXJ5:.7$2N MPE1T5A3QC)YB0"$;Z&P@1$6DDR BC*+FQ$193\>R$6:%D68DT]K>!$^.504I M>.F!~~
~~[%F_I\>8:3_E:_+VVN-#.H8O[FZH MR#:&HZ$1("&&Z&+:]%8@OQ5-G9YJ;]?M_W*2"(/=T-WE]ED$R=\0.Q&#?03J M@9PZ 7>B[.P?P5VCL(;WCRA[G@CPN:Y)5XKQ@AJ8$LV^ZD,W(^!:-(#?~~
~~>Q6H M7*WF"J5P[GR3;>Q\SY%DPULK7!4)*4<3R#K_%%-61WCAH-9J,,U#1V2R&BB MXZ+[C]Y].F[Z2@7>;54(B#N^1]QR;4II7<7EF2KC&. N@:GB#[EU5BNY'1][~~
~~MS/*#R=.B6\7YRLFG=*4AM_=C_";-+F>KJ?Y_TFXE:*G6&-IL7X[7D&+LW4 MM BVBW-L:0-Q?C9T,\0='R!SFM+]3XLV,'^A\W\'U!+-P04 " #:B4I: M%T5<\("_"]!P &0~~
~~'AL+W=OO22+0I&M*8*CJVSR:Y A:)G=E."_]^MI-F+0L58GQ) M[/,]S^,[G^ZB#1<8K8/IDR45)E-Z*%9:5 M)94%E@WW7/<4DH<^+(VN8BCGBM"LI@+I"LRY*(IPD4?#-V/&=KN*6K7!D#~~
~~MCJ.*K& !ZJZ:"[W#'4M&2V"2:A<;?.ORDL)$[:V0BN>?\P6RN-ML['CF@M! :DR#$3_UC"%HC!$^AJ-6TZGDS3 W?66_8KM/$,#%_*"VF_:-/X#@8.2FNI>-F"]0U*RIH_>6SSL-/P M7@+X+!^]O~~
~~M)_Y!P@32,Q1XGY#O^F'/?::OAP=]X?R?^NS-ZGO)"+HJ""Q?\)8JZ'OLAB[L MIS.];20KDL+8TG0'49XO9O?'B==-\^\DG^]!L$PV'>: M]5&%X47GU42*=_I1"6)E!X%$*:^9:HJRLW:SYM*VV&?~~
~~VB3>:>CWV1,^F9I3\ MI6\&VPT1*\HD*F"II=RSH6Z7HAD6S4;QRG;#>ZYT;[7+7,]7$,9!GR\Y5]N- M$>@F=OP'4$L#!!0 (_J)2EHL=6B^0P((H& 9 >&PO=V]R:W-H M965TNJY_M2ZBPG/~~
~~:F"Z2B<&4M-&>RL_.5Z M8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/-^G: .Z#4@+3&GY[I#%N:Q-/Q MD?[-UJYKV6,)=YS^)IDJ8^>3@S+(<4/5CK??H:]G9G@II])>4=O%AI\=E#92~~
~~M\.I/U@858=T=O_3G<)*@.><3@CXAL-[=1M;R'BN<1(*W2)AH33,#6ZK-UG*$ MF9?RJ(1^2G2>2C;Z>#,0Z$G@C+ "K83 K !][$I&KM([F#@W[6GKCA9W+S06Y^ MU:D]@=!?$;[@-~~
~~LY\SVTQN"VN/KAQOW'N13_WI#]4(K;!25*><-4URJ&U:'1 MKKK^\C>\JZL/6!2$240AUZG>9*%?I^@Z7S=1O+;=9L^5[EUV6.J?!0@3H)_G MG*OCQ&PP_'Z2-U!+ P04 " #:B4I:$WM9AG(*/'P-&0~~
~~'AL+W=O M.G<3VC)W' MK:=-Z\;)[8=./T D)"$A-08 +:N_OF<7X$,.S>1FTNF"Q"(([-MGSR[-TXUU-MG_U:J2#NRL+XL\DZA.K%;.:SM2JEW[.5,GBSM*Z4 8]N-?.54S+G164Q.YC/~~
~~MG\U*J2Z5,9K:X13R[/)Q?Z+RWU>P#-^UVKC>[\%N;*P]C,]7.5G MDSE9I J5!1(A\>=6O5)%09)@QY3Y];,;X6@VI-$/=I57PSAM:%=N@L-;C77A_";N MAK!+~~
~~<:-71B]U)DT0%UEF:Q.T68EK6^A,*R\>-;\>G\X"5). 69;47$8U!P^H M>2[>61/67KPQN)=,+7\E,G4V0+5ZY6S4Y__67-6?SER/6 M'K;6'HY)/[^47GO:LVN2;8*,"#>Y>&6-~~
~~A_TYCPR9/2[XPUHA43);5M)L*1BU MD76N@\I%9K%UQL=?20<>EMI(DVE9" \S%!(V>+&6MTHLE#("SE?289XV+-CE MF*T \K 6-0SA3E\"A74H/-[XBH*L)4V9!*L+*4!Q=%K=NEGA!@S~~
~~M@J2@(@XR_P2FX/$I+]6>_81F0Y$I$(BL=H[&H-K5LL!$HS+E/24_XEY%((FE MU [!(",[M97U.B17Z,VK:+R002 /5;E0+D*[2,L,<"C*2!&**.(!P3P9/YY.(]JE7XNWJ"R=S#\L:4\0Z.$^>)P-M3_' M4*~~
~~<8KTV4-:*]30YZI3+41#+IPKXT!JB["@6+=CWI7FJ?80^V2CK22'/?29>M M=_0=L1=^&)"KVU=(G(3\F@?\2X_ICX&Z2O,F5.F'H6H5W6//FCN*"%\95-&R3.-]CDS/0GPTZ6&S MMI3;=D-~~
~~F^GKA=:ZQ%PI9>H'$\;V2ITU0+J6E-.T;+Q,M=6RF"HT:+!-+9'VN-MW1NA]:.6UH]&V?>C9V"\0?:6Q#I#_#TN@4(>*5TX/(0[9-%I?FA-U$+N-8GV8U$@P0_9Z]2M,G6RD+(6,@"~~
~~MFEFV6\3U1CEMS M47"\!;>+WV51M@Y?<0UFCX<0-RZ4$)=)Y[B4]<+3JQ-_@JM$U!0H_D$8 MNI5%K%=M?B-A%887A8KDWKZHY)9&A:PJ9^\X'ERGQ"W[DN,?($@*070N/$$@~~
~~M2X1#Z@3(RZO(+]-M[^\2A3-ZJ9>3@X/YRW:W(;H>,]O<31-#8)&@FG' M+$SH4+1I%!V*/-K4M01/1C+7+JM+4!NPX9M&1$5B#E*G;.AHR^T+]PP9@8%2 M<~~
~~]P3P_$M=L>;VO:9DD<';MM;I)1:GW7-M[7D899P-@^/&_WX?GH/OQF;;[1-M13$4_N];V<2]-Q"QBCMQ*TS-)T+E^!24%AJR^$4&@-'BI0$XU";OJL MB!GPB4:MZ3<)-~~
~~;:3@T&OH!:MJ8J1@7+X(Q:R:)B]]9?K'L.F+P9'T'L9UZ(3 M4?LF>!CV*H\AZ<]Y<5=:."1^7M%@W!NFO16M.'10AE2*HV5WOUY=V!@F4\5A72AQ5ZHK#2R<'/!E9*C"R!B+^~~
~~MW[G!Q\QAQY(W&YSGOITU8SO7NVW<'XTZRH>Z=[WHK,'O3#W8?WY#9#_7Z*IV'#_SIPHV_X]"4-RWV^!AT\,S=W*=/@*@OF:F^8E77/PY=+?4'EX M;^?\%"*GIFOE>:&\\:!\2EQ9^VRWI[<7/9-~~
~~%@!'N)CQ:B9 M0MV4;VB8S6\T]-Z=R8YTP=8E?E@[6Z]PGC%K4MT_J((C%A80Z]\P-)*;P^*W M;$LWGK&+$VODFMR)%<"+5:.;62\>*&CI1#DX"Q=D]@ M$MB(Y$B_D:Y)7@:-)X&E#H$ZF9[-~~
~~W659 M# F=-X*SOHIN%-L6MC#'M5:EOK&[/QZ^&[[7[G6LDDI$F#O*/[[)@AQX=#R=S-_/XD-CI[?;WXQ!<^-M5K3*OC,==30@P(!^2G69YU3!/)K.-2ZNI?*(_%5#IH[XZ M-?L-4DWJ^3/E^(J]J9Y#-~~
~~HW#/?63#4;^IR@EAQ"A%JCTL5+[6.AV$!Q79/(! M!3\!G4.MPJSWC;)4;L5?8OD.S(3XN;(=;;_V7L1OG-WT^*D89WO$T8M"+;%T MOG=\!$N?GV-#\%6_,5S84.P)?]<*[1ECB;@/7T@:AY(0?L-~~
~~/R_4$L#!!0 M_(_J)2EH)MH"C&PO=V]R:W-H965T.CB ($O4#\N98R!)5ZP#4@1)MCT,>Z#ELR14(CV2-MBIO]]3M2LN*TJK?U80^)1.KNXW(!CXUM="7D]*8W<5LIO,2 M&ZY]N4 !7[92-~~
~~=S04A4SO5/(\ZIJ6SFY M"B^N$VOO#'ZM<*^/WL%&LI;RHUV\WUQ. DL(:\R 1>#T>,(;K&L+1#3^[#$G MPY'6\?C]@/[.Q4ZQK+G&&UG_5FU,>3G))K#!+6]K1JX2]E->CZ&M%?~~
~~F9UCT\H6H1[S&4A*J?4])&O:]3GRYFA$ZS=+._1 MKCLT]A6T!=Q*84H-/XH-;E[[SXC90(\=Z%VSDX!O,?(M;5 HWT(KR MZ2\B>!;Z :5N7;LJ%+01^? A@T*ATY\JV>KZV=93%Q47HN4U-~~
~~BL4>FRVL$6 M41]8F5(A.BQ!04'3)1W-I"-A@!]/G+'?3^'MQRE9>#'YP!\],7LY=H=!>.)28I(*6M8$C]:0.A'XYY M6(<7GJ_\#D)/0S\9(_5S2QI%0<^)C>.?8!30=7TS(S;&Z %WII?X0"O\ST(% M?~~
~~O+MM((Q6EJ].'3L(]?EBA0>K:V M@1G23?/Z4#52(^2T64A5H;Z 1U=#Q_WZ=?SO14Z_\N0TI6WW=@X?:$IX<)#3 M#K/5I#!5@A/KC7U$]#BCOWN4RG:*CL$9Q(D7S%/($DH_:Y'$7I#.(6-^YM;3~~
~~MS%LLPG.ZF]1/SVGK_VB'T.DY)] 2#E.'S,O"R(((>8,F_,C*.W+V^@=O/ MND,H95$$G3'SXG@.M@.18QK&Y,:(DW5[E(9:CJ 8#Z03YBTRRLT@H!9F6:)~~
~~M%X7SHXUIR+PHBBSOS%\XWK8C_6^RAO'"BSH=Y\XDG,<>2P+(0K_SF5('S#+' M,/:C,67)8!$Z>U51)$7)!1SXMNCZ5K"V%X+=<%T3-O48RPE/:WQGX^O]# M+XB"~~
~~[E0VKFZ8!5X2I$=JLC#VDC0XUC>*+1V+DSA]QVIQ=C3_T"]XX:8\#;EM MV=TH .P.@^15-S^]F'=3*#7PHA(::MR2*W4^JC_537;=PLB=FZ,6TM"XX%Y+ M&H9160/ZOI72'!;V@&&\7OT-4$L#!!0~~
~~(_J)2EI(I+JHC_,"@(-9 M->&PO=V]R:W-H965T6F6!&C:#3?@5A1K[_;AZ$GH@E=8,8TRRC2>0DUTQ/9@,"=O5OU,ZBJ0Z0,!:QP3G45T3B> M137C(MBLW-JMVJQD:RHNX%81W=8U4_]NH9+'=9~~
~~$IX6O_% :NQ!M5@T[P!V8-M/YM;A5K4HQ2\!J&Y%$3!?AU<)LMM9NV=P5\A?$+_Y'+'7'9,PY6LOO'"E.M@$9-"]JRM MS%=Y_!VZ?*86+Y>5=K_DZ&W3>4#R5AM9=\~~
~~[(H.;"?]E35X>!PR)^PX%V#M3Q M]H$CG]G^@?>1*<'%00^R_?MRIXW"+OGGM7P+ M7/8ZG)VH1@_Y=,HL_G"&;]62S<^B;.YS$HJV R#UY2?PU MMN?Q[DL@>UGA/"~~
~~(2X9HP"*],EN2\5P+/6(]@X4._0UC;/#1;B^;9M M)_N3#J2;%PF,^D)@D)?;@C(J/\Z/[9>&,772-$SGJ5_)LL78'Y4FHT$>$>N; MNS20!WM$_(.KN"6+Q47D&D]">S^\3K7!M.V!M1H=L$*^]~~
~~(.2(OUPEF;A;)I8 M,:/3D"ZH%:>+)+Q(;))ANHA#.J/DZAD^U[JUPT[:!AF#AQ'JX(]NL:3 M^30@RK]+7C&R<6_!3AI\69Q8XE,.RAK@_EY*8_4$L#!!0 (M-J)2EJ<8C6>$00-/(* 9 >&PO=V]R:W-~~
~~H965TDYM-T[2=GW1S4C:],6P%[1$VT(DT2/IN/GV M.U*VZB6.EP$#!@0Q1?+^=\?[D;C15JI[O1+"P(^F;O786QFSOA@.=;$2#=>! M7(L65Q92-=S@IUH.]5H)7CJCIAXR0I)APZO6FXS_OQN1Q[Q~~
~~8D:E$8]\#QYT%_6/+G?,95"*!=_4YD9N?Q&[?&*K5\A:N_^P[?9& MH0?%1AO9[(PQ@J9JNU_^8W<.!P89><&0 [0R8B[MSY**\YH9/1DIN0=G=J&8' M+E5GC<%5K2W*K5&X6J&=F=P:6=R?~~
~~7V)=>)5S)!FNMN3NNP5<^KX4^&PT-NK&; MA\5.\K*39"](YO!%MF:EX4-;BO+O]D,,KX^1[6.\9"<%KT410$A]8(1%)_3" M/N?0Z84OY;SB2NQRGO%'1,S~~
~~5"G>+H4;_SZ=:Z.0ES^.)=]I1\>U[1VZT&M> MB+&'ET0+]2"\R;LW-"'O3T0>]9%']0GMW@GRTTM0"[@1F"056$P"5=$F&ZY M*O6QD$^*'@_Y0%T[=6[5NTM4F4>H6C K 2UJ0=.56]AR Q9+-~~
~~'.A^H+!EFO MOX6L\070%SA)8[BN%-Y+J6!6\]9.)?"A6=?R48C]%&-/IKY*PVOX[BZ:*,^G M#T+ANP&?L'(&D'X!'WFEX([7&P&_RO;\ 9/ D-337/!QTH:W9=4N@1OXPE6Q M^ADO" V4I)"0V_^C$-+~~
~~()VD"*0E]RA)X"S0/PKSSBHHH Y76&QR^>Y,Q2M^_M^/NV']UU@0UHZ"=)<@:#A/AQ1' 0)7X:,1Q01OP\RL[0BK&-$L!':"$J<^!G M>M=(=H'U"'2%L'D^+PTE/HDH4.K3A/6ZC/J, MA-8Q#?($3G~~
~~;]]S&K^?V]AM,=Q@=@_6DTG%8\6A>2Z/O_/<8;W!79_N<_\(MJ;MS^ZUIJ_E&=UA: MSLY[;<%-T3XA:>@H^>]7-\#PKT!,0L]DE&;"59D,8]~~
~~M<=0G8>JS..5*"#1GJ8#$@<)8A3FEH(L"+,#=@8Y\2/JL(J#+#J-1Y[$/LVH-M\Q.&IT!(>A"25X,P^P<03BK]!R#,_C<09O\2!,I\0AP()BR'H07WY5#$IRI M>P["((\/2;"7OUO*@S0_3<)S5\=@&!~~
~~[T(8U02]=M:2CDIC5=2]+/]@W=M.MC M?F[OND$\@675:JC% DT)\N^!ZCJL[L/(M>MJYM)@C^2&*VQ*A;^<'TAI=E_-M6-=]FSOY"U!+ P04 " #:B4I:%6/S<#-#;"0-&0 'AL+W=OT4J% "~~
~~MJ:KZ86./X]6M=W.[ZP3ZZSN[#L&@P(=6_=(O]LI.S#//S,Z^C-=*?S!@UC,M@.O9S MUWHZ5JT57.*U!M,V#=./IRC4>A(DP=/$#5_4UDU$T_&2+? 6[=?EM28IVJ*4~~
~~MO$%NIN)*@L9H$L^3D=.#LO<$]Q[7IC<%E,E?JNQ,NRDD0.T(HL+ .@=%OA6(42QG]AW=GF60!%:ZQJ-L[$H.&R^['.31UZ#D?Q&P[IQB'UO+M-GN4YLVPZ MUFH-VED3FAOX5+TWD>/2+G%]~~
~~(RN>!S@5+_XAH;KFF3UQ/TW%4*;5"'-_YL9J MZJ_=Y6ABS+8'<7MJA.S9 5. MHV!O4*@^G'#\DP_OQ.#H-M#H/WT*>WM$O+-MEDBK:D<*KY=T%_MW\7>S[S?.M% I0:< EPO8~~
~~MYY)F5&O(TQR#52O@5UXA?-'*&+AGHJ5$BJ)M6L$:WH#-@680^R44[?CQ^.TB3YO)%[!@2,VE6D5(X12-@-MZ1L,CO*MMQOW5'>:E0A7WN,37*.EK/'FH6^2AL,XWOIW4D]]YH\1HGR#PA?/~~
~~MU'Q)8,]8(WAT-8%A."+7_20)+JO-=%K540BT>-M7W#*-H99&'GVA=@:DKY2R3X(+L'W/3?\& M4$L#!!0 (_J)2EJ87,+.(*-9->&PO=V]R:W-H965T:CZ8)(#~~
~~ML<:)6=L,L_WT/4Y"H,M%@U3U@<2.??[^'1\?7JM@!6-424\ZON)5S%>.[-)\^U)S29R8P2O MX4D1O:DJIK[>@Y#;J1,XNP_/?%4:^\&;3=9L!7,POZV?%:\7J7@%=2:RYHH~~
~~M6$Z=NV!\']GYS83?.6SU09M83Q92OMC.3\74\2T0",B-56#X>H4'$,(*(<:7 M3M/IE[2&A^V=^@^[^C+@FEXD.(/7IARZF0.*6#) L(\R^V/T/D36[U<"MT\~~
~~MR;:=&T4.R3?:R*HS1H"^U^V;O77[<&"0^6<.:&= &^YVH8;RD1DVFRBY)V$*"$\ &@FM;2RSO]^U:?GM$?D<^R-J4FG^H"BG_;>\C:],=\#V] M*/@(^OT) Y=0GT87],)^~~
~~\)&+SRCUWGXY]U"&X5GY*]3/K82T6D)FS=CO68Y M3!U,# WJ%9S9QP]!XM]>-(QZP.B2^FR.>5AL!!"Y)&>B]7T7IU/H%\5/H[_O M3."%0$P)^%, A-4%J5&<5&VXP8:;8+"@6H#J-T:X[O*?~~
~~_XWC"WLID $N9$JY MT2BBAV/R("M4(7,C\Q=R5Q3H;IHU]\-P2MZR<20-)[26S+(-M7.I'^_XC?^4%>J:M\TO@!C5V8[MWX-+8)[_@=C":&;QI%-AV_X?][@-M[H7^_A!XHXB:O$3Q!^=QXD"?~~
~~2>NG$0 M6_#,S;(KP*.87@4>-^!":GTT-$C]='@"^^A8'E*/DK2E#K+T7,+]ZD0_E^I M$.Z=P^.<6N=&@9M<X*<<\/^QN=?Q@8M[N0-0Z&D3,ZO*=\J-?%R46.FI*%Q9"<"9!974]3TO9,W&."~~
~~[>DV"FSX"9QA0O8@+]KUD+/W(XE(R4P23A# O*9 M,Y]<+B,3;P,^$SC(WA@9)UO.[\WD.ILYGA$$%%)E&++'^[6$)E!HB+>-[R^ET M*0VP/SZR?[3>M9((A. /P6X#\!^/X)0-"FNT469MK;#"22SX M~~
~~0D3K=G,P.Z-16LWA)E3W"BAOQ*-4\FF.3W$<[0A!2,Y23%3:)ZFO&:*L *M M.24I 8G.5J PH?(\=I7.;/!NVF99-%G\$UG>H1O.U$ZB#RR#[#'>U8H[V?Y1-MJL(?)5Q!>H&"R6OD>_X4W6U6Z.SEN?~~
~~ZK*BZ,Z#M&U(#*Y3CI#1;/24?$!%T$I*]MT> M!Y8W.,$[M)E?YUNIA/Z)OPWM9L,W'>8SA7TI*YS"S-&5*T'LP4E>O9A$WOLA MT-]Q'U:6=].L:NSRD'(2#31[,'5L.0V88AL@RFZ>R3R22,/,^+W7W?Q_,X~~
~~M/_*"?MPCB6$G,1R5>%U6F-C=F)0I-LKU*5'=63*$I00EAQ2'SY0\U3J:\A_W-M/.H,1:.&/M7E%H0QT]4JG5!2/3SCQ6R:*C#_F$\L3::_&^MN;W.58(H;$.7-MR-9+T\2ZU>[.F-M6Z?~~
~~X.;RX<7;T%81)1R#74NWBC38BFB3<3Q2O;![=&ULM9Q=C^)&%H;_2HF-5HF4 M#'89&^CM1IK&'S6KS*35DV0O5GOAAFJPX@]2-LW,*C\^MC&8LDV!1R\WT]C4 M>4X5]>+C>O'4_2X1?~~
~~Z1KSC/R0)KC]&&PSK+-W7'8+M8\M-WR8;'^3NOB8C\ M+#\4JV&Z$=Q2EP4.1:?@TC/X@'L_ORW).8W@2?;+-QB_B1(NHTB7WQ]Y&&R M>QCH@\.)YV"USHH3P]G]QE_QSSS[;?,D\J/AD;(,~~
~~(AZG01(3P5\?!N-U.V9, MBH"RQ>\!WZ4GKTDQE)UG_NQ>)#LBBM8Y-MK7A1"J*,SJATV/0'ZD2://%.V+H/Q*JT1'Y[;-OO-N![+AHKPBQ O^-MRTL8K/SR(XF2)0\[^CR_/H5Q2-$U=%Q/=~~
~~[[@Q23QLWUV,'UVU9C/?) C-+G/ M'1A/C?GW-KX*P]28C[YH?X(*#1G'KX]17"I$P&PES MD# 7"?.0, :"21H<'34X4M%GG[,1"Q>%]H[?_93\51]TJ4])[*L^),S>P\P2 M5MQXO)65>*:F3(D.28Y4I]-59?~~
~~KJT9K9F M5)=G=*[L3%\!74SG(.Y2)B'A#$03!*0=120I130H0J*D]O*7#!!LB01+[25-MKH--+J)S]RB/UJ7+P%S9@-ZBN9C.0:9SD3 /"6,@F"2:\5$T8Z5H;/[*A>#+~~
~~M7#6E>KITL2=8I]]NW;0:TE"FZ2N-:S(ZR(PN$N8A8:S]65!+,XZ?A33KD^.L M3Y2S_K&^'KSR_,Z%^R+N7!\^3EK933J=C!J3WVYEF88^EEO9[5;Z1#.UYKRV-MFU%]9%J:W,Q5CK#6C"%A#~~
~~239G9ZG-GIM3,[+YV,_*!K7I64OC>C2)B-A#E(-MF(N$>4@8-\$DQ>E:;6=I-UJ05V"0#*$T&TISH#072O.@-(:BR6(\\59UY07P M?1QO_?#TCK>L<(+'?)>?~~
~~W]\0=VI1S=7)U[Q*=LI.&=A;=M_8#0?:#1=*\Z T MAJ+)"J.UPN@WKK,Z9:6&*62E#.PMJV_LA@/MA@NE>5 :0]%D6=6NMJXT+.N5 M6'WI2@_7KKW@_'A)DFR=OW?0WO^[;]JK3-~~
~~*=MJ8U;J#GZO[T%E@[IS%NYG2@ M.5THS8/2&(HFJZGVIW6U07W-NEYO^[XZ;KZXV?[N6;>0O\N2++.:"/(ED)?RH>0ON@<2K.A-=*BD7:0Z6K4*AJL>7N^IA5K+*)H\M;4)K?=RH3OG~~
~~M%&G,SJ$T&TISH#072O.@ (:BR:JK#7)]>JOJ!C7-H30;2G.@-!=*\Z TAJ+) M3T/6UCE5NJ$IJEL%DA9.$\ HE+>.5G0T:OX0U]'*HK3Y.UQ'JS%M_@KKJ@?8 M=W*A (:BR9-;6]%4[=4^\T0L\]5;ZH?~~
~~=U4T=W->"J794)H#I;E0F@>E,11-MUEQM3E-ZH^I&D6;J'$JSH30'2G.A-]*8RB:+,:TJ9J2[M'=3-:M69D:N/F M0T8=SIT)-4G MD[85"LWJ06D,19/U4KO<5.UR?^([;*\4VS#-T<]2L<%"G&TIC*)K\?~~
~~[9KI]M0.]V-"G?] M4E'-[7NI@=)L*,V!TEPHS8/2&(HF:[$VY@W]1G7/@#KV4)H-I3E0F@>E>5 :M0]%D,=:.O:%^]KZNJ &<&]18?;54_L 4DI@W-Z73DU>MI"XTJ0>E,11-5LO)~~
~~MWB<7+/4@#J)MYY.@ZLC>\L#N;X+=X 2[PPEVBQ/L'B>W-VMTW1K ME,90-%EMM? OC&]58J$_"$!I-I3F0&DNE.9!:0Q%D\58_R!@J)-([U%BH3\ M0&GVA4$:YTLLU.N'TCPHC:%H>YT-~~

3_;"C;A8E?LBIV21;.-LOZ_G\>QQ[^7W MY8[#C?./^MU<[SAOZW?.?F?E&K_?Z/FC+U9!G)*0O^:IM'?C_-Y!f/=.WA]D MR:,&ULO5?; MCMLV$/T50@V*!-
BL+K[M;FP!6:M!6W2!A=TT#T$>:&EL$9%(E:3LI%_?(24K MMB4[,:#VQ1:I.8=S#LD1.=T)^5FE)I\R3.N9DZJ=?'@NBI.(:?]5A3 \V[UF&4U'JC'%XED25>4[EUT?(Q&[F M^,Z^8\$VJ38=;C@MZ
:6H-\7SQ);;L.2L!RX8H(3">N9\]9_B'P+L!%_,=BI M@V=BI*R$^&P:OR4SQS,900:Q-A04_[8PARPS3)C'WS6ITXQI@(?/>_9W5CR* M65$%/5/O]1&' "0IQL0U(#@%# \ QC4@,&/
H8U8&B=J:18'R*J:3B58D>DB48V M\V#-M&B4S[B9]ZE66^)8A3H<+V (O@2P@%AO.[%R\)DM<7DF9 1%KL:I(2$ M[$?1J IR]K0#'R-C,C+%Z_("\(X^3,5I:(\45-78VIF #>NTWBLT@C.I#$@
M3X+K5)%?>-+),=Y%28VN8*_K,;A(&$%\2P;^#0F\8-B1S_PR? D%PKVS\.@R M_/>2GX,?]1DTLS2P?(,S?',T1^(6(1^83LG<+@N0-^0/1EP>RM29!U70&&8.%A(%<@M.^/-/_MA[TV5CGV11
M3V1'%@\;BX>7V,-FF9%TFO-[),LJLC&ELQ4 M_VT8C+W!U-UVF#1J3!I=:1+PY#/P.C5IY^/YHW.11*,\X[+7*>R([[BL>>=[.*[=LGQ3X.B E-PR'0DZKX1=?]CHO)F^RFR!E $ MCR-$Z!3[4'
,>,9,NN3=MY(:M=2U8R8M<>T8WS\GSO>^G=&\:^49=?LI/!%I MSG'_=,NLQSG,[S7F=ZJT,RQHB>T,&YV5>W D]7O_RM241Y^95L;SKJC6,HXZ
MHH+V++H'AVXL4AM[>5$D%B77U3FUZ6TN2&_MM>"D_]%MZHA*W MIB(9K)'2NYV@U;*ZR%0-+0I[M%\)C972/J9X^0 I O#]6@B];Y@!FNMD^"]0 M2P,$% @ VHE*6N?=I@1J!0 I2(!D
!X,"]W;W)K&ULM5I;V1@ZW9FFDTFZ[4.G#\26 M;68!N2#;VW]?<0D8$,)LE#S$7,YWOHN$#A\P/Y/D:[K'F()O41BG"V5/Z>%. M5=/U'D=^.B4"+,S6Y)$/F6[R4Y-#PGV-[E1%*I(TRPU\H-
86<[S8X_):% Y?7 4[#;T^R NIP?_!U^QO3+X3%A>VK%L@DB M'*$0KVE&X,.? M$U[A,,R86!S-EJ1*S?Y3<[D\VK%L@DB M'*$0KVE&X,.? M$U[A,R86!S-EJ1*S?Y3<[D\VK%L@DB
G$NLIH#U,:4D*HU9!%$0%[_^M[(0%P:,AV^ 2@/4-C!Z M#/320+_6M#U$:&-=Z,$N#/'6UR#F#TOG.M3?SE/R!DD&9JQ91MY]7-K5]\@SB;* M,TW8V8#9T>43/N'XB,$37I-
='.2#=PN>V7S<'$,,R!:X0>KO=@G>^?E)=N35-M9N)BZ@=A>L,LOCR[8/+A!GP-00S^V)-CZL>;=*Y2%F/F25V7\=P7\:">>'3P-M0&*Z3X$7;_"&8^^*[1V!O AU^!$A#!B>>U?7F.B^=
MMWGWOMM[HQAZ-5OTG$_OX^N="W__QJ#@,\51^@]OU M>@\^;K89WZ<%?XX7" MEKL4)R>L+'_Z 5K:S[R2RR1S99]YDL@:@V 4@V.(V)>_,UE)_1!SK[K"U,I-
M,_$X+4WDV&Q*G2X+VT59!YG393;14%;,S6K"?.Z, 0-T](J6"-+L\K2%&;Y MG&7X$1QPLL8Q95K&R[:@<"XC;&4ZB' '$9X(T!'Z^YF5F=
MHMY"I.MZ*SVAG[%7",>G;FAF:_)XDGPV*C>K*C<;4[FA^2$FFT!ZF@_WO"6 M'J'EV,(.A6'VA>%)"J-1:[NJM2V,ZPF39(.3_K5&:#YVK9=)YLHD\R21-<; MJ<; >2^7XM+VQGD\W,Q
9H\0O=#3VBN(Y189MZ^TJ2?+:+%_=5$#A;?%8 M\1Y@FT!K:O6HMJAT="F' C&F>H]^RPJD6?&Z4X!#K<(9#(BXF&&L4$AE;+8FF-1]S/0?"6=K,"_L M791M:WI,UKHH9#BPLUYW8,I^V9
U\ZR;*'A5%S6P_,YXD@IA)V,^3C?;.??@ M['\;2?%QOUG4[\7]S#7J;7.$=-:^*UF)'8V^A#A.;6BTGT+("-A5S5ZB&2RN5+9/%ELS2&JFS,D;LZ$
MXHVZ'1*T.T]3.2AD&.U.G(.R$&H_%>>@9LBT^"*&ZAX*7=5#B1??DJ,EH5I; MDE=]N$[&/;CVD^%A7#/KNH]!XC[F"NE&W=<0MQ9LO_@0^QE]_7!\0DW7VF5Y MC\8#U8T'NNI-RK7*/<
V0>84]BBWV'1T=0<"86TWZE%N68$4%5]59'JV\J/N5?$K2.W\.[%>0<<=^&=5WPQ4=,7'W \^,DNB%,0 MXBUSI4UG++&D^":BV*'DD+_T?R&4DBC?W&.?=?P9@)W?$D)?=S('U9&PO=V]R:W-
H965TRL;9+9?[_7AM"$N+2=Y4N"S;G'OL?'+Z8'+I[DEE*%?A0YDS-GJ]3NUG5E MLJ4%D3=\1QF\67-1$ 5%L7'E3E"2FJ-B=['G#="V"9,R93TW=O9A/>:GRC-%[_M@619%$3\>T=S?
I@YOG.L^)9MMDI7N//ICFSHBJJ'W;V DMNPI%E!F(YC11FH+ WYXN:)YK)NC' M/S6IT[2I T^?C^R?3?*0S".1=,'S[UFJMC-G[*"4KDF9JV_\\#NM$XHT7\)S M:7[1H<9Z#DI*J7A1!T,/BHQ5_^1'+<1)
/#8 W =@ L!X0L!01T0O+6%L X(MW)I"5 >8U-TJ=R-<3!293P4_(*'1P*8?C/HF&O3*F#,*2@EXFT&6E)"R54U=!SW7[;E+W\J[J)7ZAEP'Z
MRIG:2K1D*4TM\7%W_*0CW@7%&MGP4;8[W$D8T^0&!?Y'A#T<6OJS>'MX8$G M_[6^_.G6S\0(&@\%AB_H\E!N/)15'AJPLJ""*"ZN;FVC7?&%=CZ]-M[*'4GH MS('%3U*QI\[\UU_\H?>;3>H^R>
(^R98]D9T-2M@,2MC%;@;E.!IF;&SC4%$, M#87>4O;SZY$WFKK[4WTM(#!."Q5?HJ)@%)R#EC:J,!PWJ+_,HR;3J_^JVJU M&:24<5@A7W9=U*?K^B2+^R1;]D1V-A;#9BR&G:
[[;C9FFB*RA_F_H0@6@D?8 M+V#__"L6<#*H]P8XLT@%FP'L**B4$;!&SX6:)QNU(1, B'D=^RL T8X@B/<,Y$F32B3#%J1>]X]1)[LS49GC'Y)F\=?+8@-;)8P-.QB,\;&FVM &[)H_O
M/9]FO7<>17:P^IPN/=:=H6;M:6OHE2WNE6W9%]OY^)S<-OQ.V]Z9)5X[,^5Y M3H0TXV,&QFK2FFY\>F+P;KS6:KRPPUI&CBTH[P8/6^9\@>LE:^+GU'%GZG$] M1=^1/'Y;\E;81?
*7%OR=JYV\N[)A1,.^AMSTY]F!,N(J+X&5-7%=^:Z^\@5 M7)[-XY:2E-H-@/=KSM6QH!MHOLG,_P-02P,$% @ VHE*6C?'1O=3 P M#@X !D !X;"]W;W)K&ULS5=M,],P$/XK5I#0 MD-
CRVC8;,:6M":+20-6JP0?$R!R^YMM82.]A.._XJMI-ES9:5 4%"JAJ_W/.< M[Q[[(9(]WC-X*#8!X=WE&Q<3:%2FKRM2T*#C@U-MH#RS/<<9VCDFU)].S=B"3\>LE!FAL.!(E'F.^8\+R-AN8KG6_<
566^D'K"G MXP*O80GRNEAPU;,;EI3D0-5A%'%83:QS]RP.M;TQ^$Q@)_;:2$=RP]BM[LS3 MB>7H!4$&B=0,6'VV,(.LTT1J&=]K3JMQJ8'[[7OV]R9V%2RLW$ M"BV4P@J7F;QBNP]0QS/0?
G+A/E'N]K6L5!2"LGR&JQ6D!.??%=G8<]@.+I M!G@UP'L,")X!^#7 ?ZF'H 8$+_4PJ $F=+N*W20NPA)/QYSM$-?6BDTW3/8- M6N6+4+U/EI*K6:)P//C(J-P+%-(6T Q\=Q\>P-LJ[B9X
M[S[X"^\@803)"?+=M\ASO*!C/;.7P_VN_S'WEO)\)N=X!N^X!D^H[E MF2AP A-+U30! M? O6]/4K=^B\ZTI^CGV11GV1Q3V0MF8)&IL"P^_(=$XE24E6FE.YA*3D1!*E
M6WR79*4Z%FC%68YF+"]*B4TM5MK%F%,EH]@[W%\O%3&:2\C%MRXI@SZE[),L MZI,L[HFL)>6@D7)P\,2UI!0/4AX16M8-UW*5*0#0ZJO =OI:3CT1^'8WN[G M_*E9Z W4KVT6/34;N*?
AP&N;Q1UL_L@)@\:LE8%ADX'AP0S,&-T"ET37FX6Z M(0#GA\K+0;+?W9-]DD5]DL4]D;44&36*C/Z+\C+J4\H^R:(^R>*>R%I2AHV4 MX;\H+^&3D^XZ[N.R,7N15?
34RGE45W[%4T5N[UUP<^!K\[(0*&$EE=4-IQEM M'B_GYL[^:/S"/9NY'>.1>NQ4,Y_'^NJE]!'S-:$"9,!2KIR3D5HKKUX?54>R MPERO;YA4EW73W*@'&W!MH.97C,G[CG;0/-&G/P%02P,$% @
VHE*6@@J-ML_S\+0-\P4$!D !X;"]W;W)K&ULQ=UM<]M&- MNN;QK\+RGMI*JB8QGREE$U=-@FYT-XUNH),Y6UM;^X*189L5B?2A*#NI.A]^ M28DR'D@UB>2?
85[,T#3Q:\B,KU"W<*&__[Q-_W;_H2PWO=_O;I?W/[SZL-E\ M_.[UZ_N;#^7=-/[;U<=RN?V==ZOUW7RS_>7Z->O[C^MR_O;QH+O;U\-^?_KZ M;KY8OGKS_>-S^?K-
]ZN'S>UB6>;KWOW#W=U_<>/Y>WJ\P^O!J^>G_"+]QV MNR=>O_G^X_Q]^7.Y^=?^?]+Y\U>LORMO%7;F\7ZR6O77Y[H=7_QQ\YP=7X]T1 MCR-YST7Y^;[VN+?[6GY=K7[;-4*__>%5?
W=*Y6UYL]D9\^W_?2I_*F]O=3V M1/YKK[[ZLNCNP/KC9UT^?O7;K^;7^7WYT^KV?R->;C[\\.KJ5>]M^6[^<+OQ M]\^JW']%DYUWL]D%J]_S?WN?]:_NO>CW_K!XWO_M^NFOXN/?XVB^F;_Y?
KWZW%OO7K_U=@\>P^#Q^.U?W\5R%UP_;],;WUULC]N\ M^7FSNOGMFQ^W?_/?]GY.W6WS\[^&"C?].Q\O9[O4J7W551NYHO;^Z^WS_[K MYZCWU7]\W?N/WNO>_8?YNKSO+9:]?
RT7F_M_;)___]Z\WV M#'?KO+[9GXUZ.IOA"V;#?4\LWY9OCQQOPL>/3AWOPL=?!XY_O?V3 M_?+'.WS^X_UQ& 3_^?#^\]YH\(_>L#^<+[F?G*'_UQ^_+8WG#?>/CYR>'3^_MZL<.%^'#DX?
E]O#^BX?+\.'9_(>8/KBT?&>^XWG[IUR\>KLXX/'#N^OPO M?73D\.3V-CAD_[JQ_[HW%\[^?ROK5Z<-M\2??OWIQ=7_J7_GU2R??B(_1EW0>/7JCE_[^[P+V6#K__M'[.%_W/LUO'\K>5XME[^WJ
M]G:^ON]]+-=/\X6OC\5GT.\GR06D9@@,4EB,8DI$M,DEI!82F+F"9O5$]/_M:;\ :$9&1BYI2"N/MXN_]C+'OY M[7S9FR_?]K9/3WK18EW>;%;KQZ>/96*0[I]))!:1F" Q26(QB2D2TR26D%A*
M8H;$,A*S).9(+^=AX6">(T)=8B&<7'KS.R+0FL8C$!(E)$HM3)&8D5)&K&$ MQ%(2,R26D9@E,4=B.8D5).8AK)'65U_2^QE^'D-U02J252+44VAFD:U!-525#.HEJ&:135W(C9&O3_*^?K8IK4Y M>AX%JGE*.X9M54#>/NPZNE@L7QQ=!+'.P4MJ$:H)5).H%J.:0C6-
:@FJI:AF M4"U#-8MJ#M5R5"M0S5-,XRK[MEP_^V,T07/$.U"-4$JDE4BU%-H9I&-MM0354E0SJ):AFD4U=R(V!H^CBZ-9BY;,4,U36C-KJY+9,%PR.S*Y.Q^\V@$
MHZ4S5(M03:":1+48U12J.:51+4"U%-8-J&:I95'.HEJ-:@6J>TIJY7%73AE>7 M'F*@M394BU!)I$M1C5%*I5$M0+44U@VH9JEE4E^&ٺ MX?+;SXV.VV/R;;E^ND%V%E8V_.WL?=[O8G2F_AE3HG-
5IZ0S6!:A+58E13]*91 M+4&U%-4_JF6H9E'-#0^+9>/A:#JX,C=%T'(73"2.=X1,MZJ"93):C&H*U32J):B6HII!M0S5+/%V; /?9-QN.J.+%JCF*X9KL]7+(>-Q?T-]
)K]@YBM'6':H).H5).H%J.:M0C6-:@FJI:AF]EKC%E^#P738NDL$NJA%-7?>EY"CBQ:HYH]\"=O_3(S&H^X_W MT!E5#;A1N,IRUJ4-VR=_^K-HW_7$[^7-P^,NG.[=N\5->>Q"DA_#*W9.3[0R
MAVH"U22JQ:BF4$VC6H)J*:H95,M0S:*:0[4-F+'O8G M0 4XJ46H)E!-HEJ,:@K5-*HEJ)B:BFD&U#-4LJCE4RU&M0#5/:BB&:I9 M5'.HEJ-:@6J>TIHA6]7C1J?K<6?\S VMR*%:A&H"U22JQ:BF]EIC
^G#$-'H MH@FJI:AF4"U#-8MJ#M5R5-,UVKO0MP(*,1MGY4O0@)@ MA-7*(Q6!>F\V\V(Y7Y7]X?K3#I*X%F#$,,/.U#;A(@$&F|\@EU&MHDRA;(S&X7-F$TI>R$'\HF2"-\]F>.J&:F^V\E\H63=,P(&B/%&J(\-(A%B?#ZA[HN
"<"&W,H5J$;Z@:@++5)*5U+J5&8&K'*YI[\P)-Ur^@-+*93T@C&V[\!F&K%%HRhuP&D"]&C%\7)>U+@3O@FX&X(J&IW4O7JP&CG8P&J\PI\)?X&3&^1-JI$GJ^JHN_XDXW*&]PI3*?_K@MC%+G&\]K
/W5@L#79,5U2)4$Z@F42U&-85J&M62$__" MOGQ#\A0]#X-J&:I95'.HEJ-:@6J>TIIA6[7CQIUWM!OVA/\3-U<+NYTS&"W, MH9I
-8EJ,:HI5-.HEJ!:BFH&U3)4LZCF4"U'M0+5/*4UTIH!7E7[QN%J'WAS MM?!*G9,:K?2AFD UB6HQJBE4TZB6H%J*:@;5,E2SJ.V6N/6/Y/^;-SJ3:.+
M%JCF*:T9P557;_LP%,%GWULM['0.6%*+4$V@FD2U&-44JFE42U M136#:AFJ M651S>ZT>L,/9:'00L.2B!:IY2FL&;-6E&X>[=.?5/,)(YW1%2W2H)E!-HEJ, M:@K5-*HEJ):BFD&U#-4LJKGQ8?
EP//V-V(?]01L7,4HXT[5!.H)E$M1C6%:AK5$1+4M%B7*YL5NN7KV=-JV^H%]J&.:0#6):C&J M*533J):@6HIJ!M4R5+.HYE M1[4"U3RE-7.YJKZ-+UU]&Z/5-U2+44V@FD2U M&-44JFE42U
M136#:AFJ651S):C6HII!M4R5+.HYE M1[4"U3RE-7.YJKZ-+UU]&Z/5-U2+44V@FD2U M&-44JFE42U
MQDV@S>+"3M>$1;4(U02J252+44VAFD:U!-525#.HEJ&:134W.=PLKCT21AEY"CBQ:HYH]\"=ZU#N'E.BT9H!7O;9)N-?V=PPKT!(%IL_FA]\#PY\
<3*!%M10+4(U@6H2U6)44ZBF42U!M135#*IEJ&91 MS:%:CFH%JGE*:P9XU8Z;S"X]F4!K=*@6H9I -8EJ,:HI5-.HEJ!:BFH&U3)4 MLZCF4"U'M0+5/*4U-[RJT4V"+8]N&Q"0%K*\U;H1->I?
MM^Z$HM!5-.HEJ):BFD&U#-4LJCE4RU&M0#5/:CU%L-Q3]RJO MMI^$%Y*=%*=Y*=<8EQ\Q+-AP:+=V%QIRZVs>Y+^9+S#XTE/>J$+XS[+@D)-*8P&YS?S\^&1^.C?HQ8(&]8I2P9T\+H&;E)N8MP&XZ
<.U2)4$Z@F42U&-85J&M425$M1S:!:AFH6 MU&N4I9JRY:A6H)JGM&:-5_6[Z>GZ77C7SS#0.8#ZAVJ]"523J]!:?>!M?W@M3H>A M42U!M135#*IEJ&91S:%:CFH%JGE*:X;ML K;50S5/:CJ]TIC[QHW-
KI MN$!/W5-:,^BJJMLTO!'<+ZO-_+;W?CU?;KYY.]^4O?7 SQ;KW:7[[<#SET-X:MJD6H)E!-HEJ,:@K5-*HEJ):BFMEKH9TQT07MZ07=Z9?D1UXR:'\T+-3]Y36 MS+BJ#38
M\%V_TD(0OYC4[^!$4NFB!:I[2 MFAE;-;UFX8K0?FIQ]#-P]3'Y'[U?MH]O/I0]MSPZL0VOTCE^T3H8]@E4DZ@6 MHYI"-8UJ"JEJ@&90+4,UBVH.U7)4*U#-4UHSI8=52@\O/,J8H64S5(M03:":
M1+48U12J:51+4"U%-8-J&:I95'.HEJ-:@6J>TIH!7I7-9N%-XT[?4"$,=Y@ MM"R&:@+5)*K%#*9IJ*903:)-@FHIJAE4RU&M0-HIH[$1N@QQMX",M!>&:I[2FEE;M]<V*UX#F1^?5T<#>$:A*@TF
FM0C5!*I)5(M13:&:1K4$U5),ZB6H9I%8-L-5J&:I95'.HEJ-:@6J>TIHA6]7C1J?K<6?\S MEKL4)R>L+'_Z 5K:S[R2RR1S99]YDL@:@V 4@V.(V)>_,UE)_1!SK[K"U,I-

XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 192 217 1 false 50 0 false 8 false false R1.htm 0000001 - Document - Cover Sheet http://www.1800petmeds.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 9952155 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 6 false false R7.htm 9952156 - Disclosure - Revenue Recognition Sheet http://www.1800petmeds.com/role/RevenueRecognition Revenue Recognition Notes 7 false false R8.htm 9952157 - Disclosure - Net (Loss) Income Per Share Sheet http://www.1800petmeds.com/role/NetLossIncomePerShare Net (Loss) Income Per Share Notes 8 false false R9.htm 9952158 - Disclosure - Stock-Based Compensation Sheet http://www.1800petmeds.com/role/StockBasedCompensation Stock-Based Compensation Notes 9 false false R10.htm 9952159 - Disclosure - Fair Value Sheet http://www.1800petmeds.com/role/FairValue Fair Value Notes 10 false false R11.htm 9952160 - Disclosure - Intangible and Other Assets, Net Sheet http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet Intangible and Other Assets, Net Notes 11 false false R12.htm 9952161 - Disclosure - Commitments and Contingencies Sheet http://www.1800petmeds.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 9952162 - Disclosure - Changes in Shareholders??? Equity Sheet http://www.1800petmeds.com/role/ChangesinShareholdersEquity Changes in Shareholders??? Equity Notes 13 false false R14.htm 9952163 - Disclosure - Income Taxes Sheet http://www.1800petmeds.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 9952164 - Disclosure - Related Party Transaction Sheet http://www.1800petmeds.com/role/RelatedPartyTransaction Related Party Transaction Notes 15 false false R16.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 16 false false R17.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 17 false false R18.htm 9955511 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 9955512 - Disclosure - Revenue Recognition (Tables) Sheet http://www.1800petmeds.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.1800petmeds.com/role/RevenueRecognition 19 false false R20.htm 9955513 - Disclosure - Net (Loss) Income Per Share (Tables) Sheet http://www.1800petmeds.com/role/NetLossIncomePerShareTables Net (Loss) Income Per Share (Tables) Tables http://www.1800petmeds.com/role/NetLossIncomePerShare 20 false false R21.htm 9955514 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.1800petmeds.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.1800petmeds.com/role/StockBasedCompensation 21 false false R22.htm 9955515 - Disclosure - Intangible and Other Assets, Net (Tables) Sheet http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables Intangible and Other Assets, Net (Tables) Tables http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet 22 false false R23.htm 9955516 - Disclosure - Changes in Shareholders??? Equity (Tables) Sheet http://www.1800petmeds.com/role/ChangesinShareholdersEquityTables Changes in Shareholders??? Equity (Tables) Tables http://www.1800petmeds.com/role/ChangesinShareholdersEquity 23 false false R24.htm 9955517 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies 24 false false R25.htm 9955518 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 25 false false R26.htm 9955519 - Disclosure - Revenue Recognition - Schedule of Deferred Revenue (Details) Sheet http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails Revenue Recognition - Schedule of Deferred Revenue (Details) Details 26 false false R27.htm 9955520 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details) Sheet http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails Revenue Recognition - Schedule of Disaggregation of Revenue (Details) Details 27 false false R28.htm 9955521 - Disclosure - Net (Loss) Income Per Share - Schedule of Earnings Per Share (Details) Sheet http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails Net (Loss) Income Per Share - Schedule of Earnings Per Share (Details) Details http://www.1800petmeds.com/role/NetLossIncomePerShareTables 28 false false R29.htm 9955522 - Disclosure - Net (Loss) Income Per Share - Narrative (Details) Sheet http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails Net (Loss) Income Per Share - Narrative (Details) Details http://www.1800petmeds.com/role/NetLossIncomePerShareTables 29 false false R30.htm 9955523 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 30 false false R31.htm 9955524 - Disclosure - Stock-Based Compensation - Rollforward of Restricted Stock Awards (Details) Sheet http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails Stock-Based Compensation - Rollforward of Restricted Stock Awards (Details) Details 31 false false R32.htm 9955525 - Disclosure - Stock-Based Compensation - Rollforward of RSU and PSU Activity (Details) Sheet http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails Stock-Based Compensation - Rollforward of RSU and PSU Activity (Details) Details 32 false false R33.htm 9955526 - Disclosure - Fair Value (Details) Sheet http://www.1800petmeds.com/role/FairValueDetails Fair Value (Details) Details http://www.1800petmeds.com/role/FairValue 33 false false R34.htm 9955527 - Disclosure - Intangible and Other Assets, Net - Schedule of Intangible Assets and Other Assets (Details) Sheet http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails Intangible and Other Assets, Net - Schedule of Intangible Assets and Other Assets (Details) Details 34 false false R35.htm 9955528 - Disclosure - Intangible and Other Assets, Net - Narrative (Details) Sheet http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails Intangible and Other Assets, Net - Narrative (Details) Details 35 false false R36.htm 9955529 - Disclosure - Changes in Shareholders??? Equity - Schedule of Changes in Shareholders' Equity (Details) Sheet http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails Changes in Shareholders??? Equity - Schedule of Changes in Shareholders' Equity (Details) Details 36 false false R37.htm 9955530 - Disclosure - Changes in Shareholders??? Equity - Narrative (Details) Sheet http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails Changes in Shareholders??? Equity - Narrative (Details) Details 37 false false R38.htm 9955531 - Disclosure - Income Taxes (Details) Sheet http://www.1800petmeds.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.1800petmeds.com/role/IncomeTaxes 38 false false R39.htm 9955532 - Disclosure - Related Party Transaction (Details) Sheet http://www.1800petmeds.com/role/RelatedPartyTransactionDetails Related Party Transaction (Details) Details http://www.1800petmeds.com/role/RelatedPartyTransaction 39 false false All Reports Book All Reports pets-20241231.htm pets-20241231.xsd pets-20241231_cal.xml pets-20241231_def.xml pets-20241231_lab.xml pets-20241231_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pets-20241231.htm": { "nsprefix": "pets", "nsuri": "http://www.1800petmeds.com/20241231", "dts": { "inline": { "local": ["pets-20241231.htm"] }, "schema": { "local": ["pets-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["pets-20241231_cal.xml"] }, "definitionLink": { "local": ["pets-20241231_def.xml"] }, "labelLink": { "local": ["pets-20241231_lab.xml"] }, "presentationLink": { "local": ["pets-20241231_pre.xml"] } }, "keyStandard": 181, "keyCustom": 36, "axisStandard": 21, "axisCustom": 0, "memberStandard": 23, "memberCustom": 24, "hidden": { "total": 25, "http://fasb.org/us-gaap/2024": 18, "http://xbrl.sec.gov/dei/2024": 5, "http://www.1800petmeds.com/20241231": 2 }, "contextCount": 192, "entityCount": 1, "segmentCount": 50, "elementCount": 467, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 521, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.1800petmeds.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R3": { "role": "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R5": { "role": "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R6": { "role": "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952155 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.1800petmeds.com/role/RevenueRecognition", "longName": "9952156 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.1800petmeds.com/role/NetLossIncomePerShare", "longName": "9952157 - Disclosure - Net (Loss) Income Per Share", "shortName": "Net (Loss) Income Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.1800petmeds.com/role/StockBasedCompensation", "longName": "9952158 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.1800petmeds.com/role/FairValue", "longName": "9952159 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet", "longName": "9952160 - Disclosure - Intangible and Other Assets, Net", "shortName": "Intangible and Other Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.1800petmeds.com/role/CommitmentsandContingencies", "longName": "9952161 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.1800petmeds.com/role/ChangesinShareholdersEquity", "longName": "9952162 - Disclosure - Changes in Shareholders\u2019 Equity", "shortName": "Changes in Shareholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.1800petmeds.com/role/IncomeTaxes", "longName": "9952163 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.1800petmeds.com/role/RelatedPartyTransaction", "longName": "9952164 - Disclosure - Related Party Transaction", "shortName": "Related Party Transaction", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": null }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 -

Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "pets:BasisOfPresentationAndConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pets:BasisOfPresentationAndConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.1800petmeds.com/role/RevenueRecognitionTables", "longName": "9955512 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.1800petmeds.com/role/NetLossIncomePerShareTables", "longName": "9955513 - Disclosure - Net (Loss) Income Per Share (Tables)", "shortName": "Net (Loss) Income Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.1800petmeds.com/role/StockBasedCompensationTables", "longName": "9955514 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables", "longName": "9955515 - Disclosure - Intangible and Other Assets, Net (Tables)", "shortName": "Intangible and Other Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.1800petmeds.com/role/ChangesinShareholdersEquityTables", "longName": "9955516 - Disclosure - Changes in Shareholders\u2019 Equity (Tables)", "shortName": "Changes in Shareholders\u2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9955517 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R25": { "role": "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "longName": "9955518 - Disclosure - Revenue Recognition - Narrative (Details)", "shortName": "Revenue Recognition - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "pets:NumberOfWarehouses", "unitRef": "warehouse", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pets:NumberOfWarehouses", "unitRef": "warehouse", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails", "longName": "9955519 - Disclosure - Revenue Recognition - Schedule of Deferred Revenue (Details)", "shortName": "Revenue Recognition - Schedule of Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "pets:ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R27": { "role": "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails", "longName": "9955520 - Disclosure - Revenue Recognition - Schedule of Disaggregation of Revenue (Details)", "shortName": "Revenue Recognition - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "pets:RevenueFromContractWithCustomerPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R28": { "role": "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails", "longName": "9955521 - Disclosure - Net (Loss) Income Per Share - Schedule of Earnings Per Share (Details)", "shortName": "Net (Loss) Income Per Share - Schedule of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R29": { "role": "http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails", "longName": "9955522 - Disclosure - Net (Loss) Income Per Share - Narrative (Details)", "shortName": "Net (Loss) Income Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-42", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-42", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "longName": "9955523 - Disclosure - Stock-Based Compensation - Narrative (Details)", "shortName": "Stock-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-54", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R31": { "role": "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails", "longName": "9955524 - Disclosure - Stock-Based Compensation - Rollforward of Restricted Stock Awards (Details)", "shortName": "Stock-Based Compensation - Rollforward of Restricted Stock Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-90", "name": "pets:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAndIssuedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R32": { "role": "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "longName": "9955525 - Disclosure - Stock-Based Compensation - Rollforward of RSU and PSU Activity (Details)", "shortName": "Stock-Based Compensation - Rollforward of RSU and PSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-104", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R33": { "role": "http://www.1800petmeds.com/role/FairValueDetails", "longName": "9955526 - Disclosure - Fair Value (Details)", "shortName": "Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails", "longName": "9955527 - Disclosure - Intangible and Other Assets, Net - Schedule of Intangible Assets and Other Assets (Details)", "shortName": "Intangible and Other Assets, Net - Schedule of Intangible Assets and Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails", "longName": "9955528 - Disclosure - Intangible and Other Assets, Net - Narrative (Details)", "shortName": "Intangible and Other Assets, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails", "longName": "9955529 - Disclosure - Changes in Shareholders\u2019 Equity - Schedule of Changes in Shareholders' Equity (Details)", "shortName": "Changes in Shareholders\u2019 Equity - Schedule of Changes in Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-162", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R37": { "role": "http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails", "longName": "9955530 - Disclosure - Changes in Shareholders\u2019 Equity - Narrative (Details)", "shortName": "Changes in Shareholders\u2019 Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.1800petmeds.com/role/IncomeTaxesDetails", "longName": "9955531 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "unique": true } }, "R39": { "role": "http://www.1800petmeds.com/role/RelatedPartyTransactionDetails", "longName": "9955532 - Disclosure - Related Party Transaction (Details)", "shortName": "Related Party Transaction (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-191", "name": "pets:RelatedPartyTransactionServicePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-191", "name": "pets:RelatedPartyTransactionServicePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "pets-20241231.htm", "first": true, "unique": true } } }, "tag": { "pets_A2022EmployeePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "A2022EmployeePlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2022 Employee Plan", "label": "2022 Employee Plan [Member]", "documentation": "2022 Employee Plan" } } }, "auth_ref": [] }, "pets_A2024InducementIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "A2024InducementIncentivePlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Inducement Incentive Plan", "label": "2024 Inducement Incentive Plan [Member]", "documentation": "2024 Inducement Incentive Plan" } } }, "auth_ref": [] }, "pets_A2024InducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "A2024InducementPlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Inducement Plan", "label": "2024 Inducement Plan [Member]", "documentation": "2024 Inducement Plan" } } }, "auth_ref": [] }, "pets_A2024OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "A2024OmnibusIncentivePlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Omnibus Incentive Plan", "label": "2024 Omnibus Incentive Plan [Member]", "documentation": "2024 Omnibus Incentive Plan" } } }, "auth_ref": [] }, "pets_A2024OmnibusPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "A2024OmnibusPlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Omnibus Plan", "label": "2024 Omnibus Plan [Member]", "documentation": "2024 Omnibus Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r40", "r553"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, less allowance for credit losses of $88 and $273, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r693"] }, "pets_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r204", "r205", "r206", "r208", "r517"] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Useful Life (Years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r206", "r517"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r608"] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r50", "r553", "r804"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r456", "r678", "r679", "r680", "r683", "r758", "r805"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r621"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r621"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r621"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r621"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation (reversal) expenses", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r29", "r30", "r282"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Advertising", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r318", "r544"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r654"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r580", "r590", "r600", "r632"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r583", "r593", "r603", "r635"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r655"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r621"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r628"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r584", "r594", "r604", "r628", "r636", "r640", "r648"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r646"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Compensation (benefit) expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r312", "r316"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r115", "r185", "r195"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r4", "r203", "r210", "r531"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r164"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r16"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r16"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r348"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r85", "r93", "r111", "r129", "r168", "r172", "r179", "r180", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r349", "r351", "r374", "r412", "r480", "r526", "r527", "r553", "r571", "r718", "r719", "r766"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r106", "r117", "r129", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r349", "r351", "r374", "r553", "r718", "r719", "r766"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r129", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r349", "r351", "r374", "r718", "r719", "r766"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750"] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r643"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r644"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r639"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r639"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r639"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r639"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r639"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r639"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r642"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r641"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r640"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r640"] }, "pets_BasisOfPresentationAndConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "BasisOfPresentationAndConsolidationPolicyTextBlock", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Consolidation", "label": "Basis Of Presentation and Consolidation [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation and , used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Also consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements." } } }, "auth_ref": [] }, "pets_BeneficialOwnershipThresholdPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "BeneficialOwnershipThresholdPercentage", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Beneficial ownership threshold percentage", "label": "Beneficial Ownership, Threshold Percentage", "documentation": "Beneficial Ownership, Threshold Percentage" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r204", "r205", "r206", "r207", "r208", "r345", "r540", "r541"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r31", "r33", "r204", "r205", "r206", "r207", "r208", "r345", "r540", "r541"] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of equity interests acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": ["r32"] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing activity for PPE additions", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r13", "r14", "r15"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/FairValueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r11", "r108", "r520"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, at beginning of period", "periodEndLabel": "Cash and cash equivalents, at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r66", "r127"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r66"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r619"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": ["r692"] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefFinancialOfficerMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Chief Financial Officer", "label": "Chief Financial Officer [Member]" } } }, "auth_ref": ["r692"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r616"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r614"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails", "http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r102", "r112", "r113", "r114", "r129", "r153", "r157", "r161", "r163", "r170", "r171", "r190", "r226", "r228", "r229", "r230", "r233", "r234", "r236", "r237", "r240", "r243", "r250", "r374", "r447", "r448", "r449", "r450", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r477", "r485", "r494", "r507", "r508", "r509", "r510", "r511", "r658", "r675", "r684"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r112", "r113", "r114", "r170", "r236", "r237", "r238", "r240", "r243", "r248", "r250", "r447", "r448", "r449", "r450", "r532", "r658", "r675"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r27"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r251"] }, "pets_ClassOfWarrantOrRightMarketValuePurchasePriceRate": { "xbrltype": "pureItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ClassOfWarrantOrRightMarketValuePurchasePriceRate", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Market value purchase price rate", "label": "Class of Warrant or Right, Market Value Purchase Price Rate", "documentation": "Class of Warrant or Right, Market Value Purchase Price Rate" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding right shares (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "pets_ClassOfWarrantOrRightPercentOfCommonStockExerciseThreshold": { "xbrltype": "percentItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ClassOfWarrantOrRightPercentOfCommonStockExerciseThreshold", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock exercise threshold", "label": "Class of Warrant or Right, Percent Of Common Stock, Exercise Threshold", "documentation": "Class of Warrant or Right, Percent Of Common Stock, Exercise Threshold" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r620"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r620"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 7)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r46", "r86", "r414", "r476"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.1800petmeds.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r74", "r220", "r221", "r513", "r713", "r715"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r49"] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared per common share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r79"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails", "http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r563", "r564", "r565", "r566", "r567", "r568", "r569", "r678", "r679", "r683", "r758", "r803", "r805"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r49"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r49", "r477"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r49"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r49", "r477", "r482", "r805", "r806"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $.001 par value, 40,000,000 shares authorized; 20,656,457 and 21,148,692 shares issued and outstanding, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r49", "r416", "r553"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r625"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r624"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r626"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r623"] }, "pets_ConcentrationRiskCashSettlementPeriodForSales": { "xbrltype": "durationItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ConcentrationRiskCashSettlementPeriodForSales", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash settlement period", "label": "Concentration Risk, Cash Settlement Period For Sales", "documentation": "Concentration Risk, Cash Settlement Period For Sales" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Revenue", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r723"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails", "http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "periodStartLabel": "Deferred revenue, beginning balance", "periodEndLabel": "Deferred revenue, ending balance", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r253", "r254", "r273"] }, "pets_ContractWithCustomerLiabilityCurrentRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ContractWithCustomerLiabilityCurrentRollForward", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract With Customer, Liability, Current [Roll Forward]", "label": "Contract With Customer, Liability, Current [Roll Forward]", "documentation": "Contract

With Customer, Liability, Current" } } }, "auth_ref": [] }, "pets_ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ContractWithCustomerLiabilityIncreaseForDeferredFeesReceived", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred memberships fees and others received", "label": "Contract With Customer Liability, Increase For Deferred Fees Received", "documentation": "Contract With Customer Liability, Increase For Deferred Fees Received" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Deferred membership fee revenue and others recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r274"] }, "pets_ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred memberships fees revenue and others recognized", "label": "Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance", "documentation": "Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance" } } }, "auth_ref": [] }, "pets_ContractWithCustomerRenewalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ContractWithCustomerRenewalPeriod", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual membership fees renewal period", "label": "Contract With Customer, Renewal Period", "documentation": "Contract With Customer, Renewal Period" } } }, "auth_ref": [] }, "pets_ContractWithCustomerRevenueRecognitionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ContractWithCustomerRevenueRecognitionPeriod", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition period", "label": "Contract With Customer, Revenue Recognition, Period", "documentation": "Contract With Customer, Revenue Recognition, Period" } } }, "auth_ref": [] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": ["r236", "r237", "r240", "r566", "r567", "r568", "r569"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r57", "r58", "r402"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships - PetCareRx", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r36", "r703", "r704", "r705", "r706", "r708", "r709", "r711", "r712"] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r320", "r321"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r4", "r99", "r677"] }, "pets_DeferredTaxLiabilityNondeductibleInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "DeferredTaxLiabilityNondeductibleInterest", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disallowed interest expense", "label": "Deferred Tax Liability, Nondeductible Interest", "documentation": "Deferred Tax Liability, Nondeductible Interest" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r168", "r175", "r180", "r526", "r527"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology - PetCareRx", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r83", "r703", "r704", "r705", "r706", "r708", "r709", "r711", "r712"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r272", "r533", "r534", "r535", "r536", "r537", "r538", "r539"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r272", "r533", "r534", "r535", "r536", "r537", "r538", "r539"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r724"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r280", "r285", "r313", "r314", "r315", "r543"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Dividends declared", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": ["r2", "r79"] }, "pets_DividendsForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "DividendsForfeited", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends forfeited", "label": "Dividends Forfeited", "documentation": "Dividends Forfeited" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r575"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r607"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r618"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r123", "r138", "r139", "r141", "r142", "r143", "r145", "r151", "r153", "r161", "r162", "r163", "r167", "r343", "r347", "r362", "r363", "r407", "r424", "r523"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."

} } }, "auth_ref": ["r123", "r138", "r139", "r141", "r142", "r143", "r145", "r153", "r161", "r162", "r163", "r167", "r343", "r347", "r362", "r363", "r407", "r424", "r523"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShare"], "lang": { "en-us": { "role": { "terseLabel": "Net (Loss) Income Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r150", "r164", "r165", "r166"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate, percent", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r323", "r545"] }, "pets_EmployeeAndDirectorEquityCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "EmployeeAndDirectorEquityCompensationPlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2016 Employee Plan and 2015 Director Plan", "label": "Employee and Director Equity Compensation Plan [Member]", "documentation": "Refers to information regarding employee and director plans." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r573"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r573"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r573"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r657"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r573"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r573"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r573"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r573"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r612"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r653"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r653"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r653"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r103", "r120", "r121", "r122", "r133", "r134", "r135", "r137", "r143", "r146", "r148", "r169", "r191", "r194", "r219", "r252", "r332", "r333", "r340", "r341", "r342", "r344", "r346", "r347", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r384", "r389", "r423", "r435", "r436", "r437", "r456", "r494"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r187", "r188", "r189", "r339", "r660", "r661", "r662", "r754", "r755", "r756", "r757"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r187"] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails", "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minority interest investment in Vetster", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r168", "r177", "r180", "r186", "r669", "r694"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r622"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r580", "r590", "r600", "r632"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r577", "r587", "r597", "r629"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r628"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.1800petmeds.com/role/FairValue"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r405", "r546", "r550"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r6"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [

"http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Useful Life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r110", "r197", "r209", "r531"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r202", "r204", "r205", "r206", "r208", "r209", "r212", "r213", "r403", "r404", "r517"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangibles", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r197", "r209", "r404", "r531"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r202", "r209", "r212", "r213", "r216", "r403", "r517", "r531"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r202", "r204", "r205", "r206", "r208", "r209", "r212", "r213", "r517"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangibles", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r403", "r709"] }, "pets_FiscalYear2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "FiscalYear2023Member", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fiscal Year 2023", "label": "Fiscal Year 2023 [Member]", "documentation": "Fiscal Year 2023" } } }, "auth_ref": [] }, "pets_FiscalYear2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "FiscalYear2024Member", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fiscal Year 2024", "label": "Fiscal Year 2024 [Member]", "documentation": "Fiscal Year 2024" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r584", "r594", "r604", "r636"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r584", "r594", "r604", "r636"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r584", "r594", "r604", "r636"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r584", "r594", "r604", "r636"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r584", "r594", "r604", "r636"] }, "pets_FormerChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "FormerChiefFinancialOfficerMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Former Chief Financial Officer", "label": "Former Chief Financial Officer [Member]", "documentation": "Former Chief Financial Officer" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r617"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r61", "r486"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r109", "r199", "r406", "r527", "r530", "r548", "r553", "r700", "r701"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": ["r198", "r200", "r530"] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": ["r201", "r215", "r218"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r55", "r59", "r92", "r129", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r374", "r525", "r526", "r686", "r687", "r688", "r689", "r690", "r718"] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long lived assets", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": ["r4", "r20", "r72", "r547"] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r73"] }, "pets_IncentivePlan2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "IncentivePlan2024Member", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Incentive Plan", "label": "Incentive Plan 2024 [Member]", "documentation": "2024 Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before provision (benefit) for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r56", "r88", "r92", "r408", "r421", "r525", "r526", "r686", "r687", "r688", "r689", "r690"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": ["r753"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r130", "r319", "r323", "r324", "r325", "r326", "r327", "r328", "r334", "r336", "r337", "r338", "r452", "r545"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Provision (benefit) for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r94", "r100", "r147", "r148", "r168", "r176", "r180", "r322", "r323", "r335", "r425", "r545"] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": ["r545", "r751", "r752"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r12", "r126", "r329", "r330"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r674"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r401", "r674"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "(Increase) decrease in operating assets and increase (decrease) in operating liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r665", "r674"] }, "pets_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease right-of-use assets, net", "label": "Increase (Decrease) in Operating Lease Right Of Use Asset", "documentation": "Increase (Decrease) in Operating Lease Right Of Use Asset" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidTaxes", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid income taxes", "label": "Increase (Decrease) in Prepaid Taxes", "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPropertyAndOtherTaxesPayable", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Sales tax payable", "label": "Increase (Decrease) in Property and Other Taxes Payable", "documentation": "The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "calculation": { "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares issuable upon conversion of preferred shares (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method." } } }, "auth_ref": ["r158", "r159", "r163"] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares issuable upon vesting of restricted stock (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r154", "r155", "r156", "r163", "r284"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r202", "r207", "r211", "r531"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangibles", "verboseLabel": "Indefinite-lived intangibles", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r197", "r211", "r531"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r202", "r207", "r211", "r531"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r584", "r594", "r604", "r628", "r636", "r640", "r648"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r646"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r576", "r652"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r576", "r652"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r576", "r652"] }, "pets_IntangibleAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "IntangibleAndOtherAssets", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Intangible, Net Carrying Value", "label": "Intangible And Other Assets", "documentation": "Intangible And Other Assets" } } }, "auth_ref": [] }, "pets_IntangibleAndOtherAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "IntangibleAndOtherAssetsGross", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": "pets_IntangibleAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Intangible, Gross Value", "label": "Intangible And Other Assets, Gross", "documentation": "Intangible And Other Assets, Gross" } } }, "auth_ref": [] }, "pets_IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "IntangibleAndOtherNoncurrentAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Intangible and other assets, net", "label": "Intangible And Other Noncurrent Assets, Net Excluding Goodwill", "documentation": "Intangible And Other Noncurrent Assets, Net Excluding Goodwill" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNet"], "lang": { "en-us": { "role": { "terseLabel": "Intangible and Other Assets, Net", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r201", "r214", "r217", "r516", "r517"] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": {

"http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": "pets_IntangibleAndOtherAssetsGross", "weight": 1.0, "order": 1.0 }, "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Intangibles", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": ["r109"] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwillAbstract", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross Value", "label": "Intangible Assets, Gross (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails_1": { "parentTag": "pets_IntangibleAndOtherAssets", "weight": 1.0, "order": 2.0 }, "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Intangibles", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r202", "r709", "r710"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net Carrying Value", "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "pets_IntangiblesAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "IntangiblesAndOtherAssetsAbstract", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangibles and Other Assets", "label": "Intangibles and Other Assets [Abstract]", "documentation": "Intangibles and Other Assets" } } }, "auth_ref": [] }, "pets_IntangiblesAndOtherAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "IntangiblesAndOtherAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": "pets_IntangibleAndOtherAssets", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Intangibles And Other Assets, Accumulated Amortization", "documentation": "Intangibles And Other Assets, Accumulated Amortization" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Interest income, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r526", "r673", "r687"] }, "us-gaap_InternetDomainNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternetDomainNamesMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Internet domain names", "label": "Internet Domain Names [Member]", "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site." } } }, "auth_ref": ["r35", "r703", "r704", "r705", "r706", "r708", "r709", "r711", "r712"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r116", "r521", "r553"] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails_1": { "parentTag": "pets_IntangibleAndOtherAssets", "weight": 1.0, "order": 1.0 }, "http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails": { "parentTag": "pets_IntangibleAndOtherAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minority interest investment in Vetster", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": ["r410", "r411", "r560", "r562"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r9", "r41", "r42", "r43", "r44", "r45", "r46", "r47", "r129", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r350", "r351", "r352", "r374", "r475", "r524", "r571", "r718", "r766", "r767"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r54", "r87", "r418", "r553", "r676", "r695", "r761"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable in accrued expenses and other current liabilities", "label": "Liabilities Assumed", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." } } }, "auth_ref": ["r13", "r14", "r15"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r43", "r107", "r129", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r350", "r351", "r352", "r374", "r553", "r718", "r766", "r767"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": ["r183", "r535", "r555", "r558", "r724", "r774", "r775", "r776", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r278", "r317", "r364", "r400", "r433", "r434", "r445", "r468", "r469", "r502", "r503", "r504", "r505", "r506", "r514", "r515", "r528", "r532", "r542", "r549", "r550", "r551", "r552", "r556", "r720", "r768", "r769", "r770", "r771", "r772", "r773"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r620"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r620"] }, "pets_MembershipCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "MembershipCustomersMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Membership Customers", "label": "Membership Customers [Member]", "documentation": "Membership Customers" } } }, "auth_ref": [] }, "pets_MembershipFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "MembershipFeesMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Membership fees", "label": "Membership Fees [Member]", "documentation": "Membership Fees" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r278", "r317", "r364", "r400", "r433", "r434", "r445", "r468", "r469", "r502", "r503", "r504", "r505", "r506", "r514", "r515", "r528", "r532", "r542", "r549", "r550", "r551", "r556", "r720", "r768", "r769", "r770", "r771", "r772", "r773"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r639"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r647"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDeferredRevenueDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": ["r183", "r535", "r555", "r558", "r724", "r774", "r775", "r776", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r621"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r125"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r125"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r66", "r67", "r68"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails", "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "verboseLabel": "Net income (loss)", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r60", "r68", "r89", "r105", "r118", "r119", "r122", "r129", "r136", "r138", "r139", "r141", "r142", "r143", "r147", "r148", "r160", "r190", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r343", "r347", "r363", "r374", "r422", "r484", "r492", "r493", "r570", "r718"] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income (numerator):", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "pets_NetIncomePerCommonShareBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "NetIncomePerCommonShareBasicAndDilutedAbstract", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per common share:", "label": "Net Income Per Common Share, Basic And Diluted [Abstract]", "documentation": "Net Income Per Common Share, Basic And Diluted" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "pets_NewOrderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "NewOrderMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "New order sales", "label": "New Order Customer [Member]", "documentation": "The disaggregate of revenue in new order sales." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r620"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r584", "r594", "r604", "r628", "r636"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r611"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r610"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r628"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r647"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r647"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r62"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Other income:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Awards", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": ["r8"] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportingUnits", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting units", "label": "Number of Reporting Units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "pets_NumberOfWarehouses": { "xbrltype": "integerItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "NumberOfWarehouses", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of warehouses", "label": "Number Of Warehouses", "documentation": "Number Of Warehouses" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r92", "r525", "r686", "r687", "r688", "r689", "r690"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r386"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r386"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r385"] }, "pets_OperatingLossCarryforwardAndDisallowedInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "OperatingLossCarryforwardAndDisallowedInterestExpense", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total operating loss carryforward and disallowed interest expense", "label": "Operating Loss Carryforward And Disallowed Interest Expense", "documentation": "Operating Loss Carryforward And Disallowed Interest Expense" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforward", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r331"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r39", "r69", "r70", "r84"] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r63"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r620"] }, "pets_OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2015 Director Plan", "label": "2015 Outside Director Equity Compensation Restricted Stock Plan (\"2015 Director Plan\") [Member]", "documentation": "Refers to information regarding 2015 Outside Director Equity Compensation Restricted Stock Plan (\"2015 Director Plan\")." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r582", "r592", "r602", "r634"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r585", "r595", "r605", "r637"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r585", "r595", "r605", "r637"] }, "pets_PartnerProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "PartnerProgramMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Partner Program", "label": "Partner Program [Member]", "documentation": "Partner Program" } } }, "auth_ref": [] }, "pets_PartnershipAgreementWithVetsterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "PartnershipAgreementWithVetsterMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Partnership Agreement with Vetster", "label": "Partnership Agreement with Vetster [Member]", "documentation": "Represents partnership agreement with Vetster." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r609"] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": ["r65"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of PetCareRx, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r10"] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire equity method investments", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": ["r10"] }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of minority interest investment in Vetster", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." } } }, "auth_ref": ["r10"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r64"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r619"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r619"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r611"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r628"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r621"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r610"] }, "pets_PerformanceRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "PerformanceRestrictedStockMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Performance Restricted Stock", "label": "Performance Restricted Stock [Member]", "documentation": "Represents performance restricted stock." } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "PSUs", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "pets_PetCareRxIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "PetCareRxIncMember", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "PetCareRx", "label": "PetCareRx, Inc. [Member]", "documentation": "PetCareRx, Inc." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r612"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r656"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r611"] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, liquidation preference (in dollars per share)", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": ["r23", "r24", "r48", "r675", "r721"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r563", "r564", "r566", "r567", "r568", "r569", "r803", "r805"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r48", "r236"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r48", "r477"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r48", "r236"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r48", "r477", "r482", "r805", "r806"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $.001 par value, 5,100,000 shares and 5,000,000 shares authorized respectively; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r48", "r415", "r553"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r672"] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r522", "r529", "r698"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r181", "r402", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r519", "r533", "r554", "r556", "r557", "r559", "r561", "r716", "r717", "r724", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r181", "r402", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r519", "r533", "r554", "r556", "r557", "r559", "r561", "r716", "r717", "r724", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r387", "r409", "r420", "r553"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r124", "r196"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r609"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r609"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r276", "r278", "r308", "r309", "r310", "r317", "r364", "r398", "r399", "r400", "r433", "r434", "r445", "r468", "r469", "r502", "r503", "r504", "r505", "r506", "r514", "r515", "r528", "r532", "r542", "r549", "r550", "r551", "r552", "r556", "r565", "r714", "r720", "r760", "r769", "r770", "r771", "r772", "r773"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r276", "r278", "r308", "r309", "r310", "r317", "r364", "r398", "r399", "r400", "r433", "r434", "r445", "r468", "r469", "r502", "r503", "r504", "r505", "r506", "r514", "r515", "r528", "r532", "r542", "r549", "r550", "r551", "r552", "r556", "r565", "r714", "r720", "r760", "r769", "r770", "r771", "r772", "r773"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r577", "r587", "r597", "r629"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r184", "r277", "r393", "r394", "r413", "r419", "r470", "r471", "r472", "r473", "r474", "r481", "r483", "r501"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r131", "r132", "r393", "r394", "r395", "r396", "r413", "r419", "r470", "r471", "r472", "r473", "r474", "r481", "r483", "r501"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, expenses", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r38", "r393"] }, "pets_RelatedPartyTransactionAnnualAmountsOfTransactionAfterYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RelatedPartyTransactionAnnualAmountsOfTransactionAfterYearOne", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related party, after year one annual transaction amount", "label": "Related Party Transaction, Annual Amounts Of Transaction After Year One", "documentation": "Related Party Transaction, Annual Amounts Of Transaction After Year One" } } }, "auth_ref": [] }, "pets_RelatedPartyTransactionAnnualAmountsOfTransactionYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RelatedPartyTransactionAnnualAmountsOfTransactionYearOne", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related party, first year transaction amount", "label": "Related Party Transaction, Annual Amounts Of Transaction, Year One", "documentation": "Related Party Transaction, Annual Amounts Of Transaction, Year One" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r184", "r487", "r488", "r491"] }, "pets_RelatedPartyTransactionNumberOfNoticePeriodInAdvance": { "xbrltype": "durationItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RelatedPartyTransactionNumberOfNoticePeriodInAdvance", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, number of notice period in advance", "label": "Related Party Transaction, Number Of Notice Period In Advance", "documentation": "Related Party Transaction, Number Of Notice Period In Advance" } } }, "auth_ref": [] }, "pets_RelatedPartyTransactionServicePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RelatedPartyTransactionServicePeriod", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, service period", "label": "Related Party Transaction, Service Period", "documentation": "Related Party Transaction, Service Period" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r184", "r277", "r393", "r394", "r413", "r419", "r470", "r471", "r472", "r473", "r474", "r481", "r483", "r501", "r765"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransaction"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r390", "r391", "r392", "r394", "r397", "r453", "r454", "r455", "r489", "r490", "r491", "r498", "r500"] }, "pets_ReorderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ReorderMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reorder sales", "label": "Reorder Customer [Member]", "documentation": "The disaggregate of revenue in reorder sales." } } }, "auth_ref": [] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": ["r104", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r144", "r145", "r146", "r147", "r148", "r149", "r167", "r192", "r193", "r341", "r342", "r343", "r344", "r346", "r347", "r360", "r361", "r362", "r363", "r381", "r383", "r388", "r389", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r446", "r691"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r578", "r588", "r598", "r630"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r579", "r589", "r599", "r631"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r586", "r596", "r606", "r638"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": ["r104", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r144", "r145", "r146", "r147", "r148", "r149", "r167", "r192", "r193", "r341", "r342", "r343", "r344", "r346", "r347", "r360", "r361", "r362", "r363", "r381", "r383", "r388", "r389", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r446", "r691"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r16"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r51", "r79", "r417", "r439", "r444", "r451", "r478", "r553"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r103", "r133", "r134", "r135", "r137", "r143", "r146", "r148", "r191", "r194", "r219", "r332", "r333", "r340", "r341", "r342", "r344", "r346", "r347", "r353", "r355", "r356", "r358", "r361", "r382", "r384", "r435", "r437", "r456", "r805"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails", "http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Membership fees earned", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r90", "r91", "r168", "r173", "r174", "r178", "r180", "r181", "r182", "r183", "r271", "r272", "r402"] }, "pets_RevenueFromContractWithCustomerNumberOfMembershipModels": { "xbrltype": "integerItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RevenueFromContractWithCustomerNumberOfMembershipModels", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition period membership", "label": "Revenue From Contract With Customer, Number Of Membership Models", "documentation": "Revenue From Contract With Customer, Number Of Membership Models" } } }, "auth_ref": [] }, "pets_RevenueFromContractWithCustomerNumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RevenueFromContractWithCustomerNumberOfPerformanceObligations", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of performance obligations", "label": "Revenue From Contract With Customer, Number Of Performance Obligations", "documentation": "Revenue From Contract With Customer, Number Of Performance Obligations" } } }, "auth_ref": [] }, "pets_RevenueFromContractWithCustomerPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RevenueFromContractWithCustomerPercentage", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales, percentage", "label": "Revenue From Contract With Customer Percentage", "documentation": "Percentage of revenue from the specified category to the total revenue during the period." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": {

~~"terseLabel": "Deferred Revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r101", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r518"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognition"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r101", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r275"] }, "pets_RevenueFromContractWithCustomerVariance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RevenueFromContractWithCustomerVariance", "crdr": "credit", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales, variance", "label": "Revenue From Contract With Customer Variance", "documentation": "The amount of changes in revenue in current period comparing to the same period in the previous year." } } }, "auth_ref": [] }, "pets_RevenueFromContractWithCustomerVariancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "RevenueFromContractWithCustomerVariancePercentage", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales, variance, percentage", "label": "Revenue From Contract With Customer Variance Percentage", "documentation": "The percentage of changes in revenue in current period comparing to the same period in the previous year." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r647"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r647"] }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesAndExciseTaxPayableCurrent", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Sales tax payable", "label": "Sales and Excise Tax Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r40"] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": ["r279", "r682"] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": ["http://www.1800petmeds.com/role/RevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Previously Reported", "label": "Previously Reported [Member]" } } }, "auth_ref": ["r104", "r133", "r135", "r136", "r137", "r138", "r139", "r148", "r167", "r341", "r343", "r344", "r346", "r347", "r360", "r361", "r362", "r381", "r383", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r446", "r664", "r666", "r667", "r668", "r681", "r691", "r696", "r697", "r759", "r762", "r763"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": ["r149", "r279", "r659", "r682"] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class." } } }, "auth_ref": ["r204", "r205", "r206", "r208", "r517"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r16"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r685"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r187", "r188", "r189", "r339", "r660", "r661", "r662", "r754", "r755", "r756", "r757"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r129", "r187", "r188", "r189", "r190", "r374"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r202", "r209", "r212", "r213", "r216", "r403", "r517", "r531"] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Other Assets", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": ["r699", "r702"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.1800petmeds.com/role/RelatedPartyTransactionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r37", "r38", "r487", "r488", "r491"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r281", "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r80"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails", "http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r21", "r22", "r23", "r24", "r25", "r26", "r75", "r77", "r78", "r79", "r112", "r113", "r114", "r170", "r236", "r237", "r238", "r240", "r243", "r248", "r250", "r447", "r448", "r449", "r450", "r532", "r658", "r675"] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Shareholders' Equity", "label": "Schedule of Stockholders Equity [Table Text Block]", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": ["r7"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r572"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r574"] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r670", "r671", "r722"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.1800petmeds.com/role/IncomeTaxesDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r543"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in shares)", "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r302"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r302"] }, "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAndIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAndIssuedInPeriod", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted and issued (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period" } } }, "auth_ref": [] }, "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAndIssuedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype":~~

"perShareItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAndIssuedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted and issued (in dollars per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period, Weighted Average Grant Date Fair value", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted And Issued In Period, Weighted Average Grant Date Fair value" } } }, "auth_ref": [] }, "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedGrantDateFairValue", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total grant-date fair value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Grant Date Fair Value", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted, Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issued shares (in shares)", "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-vested restricted shares issued and outstanding (in shares)", "periodStartLabel": "Non-vested beginning balance (in shares)", "periodEndLabel": "Non-vested ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r297", "r298"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Non-vested beginning balance (in dollars per share)", "periodEndLabel": "Non-vested ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r297", "r298"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Grant Date Fair Value", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantDateFairValue", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (in dollars per share)", "periodEndLabel": "Ending Balance (in dollars per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested and issued (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period" } } }, "auth_ref": [] }, "pets_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and issued (in dollars per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Issued In Period, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested (in shares)", "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r281", "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r81", "r82"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under stock compensation plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r28"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRSUandPSUActivityDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Three", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-

gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of PSU Activity", "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares." } } }, "auth_ref": ["r8"] },
"pets_ShareBasedPaymentArrangementExpenseReversalOfExpenseNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "ShareBasedPaymentArrangementExpenseReversalOfExpenseNoncash", "crdr": "debit", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reversal of stock based compensation", "label": "Share-Based Payment Arrangement Expense (Reversal Of Expense), Noncash", "documentation": "Share-Based Payment Arrangement Expense (Reversal Of Expense), Noncash" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Initial grant percentage based on performance targets", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r725"] }, "pets_SharesIssuableUponVestingOfRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "SharesIssuableUponVestingOfRestrictedStockMember", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares Issuable Upon Vesting of Restricted Stock", "label": "Shares Issuable Upon Vesting Of Restricted Stock [Member]", "documentation": "Shares Issuable Upon Vesting Of Restricted Stock" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails", "http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r102", "r112", "r113", "r114", "r129", "r153", "r157", "r161", "r163", "r170", "r171", "r190", "r226", "r228", "r229", "r230", "r233", "r234", "r236", "r237", "r240", "r243", "r250", "r374", "r447", "r448", "r449", "r450", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r477", "r485", "r494", "r507", "r508", "r509", "r510", "r511", "r658", "r675", "r684"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r49", "r52", "r53", "r103", "r120", "r121", "r122", "r133", "r134", "r135", "r137", "r143", "r146", "r148", "r169", "r191", "r194", "r219", "r252", "r332", "r333", "r340", "r341", "r342", "r344", "r346", "r347", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r384", "r389", "r423", "r435", "r436", "r437", "r456", "r494"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": ["r149", "r279", "r659", "r663", "r682"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r581", "r591", "r601", "r633"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased and retired (in shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": ["r7", "r48", "r49", "r79"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/ChangesinShareholdersEquityScheduleofChangesinShareholdersEquityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r49", "r52", "r53", "r71", "r479", "r482", "r495", "r496", "r553", "r571", "r676", "r695", "r761", "r805"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.1800petmeds.com/role/ChangesinShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Changes in Shareholders\u2019 Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r76", "r128", "r235", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r249", "r252", "r359", "r497", "r499", "r512"] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r627"] }, "pets_TermOfAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "TermOfAgreement", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term of agreement", "label": "Term Of Agreement", "documentation": "Represents term of agreement." } } }, "auth_ref": [] }, "pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "The2016EmployeeEquityCompensationRestrictedStockPlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails", "http://www.1800petmeds.com/role/StockBasedCompensationRollforwardofRestrictedStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2016 Employee Plan", "label": "The 2016 Employee Equity Compensation Restricted Stock Plan [Member]", "documentation": "represents the 2016 Employee Equity Compensation Restricted Stock Plan." } } }, "auth_ref": [] }, "pets_The2022EmployeeEquityCompensationRestrictedStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "The2022EmployeeEquityCompensationRestrictedStockPlanMember", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "The 2022 Employee Equity Compensation Restricted Stock Plan", "label": "The 2022 Employee Equity Compensation Restricted Stock Plan [Member]", "documentation": "The 2022 Employee Equity Compensation Restricted Stock Plan" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": ["r692", "r764"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.1800petmeds.com/role/IncomeTaxesDetails", "http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "pets_TollFreeTelephoneNumberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "TollFreeTelephoneNumberMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Toll-free telephone number", "label": "Toll-free telephone number [Member]", "documentation": "Toll-free telephone number" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r619"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r626"] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Trade Names - PetCareRx", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r34", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r646"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r648"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.1800petmeds.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r649"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r650"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r650"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r648"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r648"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r651"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r649"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetScheduleofIntangibleAssetsandOtherAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r348"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r645"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.1800petmeds.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r17", "r18", "r19", "r95", "r96", "r97", "r98"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.1800petmeds.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750"] }, "pets_VetsterIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.1800petmeds.com/20241231", "localname": "VetsterIncMember", "presentation": ["http://www.1800petmeds.com/role/IntangibleandOtherAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vetster Inc", "label": "Vetster Inc [Member]", "documentation": "Vetster Inc" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r615"] }, "us-

gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Shares used in diluted computation (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r152", "r163"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares (denominator):", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.1800petmeds.com/role/NetLossIncomePerShareScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding used in basic computation (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r151", "r163"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": ["http://www.1800petmeds.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares outstanding:", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r613"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-

03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":

~~"https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)",~~

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r224": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB
Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r227": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX
210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r230": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX
210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" },
"r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r234": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX
210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" },
"r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r239": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" },
"r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r244": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" },
"r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r249": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r251": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r253": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r255": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r257": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" },
"r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r262": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r264": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" },
"r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r268":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" },
"r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r273": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r275": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r277": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r279": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r282": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r284": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)
(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
}, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r527": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r529": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r531": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r533": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r535":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r537":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r539": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r541":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r543": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r545": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r547": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" },
"r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r551": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" },
"r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r555": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r557": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r559":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r561": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r563": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r565":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-
S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r569": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-
14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-
10" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number":
"240", "Section": "12", "Subsection": "b-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",
"Subsection": "d1-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" },
"r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r577": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r578": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r579": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r580": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" },
"r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"C" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "D" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "ii" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "iii" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "2" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r588": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r589": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r590": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r591": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r592": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r593": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r594": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r595": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r596": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "2" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "3" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r607": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r608": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r609": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r610": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" },
"r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r614": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section":
"402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" },
"r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r619": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" },
"r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",

"Paragraph": "3" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "4" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "5", "Subparagraph": "i" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r631": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "A" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r635": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "E" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "ii" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "2" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "1" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r643": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii",
"Sentence": "D" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x",
"Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r651": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" },
"r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" },
"r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r656": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B",
"Clause": "1", "Subclause": "i", "Number": "229" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section":
"405" }, "r658": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic":
"450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
}, "r660": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r661": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph":
"(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740",
"SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r664": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r666": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" },
"r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },
"r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r672": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r675": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-
1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
}, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
}, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r684": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" },
"r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
}, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r691": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r693": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r695": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" },
"r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4",
"Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" },
"r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/350-20/tableOfContent" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r701": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-
45-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r707": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 58 0001040130-25-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001040130-25-000014-xbrl.zip

M,$@U2UVP=YN\U.6Z*'LWBM4Y2X<3]I7 EV&U9#J4$'(;.WU P6(.@,AG,R8PIZ.L<%.7)BG1Q2B'!\3"ZO3EYO[5Q48M+3TO?H"T2'N:.O*R S=0J=W(SF\1)B*)#,H-"V1]R:JG;4L$>
M$;5,Q5F(\]OT6BYID="]*PUWB(9:T<15SIP7"EY8FM%$-5*W6:#E_TN$5HZ-M?6CI7;342]T.-Z=2BN+S" 4I5&=&UU&HPWP=PZSF>0,\PG:YJ2B[LEXT@8<_?^)0C6P5ASR=BQ0-EX?Z,7PO@S<0
R9?=SZU4TS)>H[;") M"CY_I<0;A*9M .M>53J4RTZQZ@]NE!?B^8[^LRS]Z3WQ]$!<"I-W3=;;NZ\I MJUBR7@;8R8/FWKL#7 .)\3? "LB\U=!BE6/9U7E?7*X;3^ XVC+I6Y5EE?]
MKI4OI*GF2B_86EF2UD[!PVZ\=T834K"FI2++ M98#9ZB38^*B=E7$.S2/.0<4YR)OF$#D"UZM7>0 MG]?([@/?\V%Q03)E'5X]_"RHWJ/X36.,+S=UK6)F3F-%*#N\ 5.@2H?+&,2
MXMRDHV*G4^;TDUY-?RQIDF6"7C=HL0]I2N<$QB+!#:^=Y'XV.?MMWOE#W'<*-MB5][''?UL2FC;P6#&ZC,BGKAL!6*+'';0_S]F5/=?4+&Z"H8MK0[7P:OR]#=;
MWDDP(D.2&TQLOOQ\,R8Z,C^8.+:76 3_ @,4CGU0YX)UD=&2[RB'\2QV&XRZ MBUN1JX&3&/>>YG@G;\LUQZ&!U5]7U[H*6_@.F=V%C%3?W>3MY&WRKHQM)WNW
M@_:N7&XVFN5ZRC6DJR3/W=?.:1[O&:6Y#&N/\<=K7I6R@GO"G=5DJ;6P3G<5 MR@O^J\I[F(&7LUFX\+!0O\SH+IH.KQ\F.K-C)/^K!GTW84&29(W!IR I%*JRDI=5[.W%Y4
8]'XFOPI2$1S,5A]"*/=&>A&I&R'U*RI^O! M)+ P['!#1J9N9CW]I7K>2\F6$CILYZ*KZ .'U.Q36F:6,8U2M],$G<7+C2O"9QVST.K^^&E2 M_+1JG 5,A([B2T<50#4E3N?1V/XVJFK+
@YL=FLO3SK'JP&R$^!\I.[V)QA[MMI&##&[E?;/@]]MV(A4O^$[PW3XG0//ANW;>UQD>EN^H*O_D8R7]:&,ZD0HU MT=QGTZ8V0?.D:4\#0B1-UYT)]#W#_%O;\?&&#@?670L,TR?TY**!.:GI7]1T
MP1B+-#)MS=9]#$Q=XB>[:HN;L,G9AOV6F_L*:.1R/C5RZQ-R^_QJ&OX8 MQDP:F'@K7!AY-HHVA!$$_OI7$LO#[C$\/F65!HQ?7A__2]?R/U
M__[PV!\,RM+MW765W0'YX\O@]N:VJWC;'ZQ%)"^SN+Z_N^G?#6-B\-?@_MOM M3>\)/@R>X#_?^W=/-^G^JW3-T"-L/=W"'Q+W$-IP:TO^V F@#<,K2^1)R \ M0=0S"Y :^G$:NJ1-
Z*5.'Z4//R*)\W'M%)>0B"ZF1L\41.*"BG.8]*5-/7(5-M_?$Y*BECVG2X]*7/86.AC$$>69+DE*#LYSG[5&7&0]&+%O8<_ER%GSZM?E^O M5VN->NI/4M3AZ?)6GN MX)N]*7-\)";\WVUK?
7*^$"]]RW#S\?>]@Z/G0Z_:ODQ[EE01*,H?1<56VSFN MN^AGMWZX\I!9,$C=$5@;O 1SG]W3,XULGVGLNK4INXS>/O35=29IJY[TWW0K M0++T/(_
_XPG[2US.+M3ZC;4<4D$$OYPKO[1/SB^*C$76RS7EC-)]!,^< M*[\HI^<7/'[4ELL->>^C(X)A!,,^UX](:=5+]PJY3GRS@&N<&10C+>CWYS'(,F-1'WQ=2)-W"L+2M;)-BS M5NK6VF6YM7?
6G3A.RR&.-C@8.>*H3B\JK-?V]KL%CCC$T0;#.T<<-<"*KLG@ MD-J!=(Y-VF"0Y@BD)@"I42_+;5XJ!')N=RXEE;8S'3;*J6K[0X;B9$5=V3< M\,99^V2_N8[G25/7&9F^<,EV=P%%QNU@NUUM\ M
X<;PU$X56)DG(V,&]XX:Z(F]3/.CK[7:=7DZU4L3[1WF_@+QUH&M(M3G?IR&_$!M:SZ(E8S9B8MNGY+CT1OW3*5U1JRQSC8*3MV49O@;!]]N(R&Y.8-R2R676^TS2J428-HZ[I$SF%3<."S755[JC
HP'3,6DC.8:J6NVBPKC;T#:P), M'()I4WPD9S!A:HQ2ECMMKL%40-OUG1@2]T7P>P8=C0<#%YMNNQID^2+NRIP-MO)*WLW^U>Q$(YQ-^&TS0'.#3Q.O'6\W5B]<$?
(H/GPU&9P[P83O_#;&!>Y,X MV6!GYH ?3 !HEQLUOC-'"FA:%OE^I1LR=0$R]'I[%@:=.#"Z?],OQ#T5NQJ; M2;+"WQ;!/]!)3% W,P-W@(%!_HL(Z#D":H/Y>0A-U60$5*O%]V%+-:B#&*0' M
912ZM;+G:8(JY\CH#98] 7F#^1IG)(6^II>9<6MXHJY<:^3E;&Y=MI+W,,;%0FZ#@;L_Y.I8%+3< M:>05GA>0*SKD-IC^T.N-?9NH]R2\\IP%Y K.N0V&,G[0ZY9ZC;QYK.]$P1.
M!#ENC&5QW$*,C+.1<<,;9^U(?OCF>-Y'R;1U9T*DD>M,(J_2L2^MSMB'O9Q& M#\8/?ZU54Q$CN-$W60N-I-?;\D8]]2+&/O2-*5OR\+"C)-RU2]U:66ZM-MUA$3(.(.1(=PW/:-3@>W*NJ=O?
>^!'YX%$(K,MCAA%!=1B35U-6P$R="B!NK M4GA<8F2'Q,W=+C$T?,S?[^ 7%7D',Y,O)R/>'[(867)]KL5 MY[N,/)8->]\1-9E%&,;I[QP[SCRX(WZ:&:B4NBK?I_9$XM !=JYW!0P]A"Z2 M><\1,1OB%
[LB!N]?D(6,.4?$;-@WWA4Q>)R\+,(GQ5GR15]L=Q.QN/'#/..C MD89)[EM@RS0^;-";X$2L^0RQLBFO,3-6FN!(=,0AWW/$RJ9]K%G>OX,59>QD[1M7Y-I'#__:)&+V^P03+S83>(,-
MF4G,=_!H0UZ._^F3S'.*"5PLM#:8G%F@U<#L!77O4UH"6F<"K0T6:B9H*:5N M1\[K++B-5M&AM<&@S"'G<6+E[Y6OEE'%P@-PC,;+BCHP;-MWCAK#W#QA,R0@/PE>.GCB^FAD/\P)#89F?
Y'%,S14[[VMF,MAN)N\!WD],P\ M$_FKZTRNH0W3#H P]-$9I2]T0=AS3TCV_IOO:L!:IJYLUN?3#Q0IMB[ZU@6 M5:=L]S!-66+U\OI]2=+MO%7Q?B'>YP:S M9^U%/@B'\:#'%$+=$T9)OS
2IZD0++0@:K(6!B0']/.V@DN[U&T]JYO-G-@; M-BD'=-*VP@TWQC/3MMGN"))W:^DUE5*W)>]3@8@? M>TS_-6SAOJVSN@3W;!'SIHH1ER"&P0WG#K3=B\>J-%]S-8974DO&*%(MC'"0J,-
^+$&S2^IU;@.,W+A;G(4B:D!APPF&%N'.KQ9#.^+0N.&/"PM'3(D+ MLYU,0(A[8\W=L8!C3@4_Q?M'>,^ O+8DIQ9J\G0X9[HOFF?J^QRQ/S>#-VV* M!39X'X@[0-
'Y,OA/76OW]C7?!C)X43,4+K&)*\]-W$:I*U?E?5(%W^&B(U<" M$?__>_BW-,@+-^18+_+NA7EM"_(^A;"'IU[S*R OD"^4<3_)V<
M!7^,"OY]#C$>%/X%]*;>*X?/NS=U8UJ!3XPJRCRLBU"=H\C)./LSE$8[>F$A MS-+D46=O/RS;JG"Z)22]73O!48*CN)CVX7W%=_A(R<=;
M%,PDF(F+:1_3_7R'K=2]'=!3<10WOJG(.A%#XW!HW/#'66>=_$X_$$/28%3: M,Y'L8#(DKN2,%E)//,D)?,_7;#HQD8=RJN\7D/O>RT/A_6ZHU#R4/6;-M^VX-MUG1DLN;=,*&\;"Q&$JS'!-
@=E5_W(VHX>O=SJ17N86R3NYRP+[%(HUQNUNKE M9F/U-C<>;E0^QQ5OGW#%ZW3%ZVJCK+97_0JQXH=9<>6$*]Z@*]YH*^6.LKIU M(%;\"O>.>&*-^F*U]IR66WNQ.,%-
(^*?_ZFHWE+\//>/KYS5ERVD^T4DGN% MV3+S62M_ZRDG-^A"X;"3894;'-KYFU8"#D>WNG*# [U;K=QIMT-+KVXP"S@4
MPR3+"PYM^6R,,K&C(H;&X="XX8^SWE&YUKRQ9)@OID%LPT.!:H%D-%9.\^ZX M0Y__V=;5=3/^>8K;;%V?*Z[2.Y;3JL]+/>I@OL$]PGNVS('-V_N MJPGN$]PGN&]MSNXNW+?
*977,VTV)^A6'Q3CQIC_Y&DP4_@LN9_<7^%?T]$1S MGTV,52&7:03]%(@;$")I.OB]T/<,%D&R'1].]QW GA88]J8> MX,O,N_D6K-MI6OX]ZTW8%A3QS,135K.MZNWZ2&[)RK#=)D;
[GT]G%+TTCL.64^V95(8NT7Y6M',M\$]S7K69AY!+X@O E23Z,KT85;J_# U/W,2AKH?]Y^.3N)4*WH?^T_?^C=3_-M^\ C?S H2[=WUU6I=WW/8>;-N#M8CD91,7]W=2@*H/F(^E33UR%?
WQ.9*XIDV'05-Z'#86B@Z$_I+FH(1B-M/\^YHBHSS@BCGV'/X<]5^.G3ZORTM(!?@??2_AL;$G]4$U&E2&@C5% M:&I^32DOV$?[D"CA,6R\M*08Q%-EM;[-UO'>M\><#[UJ6>!T/GLT(\MY]:21
MZTPDAUTO#.8INB$O8-D2;Z]3+@>XG"C_U(9-([NH$QA8?>LN\N]\(JJH$6N MCL7+?1#M1D[W08@R<8(1SN,^B'9S__L@Z%W(Z^(G37V*51L6)B
M7"6+:;272>.,I1U:.#GHY,A6LGKU)_1Q>NQ,9J1\1U MJ<-"_1E?>R/>A5FS!Y&L$6&9V_^DO?7?D$/(%V*3D>YKR=C==11+Y> MY[KR]L+>ANJF^X_[1]K0=MY[KR]L+>ANJF^X_[1]K0=
'I0_1HQ\7G[5,;6A:>P3.>K+ M6HMS2$1\BALHQ'S!E$"A,O?V+R(^NPE9Y]:.Z/P8DSE-,C9*W9:2I2]J7FK?U";-]Q0?>5<6_YPF(RQQ&9"2)GCEJV@"N: MY18W>T(B:G-:6;H/EMJ);588[N+BG#F#
<+X#C^&&MT M!.X+FB^,[@[]0!V:DC]:(9H,7DT:8P< MVIIJLYWWM2[$(-E_8^N!$3FS$8+7%37+P+:[E<21A^^!B_HT_BQP_&HJ+^665)5I@?*0PA(C@-M%AM ^X1PWP-
01H&+&V/E3IV#'8)+LVO=@+P;[4WDYEV8U7O0#,.0\M_FU(WX M:.X6SG_+S$]X@U2YU=C[J)4PA\]+:\6=HJ,8EQM<."793]3-(>TOJ"[%X M=C>9%P-V$9_TAA!*75K=6$MGQMV=A>\&;"C@]?
56MVM%9;P434 M2]T6+T6C-HA93F[3./.ZQW?;%/7;QZK>KBIV09CY(H"E@"K3],3P 8QOLQ^ M>%@C(3:<>O$Z9%84N#%85E.VSC/;5%L7-?=4K]=6,/_[(+D&++M\>8-HOQ!.5<<_E)H"'P-
7'&&ET1M+$M!T7K&M8 M8Y^XL,KA8F,59;2?_D9\#WZX,#OJ__M,%-X<1^M8>'$// M-$S-9>'[WF@$CH[F+RNBE-L\$SJH%=[FJ>QJFZ?PH0MAYN0!KU48M4O=6DJ9 MB4+O]W
OB.F2L6L9418_H*7]DL"7_9?) R@FDZNL4UT#K)W:UAMJBU5&<^9E-L-#C8?+]XJE#^ M3L/<.)I/16 EI[C@%V8,YUEQ8(5EHNS#!TNS?;!2^A&1,S,,/I[;4E>W-\0N M4K$AE54*YPT=PK\A7^Y
M#B<9[8XF*QVZE]TAC,K=G,'>L5[LA>P7;ZL143KA M__?G9'TDGN^:ND\,NFML&XM?))Y\@(DXQNKA&=T*D+C]-WVLV<_D4?-)?S0B M>O9MCPZ[WS6'4&W!5.NYXW-;!8) M:RHX3G*]++=Y
5L>3E).&QH'<)*./S*A"0G67%NG__<61MP1XT][3?%\Y&R# M)S%; Y4NEQ7YC"ZY$YQSKIRC;-BA/2[KU$O=>]=A;!S:)9@H@V-ZM0AN6&N69)B>;CE>X)+X,!DF!DFFS7@#P'V6]I0O\4SS
M%#S#W?L7E25%+75Z-1X@_=WK0H5Y<;;FQ<;R8P"*L]Y:=REWM53:X!5T-K[MKAYA30NXG[[:WA9P,P+<:YR@G2,#F+OW+TJ9)U.>Z,44F*"@[77E@1"#YRH&-M-
VC]9,5\SPLFQ%#2YA&"KU*VM7F(BM#XWD!!PWTKKI\(J8V",WNE3[ZQ6.>3) M+.@(L^#2S(([QZ[0W-P^,*.?$9]?H?'OH2S@NQ*@R-BY&(&S<5IJ.O6?2Z=,!& MX!(/7".T&
(TO@7_G^A\@/CI(F<4DO:JI4>/EKDEA-0@>V=5JV(U'WJV55I=Y-MJU-)=>4G'_U)^*]AOG1_@7]%W4XT]JFT6>:+3&V+D^SF$(*.KC.!OF>HX&S'
MQTM5'5A=+8"E(,/V+9NAH^'5XSDVS8,SP!3W"6(UIO#S=L-=Z X8U M=5A)PBN76!KH4-+YU33\,8R9PBSQ%B/FE3Q_11O""_)__2N)]=$)EJH\/F65
M!HRIODB*Y+]QM(A:L]5L&&UMU%$U5:F/]@;U=OUD=R2E6&[38SV/[% 4/C2 M.#9(I]HSJ0Q=HOVL:".8X)5FO6HS#R&7Q!>-*TGT97HQJG1_&;H(U=6AKH?]
MY^.3N)5>2:W_]+U_(_7__O#8'PS*TNW==57]W=U(@Q]?!KD]P8>OMW>]N^O;WC=I\ 1??._? M/?$_J0_(O'Q<76L6V*_4=H"BZ&0KJ E<*6T(W2:*++\JXK2/H)H7;.N($DE
MY8KIGM5_A]KT#EQFU]173N*IV/^J' M7R.Q/(BE\DV)EY\#^ ,Y@@4ENV'EY\#^1Z@/1U<^"<8PA>+GCJ/U*K"5+MI-M!\3H^>%W.$
"*GB*D',#@FD!$UB:&:8!)'J0YEU(41^1=@YGOB1\X+>P.SJ? M^3-J?D-13?M#?N*JC\"<.%&LQ.A(;F-;[EW\^@7T'T4<*\I8DG\[V-#@-$'X/_M]-IZE0;(O41-Z+)D?!I^TB3VL->X;]4_TZ<2A8CIF_%S[-
OPR0\P&XN@QTVL-M65GRQT1""T^5/U\S@X5^4CY_+$NF)VF2132#VE"4RJ#PB&28+C0-%*V@[8*(MDZ;$EZ9C#&(A0=>;G,7AI]_H?;#]$4JGTV103V!<:7WV)/)&]\(#2? PX_U>@
MN3XN#:P5A14P3K0O!0@!&4Z-=&CQAEBN-I.^$$T?EZ6O,"_0'0OK'7@(@KYL%(7(++Z42OJK+:D-2\XJU]CP^ MDYC5GQ-[.M@%AX5U1HMR/DB0!(V6!
(-1PF*68)NJR$8*87O!F=W)BI;$&3#8DQ$8] M,-5] S#3)0I_FKXTXD1:[\%9>5LC&-WW%!J!D. MNM:8*&8%!HI0"Y' VHAS)2D80&3ZS-MW"2OM+0UGM/?0D-(Q"4,&5>-)S\0F-M+K1%?R?
3D..QU1\VG38U-CWI0^FW7N^A]\)&*:Z2/1<-X3?7@02'3!IPIB'1V M,0#@-5Q._)E)IAQ(3+42$A7HH!D(WU!OX]LFB[5#SS92Q@]"H&1C\7?=#33+ MPPL,0-!Y:'("W:<,/M)
(,UW4C^/DY*+8043P2,MI/LA&G4R&Q%T0.74VR[G] MC"^&MWGA.B,-\0%0O!=@]0>L-[8<)3&E,)1E,.KWA2);5F"'E.81?62@]L,W, M+3%!#M,/+#90)Y^!@C9!O$94!AD!R&**_85$E)S??1@-
),E=+KJ8=]+*F6-MD*>S\-(1*7EC)["_"7":&@4X@.2/P&91R)@7(QBFML%L.!K:0IYD!A0B,+S$-M,7#9O",&_E]&U]W-'3$@YQ"M!B*&U1C.:;LRX8Q_M\,/KV$'>=EYQF$G+NBKU-M@'&\A*
%;U<*V5("2\WVM% LS:49F%,3&&\H)?2DC*TN>V52\?3K#W;A5!_&-M,*%2[V(T:10E-K0G=-M@7]ZHOTD$HD7",&N8=,_-2@8Y#)&JW90]D'1NBXV+L>=U[[!><'J11-N-"MCPNO&&UX2SA^)
<,B.@ZFS^$O.>\&-G\+;N-M!U3K,9FJ4_%GF.B424@XUZ0JGQ9?]<>.ER#I.?#Q5U#BTM_0VT/ZQ?L)=H-M,#&*7QQK(U$H31(1O@1!F(T\Y_AZ&L?
KFNM2FRT!ST6?;&U1IO)G4==XH'JE!QCQW@#R)G$#0Z*Y?P2-QFI"?O6I!6#.YW0. M6+Y!WQ=-^$-F=;P=S6$.=_VOV<>V,E9R-%]%'VX>R: M1;[BO(#F'/]8#[>ZFFHK-4:MR.?.,
[F8<8)5%.K]\5+HG$NA;^D[XDU"D/7-MU-!"60Q(P%@JP+L,5@+X?F"KV(;F@A,!ST-I]R\$#0F;.M#$(F.B60"_.$I-M,24'73>$'<:BI8AX!B3G4"\VJ MD ;@/B@5>CUJ\.ZA;&Z!NJ:+-+]W
M,TQOZGB:=3_"'KYA!ZS]M2JG>,5UU[=,^2,JNEY' FJ1FX$52\O)GD-XQOF M3"RJB-@B#=&'HMZ56#BJ9KAY,D!EU^@6-IQ#F]OBK!AH8^S,:=&A#QT1-MC-9650)K(OQ$A4K"+3)1I6CH
K&H(0WV-:[IS<-?RYV$7],&I/>YX-/2[NQE-M9_@TUF?X'#M99_VN.7-[X^G$7#4L%E!O=T&\([(2&BZL-)**.\!SP"M,)U%N/-M=-E%=W45P!)80G&-PD"5.*$Q0@+HO1OQ#+^.JX/SRR,=U1
MGLO83JEK.ZO60D(6-6-,**+O)D>C5"\8R&N[JVMQQ]?V$I7C+\YCO%JXDX#-M&!^W-HC?9Q,=U;VU9-1PSS;FS,)6HY^6'/.&O*T2K"MC<4D3;@XR&?D#?<+
M(ITR#:\Z93O[@Q:@3WDQ=+7@'I=#RV\NJX!@B-M%!W5 ,T-;MVJDIJ'O'%L+ ,*I@)T-E%'&(Z-6K#ZTE"SHJ!-C-YJ#5#63S8# M%+M=LG!C$8/1BTT2@,HN8K!%G$NH,GUYOIB6XWE+
2$45G9D3A/D#S9$S0_E-MX0;G,B^=L_QY6?>LY$OD&PD\I?B26__%8MS+*4U;BW.TZWD-3=A>]T0SP-R<-M4NS@=BI\PF4__\X$!CVUG*1[[^D3"V?S2ERRO03-/^:Q"0L'M_G-0R9+^<>N
M8\/?.DG;00FC&?B+-M2Y<-K27/"XA1'GO.IT_4-C275Z-;#F9VA3%*;TR-;'B=$;-<#"YJ2R]TKU0-M:E5I\5YHV)CDV,O;6>D[MU&HH9R>-T,MOKEW63V'S<9;6[H#\YNR/TM-0DK_MJU83?#*
(UD#ZXF#(.J!^-H;?(DV"\(EE7Y,Z>8YMEB16V6I-"#/5,K%=H/T-MXL(O#8/Z"$SY&=PVC-^>"%;P2&ON(@:L->M#!_&-U]L-*F MP1"XC-H)=#>?X8[&YN8>-3,1)"]L/)EKEY+2%P^5>1G
]+81YSGXB:%@^,^+-MMN[I*,>$CD(X3C"Q+:Y,HD2MHD]QJZ3>0N@AH8.<$DRLR=J.-98PA1D&:0\!F\1K-D," MA8?M,XV'.6?>V+$,NEYQ9(5VN$JV<%+A#&-NL7B@VG4A57A^'P0-J,W5FM(H
M)Y+K:$*4.0DWY]CN&KV=+T-3]:K4U]Q(_E#0>-C@Q/1]=.<28YXGJ3&2X%Z< M[SKS'9L8MC-<-QY5Z/E$/S;3)H_F3VXNA5?GC!<,_:-:3(6=-M;2E0YG4D%&X3"7';0>#H3;723B[V+
J1IF?,9]C0!XY0?E^PPGA#FC$:N-R>J;'K(T%'DR>=TGI-M('?^VF[W9,O#D.TS. RIYG083>&([&[;"SU!M>A?&O*3>E#*?(>W7.)UB7,;HF6QBM]7#C'6N-C-Z:K)V#/=&<8CU9@[,7!*8LY
OXF^!4MFL-@3W5U-^VT-M-$J\!N',P\2T^1&$.Y-MU&<*@8PCE'Z2F?1'8%#_9(ZKQ<@OS3L,@1OCTEM&933=J6.&6P-@FO%+-E:6-M$6M.HTW,Q-JPK2,O-$"3(V)+$^]7AZ9XMI,A$!D,:
($93&O22#E,V\=YW'/9R1#?P@B@A#5-0O7!/PL/L.MJG M&@C)OZ#(D?$KYEME;!]@ZZ^0T5NAC*<&!Q)XTPM@(]*C7M$K0\W'^B6 PM!E,-M]'H^YG!&-!US-CA>/*@TS^^.-
E*4KCP5'0=Y>#8B(S*\$G,TN0^,XC.HFD6-M,JVH%NI]X-]OOVO\N-]FVHFU0"W)$0A,6[(6SM#12+Q%:9B*T+?$I,]J4-3X-MV=],ME8RVCS/Z%&\2]OBJ^"V7LHLT+S#%/1DT
!U0>:C1[10F459O56I4$T-M2=WQ?"I7'=VDD0%];SL1,48NI5'H=T>:BK:EQ4HF199K">6U-="1\(M,6AT-M%%@C,TS=#0>:0E_\)("WJD@5APH?E]
(@_;F^I=A8A+=VB(L;B&T_BR4%3J:6,R,T.:=B$QBI^Q.A_8<3,F?*$(C-MGEUM$H?HX3'3C5H*W9ZE\Q&GS[U?MO*.+@%;85=5_#4]&R->\.S[,9L+,?-M0_##1V84=$Y;ICBS/Y@"
<.4]8T9_N\'>>H+"Z[2,VHUGL^N]5K!J!&V.U-M1&A3IKX2C?.O'";+=LY@E],%*<2+G;'YN87]R4*DHA99:&0LIY"U0U#V^;@-M"TU$Z=E&?-#F"0W+U0A=,\4::]K$;H>+0?
P:L\3]9#9:1R6G4C$0CKN-O5#-MGEYT(1+"_]/9'V7-(.6UJO-/?'&9H./^6WAA_?V48&W,"S.V4XX&-6MXA&GU-MVL#=CS-I:\XP'78:]5*W5FVMGP8KO/5B.H$'?!$?:@O%RV1)JX8(R%[<(BRY-MI66E6?
T@Y[Z:C0WGTV@AK-SG^U:.S6X5LJ,,ECWG)]S%C3PV>E4B5FW3IAZY-MBO[X#+IQ:FFS*Y-66JO0ESZ'[8=N'OHV2Y5T:8!LY[G;4Y69ZQ/6H-][#G^N-MPD^?
5K]OU:NJ7$O]2:XJJ=^O:R]_EI1V5>W4-S654F$[(B:L,_G^J+GO&M>^WG/SY5,576H16,NC-HIG1Z.8H9D^,-ZMC-1M]4\56P3FXO:OC=&OK+M$\-M\M5QHR7J"JOX&*Y<&ENWT#-0]F7K=.
7BWD+;W0LQ<[$/VZ!A:.(Q&%,D.VX-M>-N+=_CCX@]YL/%6BG@E!)+&NWBG7,6QPKL?LVKC0K-MX75N["O\3V-3J2;O-M[2KDI&7W-9T"VY-MU)53=AQXNC!1J&*^+.C+]8,S6=#KV#@W"
[JEI.^+,6]"\>7-[.-+>@!7D_!-MR@_L,T;GI&HOUHQ6E8.8T2T5>58$HB]%$XM-].D*>)U&$V[98@S3-ZK-1X,)\4-M0&J?76962YZDX5O$<9-VVUJ3-KM7Q'ZO->-"*"ZBN;5;G&\T_8/5E-G;QB-\\W-
*J^>0-MH@ZK>)O@SCGJ&Z<7=1R=6:(E'S-EM*QJ^ZRYX1A9G/G?H]4MB?&DO:5Q:A.]-MATZ.IQ?4VE'&32]D:6]](:#>!U-MBWT&IU27RTO;SKRP1U3+(ZR,#,B.[DVZ6@2&T+*P-
ZOIE64TTFJ6FW4-MFIG.%*W-OBYG:VGMZ23X0G2*2A9HCT6Z0-0@_ZU&&-=$E)\-MQ^X#HD2?@]FYY.KS]EV-P^"<.*1M#_2B-H:!=@$8XE>:#!O]C#4SFU1-M1#^BGX4&CKU-?XH(X&,RB+>-
LYS%_X"=M//=%=<72S-5;_=3"J&-MXU?"3N(MC]H\VJN4NO5&66[MG:]T,0^D2"Z!<)L6M'S?9#5LI0(?2-N6D?: M\[R0&Q8,CJ"CEKKM!A^E"4ZS$EOYID+4"U$/7-@ZO:BOE;J->EEN[GT44HCZ
M4R-LC:AO'4K4UT'4Z?!"%$O1/TEB/ILIV)7S'J\R1/^RL*0?]-P5R;ET#Z]([J=9MEN;7W6U.-M-!P>5(-;JZBL7-ZT=A!Z[DMUWA-N\"IQ"-G0.)QHX,HK$F1*.0C8>)*:R8
MC4>.*7244E+*7344K=V^C(4/$C'2TB*6;H-M,^\-^IF"!K,HAYI\-!-M,PC@YBH9E=-+Q@8:S_6ZR+HH/,#62$;E4)*QF7Y5JI",-KC[1Q16C<:](@JK-M<@]WF92Z2$,H,FZVM
4/%S)H@_),RS&^V#2$3*?"=@J+'>']_0\'BI&)D5W(-MR"XA5OCD^)HEV<0_S1&Z]RM_7D-J,@8"*TSLUC-IS^2T>F4N@VUW&FOFLF'-M*&%;,$MZ3ZXL$#C3S>P#G>:HR9BJ@&7J^
<=#X:WT#]"_QQ$_YP\$[@F*Z5N-MLU&N*7D%&87^*20XT_7/@;*(.([]Q(_0/T+_G'P+8,4!.EY.84W&A!&U7$O\-M&,DA^VFI
M_'OBI7!$=:R[/G4\>O7+E4LL#>\.F)=;_Z_%TG[A(LCS5[2AYUB!O_Z5XU<#-M7*&ZTH-QM9.*-2;^C:-%V)JM9L-H:Z..]JE*?:0WVZK>KH_DEJP,VVUBM/]9-M-YL^?&D<[Q9-
@04]0Y=H/RO:""9XI5FOVLQ*#\91<5)BB)-&7Z;5^U=XMW=^H-MHVY9+MT/W]9+[Y7[?[^P?\I]$*+6_Q9O%*\NNQB4&]2H]<]+R>0[O,[JM*7^-MBU;D][U[-%:J_FXB&U_NM[@-0-P&<$QZB=L
Q&T-)P67*%Z?B+**VP#$;0"B-M'J&/2&84MP&(N]%[GU543Y\TBAUE7G7!,UH@NSO9;U[(YZJ*R:)]T1S05P-M>@T$[)>R/KULKYV>EQ?-EG?JI?51EYY6$+6\R;K:X>2]6V0]4J5BV(O0M8+
M6<]13M-6AOTQ\^PZI:Y:+[?;.>39"0'?[@[Q_Y-MS'-1A+>X$.!HKD#]Y*Z-HE-=T5%$V>O"(VR-GJ@?R!-05%KV>N^?+*C31\]CKFL%SD8Z7D!DCK@0XFN6\-M<@?M\2UG>LV@[JXRMJA>+!C
UJB)Y=MH8&LDXZ%*]ZFRD(Q",AXLHK!B-!XQHJ-J>(.47-OG>C@A-M#T\,JRU-Q8-%%%25YBFH(D]!W!@@1B9&=HDCNX10HK@Q0%3,/'KLX.2W"=94-M+)O9ELL.:_@@2B>64ATIMO9!
[J*L*;616_9[#;2^T:4ZWN#,@ESL#,I5W9U^9M@&K.$(IP=?_$U@S22E+6/6U+/F.9-IHD!,6-MPI1&@$Q)#^'H2:]C1QIK+T22;,>7IBYY,9W-@Q9HH]-I?=Y/C,8!-OIIKG-M2_XKL>#MB4-K-
>OX#+X%W=)'7-QDV-^'9OZ6'K5//C9=/T9T.0M?+DJX9S=ML*R99AM+<_,D,0(([SV4Y[1U?^P2PI[$>M'A&,A"O6AFN-5B>N#3_J[J4'S-M(XOH/L[2H^U"%$\2@ZUK=;D>XWD
^)U[&NJE[@_,B%-40BX5V1'5RN^NURL-M5?I3IAR$Q5OQ&KFXN*$<,\[%.%Z\VDHI5B4!O2T<(\XFV\-[QQAX38:!I^QN
M1^/&Y?"F@&-SA5BS,F44!C)Z>X@Z4G6C4VN.P).J=QI*I]E6Y#8,6Y7)L*TT-M-MEL-4O1W1YS!DOE*REBJ:IT8LS4%.0'A-4VNWJZI&7W4%35XXRJ$Z7_Q5J;@D-
;/>X<+>3;\9:,LK<.JE+3H/3:P*>)4'"_(Y\I1!/2:-M^OF.3Z3:%5-TM'+I^B;L-M(Z7GS#?_*)9;T$$Z#H(,W0DI%?@U%-H.B^F!S/W4!;V!M?2DS.%E5.,LO3A-MO_^SK:KS-:!ADU;O#)]
()N^Q40BT"17^*#C>WU%,RUZ0138P/-"#;V\MBQ#+2XX3U<-M+C86:>,;Q?\0(GYG+AVR;=@,0/?\T'F8S]&X.)-Z'+#+!VC*MV8%AW.TGB3-M;40>@,<\"'P!1+-$_B&;J-#A%$0!\
(=FH83V@;7HN$#-0$LT>()-V6@_X5M-M9_8RA1H=3=P"C-M9=WZ!>53SS9"SG]"89.B;^O+FK68V@Z#-B/'LIQ7%!8@@#5@4:"=;EJF%EG^-MU(Q$NFJ^
R(6I0.,VX'E9%^$CS#)3G]-2,T/%K4V5H0]D_2TCWDL@(E=3PKE-M"#2Q!N44FW6TG]*-)6R2/1$@R^G-MO6R/0[*L7$%(E7Y&RAP?A>=W89:XO>X@%](=)'E4$BO)'$?"D?
M8F\GX4GLD).U$USYRPI(3_++3E&$)(G0N[.\LE'5D!A^4[=L^6X$?]267IHV1;Y%4Z8$TI7R.TNY>E&4%3#"=AEQQS$E&;36*'5,\FH&1Q'K3PJX-M[P5WFA6@MUO#84=IZ\-ALVZ,Y'9-
;S=K6L,P1JV&2O1_UBJUBH+_UVPHK5:<-MY<(_Q[1WXYALN=4UK,19EE7!4(*AN#ECE/T(JGX\-%*A4:ZUSN@:#,$(16*$-M3&IAY2SH0=1"&]5"0;YZP0%0U)THX\-'%T(XX-&X8-M9__0!M=::<
RSCXDFN/V&3.]>4$N<[I_0+*KG>*1W(?EOU]-ME\3GP&,)N2R#+Y&9MQ;?YUD2=:WISFCV;AA47K,9HY7HL86XH^MP/V).YGY.-M?9IPNIU-+\]M>KP26"XW:_5RL[%ZFDG4(#\+@+5/![!"Z3
%65QMEM;UZZDP-M["P-IIP08-H%6*.MY'%IK0-8GP#KG!!@*@58K2V7U2,?$JR-G*14Q>N%PQA-M/,M&CX-$4_@2C\2A20SV\O*QN)V,X6UC]7G]/>X5M;=\D$:_)8C/],QWL^M4'@8T-
,T3TYT_HH8#]H,'^ZY+M,PP#^7HMXC\XT8E"\3UTGC-!H[,ZJHG\]G-M%TB@;7O+^+AHJPNTG3G:WC>3\T;,%J9-H]2M=<_S4_>V:P3D^(3<^X,S<05<
MLQ@"KH!6=)$CS>]9T>^7J1!1Y0;;TM]'#'Q'Q!SXM8+-]V[=R8WL1G>$3-M:CE8T?E-K2V@=N90R\&$WA9J6]C/':Q$7U:4AH#;><(M!_,Y%\G6D(LAV0IH-M.Q>:-G-B6W-CSXDB5&!J/0^.&0<[Z2-
5J::WEZNFY'+#B_C,I;_/#:]Q-MH8S$^X5XGQOO7D9$E*9XBQ)B9UOY(KI>X=UX+;K%Z04P4F]I2'/>&J6N7)57-MSY-P4NI"%'X1\%\;%\X!_DV$O[(:3!/PYP$BYPS_7="O+*%_1]"W$/1]D^OD
M5("\LT7^3H*-D[/@;U/!OQJNYD3P"]*;G)N=K@7DN]]EL$7^]1(.5*FS.4-M9#G<"%$TV199V\!+3\HU!U$^I^!5P:N\N)OK>;4I[^UP"EX5O'KFO'IXW_@=
M#E7R\8X%FPHV7,V/:8C_P#JGN[\GSR*B$%O^[:WA]-MMD\OFYTX]%5LG#9+)V:4LX5V-]-ILO(2P+&5,S:RK[^9F]FS?I*=9S!GW%9O7RJ1^_OSIJQV:R5NIUVLUQKK9:XIS/
M.L<:AW.LE[IMM5%NIYQ9S%S):B>BU#DD2F/M.K21.NSEC9V=^'=]\=]Y-M]C@$N=T9J.UA]TQR>WWIV1\-LK8@NC^Z><"?#H/P]84B9T'XH"T%]E8"&Z&#-MZ+3=B_,13C-
1ST>].0F(QT0]>Z$[_U,UA=]<>M+7Q<,BLX3\[-/MOD]P7-M,LP=>M\DY9?$_MU)Y[Q_&_EHQ27YR-RG?]F!R:-/O+9-MIPE2-',#@N@7YAB-FR:-F"'?T,"7[OIPSM83O%72G+[TK?
BVXP*40N*X1RU.5N&-P"$-/>OFDI63RA-ME*NH?'KMMS>::MV!,>??OR-X7-M2RA5OJ3$RQ'^V0'DWN+-@DB7GX$-QJA0;E^GMCE5\E$3WU0V-ML7OKJZG/2Q-=,+5[:GM08(7N1@]9#!31-T<_8
^-@![-FQ5:6,5@3-OJ+H9@-M;WU4ZKR@QWKBWD#M]?-S>7?EQ9Z"!-MPQ(7%/-#3)2=-'B06GRP0-_L<'A9P6Y7OB2LO$-DOMLGNQF0ZQ(X.H-*R<;T!-MOPJ7"!8NF\?6;%5B6!^^.R\Q]&A$
MP1+4LO83ITFB)T,!V-$[L%1":#%1AAX]-Q\-NVR.VFRBO/L!GB(Y.9\F$]BF-MGQA93-^\^)0H+9509PN+K/W_J^TANV&$E[VT7GFT,3GXE[S,K"8#8-].WQ[R7-M%'^,XWBOR%MSPS=-V\VG
>!IBV,"I2#2%.8H+#9OUZ'7Y\X'[BP?QA!$-U%^-MJC(MM[<4@K[K;-"&?DF'PCZ>-[-EZT+8%5FL?0X]T#8-M&MX\#%H%)[W[TMK@)+0V-INR8/5K:4U1FAVV;P_A_R-6MAE&4;XU0."0WJ+
M[:G$YB+L(8%R8HWMMR6[BZXI<6QN85-.&O_#]V[PA^#F#9(^Q>PL1M\;8]M-M&Q"^)@\GSQ="0=U\-=5TLUZ+;1.L6RZG[_8PYN8%I-CNB3UAT6]?;2N<-N-H-M$2ISETA+:*>W&./

PVABZ2T9BC"!!)A_>OQK/5C3: 4XF7^G29.!N?$,EJ[/ MC.]WQ@36>F\XK\8BP#R$+-$#Q6?AM[IUOL&'OXW]7QZ*WEH>5=,+HV]=JE&U M,['8[2EH(!94%,T]+:\Y%?S ?SM3E(U>7^P[
MUA)2RY;,+H'-]2=L._N;W*/_X((,CXC6/V$LZ]O4<#^1:QS\CD(^V-45';;Q M9%+M%?FB]!^6)P1G(S]=Y=/,M<=1H'QP40ZCLU00[;? ;>4(4NI*4 M%,7O:RE/G#23O*M="'1]8F:="72XAD
%'.%_D1/RDPE0V96BF/U<%',E&#MG M87"?WWT*FW<\5OQ%1*0_3<07'SW7-()IU8#G< 0>4RM?8[M(#VW#Q4LD"'1EWMD_[J.V!51ZCWL KYX.]P6A M R&X-FDCW^0>&3[* E&,GSF"
T]Q/!#)/ N<+/CXV"! >WS,!+FDZ7:^]V('E "$:1UP'U];L/+"5L//#BG_M="F,H!\BC#!H9N!NU+UYT#IE-GJ12U,5+LT,S8UPN/LN7MJRC."_T^C_^_+H M /SVW[L%!#XE0DN(E0(G"O/-
G/*K,CAB1HD\7:2,/W*D@T46C3^%Y.IQ(!Y MGX9-DI/1[-Y3J A^A#=ZT3/_#A2M8YM4MK,L[WC(!JY.W$D2?&.&ETQB)XNG MMHEE*"8S OR9RU?8.
(N!*W:22+QOFW/<$,H\44:\P0A1QL:GH=F[31_6-D:B MPOX=D0/R*F;IP#+"5\: 2"R4E_#%NU_?/OM41ROOC" %>*\FQ:,KC1?)ZX[3C+, #E[*\!TC,,:0,0 NS@98@O@) &D M2R@9S>>>Q
B(L]K+A$!E^=C,\/0(4^ T== K.W9;=P2D(L?PX$]5:#4S5CT: MHK8I!Q8Q4)SZ8+N4Q??LVMF UZIPQB3 :G %$,7<:]"?I=,]>FP[.W5V#:+5#(*?X.HH ! M'%V,#LX(Q:U5<<7
R!]&Z.TGZ95SQ6+H[8].@-F%J\HF-SDLS8K)MBK_GNM8 M82_^[;:U4O[]S)W=PM.[5M.37HD@P/C[TU@H6K\H#)6U/?:P.,YU%K(G6>@W M#X.N.BQ5HCO;%(T,>'?;';# NNIH4 /?I 6ZR
2+IUV3%%5P7.N2..>X.E2 M[DVW5Y"PE &/B!(M55Y4!="Y,N?V!!!&0 8XKWH3_2S#]->"5DBIM%IQ-5-A M14(=+%LA\TR*H9"MY3 \+B MGLG97S5N,]86/&R!;TWL*W36$Z/M,8WZ+,$K.[[
(=,WY.:Z,1!^% M L@(]7P;.!U%'0KM43!JQPS6SA*LD)C]*_'8,@M=IW%7_7Y%>8RW$J/6+#BZ M+X!<;FLJWQ<^@E:0/>'&NEWL.8+/!..\]%RT:M';L'V"L]YNFXK> M3RQ,>4 M!?
6#2X+\F&&6JIZ"&$$_&'#N(\"KJ+^)U[SW_?82EOEA6C1Q965<,P"3O;LU \?WZ_9]$#^_1_I=]OO^,+TT?F=S+YD6=.1PN[.YYX4=Q.=O_TF/BA:^YSAW<3>,;\-MO%[T!^-F
2$GYD+GK##S].MF>W:V/F'_;DMP<*M0"R021D;UPEY\@U(HM. M5IX\A"!O".D&GF-;!N\$)\]RBRC@]!:;#('>S0 8%;$9 !M8VVAX MN&6P<0N;C/[Y.U\X-[NT);L+UWIO1?
XK]]JC;FILQ?E_E.D0K'88;JW?0*Y3 M\D=/A*Q3:B5BY6[D(W;9 =/Q&V88Y-HC=[5!3N+!=_GVR%*B4(QQ--+BST* MNFW1$7L@#@V"^UT:+/,E5A?*."4G5:8T*PA;$1GS@-W'']&$W9LE_B&;GHK
MGB\T,&J=E4E!]$+^\[_98VT M_:K>TPN_+ M'C5J#=NC2D\J_[[;[A]D31K\H%=]^;4NJCOHU7%1FP[6/VC"5NFB*W9K+"B;/ M<4/V3&/6BBT%?J94T-5M=;[9U0%DM?GUM0,DUZ#EN@'RS4/OX[IA\
]1L'#W M"&L##UBA8)[R&P:OWJ.13]'H92!M$+(,9X@V8: G6+9W!=D89']F>_F-3_&G MX9M39;4G6XZ<],T RHR0Q#&1Y-]N.1&U?M,_]T:OSY6KF/@P'ZE_8>7P]?#F M0>^H@W99D^
=IXQN(((SC?R5U+PE-9\KTW1?:A[=//3;/;73[4AREN2]39GD[<&!Q[5+:FXT-9\KC7M?:M: FML=5=.O@IR;2,*UV&46'C,YS.@OH[M,WG(1Z^HW#]JHU,3MY[04[OTR%63(.;J5?
X%'2RH#-7&O=C+!UTY&[M>HFQ]K9V-M[M$5;;"BKK?%;E_E-/S._;>'#;L^0@[HQY#4< M4/.6$/N<-C=0QY4/"ZWDN-:]88<^I%:N_7X^SONF:J2H!H%<293;>*RU)THZ
M&E9[W7R9GB3*YA/EN9H[[T>4G?;-0[>O#KH%0\$E43:=*$M\U-H3I0;J6V^K MHVY^MDT3J7)O2]R=\5SYN/4ZG=-3,]HN)ZL=';O_M,2\5;+;R:HV/]U,8LFH M,WEL6DOO<\,HNK71G(X\,FT<73;&
]UW1F*WT[UYZ'4Z:K^;[WVTO6DE";.N MA'DN+W1_PNR!&3)0.YVNI,O+H\NS.-+[TR5./>Z#+SK(-W]N(F'*@U+IBQZ7 MUR+@_YT<49R3-&P
R@;\RD/0P]-7W/?)"//-7@Y0B"LZK]QD6%]SZ@ZOY8.U !\XU/"/7=#5,AYT3=7;!V[UT$ ^D"?< M%Q]5Z#:Q;+B+A]M::W2H>O\CQQ3B[J6P4%;.F?*]_:Z22*C!582$7Z@_[U9-
M]YO3GOLQC.5Q(;.T,3.97.PS/A2PJK%TKDG%^QI+G5)C:9=)H].&=KOK=F\> M!OI0[7;S*DG!NS9->5QXT1;C(B<) 'V; M%%:^;,^SFS9Q%2WDO9@@53$7, M_1>(LG,N"S3HS':&R>
Q@:_^8+6T^JK3)$=+?=[RTR0?'<U'@5*$CFL:S"[&5GT07(2@WNQ1')"GV*9T,6##5]LR_=C5'K7W[8X1L7U6P?]<>U#AI8'3% L_&X MG$N'#62^S(P= %6!$ÖÖ#]I@]D\[]VG"ZP[P'@%O=O?
8+3T-.#XDB-UCY2]L="M3\1D\C&;_#BR6Y2FIX.CUE/;P[QW\S7IW4EB;5/:LA^\&L2H98]MF?/B>UW@4K7=&:AZ+]]? MX=#4(NM-+E]7=-S) M6VRUS&2\"]JZ4(=1T4UH#%
;WCS,&JK76V+'G72B9).5%V=J#VK]GLC MS (:2@^]YD7[ISO?VK \J:&\7:,?CE3;=L3#KWX,%%N_IVK#?(*L=+RDXU55 ML147CM7[)*NO85RPJ'A
M/S;.\R_S:,W>A.>U1LG"5N1CTFY&TI/2D]B*NR4M*[UNX59[V?9B+0&C&2 MILCW=:PSR22*]E4_V],[M=MTZM)R&!@)$G(>8!T;AZPK40.(]MU-GL0W[:Y MP7O17]=N:,B#NHL];
/M5=QU2;%6G7;=PV*HO.&]E-2CG+%:[]_JU7*E,J]] MI4\>;GV45'DO?AJ]*1%5QZU*Z@^V*.T[8C7<"6B@1/;L3P/#];QS0(EQ9!H8 M%:O=2Z], Q^, (7!H4QI6OG6LNON])-U-]ID+2E
^RP*T"P6,GJFX[=1$)L, M>U2D4?69@7HL4%[M<*H86):6H-'XP,)#(C?DGO%"O-50_D1.49X,W_&4P)Y% M#A<3^<>)Q25/:O&]K'M9IKP-:^44#SS+3,5]P[/7]@W:5%Y'E6KY0K6E7:_"M9)<-
C\Z_86U#<=[7C6730>"9-ND3@LQFRH#U@^"[@QM9@(]EACF%+^:>GRVI MY*^,YH+<<6LS>DOVH488&K9+!7#BNO0YQ!H1.,0._5"XEH-6,V/AJO!=VPA$ M,'P7J]KF7D!/NB>E"H(\+6;
[^6;I+A&4,J>W&./ +EO)ORZH?)WH*_6^)89*&>T M*Z]7'7*7]EQ#ONRD%@6$LM"XMA'DH7$NQ82?Y:%Q+*0^(RY%-]1A@@=,9=B M0!61*L#Q[*D4LI#X*@N)EYFF(>D7-RQ1!
(OI4,GNLI!8%A+7@5'+%-NYA@*M M*R1>.P-BT"N? 2&3WV7R>U4EI36E@GA[#NG7,0ST-;AKLKCX9)5;)4JK&<7% M@\'-0[%;)FN+98K[@=17(BEB*U!O@-,+3VH\U&U@ M9Z@=./0I?
<>KJaT;T.AW>]J[0#ST:6]KL*ZB<7IJ2.<0 M]<$%N.JDN!H>4);U#K/X_'")'P]Z@=X+IUX$=H4S5VL3@F/7KRNV8N6QBAV\J MDT2U(.VKJK*S]Y36'(!'[9N'3GYB[IL$POMKML-
1PPA[415T9BBAAKP%?;#Z M;UR0/>CWK*$Q&>F&KG4G9G^HF\/NI#UH:^/AD%G#?^*D[\U5],*QN\,(!=GF M2\;ZW1FKZ#]Z8#?V[KG8S?],K6@NT2>_V8'I> 'R2*X(KM?.5T_"=P7C+Y."
MC%VF2_)'UKZWP>;AM*,A^S8\VC2"#7$]?6"@Z\'21RV/8=^,Y2]T;.0:D87. M CP(]Q/P3Q1F)9$5!XV_3AE54K[// (!!TRH;0#6VZ%:M$7# .2_.:"5N6'L M3Q@S+W)#7C?ZZD6.I8RQ/M1DP*
(D&0/F./@4+,.L1)T;MB\]A/,@F "\MI0 M-L8VP[6#]I8_J=0<-A9\$N$1!JS\)4Q-VE@8&-8Q)YC4EM+H6'RYE1= D60 M5,\+(3]C!E(E%132@H-IO.),KP1^K4PS]]/RC=O#LPTU-
O*+9I(>AHI.A*QT1/O;7 7;7.;T_JT%.K/%&!"7N/: M%1&8M+=OL#C?&#MV,,7AQ]P6O MM(*$,VJ?P-Y8O+53E=6],4T2*Y]LAO(\7 M+]ON/
+$14%JDN*=7'S,&.@:"_;UC%QGNX)F$*GI._*5I]L+F3/)E#\8:$Q% M4^Z43V-XQ O5R0I($&WI:.* 8E7^'7G4_#9/5!N09!8N')FO:%^'38*1PP_M<@(/D,)C^A80HUK@N-%(T*H0Q#HK;'2-S0?
7="*+*1ZZ3DO@P9)XBPJ7G:2< M/?XK"]!,CY6Y8YBL,=OOP/;_PNT'T1Q;7C!J[0+H#N$B@3KQ7(Q M+@(ÖWW.S=''14%' Y/6-64 !^XQK1^'4%PA@N&'/8-W< T<4!@N#U :VFZ[
MN2NC0N"S8@D$FB1=JH7[6"9H:*/Q>>-XQI]E_H91EW6T<._3ZW3;M_$=EDE5V)#C[M70O_\RXU>1[#)[""*%@*1DM9XO7;OYJ%7%+O:O;_7A@YO.Z*T#ROMM?+==Y.5
MEEM^8V'#H9;R7+.(^7 2N5:6<4T'NT-; $Y!RX7VF"%4=?VHMF==3>=<95Q? MDQN]O,E-!=>SG[B>I^Z,DUQR0G>5($?N:O]^0[>K5=;\X(:&^VR#6'TDDR5U M3PN\TT&!=SK(>Z?
I,XDU*=2J\>KL-MPO<^ZJ5%-H4,[((>V6AL;<\JLR&&? M]JLP %'UN^=9KR!CBIO5]+!)6NV,U631P,U1Q :WW@R!#9"MX4]919(\,:TG"F,VJU>]5ZN)0].MC2NOI!NL3-&[1J3RI;_M4_7=E7_[%?
K@5/:N49K]?5#]?CI].H]J1Q0>KM3,^1I>]L]])VPQ4\S^M?\ M%;!)Y"A-VV-VK2U\?O>]((A#P-<)@D?3C*A=*FBNQQGVF_P/&077"@^PK)38
MH[INRHA3&161RZA\83/#=A$N&=&AW/XO=EM=KJ.YK)SX8O-<.!%^6A[$]8H.#.,&-QOPA'4>]&LP*%4G3I>WH^-(6JSJ& M>TO; W6VD?1S'-M0HN=:V5N_5/:^%I5Z%,%0W["8\A%-
.5.^B;MP]#2+ M^[N7R_W7HI"O(,+U%-7PMD5N0-G0E?5!_^:AKP[V MUP79S/+%#:X>=#4?L%6]YYOR2N"[T="#36M?1M![TMIB+)8GKW,1U*MK:P,36L;V\]A?0 M4?.EU;79+-
W3FM9Z%TCG2*9U70O#MG NMQM>=6EIY]4V?SGB>D/K\T)K"NR/YJ;G#S,%('G4.%_6O-;7O=?UFAZ^*.']DVFN><7"OOO[#[MKR&GZD_;Y0V\;0QJL"
4_;UIVH7M*G\'I@IW[/S1R%/*C[\RERF(P8Q-YH+ M,?55/UNA9("3%M]#.7(DL%:H^>@C,T'3?Y)@W+V8?+1Y3+YQ>M285%RTBN MI4[PY[;VY/W7??\U6/OQ_+[#-+]59VDRQ'C.$"-
OL[$%UV+0D%[I&=UVC31F62Y2V"Y8^NURIR%^:]M2T/ MR[8]+%MQ3X?7Z)UFD-R98RO!"!OJUVW>@5R:='?7G0S3/-O:^KCR_@;=?PV) M%8=9I5(3C2;OK]G]EZ6
3C)*I9&'0,=KR+SWD6OMZ*6RRWRACK'6Z1^] 6VG M_798#?.Q1*HVL*I>] MOT\B;0?'E[:]@\Q;]&$GA\ND']GC/#]7AAAP;,71T['0RZG0N4K%=F8X&2 M/&D#YFX'E/()NB\W07H=9;!)
(]W!#31ZI)F!W>YA!YO(.-%6NJI[XIF!W=Z! M!IO4,"YTF>14S0_8@YX.5"+>[>-BB(*:^+,0)D^>;%NPAZLLHN;0.=-EREX MK\T$._$(Q"Z>Y9Q@_F%M2LZV\)*OLP%'MF.A^C"$MW=&AAK140EM-
MXZ&2X9K.<)4:JC+ 1%9 M[U;!R,Y?R;Z'.,D[R,B87N-0AWB2F24S7Q8S'UL75^99S_MJ[U#GP^OW#FX=V*]__*->% HAR<'4(2.!D^! VII_! MZ]:!P@#I5C(:E/D[(8]AFOAATY+.29FM$ #9E0-
,Z,#O[^/R48[8<8%CJB(-MF&]PFYUT_%-<>\(R. D4PX?'>]$R9B?.%(/O!Z,3\#?@FC\+V.&2NC!5_#_M;F0XBL]>;.!HPN]L;MA^?.1HF"9(6(I8O-KAE!;]^/5)^>;-;5/I] K*+1XA MZ*EVR&
(.7,+P1*GL]"V>5)"Z9R3Y[[M<)+51D2RNDJT\N0!.;D+(.YGXQFH$$E*V9 ?WUTR M3+XQ?_9I\O@,(@R)LC#?_15H-&!NRI#:S0,)O3M,<_EOL\-/W29C[UB%"^
M,*=O<<0.Q&*V$M(67\8X4V$+3X9K6#;.^H7!+[9K^ L:_C%EA@:/.?FV.;?& M, !QXRGSR#>G1H_J93*+#X\)'_LS1),%=&4'R^\E5;/4S_& M"0B+ [M/049'MCF!-;/(+'R.0D)E- C(AF$3-0
]"85U0!B>IT@_FPLZ(3]FR:8 MF;!]^I5A6EX :U/FOO=BXQ/POI3 A@M#IH=#) M,RD6.BWEO>PK1[!+L6M88$F V/6#>\X(^7_76T^KR
2ZFMF<8A]=ZXE@^,9X'R.004_8C31%YZ02Y@L82L%=2F;\:W M%+P;#)1U]K$(H-QAU)*LX4T6\]U)3.8P99_J<1-C=PP'T!7D-] M_MGW3,9P)\$178-S*G("0.PS*-J0>[BJ\MDQ0)[;DXD";_+"Z4)Y;X?
FE(5A-M8H@GE\2FN#(!2\LB1Y:+/N,9K@"%D-6C0D$^>9%/^A%I%B[J[](!&P;\?'8<] M3QE<*80]= %+8:X;+)P7P[4-%0VB,D%,S:@0OGMJS@,%(WB:S%Z*%TS W7Q2t

P0%S5A"DG2)%O'N%XPU2OQ0F%.70$WP5C\S:DS*>SSP!N9RL"3(+?:K0 MSBY>5&;R$FC^NJ4%T&:RX\0F8!. %2^\7P0=97_S5D5+CYX:._"?)_;P"4TA M?8LA8)],"A05F,
[+XX\\/P$H392J838'>3D./VR>I%" 4XV7'\-',RP)H@3# MU%]M P*(=/!(!*&1$@A5LF>@0F6?=I#M9.EN3?.H\H W 0RP,"!8"_M9\"+_,$8:%]$"B<3.74X_1@&? M*HC0IU+?%Y8EX-CC3<=CKM(F[P
=/'R>0U_;J2#< M<[CGK"K/CC?&T$*\/SYF7G)%6 [O8!K A='R*0EBI(DDGXOW"7,AJC2\%0R M)!%# K:)A?5X=A+@\GCE!W E)>>UP!9)VOBIF_%T\$8+#G*;H4.K4POP,6)
MJU8AQ6N/39X3APV5)]A,@Y2>:'>3'.I.;!9WVL1=9#JG8,&^:= 05W%H'\P9 M[U0Q T(D.9A'<,)N%*7,6(T,QL"'>G,?;%]STTD#GF:(X"E]X%-Z5@D_19 MW*V 37 *+KGV<9\>
C5O)R,FEM*F:2EB%0'&G3"5R8FG&&$F5IRR3:\_,$[M DYH;R&<3"%0FG*L^%RW0W MPA9,>/*6#N=,VTK0J8(QGX,XSJ28,MQ09ALXD@0[/;Q1>".[\@!BO@I(K#T6
M.3[(-32,'6,>L/OXPUO+#N:.L,BW*2/KCFYZ*QXFY!2R&24(@#P4A4Q7]. M.;#5YEP8^O_*WZS^+D%/_V2_[[3,0W;H*?VBVM\/NR1VF=EM;5*SV]['N] MU1\,#
[,H>-1P<*!%=0.]0T%*'W4.LBAXA58-YFL6-6IW-ST*Z!89@/>^Y=?$ M%.R"0WV>JWXABO?+A=]2^[;B@:,N?+44>XR??X#+WR;4_FK3,CY[TPZZAL5 M,__):YC?47]N5+E9)R^15:%U5:#YB
EL^T+F]2B7B:4!>F2.1K8H)D4A-O; M9B$"@PQ;@'KS=]\'7IU]F?8BH2*IZ/!4U&RU?4"\R_?L]][:$U#^0,(T&9M, MUO$S]K8[$S<7^^Q?T;DM96>]VF;;2L&6:;1@K?9,OBP_"E_=>474TG[;]=[M
MS]LHMTW[+>1521V2.B1U2.J0U"&IXX*L.)%6TB0K[LGC-4'ISM96G,RMEH)4SLF$P/">6\L.V;[=A#Z M5#9V9KNRZW2($]$#:[^+Q4W5XQF)FU.E$G1,/8F;FN)F5-G=/"IN&JC;
MUQQ7U5ZW/Z;]E*\LUZ(GC_/KBIIAO4Z,)6JRJ-GQ,$BBYOBHJ95 ;Z B;[*3 M_ANVU# M(^E.;=A'T,N=<,G,M)@K1I?UO,Q\J3$^.[K,+PD?.]J5D?B\W+P MV6G+S#29F297UO"5U88Y+MIZ%
[U0Q:PQFHCBY1OD7L=1VVV[-7I3CZBT/##(MH*7;&DBTU XM>N5D&8F:4W&,WFK7A&-JH\6EB2M75K>5U88Y+MK$%0%J,5T) M[=PKLVNKIX-
+37TRU%0]9Y:H.1EJI'U;6]34BFMJH\:EC2M75K>5U88Y+MK& M70[CCAG.'L0.02\V3C!4;L?,91,[?,_'F_*K0N/'U76NO-6M7I/(B%3H2R'> MN@2L)%KV25"6]#D5QVBM3DTXIC8:OA;FK[R_$??
7AF@OVBS]+"W0?.Q"MDZO M*%6ID_D='888VMS;C56MW*RF)[*%16)?6=XG7L6I\+HJE. M2Y,T;)6FJ%I%O25>2KM;K/RFKFC3%\I?0 $C#?RW[Y>%O\(]B6__GQA[T>];0 MF(QT0]>Z$[_U,UA=]
(>M+7Q<,BLX3\'_9OL3>(5,_MEUNQ+?))SPN^ ?% M-JKGWOW^^/A9>6^[AFO:AJ/R8P@\C/!V-TKS]+7OZ(@M">+XVV&GGAOA_Z MK1P1>^)?V:[%7'CZ\ 08*TMAYLD<%@.OXH4%H><'
MU#TKG#(%MO$=O(Y7.YP]* NP=-]0:KL3SY_Q1EL^>S9\E!**%_G*)$$[8#QR MPD!57IDR-5Z8 CQ@@O<"P+L-&":2.-[K&WCJ$D15Q5#HBDIP;J8JUK M"*9F3A32M!?\
F2PQ^35M^+!\#Q\!,\)QZTD-8*PC[B!24OYAX"*@+T%\#(J MV*S#EQ%P^. 4V,SV0B\/+T(3#HRU;'A$Z"QHNX:/LD4I!F/0N@"ZC0$(H &4 M,VL5,@K G]DNP $T(L"V5#-$PE:^LT5"3A%2QWA!E
L+,I[9#'9%^/O5-ZI& M\/]&8&6F .BS%\.)D.SPCK0O#7P@AG!-IBK/U"L>KIE$(;XDP%-.8HZ1J*1]"0C;LA-8# %+",OCH55!-#"2\$!83%.\]H2F\,*$8)HV)\]D<^81?:GM6 M@+#TV0PH6JR?328 /*)BX
33"#;IFE(N2;GBT30]VKVS(,$!3&"S%\'WJZL6 MK!,@&B?1LE0"7"U+,WH3 0*,(/@4PI<$"OA-8#6682D$A S#NW W@3%#D>@" M?E'N;$4U%\]],2(X%PF (T.0P&4I>DV0N\\,J#R(S&DLG0$-
YO=#"&-110Z M7R6&F,V):V9@Z?()VKB(+!<8[D()YO#\"7 =IUK X0+6OR1 ?9^1+H$=X@.) M9)S%*E/ "W I8^ [EP5!IKJ=Y/LFF!7I%=IQF6])22E+ Z66_;F(__5=T<).
M]7ZD,)O$"""A\HBZPL5U@6H$=$]-5RU!D.(&7X*F44\7[NCU8T-P+R JZ)PJQ M7]C;5]L*I[!:7$SV+N%3M=-;C"@.5%8?DM&!)@,B>#T#*_UJ"/^,BRR_TZ3 M$Z@Y2+Z[L<^,[W?&!!9[;SBOQB)
_R8KYD#&90&XNG>^PX>_C7WTB_)OK8FC ML)8&23V5L?EZ2U 5!@SI(O/?D!"-8<]AA,86?@> 701V MPOJQ^C9B4P6>0Z*<[.*6\A6%*US+%[.T=)_=;ZVX193D#@^,[O7!9E5^=T9=
MCAD/>O_M^23V,KAP+@K"XM$) ?//TPWJGQ/HJJE!.C\ ND:O":DT>0BZ!>DS M&-?UY#:$*/>1+!S#Y.2%3Q$F.Q_SM$S=E@<00+KTV<1!HU98XYR3P37&&WT& M'.P+YD*2)_$O(5_"U_B#R[
LN)P5M)=JL$8-WQ9QGU<# MR?E6N=-51A P8]H>;[8%C@=6?5+K0("P(#"JG3NP;QD/[:1O)&L25YL&?W#= M+[!0%KRAG^-P6,ZF3IXC D&P>C"HG_'/#]^48!$@+MYN'^673'0")HJQF?&H
M,JW!,^X4D5,>5>*L!3Y%9,+E)$N-%\ V2 4#4402X\W"^"U7G&\RJ$]=WR3" M&%_$XS9('AZ=N?!@NP&2+8YND]V>/. 53ZZX1PI HO4D04@3U@T/]<$9EA1S M0HKY1"J1SB1<>SF&DGP9&\H
10"]OU#)]\L<'*Y2G3V9@!WFAG3TL"0CZ(B_M1RBH8&#P-H[S<-L\B(?2"U?TB':KR*JG@1)4CLE$RY1<\ 481S/=18K<1P M5A# YTYLE(0>]Y$,QW.?\2)^V,S?0;$A[EZE<:1L!#Z&=98"7L#,\"
(AV2=X MB#ICH6^;@9HY2N6?.2+$@2U&N=*WBMC1,9!8%.N\YFBSWFYHM+DN7/J-X@@. MD#KI-31D D6X"J#9EC,+XI2"Y4SR;?((D@!N/@!%="8S0&9R29$<"(M(,K.V
M#J=B,0N],R%LRE!#W6O, W8??W@;YU39+D&$;GHK'B:X 2E@)3F-4,9_3HFC MU>8$(@H(Q)O%SRWXZ9?\JYUA:]0N_JG=T@J_+WN4UFEUN[U*CRK_OMONRT6= M?E&#M8_:4)ZR-
I=UE+NL(!V5"_S96(6IP)^F_K@=_T)UTT#Y1T(26N+U,S] M(;&V:.>LVJ\83\!P0F.@A_(,XY->K"@FA.:6!%2O,J;B#=_^Q$];P$8#NPNL M,O;#9/,0508B-B-#N33FHL3P;0>JU)Q_.ML-
@:SLZ.I9);H,;U[D/UO*@>\ M8 !V]A4U>X*I:4+HIP*14R>R:QH\?RX7X2MNCJS?EBL[X[Q"Z<3G M/C4+/GDN 8+.>K[D7&#R:+&B^D.26K\2A[ZO.0_+^VMV_[7T(,# T3Y-60KK
M*6NWTY_VVF*]BR1O!^U&CKV25-8H*M/5MB[IK!:XN&0ZT]2.+IL)UQ0YM_T3 M-T6O0]L!Z2;(^Z_:37BTL,H_&H>^889O[K<)9^\D,^7][(^_,OVN,$)6]]\F M5M2.D+]F*I>?LL44.
[7>*X!$0]1XMZ=7M+#68/T8%M8VTOHR4:.I@_90(J>> MR+G55+W7W]X"EH@Y60BL0K/00V"E1G[)OJ9G,U2W.-CY=H6#(+I].5*TIJBY M[6O#)H9$+QPMFMH>=B3/U!,YM]K@>H.
(U^%G_[,:]N,QT_;CRGQM3>T-^]*A MJRMR!H.JATT2.2=3%,,3>W42+5NAI<($7NEK[YT%O50S/3I;6>*'N+'-!U%R MB\EC1RDE[V-
9^!.UY+EJ6DR9O>NT"NH$,>2/#T#]+2K(N0*K6Y>.:@VQHG4] MA),E6DYE%E8^@I&H.5FD_\235QMI?30Y>/"8]LW]Y,/AAR[S@ZD]5[ZE3-^8#=O6ZLIB"7O5-0#I')\+.;B.
()7HDXQPC2[$1.'%_F5WOL?:[N*/A MU[BCX94=;NOMD32UZXF:W7291(_DG*.D+#<"*7LKLR9[;E^IS>HWXX?R;GG$ MT96X9=+XKS5Z=%T5M<4.;=ZE>,)B9;3'25>
[UEOO(C=ZCT/;/S(^VMR_X$,_MNEK;<2NMDZH*@/53Z+?K&'=I?1@."9IZRU)=;;=WK"X\'3.9 A(GI \40Z3 MT:[G#I(C)$=<)$=H:GLPN#J>J.(N'HT_:D@,VHX%$F'#FJBE&_P3*3^U65X'W.Z(-
;')=/"[AC0$8>,1$-2&0Q"4,+]R!9N]MY1O M4SN>(85O\PZYS/Z!EMFIF+GJB/-KRY"J,X74K8]'O6T)B, M=$/7NA.S/]3-87?2'K2U\7#(K.$_!Z.;O=^T'-"ZHA%.6A-&.,G10ML\Z[JG
M^-1R47*T4*X+-7PC)PMM@I*<+"0G"\G)0G*RD)PL=$'PK#!9J"LG"\F5G6QE M)Y\L= [N.^!0(=DG7-Z_]OYKZ!/^,1G(+N91R[E"Z[=8[R.'GMH9-+>J[J2U M)M'.K.YVNXWL4"+IK$ET-
E""NM98F78@PZ%^:"DIFY*FM+S_.DWI1SERYV+O MOZZ:T&U'[E39_:79445;K+?"OAVH6I5.7/4IV9-TUB0ZZZG.J+G=LR6M-8G6 M;C5=[52935 ?
0MO#C*@W3]ZZ.=2ZF4IY:'UK;RNIH^IY@(TT#IL<>#O$>#,9(VF2%M3;.M,AI7'VQ<,J5I]C[]-I,6+CWLHZGM82-3)B\=,4,9D+OL1*K-4_9D7*%)>]]? M;ZX#*RFM2936E9/@ZXH:O5?
5K9*H.95\/H=X,]15U>1(5CKN4,GEAYI[F=&7 MINR:%SX #U4,_*(.GZ2SAM%9>]A(.KOT2,CHO,.>)5.VP,HYIM;6R)B*%R'G
M<,K[Y1Q..8=33EC;+CRB]BJ[X"UEPUZVY0I8Q<1A9@@++%M_9N6],O8] S0H+-GT/9Q" MYLW@^HEAAIX?]&1X3 %)<-7\%D0S^_+GWGX,_1HL!X9BWE-C2N\H61QRC@
MOD["C5+MQ@5/IHP?=-BV9?_36 L)?VC_\P)!L<*3UK=C,7I(:$0WH,_!52%GXICF(M-J.WY\1U,V,9)A<#].:+X!A\S.;4U!*A[\2#11^DU2XD]'Y+6[YX=],Y.=@: M+C^KEKJO$A.?
TXY0MD9Z+>&\0(+0)9%.*UI!DNV3?;4@4QKL:)]'^ %L06 4BM^\0,!]/$T:T8 MJ.@D__8[*FR6:,8$*'E@>E8T[K^=/+V4F 2^ MNAC&SW?1>K6M< K81F1F(Q*).WT%F,
<>$X4EM]R^C'E.9K4>M2^?*7G5^,? M.9*@-P<_Y&X,(O'[G3&!Q=X;SJNQ"/#4+_PX6]C^Y>'HK?6 M*T!:S,-YNMQ:5ZWAF$YW'>57M,@GGN-XK^@?TR$6*+'B;B$#4"^@@<.!C78
M$R^@&;PH_"0))CS-V'W]X:]G!W#$6]]9+ MH*;;WHKG"ZXJZ6E'+^0_IT36:G-"$YF#XLWB9["%EU,F^/<,JVK%_[4,FF% MWY<]2H,?].),RAY5_GVWW9>+DHNJ[Z(Z:Q^U(8-W?
>:&EKNN(,>"Z\PS91'L M=#JYQ9S'M7 9,0.6,1NGGM[Z*(,9!U?X6;>_"8^K] 7IEN14KS2UX@TGIZC* M+?@WX13TK^%:02X[IR@1:MN4FYKS2=95WFN[FPH.+@1>/TM@52*NCH3788GK
M"!IFL+Z22G03W6BL:8!].U0'8TJ#+*10NAD98K]UHDG'-9!)UZF%X,EM+!?"%-E %)TQVMZTI M9=:>K [V14THO'3%8 M-B3'%%[B2SN[G^I*8..SOV3)3._K&14]AN!1__Y"TL9^\
MJA^D=+7,'1P-6I?*2>>ABB5WU:^4*]UXA.(.O!KG48 M[)\\!*%]Q?>_<*\@_J " >NNLCJZ.ACO.7=\> M" TPK/8DZ?IAEBK&:X?8.EAF)TB"D@+R4@1DOZ=VM*,,WI "4@K(NL!""D@I M('=.9-
353]=SX/D;4CB>&ZO#UJA..*V#7*PV.45VC.IUAQ^Y*+DHV37]@!*T MI""0VBDRLFF4;!HEFT;)IE&5X26;1LFF46<:DB=DRZ@*6ZQW?$_KCM2.[-125_0,=9GN+3NU7(DH&G15O;?C@;0414<7
M15KK'.5U4A1)472&BHVN.AQ6/]*74NCXQ_+=UHGQ4@<))+M&77I?!I X(ZVJ M@I5=,TYEFW8]=\R\E,X9)ZY3:E0!>Z>CMGM;'5M*7DIYJ=>J6F\C>>E:B.-V
MJ&K="L724@.>SB6]T]U4CCV&HYSKKMO5%_5=3DSHZ;(Z50V%2[%XS\D;5Q: MWZB!]O?ZLC>0Y"39-^I 056UW:G0%%2JOQ-&N_6KC7972O6K0=\
MV35XRWMVCI(_77:FS9LJ[VV=/_KBI[=.Y0TW@B224=7)HMTK:OV^C+_L:;H MD,)(RJ*KD46WG2YF-LB04/TPH_5VZ$O4> E4TY!068>G&OCJO%#,J>$^,TL)X3N+36S7#FW/5;R)8BCN M4BZS
E__3^0L%$U5L,^)JH2>8KNF$UF,1Y&4B>_%!,VZ\V8'RBO4T^9&B], M45PO5.8^>[&]*(GT$/AI71]F%F-I[*;OI@;0.B$K\R!NV<>M1TR\1J\"UY+ ME_BVYV?
7_#]US:GR:@3PL^V"X#)#W%S2\$]^Z+BUW"ME,T%BC$#X@AA"QY? M0#CU&>-78NLCL0:VU/J[V]&=!!YX=7CLJW3@\1.'F2'N,J#GIS!H*H/60(&E.O@$O.RG7DN/O\ '!'. JW"
MG(6Z@II"C"@Q,EK*$5:K#810HCU"H<5DLAR9O.WRE<40TF8.[OH4LUPJMU$X\#T[3F22\H*\6I3ZP)EBHRAD2Q MWR)P8&RM?
N09V0H#JRM*QB,@JT'DS.,">RDJ6)8[\K).$7D M>F.?U*OVVY\]"S0QT 97S+HK8?]4W[6_UW+;8GA0%W6[.73VVG6GW1S6]FOV MH-
V6;ONO=OO5TY$9K]Y_]OZ3>JZ.)QV)B8=JPIF,008[]ZKB6T/8P*8ZQ!UX MSC)F#:@SEYZ\VN9@V1^@OTG?DY>J&C73S*BR%G^0@_"7PB=]3&E'Z,T-K)%0 MD69TTU A9X?
@OJITEJ41J=4M3!09:X#8)=I%M#!P!$LTP.UTWP2B1'6@_II MPL(,(%ELV$$QZNQ=K-D-@?^&4<62L&,EZAJ=@a0P[2@-4Y \>1*0G+3I1V MJ[&?HKNN"-5IY5U 942,RF4?"
MDC3E(8L;D'SLR"THH&IU%S*0E19#(]'2Z*47/XXX4 FR'H14+ #1D>E MDA=03:&6CR?!<;@<=3C<1NE).+@48\[F/Y> :C-9U='"D[GS)H1*!GWWF86 M=@HXFI.PF%%?"]'$OD3WEV+IK(
3"Z&X7J> MMFGXXLJFJ3U.%O%D86JA_Q?:")N]J.$*C:.BN)UP@D"WIA8X-!8$XH,;P+P M&H>7BJ^'RJ[((YA*:_NEZO[::>M$)BS54_3Q_':4N5T4[:Q4H6_ED6M3+;?]]
M+@N"NF76X2FNB=2]JU;*L_D8>,3(#LT+.M+/I.,C(5G'QTB/Q,A!HM!Z8K M*6&8'G+'8T&MT/4 MB\NK47#2KS(Y@C6?71<2S=@:,?TMN2<9I_D7'&]"?G&CN1^5M\|>,BBO(G#*
M#MF,8'&4O%X2?UKBV#-G_!(@G['9E ;2&':(/K48$47%Q'F8!%)[]700V7% M(X$Y^93;@JT?GEDK-T2^#R%6+-"(CCT0Q]3"3OIR2MF]]@?(8TQD8N=?T]%
MJ/W081<@F3':$9AUD@1P:^D_#H0L:?;_&S)(**$7Q"FJN";YS"[CB^IX^ M6,1P2M8G?,9S*-6/D[H-UQ26>NH#11!3-T"EDWHQ(:TJ+T'#C4X7RT)#V";B M^_16,GU(7GM,B$4/
%KTN'AL3Y5@!SR@!TIR8/!1B*^BL\TC"8998#Z49XKZ M(LHS/0S,5<:FYN>]@\#=UIT0-S)4 #M"Z>%PE!V,AN0U] MTS]$<G-S9B4HIV[1'D$=*@6N)SCCW^ ICYS%8S3E\KC+'
MKFI78+"GGH^CQSJ>#B@?:(^YO-BSB6-:((B[-6-?Y\[&J/M0XF2+A0X3A#M MEA\&%SMXM!BDBT=AE/!OYNKU@B9@[XY4/(_WB')=D3%912-2,%@B1US#MTI ME1^1S!M?
TGVR=)_62[K/*O19AG'6%46%TXZ'E$:,.," M%*[\3\H1"J6$LUL4D@H#+EN>#H"09I+&'F>D@"$++)7M6[E4XY/&3,7H3T&-#*?")4408IS1]B,?P@6
MJU\Q6,J=HSH"]I.*ZO3ZW2D6H\HR9/OW[]U3Q]]?]??^U?7ZIP<6_#!9_W[M<>-\Z/I^;>S[KG5^7#ZK6]]Z9SUNU;9[WSW[9:SGZAQ'3TPW_79<5D@RAD M8RV1OB7M#I-I5-/3T
&QIK$<0Q"$T,J8((,$*4F+7M!>X\/S9D!(6#,48M!EZCLCRFF;13XDP5=!# M54JD-[&;LSBK7HYJO(JKOQV&O41-(?PX-?A"I&=&S;J9]T4!<\XX^%,%QOI9G[5\#P0+_!*D9%?
3%A+$:RI^Q>IY\E/P.WB= M@0=2,S#]%A& 3A/L]\$'AZG$64>!M^Q/0&JOCF= MXR0(8^!2N;%IPA$F16,2!N)P;"$ED/SS:L7*'UQHHT\V0,SJ@1N2K3$*$;D" MC]$, DQD'*^2
R=DP1!BPN!9Z2T') .#$@L0_^@8+AR-0R%FG5)<[:QG_M);2,=:H4S;DJQ='I2?_L]/,XJ1-?STZ/NL>H06QF%N6*@=24\PX M4/G>_W'C/S4=Q7*ETC)YX7=30H@+2V\3;GX)CG,;G.
MP7HCXJPN$!C860K:A]T0Z_^K';RS6V_D6WK%;KD[_!NV3@?C"Q)Q:78O1U>K M8QTG>8N:W0(_@^>TE97,ZO6!Q+O MZ02=,,BSVL.'4E3Q). KP4@$8&G"?U+89-UGI?.6BN
MI/B.QTTEMGB'Q0!!)/WP:BOXQA>]SS^R?3Y XO23S<#NS!X\&O^"2)03EJ@ M0*"I,] N7T"G['N/4ZG,;"7"3&[@G8M\BX]S:?,+$]]=%Y*GC#B-AK4I02L M.X^;9O!C(E_EV(MCL$>D=F-3*X@
-7*HBQZ?&QL3)LJK/+@D#0&?*L/^OE< MKD=(V/%/X84$X*MC"_1_CG@!J "K@&4,J4 .+"F,K'.!!;=FWG J*XC(?8 M!>T#LZ [069YRN%2*P2.[EZ^IVT"[U8];.S=+IEWUBB:[543QQ]P]B*D[%J5
M+IXL)>S-%.#:N-.")+NEC4-G6<4 &&IDETTFP&$S^O_4Z7SE&+&Z>H5R$*GS M*2:1ZZ#_#?#LD"?%0*UH'&1A)=#@ E2$D""TB,X"34,76)?TQ W8T4P1!Y$6DY8/SE"
MJS\50IL6A_',T7D!%;+P54G2@06PB8N;K*EB]MX;5(WKM7>]_]>CF'ZVW[W5 M6":H80RU6,HT%Q*(84^O1X1]=B$!5!BJ,G+.8?.YLXO@F!!0) M9KM.&2X+,)>(?
ITAS%VHO;@$=.C25>XH51>9Q[NS2$N6:5S0@D6:A&,B8!/F M'OH/M .:'DF"([D]\B1\&6<:=4&SX7C%0.J LL53^)0-!O2V9-GT;NB0+R.[M]DJ#)3^_XT-
)5W75E'L'367PI1%F:L4%7:@<.>A1.GUQB[1H\W/%Q)29L%K M9/4H._PY!]=S25=2WG(:^<9E/?7L2C8)E1MB;6$I+D>&9>EYQ^Q>; M1I$I!1T'4X3GQV]_@!+[_.+T>QL9I]]@P_MVW'VFMA9[<@-
*-PR#.,LR+.') M>0HBJH-.\)W4US5$.N=-U4FI>R,XL*"2+UEF8@AI//&)*7%]4&0<#99HL7SZ M+F\P(T[Q<.4Y\SF)-EU6+Z;<#](PN\%()<;B$:"Z%N,,*J:C,37 B!TMW578 MAWJ3
73"&VE\%F.,HA*DH)&..Z-"@$C9]@HG+927DR)'W30U!&'"*-L,.SE2 M(3^\WA2./@P"26G6H7_)*A^9BOF)TUUS);HW'?>("N?AO+V(?>E9HJ*B<%3(M+D60F"/2,R)R=1B1&O/ RJW9!M1H;!QJ%'E
T>!@XK>T$]5/:885_)VZ%YFV M/DWY1MJ;LEZ4!,$.E!C_]22@]BLR:V,C2F'4!:W-[G7B3U:0_S'R?*E26HI2 M=;JB8BUN-S2O);$.7=I+Q76YH0I*1*P,WH*2P'<4]6W+F[F;ZTQ&'4>F*/ M%V\P0R^*
[9<8UO0AU@JJK95#!#$S,Y+<8N-@H @D59U5P6V@G4P>T(5(&"G*.6X4>2M MX\8+W33O:';8!VQ$"0_7[(?(WV#O2@&:&5ZHT^VDF 1S1(F?B+*-:EA.*,XZMP]D(3U@<8[RV!C!!D9U6
MR2B,PO1BE*%/00@0TN&+JFF!6Z2M.02DUV_V@\#AF5(46BX>O404&36(>2T-MJRA$XU"@[[B+%>]2]\7N*.*1/Z50J,$DD31)7X/4TPYA4YJN&72-L?8 M,\(LTE1D9H)(@'!:L(E9W11!5 R2W(8Q-Q
WA\#BR\)#*_+&PA8R1:G&FC^)9 MM%5K9:U!J29(F%D<8A!>4CH)!MU5HHANK;SQCEU"":PNM-I6CH'[]%0'B'F#L"L4Q1[$S'S=5*1%TTDG2U4!B09I1ELV"]7T1F_7* M'WGR,EL\C!,ETM
**56:ZS=[>;"\,IUWMT0>V#@EDASZ4B5V#SG#.TNZ$88L MI/ W.1I4JC] R[$+I3LTHW<,&\;'D:;4NI][ZFC4:T'"2,SN3UOO3!8D#DX MR46!O8H65$0_O[##_ORPPPHIS?NO-B!6L1DIU%\
[9WVKU[-VK-/^<%\TSJW?R M\?31.2Z??.SVY:\8X0&/#4\;MN2GCG[N?.I\Y5[Q[W@OY=*]D\0V0(5F;6:'T MH(F9;>/+"U 2E%[,W=6,:.M)",5_J$R6?-*$=D[5PH1P;E.]3?69]IK"\D
M+_BYLQ"]&Y*3T'E\'9[5I9\APH9OL+PE_T@WF/+(/1%&DY!K?@8H:X?%CAE MCOIE,;:QZ1C;F8NR6-)I?>P<]4-/SK>B>\9IH3O@E^?LB.F2ZNPNU^8QE0A-MPZ^D@!
1>]JX'6%>9$,WU\0RTZ0+-YHK51?N4$-X:E&_6(>*?LTS"XRN9,34^1!R5=:16SF-\W=X^RE6$:& M$CG^(FGD]@1&_KNVA[0YC<57]KFZUKOF9@_[V-IS^ZG/)[]O)6?=3[[S?
M/>L>6^>=S]USZ-2CU?W]6Z_^N\>-3MK-?O=;D&Z=MY%[]4XN6IRQ9NUA8& M]^&[]QM^[O/KU8T^[V=$!QM^&?]H$ZIV?&>;^9)CJ5'>OH]WZZK0%T-W=;#"HFSW%%LM@?
R.+\EHE#TOOAJ4"Q!5P%-ND!' MU7N65K_NB1W[S?!M5O]9]&R=ZH#WBW=]&(3!23]&W5##XMAV;="R.U'4<<,)6(L??7'QRF+5&KC<=7(X]*ZE"W#S8_F*6-]P M9Z^]]&EIP$A>?
>9VJ_>"W[AE]W"C.^G?Z]8V&@%,\\I4'#G]?6C<9 LN[R# M50!QUUE.M5?O=3^]V/^%@B2P9G' ')MRQ,R_.1!%B#GH,M*L!@*5>P":OM[Q4
MT6\!FDJ!R!;8_\TKX&POD6.K66LCPP7D/),7?8/1.0.B\S@[RQTL=N>V*<.3: M=GL3/+D-!&<<'N!F?P8IV.L+O9N[[O[WZXV[N%T\<7/H!,1.>DF#5*$]'AK=0>P(7\U"$_+7^7E6
M:WRF203_NWIF]745OMHM^;Q>K;7MTJ]]U?+/YPW5;E7W]D.%0^W2TGAY-&$ M[C]?-5Y-1(>UB?7EET$*^86S@-AG*R!J)N4-FIGN)&X#[J=>5H=[FAH/QJC M6G1-W2^BE/[E]<@;>,F[M2_0
F4-1/0H22;QX>[NU=55%=99O0@O=SN1,\(H MZZYT+T2TZXI$[_JU9LUNU'9AO?!C_]I$&1.-MQ_;/%>LCIIR>A%4+5K93;[?K^^C&]6&*_Q-!BIT>[1K]I;4:UH*%:7:.J+H]
M)%A_(<%M(,'6/OQV8+=JM6:K7=M-VO5&N-67O&[LU*NC9-RD9U-9D>%876Q% MN:,/0Y=U39?%P-7.B$WME4E(-JVHANYV2Y/B%W%CU>O\V3,@P8CDN%=JAV" MPTVGT+4L\%Y"$G^L-
_'G^M[N1";QCE-D%L(N%$DFX?KHU=;Q2*+7]LYONQU% MC=F]"W:;/39E)+D,JJV<)+K@O4=C-8M$UR\S@=;U<\DF7_C!=O,#>Y-Y-5)6 M[:!1N%,7UXU&,O(B5XR9'-3QEW+"_W#CBZM8],/Y
A]TK[$1<5Q!-L!T^@)& M!4,K!1PF.):5#(UI3>[W.3<1G\M)HF[HJ6G?/HN0$^P>CE_LSY<@6Z74-1_5 MO?"Q#>-W+121Y=983]G&44X?2PN(LGD=D:-6QWX0/69X@S&-%HK33,#OD]H
M(),KS+@R0UIY3B46/?G6.5WKWH\-)@P]@>)QGKR#7S*A7;U2P?@$K\42%ZA' M+D?WS=RS,].+]<2;J&*AI<7/Z.MH[/0P-KV>!BH8S>627&S,).]MFTCM"M0-^_HE?/Z!;P(M($-
N"^&L:Q:E@>PM#@#&V7-ZQFSI!@IHMTV]Y@^5S;F*/ MF95F1!JGL@!:36KHR+%;O-PJ&U[U901Q6=>QZW,1#40@XYW3:U_>Z$'JM5K] MV9!8_87$GA")U6\EL=E.WB\DME82PPMM?
WZAL2=#8_6[B#&^TF$Y&K3;UK?] M>?6HFI&+W6C5*B9-?2VAJ8/-WNTT96VYI6?7[&KOY/SGQS+WUK&G'F526']^ M./ML]0+L9@2VP,'JX,*7/LQ^[(9X:37G8F* 1[72HY8#@KNP'H,)Q1%8?2,6
MEKS2-(FXX$(=M"M<]"-HRX9XC'P]NI',VP+MPF;SH]^W5ILZHOK,-C-\"P MAG%*IW1G(L,CS:VF,]ZGQ^3L=ZE+=/M#Y[P7>]|&W[#_FX^_$Y'?[QW^S] MO,[X<^?
#+]FUY8^(R)N;M,!'U$CIZ-B8IZR-8;+ M*A*^.W]!T(H4;!W*:=ZB6SN0C_3^O[=.MC^P"3W\FJFC-UL MT*JF6MXV$&H?*2B#=?IH,SU@A>+:5X\>IS=-[A-;MV) M;4
;JM)"FXTI:3IXD)*FNKT))4V,44[[%6[/KSI+<'&UB/A#_G&5ZD:X*N> MUHO%$BOUR87+MTM=5P.S;O]+]]C[_@DZ-OEYQ>J=--VQ"/-[V=.MN;5(Y*'U40XBK%QADK!0?DWJU;9-0ZJC5;S089J-
6&H MO6=1L/?AYO"QC*:U14*98G;C7>L<+*%(6/^N6D=B#$K&RL'1&FYWA?/.GB]_M3%$A$>DDL:C?C84->7??G,J!^X&OS%@+J!\'7/<[CK8P^#!4^&
M.2RZSAT=3'07X@KLX[G"\[#OZ5'&QA_5=LO#LW!P$UC'ZH+:KN^) M%XGX^/!_!*@_/1%JYA M3R@5C\TPA>Q]5N4^M[W=1/Q#Y*(!VL3AP\,[J='Z%O%Q5D4=O([-E]DX?UD
MX2PH[RL,Y\;WGUW/P4,M80)TS0T,T)5&09]$#."@73VH+0X"E//ZQ@)6KS:K ME@]/6FZ8(C*HG1)0C% W6C_?4Z(D7?3GI]O'.@W^DO")NRFJGKD+H_GGT M.^?
D4]!1@C>$'&.E3;W6:AXLLXWZ>K91 M'D']:Z?93;2V*2-E(2"7PZV1!]K(<6&2#SZ"3XX"7>/NE\^=,^*K=DH@W*#2VG")T-^5G=0=(ORNGC*]>/;L7=9I.H MOP>A>P/_C)*Q__[_5!+ P04_"
#:B4I:;&S3@U<-!C $0 '!E M=',M,C R-#$R,S$N>'D[5UM<ZZ]LV$OZ>7'3S=RE,Z4MR79B^^+VW'/F[\]_[=Y_^8=N-G=]<69?$"6<0 M<.N"
N+@6@^83RT^!>L,H3_P/;*&/N(>H3/;_JS$+LC\B>+)E%OM9OLH*9:\ MI:?MHP,'H1/7A],#SSYLPI&-P#FTO6,7-4\^>M \\7Z>G"+WZ.0#M$[L@U8+ MV8?'S1/[N'ET,*/#HR;Z\/'8@0^N

~~GUDI\R9P@Q9PK2 G3ZRL\:4_GI_O[# MP\/>P\$>H9/]=K/9VO_MR]5(%6W$97T<_%@J_7A'_:3\P;Y\?8<8),7GP)?! M6\? IG@X Y?M.60FI J'K?9!*Q&0<+BD APPC@+GN0*74YL_S8&U\H7$^WWY~~
~~M7E;4M)LMN]W*B.HEVW;SP)9*(LXIO@LY] 1_E^"AT.=GC3#X/40^]C"XHG'X M(.E?*I!ZS1&= +]&,V!SY$ UYWQ^9UF2-CR;$\JM("/M(7:GM&:4*[&&%5%\ M11S$5&KDB\I>=R-GRD=UJ"~~
~~[K7UF'1"\QT2.0VU"&WS1>1HI-4O]FF:CQW(&,U M8DDC-100 V=O0N[W76]@]:UP0$:HV+/GL]J9?&EVH:J/R"6 "N6B#GYOJGY9E+P);VU)2G_97 MRZZ@A S<0?!9_;W:JV/AN$B)X(I?*LLM=Z-?~~
~~ZHCOZM=L=CTQ/DY*C=.I)\C(0W(2$DP;32H%:, M:D6P;X2E?#Q$5)@W!8Z%PB_*WC*RELKV.E1:[Y=J^6G7J1V-Q,^_=*_*HT%O M,.S>=,9]\7936@M0M90>5* T-6\~~

M@^R=L,5XR"G0.I;"5H\/#NCS#.;]{}\3S MAY]JH[I^JSNL&VY_E1TZ3?AXJCH4%S1MX1H4Y[78:"ZTK@5:'G)6Y%LC_3F: MHZ'?C]^J0^ JI60·:) (:+XX",X[8.AR,3$$9IM?1GR#51TVT=+^]CIL0O9Q
M5G7P5AMI1"3IQ5I OGAP$A5DP3,9,"HHWCIK^<2J.FRD PJ6==B$BZ>2%=]E M3M^K.FQ4U6$C-=E'>OPV'#\5_7792!DY@F9U=S$Q@[/D*&@13; BH&E>"?+I
MZ.U&51V.3FTWH,;_J@Y_$"$S\A6N,H&XL,%4EMMN?\X2H/.Q#61[4'G)+'>5Y+FB^$,ELV,ZUEIZ7V8(M-H+"V MCLA&->,AY9Q4Y+Q3;_1-IH1*3(
Y/.%78P^ZV>HUZDNQGM1>$)9#%DCRE/ATPI@U?)VJB=BG<+41SQ+O-D6QL_H9>H3P5K&,W4&\F4II\?"TW?4_N>RL%/;RKX=)*#;JP<'6(Z@W LT1(9O"*W1)]_[P,* M4 Y+I.V
A8[U/(JC/D_HE3H&G=Z/>=^;0C[A-Z<.D<9,VR"DAU-$"0(-!Q^S M-^&<0DPY9/=T(HTWG/SWUWB;U_CH: Q(AY_\H=?CXF NV.R+!I:K[92-@R!C MAEB8]98.* 6'Q#0'55"!I^^!R4F';#(Z
M=^C]=G/GMG42WJLQC7\VC",D& MXSV"C&A:1 6$^OOA01G-$)N"DE%4U; MN7>-_ZXNN-IEW3TPVF66#E-*.))#HS3?)9&LM3[YYW,C.Z/.5 M-J=<5]9GQC4EY%A2WUZ-K[A9/;&?
O_PM_.=D^F(49K-%RD(00085,KFW08-B MOH-71@%GR2K&LO2R]8W&AA /GS[75E$F^R.LA[/&1^!>@[T13]X%/P2-1/T\OIH[[>4$!01FGPA7,0(5I4S@=E]KS$[4_M'DE? M.W:MVX2ZUI>=
[ZMK/45\CR/\^&$RQLN0AF7O.LZL2,H#^62$S!8!$6T@=]5+ M$[A4F75STQX<9O^'&KVS-.E%Q#WD0-#4<3K&^>4DZW27N4RNH*<_!0H*"THD M TY[FG1*D,)$,EE:KV@K
%SNAK2EH<>]J+WTY#Q)A[-R!-1;#&M0*MC-N"S MU)!KU*=&G;%Y(O5=#*>O#CM)O8>2FP\X!_>V3VXLN:Z%0W8Y@TKU=H*Y $EZ MZX*S4=G6&4\,P#MQ1ZLOHO:K4RO?IRYP>W*P-
H1Z&.>J-^J[JU@SWGK8R#:& M[:(P/C@HR490,DEPD6M(4:&SPAM36N]S1Z%FCSA31ZME&]#5@W:]N)C-)^/,!-^0?@[-]XZI7* M23\\].!J_8*?<#3YB/D]I@_CR6AR]N5MO5?
\"B]FFJ]$*&31U0*FB6S\7,#: MR'U&$5G&QFKR"*335I66?/3A>-'G7I<;-]F+)96Q0""L!FLT+:F2IAZ-D9O)9-3-Z-W%WX/P5E0)W@=N3 MP;PAU,,8S-U(OEL&<@\.]:#4;-J;%M8D)-N
BPIPTG/PP200TGG/-$O*M?;P MCT*A'C&-#Z]/FQ#3^B;A39C.QSBM!M?SLRDN(YC./_P=_KA_.MQ=RA:F:1J MM#FSH+0(9(.A!>.5=E)*EN*=)@U PJ=AMN_=,K8Y->Q=V#R;M^C_YCAN5B M]-
NPX$"AS38$#\5QPIA,@1"$ Y6198[1(K:N;-<%UU$9O[\UB0IJ3D<_%U*W M9O[OT\ELJO)S&EW42,Q_GTSRG\1Z'F80 4J1@F1I #:
M%$DVGO'6M@XGVPSA":I1CQ3M/YCB'NY!,;%6,,E@Z5]0M>=RE+]F5=(@+L/XWRR$8C?"]GNPO)#2(!4IBO2,]E\>:PD23=NQC,"5+F!G!Z.@AY0\>]JK^_8[S]>^:05.8]H4TG]Q6%5D$VH4M
M)"_H%10Y]Q%:WQW?"2I4,_3TL$YM,M%5K3EF=5D2%>[@AN(C@0C@X\^.)[(M"3T]XI[OIVDU4#HS016E9NQ<*#ZIH!(\E*OA7]GIF,P>UVE"=/CMOIV&=U^; M-Z7B0.OP@!7OD^ T7UMJ54-
'>X5)!6Q(+!5ZDYQ)!UA_3UAIFM/2QU5A^G\7 MPRGF!Q3\3E+SS1-%1RY0!9$L@(46@4^)P%..188&="^M%Z!=L%[@EO\WNCK MH9+HC73KKZ\,>4HNH@C@DR&S-4DAYKX[U+Q4ENOT,
<^XE\XP0595=AW^=? M[[YKU:H>BPNP->V?3@9R7P*O_7!8H:EY,NY81!6ULH:+UI72;@R_?[YWIN/>-M5K.=+'LXY;RLE_$WG'^8Y)NP,!JM&9.0$2,9[-3+1\E 8\@ZD6HGWYKB-5">-M/MTM9-
RZ6-OUNE7OLU? F!<7+-9?H^,X*%_+V2B49$O)G+0LCN4[]R5KKO0? M'<>J$%O->9'N?>=.(^=O@KL[04V*6U!*R*+4# $W?)9'(U/#::Q$U,K,AZRN& MV1_C?1"RFNM=I=DZ<&?]I-
<=3Y)VHY86HL3:(5%+"#%QT"QS+8$RB3RH@W/8(SGP6 VEO.=UH!3)'P'&:X] M*·ACY;'?.SS;G#;$?DJ+?WJM{[7#'IY0H^)@'1SZ.WM"^ZPP% XL.#+W+ \0 MM!) NT+.*JH@9.OJEIO@.U-
&Q]:;&^Z3MTM;'9='YCMJN=L_O?Q47>_B+T6W)T M.5H.P9 #J'1-VC>HP: 504D9!>L4P4% ;N@I_>]:1W?%>/@\GMZU:'(-AO: MZ!7W.EQ767!=D&V2Z/.(OCV,9K^Y//ME==(K)?
M5FIB5$M6/*";DV@Z-/J6-M \00;+ RL\@[W?(?O#]?KK7(ZWDU4.ZQ,U#@M?WJA\/DG=!9++Q0O*] MJNDD0X_7TM)]IF30X**PD*+PFB%*F5*GE_S.@T^0W9WEM[>[N-=_7N4#OB$SG/X?
MSG"@-+,Q*@TE!P.*%PTQAP3(.)5+ZW"ZSN!.4%GZ):B'$+.KC@BS]Y,K MV-R]@O2NR*(]6'^I\1*\E5@/H2,G@9#2M[IFF[8KMA/6H%WIZ"#=;!XLS3-+2 M=L=5K('LVD$D>PDRJX?,*17'^%Z6GU-
6DA;"7QL'UOIFX<6'F@P_&XX775D^ M3$8TV.QR!M=-/![XT-ZW#]V&;C,CT8L@&MU6/.8DWXQ]D*BSQ0A<.UW[D<5J MU9(C5+Q)CB?.=?-.7)W1M,NI>#>?I-_^_.7&$:21G-BO$;TIF]H#-9+?
1Z]M M]D+0!FYY4 M*R%WWC#E-_%X4*@M28HV[UH[D6'TT<7F_=8? G3X.X$=6;^K3Y·">@P!;H.$K?29FHA]?VI1)92.9G L)]T[]V#$.B%4&3B,RFM M2A&I!SMS[L3I+MXP_YX40P^A-&)(E]2)\';
[#Z I< MDDQP)SUDPP6HP!TX$3T$3+3AL92,:DW[@X!.007-2;R'_]M=>O&F%^&Z7@X M/EN6B>/6,VY)*TL.IA:VD1].?3IAB[D/;A!]UVVN2>V\1AVKPL-IHR'EK&7M4A,3:^YRWD5QB!SQ'HF[
MYW7N)/4^ROSF_[RX>@_>3];L@HN#QGBWG_9;I G,AG \A]-/PX1O<#]8 M)F>7E%EV]3,).F·T!"9+H/GQ LX@R;2,LJ2:1QOT/*?3UM&CTHC6:2N_M##\
,X[SC"15D*#F@9>!)Z$D!%MJW"@F"#D2)B.93-$EUK'M_/UGGZ:BM!!D M#_>-7Q'=<.<&N5@MM350;,QD",I NJ9]967&,B'2Q.3.#%B%XS05H9GD>Z@X
M\3O.2023<_RMIE+:8'AFM+_F6M)1,=I?%V"4S%X,5G3*K>^<;P$X,?ZWEW4/ MI296F%CH:MR#9K3A&%)%:P+$6NDS%OJ^P\B=;WU@LLZPW>/5>8NDO$T>W_L5
M^%Z2\A;72U>73=>.8G>^-[FGWD3&QW)/?26A?RQZ M5LQ?3Q?]L"Y3'[S2&-!!X+6DKC-28O(:N,H]&:^SP=:G36O!'.]]$9LW[V3 M:"+U/JZA5@%;)CAU@_;3#?4#L
YS3]V(P"YJL8/T]ZP@##T7I99N+8R!RO1& M..$C>!4Q<&Z*EZT[<^Q=,1ZYM=Z_7FPB]!]TX1U.ASA[_H;HQ.D4\\U[5INT M)ELS03*Z5DE2!$V63*X#^8>Y"'2BM3X\ &?_7EHSVN[:
((UDWLO%PU74QDW+ MZ[(SL%460]0TX7K+RJ6%D%""X2FYQ)"USH;DRK-S.N9$&ZGW<,-Y$\^R?VL' M1/U:$3?0'#C(;3>Z5F\2N\]Z/YOA)C)+^ER$JEF1FI 5ER%XTON(.)@-S O3
M.@!V7^QWC6OKF_Q-1+QGPX#VJ&@,6H@\$S1E$*(2"E@4M/5Q9JWY%@R#K=G: MP![81-1]!2*\Q8\7T_2A7B@^'^>W.*])4K]<3(?CL\M+Q,5IX&S@8J2IYGI% M7LM8"\,A;JY
)V%M5(EA,)Y9L@&^P^1)H^.KOOCH07=6FL^_7U21D4PP$> Y MZ?V+,!IA_OG+RY ^W/[LH"#7"359OYZI@MGG:U'-)-0)^" MENV7N=8%4G[&,4D]#]*.6;VNN)"G;CWVA@'5M7M6F4)WG,+VF4I
MI3>6;LB>LIKTR$$/$2DK%[F7GTF3AS \,QTF M_/K#V=5/9WS =6&2LP#.%$YRJ>KMI(3L8O+9"&>;AZQL!?04]*A_AAJ&MBS6 MR)6(KQ;'U^5&_,YR%E]7T $*YS+MFL"+JUD,K':
CP'(R+=>N,*MZU:9>7L, M3UEG]BG^AG$QZV'_+4S_B?/+%?/*VE^H_%M:2 <\"H,*"W#<65!D3$$,;8.) M!G/QPD;3+2IRXZ%/4T>:";MA1X?5N^FE:_?\8OYA,AW^%^.!0^=SJ9F4Q2-H M,K
@1!/!)^:-]M(7*WJU9.XB>LH:TH/,[VN$[:L"? WR>Q\^XVRG0N_WGM*J MGOO#\!I%B'T=YL5D/!^.SW"$0?)(39"UT5H)0*]S ;(+4K%2^Z3: M]RI] %"##+1[#[^\C@H!BS+%00[)
7EA")&;FFV'AOSR6PVU>YSI7J/%VG&_M(GVL@9P/'3-6Z\n"[K_>6K<:YAX1=AM+BZR$8)JXH"5/7T.ML,D1GZRJ]4 M?1*Q8__(1RH+KQS\4)>YC3B=M)1MXWK2]P#]8SC_\!9'BWR@Q0'.Y"7-??
[E MZA*C"]2&5@._^4+#^LWFQ"0F-]>?%AB(6ET(^U/3J)K.X(G1R":+(M_JIA6LRR4Y_&(,CP-8;_US'NE;=)>YGU42]G)2^_IPPO]C]DX MB35KR=>*F2Y%
D.FF'7)90P^JKLG7+OG&M\$'69>$A_WPWX_AY M/6(Y6]BNLY^_7'_FJD;N8@;7TQCG-Z,POE7Q__$Y]11IUL=\#A.KMH.:W T] M.!:.^PAVZF-N1?
C"G$G@"O>U\R#YFK0<@\ZU(E&4#'GK!)RGH[>/1-D=N=IN M0FT/ZOH&IV4R/0_CA)=GDU?.?52&XX6GE62RP9B)@89$T;3/;2)]_\+'@U ME ,4$CHXSW?/D!N0U(-
]O/%;#C&V6Q1['QV24I]QQAJHQ7SP+2K74V]!&WI%9D=%9$*#YE%R./3K5.P5^0HCQBO!Q&3S81 M?^N0RS? MO7_CHK"T)^U$U]!"R#@<_(9G871Y++50V6)YX#PGFDO3EZTQ?
7+_%*P8\C;U_5TDV#$NK4&X=,W;!T6%,?YS9 MPUW=["S^24/9-5Q][^$Q+CB.7D#!K$$EGR!FZ8#3;J*<%X&EAZY,CH'#-5MI M;Q1N(K(]](E$XP@.\=[=,!2&0Z*29[BR2Z#>4@
MU>OZCK/90=I]9$&N/%L:I.*TX<6H<1V]!*<4ADHT&0@?AF)'&\=,:.N1G)(* M-)!U'PU>2L%4(N>3BR&!E]_H+F_YILS#U@N9 CL;5BK=: M_5],9O.!V3E)9]%!)*YKQU-&7C
#U@C,5@F14NOEI@GP4]*Y_3.YG[/?ZP3. MU^7ODRJS5^,Y3G$VGRVH@Y4M,]$DB#;6O*(*0^NU*YN4A0M=7'&MT[OWPII M*2G<KCJH:[SU=([/JLUA\FBGWXIEY6,9P,43
9%LR\ADCV/@C9R5KMI!+*M4GII#UMLC3VR3 ;<)[$;9<&N&O%8G8[RW'A79G]6M-C7H MV+(" BK+94D^8>NHC\?JXJ4+HIYBMNZC M.4R05E_\/- F.PA_/VHA"ZF\$
E,C395@DMP&07]U_NDDR8'L/7)X;[4X9%0 MK,-IPR8R[UD+EH"'7#JRW0LD6VUYK3U$HQ%,J4PQVM<8#] M+03;\'9RX=:M4?!;/1X'?O(258[-0ZH]'16C^2H/P3%':Z0VJ-UC+E+GT0[+ M<#-
;M1_I[HG^9:W.WR?SKSA?C9-G3S4;89-BRH).0F&J-O\S$:+6JI:L]B8H MSN3=4/_U.'!T;\!]6@G_=812&L /Q^/:Y+Z^>2B5M(K-W[R'QBFK\CA!GH=^!6P!RD$:R(I M/2/GO89=$U0GTZ*[BHM*&B-
:G\QM .]$5*IO8GJX8WZ>T@+4F_"E'O]\N)A. M<3P?Y**+X631,Z$=J"(R>&4#%++"&-\,K6[=3G8UDA/3C ;B7GNUO.:"Z.K; M]:_.S?[?_N7_ U!+ P04_"_#:B4I:7^^\8EO% #/V@< %0-!E=;M M,C R-
#$R,S%?;&%B+GAM;-R^8^<,+K#=0'%:!W4-]KU%^1H8 M<+L*=G7//C2^2/+L:S8K52-ENNW]ZY?4D.F\))*B5'[[\,9M5RD9$1]E!!G! M./[__SVM-9?5GEQ>;?-N+_U?
L+X!M:L'SS^&]_J>WA'4S_^C____;_\E__Q M_T'XOUY]^@#>%'3WQ#>;\+KD>,L9^#/??@';+QS\HRC_=_X5@_LUWHJB?+P MW^N/O2Z>OY?YXYE$*,8H\'"O'S[3+_P)PWQ3;?
&&^*@)5_K>]_N&'@N)MC?HH M7^#J$^I?L'L,JA]!/Y 0_?5;Q?]R[_\%@ :.LECS3UP]=_?/KV_2C+[13WQ MRX8_JG=[S\N\8)^WN-Q^P(2O)??U:MOOS_S?_E+E3\]KWOWL2\G%Y67797FT
MJN(R4USZL>+ROUXCJLL$]AWQNSWGU0%SM;@??$XA.E'9^P^2-O!YV>X1V8R MR\T7ZNV&+?7=W9.:S/K\'+OZ6A1;O%[@:W$@TV-YK7[P0?ZM):6&C"F-9W6 M=/=8Y=^V?,-
X8RV/E@8Y^[>_R+^M=A5\Q/AY=Y8KOERS]1?#!#<7K$$):^*74F:/50RJLX/#>__MWN<"L+RBZZ+:E1P4 E#)%!"2*Y ?V/K;__CE(.U"KV7]0X*]-L+YP!U0](%B M-'0_KQAX.A-')
[I<0G^Z/C_Z^^A8(><;16!YFB/(6MH+/-=C FE<2MQDS@ MBM3 M?0D@ 'ZA:^W5?<3]'Y26Q2G+/UR]N6\+3ML<$E'WG#[Q"^TD"?#YRT\ M>MFB+)[F
W%;S/>];KX44KB_@*)DO)1>Q06@]EK\S+?5ZA/_RC<[_DX*_;K8 MU,O]0_H5KW?5MCCBY9%X\## T/>H)SV(M+)0>1$*A0*GT$YCT+4*F8U*GLS*S(6V(*[OY?"/B@-]/R9GMEX]EL&V-&7'-
CPK73Y%=O@I[5D_&?U:_7#.B*PDVS+7X.B M8QS@/>?&T8$9WJQNM.!EWY=I].#H5>WY!9)A\+Y]51^Z5U4'#SJ^ ?D.?OJM M>6<_@SWWX,#^3&&%^?!U%F:8@<6%PP[S@7P>AIB1EMW&
<%_R9YRS!_R-2V?, M3R(?>S[T&*80)5D$L\SWH(\9R@CS"$M"$X/>7WQFO]R2ZFSN5I$T,Z1'2.@9 M0%OYS Q7)]K#H$S&UN42\XZLPM'2BVKS):%.M?#B,V;:4Y7;U2?YCGA[%(]% M%]=)R&#($(*
(TA!B*GTRJ4<1$Q[U0D%T%.=DW;GO+=1YOMKFZI#^*\?JSJ). M??CC3?&$\XVF@W#Q,#J3)#03&NLA=-6I"NB#.F0_$A/?^2_#KISNMHB:G-% MA$YCKOW:.JOYQ-?U93(NM]\?
2KRIU)FWV%1O]C=F#_S;]I7DZW^OL!=G$>4>-M3+S,5SM1"@GB&'HDBR.$4< "K9"W!>V9E:[E!-2L@!XO9KN5"9AZF]E,$)E& MKZ^@4X$#!^_/Q0FH67%XW+8 P-%^:4)YT>W4
I+3W=9F"3/[PGB^>EU\Y>7> M?4UYYB>^%\ DQDCE(%"8BC23P"_NO7?X5KY7S^8G+E7,JU5+]XC;#CG_0>[+)_)+N:2F/4/P.;_XK_[W> MJ13:M]_H%W4^^"15_*T07'[W:
(]EJI$,DB!@ZCXB@9AA#*FZBTAB/R (K;[MA*?1,6E89]HT4_$IRV-%-J\"UG*AXG]U,% EKM1_X0?&S0X#"[JBO?\$C_OB M#&V8Y.RFB0?V&+P!!]Y!\XAZCR<_//Y$(Q3HI(_=7+]? /VHH%._]"$ XUT
M[@XY+__6')V3%F6 T?/6R[R8T]/."W%AM[.]VE7YAE?5+94\5'6"EV2!]GO* M1WXG?B]4Q/3]1A[$),? 4R5G^T'DKA0*#_H1%Q^D3P=4 T M\2WMV)@['KKG0*53]9U%^E-YQP3 +1=F^XPEX'K[Q?
PPFMG]CA_08ZBVX3U< M&Z; GBMP.X.KL<&>!HLCPVO)Q*(&=!I0IX9PXFKF'JSTC961_/S]B13K59@$ M(15>! .50(^$E\KS .(P#!GQ \0BPCU=#_9HY9G-3DL+-
,3T_==CZ+PK0JUXO/V"WQ[^M=ZY?^?:+.EE\Y M:D;D%MYQ<@.*CA>5+MTR8[:AZZ.KMX?/@IF9RK9P-3R]SVX]FST-G%W^[2Q MZ(ZV9GVZB^[&QG"
<;L#F"Y@9&$[9ZG:];FW5;5DJUZ1.S6CO,35,Q=@:? MK=>@VZ'ZQ/5LP"@-PRKO4G8S#;\F]GABK;92ZPHWL&W+)5KUI>R@M:,++Z*D MNN)U.]G]O+D*OBZ>GF_I=H?
7Z^_W.&>_5_MT],.%I]8]ZJPU^PW.TS/?5$VI M8<<+4,R K]5?>ZF&^C]JA="XKKH@Q_0B2!,7QW>[II);*;06@<44VT3YM]*7 MXY464XR+ O0UX/(#=GZK:HS#=FM^)][B"-6I?
SQU.4NSUA+@K'^BZWD$K]X?'KG'W]6/;O_S;O-^%UZ\9+3YI]0 M7S$O"?V,<.A[/H.(X@AF_?)](EY5M6/$OK_FZ-'W6]J2L?GJG4*.I MD87^D2*V'.B[6]>D'W>\' AN9HE+5]`.9_*/*_+
(1X.P\M&MK+N:KC0C51]K& M'K7,FBV>GHK-YZT\,KW)52WFANT/6&\X76.5V)+B-M8(&-0]TPB%]202!\ M>ACS-$:>GZ#$?"C0W3N*,*6F0=<96L6E-5!Q5 :_9 I=@!/^4;P(]U_&U5
M_[+^Z<^&>:LZ(.N=4%Q#9QS>5,C4Y&_GH&,OF/6<>$PE]-9E<9F#HDE\V; M-#A+-O1Y+,6UXM]\Z]>KXN*/Q2_;IYS5?-2NV/:EXM75YC[:K$F#&K**E'] M(5=%U07X]>/]^UXEELE5XW4P-
"X.G>!@>,VH"4$;7W%UZS@JJ=V=X_5EE[MQ M/!"7MZ+YQ_&F[G?WO1<'-S-?KVPU[O]G*-Y[+-6^KBF^K[E?WQ3]GWUQ8TS%2\HU.' M2P],@(.+&]#]7N[C-2?@C_.L\12C0%QM*?
KTUUT8S>&XW1W-U_SJ"T=Z2J MG82Z_W(MRO,&"5Q*.U%%*40X2B *4,AC% BJ, HXXE19/.E)G+N09Z&!'@T M3!*:.K?"!*AL&FRJ8&)0"T_+J8M>/4%W2P.:?&,LNUZM27Z:AQI\'+ MXKM?
%GZJC\+NB?%/L MR%;LUK>4%KNZ3I/R_*MRD%[ORE(27A$DD*[0Z<>?9/O=Y\+?0^]XZ8^I-"2LWP+5+-TU.*&:QZ!YC9H#*, M8K0DP8F#3@&[G4#G.H^>-
:AAPVL,3!P55W2B/.R[:=M('EK)^DU2(N"[&J M59!Y @=!"J4]81!Y1!ZP,F5S,(JCE,6IEQG^[IE"9^;#U:_YIBC]+=)0BL5 M_/M=FG?Y"Q?55,k)1T 868JKE5..>PY.2+3K"51"W>B"!%5K]S)MC^E"J#>
MX^^_5[TA!(>0]8=\P]]O^=/8-U%SE?F^D9(X^%H=CJ@)@I]^J#'@/0SM[MR VZ? ME!>BGQXP!HS&2<4=)H:GE.EPF)U2] 2U.Z&,K+W9'K&_Y3MJ:
MG7O:*^9[Q$/R,!*E/%%#W!G$D3R@A"D6<>PEA'!_U1]1K',/-DI6ZZL].H%9 M)XA4[FD:7P..@Z?G%CL#Q/:]\+1WHPH/7(BR.;T^U);8W87B.,FEKQBU0;AP MZ:C_V8DY-&HB8+YYY!OZO4ENHR)
@F,*_3-)I,N" HA#'$+/[D1*/$)-AJ2 M=972]Y*=TD.>I1'D]\,T=*V-=,Q,%9\&_'M8Z9>_%N=AQ8TS%>)0.2Z5]IL_\#5$IG:1="$#';*"}_%"*/?!3E! M*':T"] M,B9^,>G4:H6[$B;+'G?!:::[1;;]
MCZMS+6Y PU7K(51J-/#1K^OIF9*W): U&L8\A2V"Q@E#,JY>I1G-O\U,>NJ>46"·"-_JZ?PY@<>(#'L:-I#M.9G3 M$QP1?C9W\!K=%-8)1^ 8=PS'%K#]>S6Q;/OZ"C.KOFHDY:QZ>P""\=BN&PC,
MU%Q#>]=UW.,RVC;>O%]G'13MIPS5/3_0[GY>]XO>O=65>'?E!>%ON,DQ@* M&E"(0N[!+(HB2$*!>)CZ01P;57L-4IM9S+AL]67+9B^]ı 9\7"5Q\TG^U\GHW'^4?\Q)O9P:N$ MQP$-@@Q&?
4A8IA#'&4A%!F*_#BC<4RU1@V,DYH]]"]HCZ^(6HQ^'H%J6!_= M F#]QIG*,C096D"L"<.B1P@L-C:3]#"4?@&G-3YAO"76NCLI ; =^&V347/CH MS+K79'#U*,%9M]M(,;8$#,EEM@)?
66VS[&Q"FO_D-M/3:Y^56=1E/=[,;5%F]4]_\5$^I*VTMAQ.,0(IY&, NEQR0R+PNR,$P3L]KV M(6(SJV#;MJEJVC;5':PJ4!S(UTVNFA_;=[8Z1U#/CW*%BYF>'G>R:@C?@?[I M6=I77170?
=NJHVKJLG60-SWDR!E,&$1@D@-?"9))* \$&@/T*8M:FDW<% >_4;S2F4CW>/O_1)QQD."(DZA+U0>L!_[D$1A M!'$F3T^9"&.2&HT8']$WM^E3U%7W'_#]*S_ECU^VM]_R M:H4H2N,L83
F(E!1P! 2YC'($B_,&,8\#HR4_"JEN;V@>J^4FVQ+6+(#:MK@ M#T7=\.!R'2] M\<%"H8^CRT YB[/F'"N_)VK=)9U=L;$/?-T1C]@I\17CH^ M2C'34A@X.L""$-8@I!$C$%H%5ANVYXOB,^],#%;NS1*
=>[HXCX;:7V:P"4# M-O*H+_N+2?G3YAI_#BX>IKO%#++#Z.1Q[M;-(7GK'ASHN[,#VJ(ZL@?C]!.U M"]KBG]H'_0].]M>JZWQ[W]Q4L"S"@D#NLUCN\3Q0!7T,!!$4.^"^E\79:JOJ M#??7,PBD!
(RNP)Z/]O6[J43=[<@ ;=!X"H]>.D\1U4Q[NW.]55+_CWS[Y?6NVA9/O-3L66&X MVGQ?OY8!H/%'0O@3\D#Z)C0Z6%A_4T%-S1-U:7ZJ)?9$,H3K_?IA^WO54[M7WJ_A77!$-_/]$A0#-
,@R>0Y5'BJ7#2&*IZ4I(C#1JIZ9#=..:CZ!LN>*EB MMV4#L^E-F@9J,161ST./9D)-30T8@2E^*0P%$TD:"$)QO&IF[7W>XG+[,MB= M,F"-X T@_#'?]F*G. "UNDZ? 50:L5@$<015 BQ$7&"8)3B
OD\R' 0Q9@RW MH+[=:+8SF ?2COP$0'ESX3L?FIK1#\?X&-9"+FY>1]Z0\WBGB<3.,H,U2"Y\ M*ZP/POGML,%G[78NU;^XE],7"M\/O)A#GA $449"2-+$5R8W2-0G!)N5NATO M/_-
N5'<'M\AUO(*%GEK;2VBFP ;"&2O]91D3)XHLJWV7!3M7LRE,6W0:_M'([W5;53MQ2_/1>;=D#HG?@D_U+F=,M9G>W1=IW"?4%3PD,<2KU+<8(IFF6 MP\6FZ2KCA^@&-
K/WRT$,/#4Y"09E,$;MZ,J@\#=G0-G,Q'\&$&#}@\S(FG7,_444=M FR!&&P/8+SH]UPX06K@[P#F6/,/FIF0QC/5V\W6^F,/>!O[YF:"""R M6J_]<=?LFAR3.&;*7H1(S6D)(.:9@
2Q3&0HC4*DE4@R2FEF>]'0KO.CCJF# MAKR>11C':]@..$?!3/NM =!6=FWA!JI=Y!J=LN_)1Z?.5%5%E,P$Z!]3]@ MV33@:E)I]?>RJ*H5)X&'(DP@S9@*D_H,8A90B'T:4)9R/Z!&]3!C!&=6XC,!
M>ETG6.>'5MB&C03&4-/;RUUB8:,*@WGF:C2L(N^PH8"FH*YZ"HR16[:M@*;P M9YT%=#\WM39F@%!39T"0'A"*GV,2011G%"8,5] G%$_$US:!Y_8%<*,D9X[M/-KP1A6B:GE+:,8ZUF,>9
SLQVGV-P<0S=C58]NS,Y+4$8)OU"]B2X@UXM+ MM%>PS#B3YQ66KW=]3.1G3G=EG8#9NV! ?!@2/_35$'H!$8EB%5$((M3'R41 M0C0UJK$;(SBS0>F3!P?Z5NTGM#'4,QTND3$S&!-
!.,4]]TY3459+;&+EED]XT MA3]+@M/]G)TA^,BW:NCZ?5E\S1EGK[[_5BF+L\]XO:62<$UR%84Q#S$-8

,9BBF,&(R6,&21%'-#!)2M4G;60Q[, M;(,!K'I68AZPS.R%PDDQ-3HN5.'K3[\UH/W83-M2:U(8EW\6349O)=LSM_F,CJ&N<[S@C>
[$9HE#=H>D\7MTLLD1]L#9&^G'*5, MUU=DK["D\KIX>N:;JKF2.721:NZ!Z_9_O:8H+1_-8)!#_U+"PA0E80QI"*40 MB81!"' *<99YR*,LB3RC2*U3[A8,Y-
Q__JU3RNO-R1=X'YH1G9="V%N?WYJ>Q6KC+3;RGU5M\J. ! $1#(9!*C<^QB*88B^" ML8C2($)9(C(SAV*(VMS)6S5)<*!IM2,.XZ5YX'>%@IF>&@-@?
OC6$*.Z4=%K25\=8G=XK:]>%V4?UZVI8ILIEH;$[M*2QL2S4K"+ M"RZF74/B]%5K\#G+!*'1YK;5A_WTHS1",?<$A[Z(HAPG$$2)0A&01!B'+&, M4K-
D(0/B<^^!6AV@-<8BL"#J9=2B%"O/F?1%Z*GO!M6#_7I%\S0+/"3),&0!&KL3B0BJ7$B@%)D6BRR)B(]X MJ)/T-T[*2/?,D_P.M-LJ&I-!1I #6NA6_'-
]+&_XVX8:$9BZ144F8)@T(C! M&1AV71I^PL%FW"B7IZ>QH[52J2[)V M,PRSV*6LSZ@$1Y9G M_&G;;@]#(_92Q&(4Q3X,I7P0J3J)-$HJB'W/\[,
(^4)HW75?%D9#WS56F?/<7Q,'712^(U\GPR@>.)MI(KR!V%91>9WU M%PO2&PC;C]F:?,PN>O9;Q>_$VVJ,/^$MEYZ\EWD^30@, AY#E"_.RX\F,8<
M^VF4=3OX(_VO[-D M9%^6SE$0[63Q14-HEP4[#:!=>Z%)/6X MU#V6D$">"R,.4YKZD" 49VF,HSA-3'1OE.+,ZMC1!ST&;KIIJ;;U].,PZBFN
M4W#,='DJ+L9]K"VK(\T>I[>HLFN+?ZK_^A^TR/5B_WPH5.;8[=-6.\&K]YFY M;[39/W?5M@XP; O0K^F0W]2G8C?097]8U/'CL*V49DIX7<
Q^UQ,W(IMI M3;\FL",ZG_*,2VBE2@/++J98XZ+UU4SC:8L=Z/%Q^_J+]"HWU>9WO'Z_^;Q[M>FH6KK:;!
[)^5Y2WSVNR_H^R#9#K,E.F"\^]EST^EOQ1'N'!ZR\]PU#5_MS+ MYY7MKZ]WE6=U2^GN:;?&]H/Z*[[A(M\"493@=KT&]_+;7?=(ELM6\GO_7)3;
MI@>,D@R?]L"#_AARN_>@E8?.^0H,-]]70-]A2LDD..VV>F-JRYT';($X.C18 M,%9\&=N\V]'?/Y':_7W6E=J?N-)(0)?T2Z$><0(1(?"0"6$0HR#@+)0^>&IV_W*T_C(7
M+C5)T-$TO5XY!D3W/L5:3*L+%$T)+:Y++LHQX7[D>+V%+T0N"G-^ W+Y,;M0 MUAO^E:^+9\X>./VR*=;%X_=Z&/H^
9,2DH0\@EY&!42<,RC7\2%)TC1A4>0E-MB=&TB1%Z,ROH8T3DTQ'86MQJ@M&K32-M%/TT9*7[,7-WX77QF:^Y&EWS*\?5KN0&WOFESR[@E^.-
W$5:PJ"E;.RC7Y1[_M_0^560SM;25UN@4/"22U4'WXH*+G66'Q.D?5P>?LZA'Q$0Z.N6'O-J>M)S2
M+4J\ML#,&M72!8KPC:F3>UWJ<55R(K"9/O5EG:7GE99<=L6(5U==KB)Q3+"C MLL31AUVVY^L5F;[Z?GBD;8I65Q]_V*?N9#@-1.HA&'*NRAH\ M7,
(T@Q"X5/ MTP"YZ,EGPM+, M*M[O$W<:SP6S6?GQ&#"Z9*_3T AL -3KO&>ULF41N%X4WV=XVG>98$$9>1#.((U5:P9(_M9M3S84J#U(M]WT^99U3EW5]]
[HN"6H,4,:O^0L=-Z!DC:_$,@_#:DIF74%^2 MP%6-]-':RQ9!7Q+KK,KYXD,6I4K--+@[\0^IJ%^*7<55E)HSFO@<9IX\@2-L
M4E5=R6$:1C$*4I^PE&K7*)VO/[,J-035UY(&13H7\!C6)P=2FFE4*^"= M-/]P)*!!^=$T0>WJCHP$-JL[NB[.8,'1A8\M5VETG>>C$J.!Q\Q#!V__M?U^
M^V?)*G=W]09+G9+_W=Y=-DVF]4[G)>'6^*V"UZSF361*??7\28@C\?%5K'=^T6B%G%24SH+!8YL1"^'TNQ^;C=H?_]AA9/_%_4_E(&YJO\V:J
M;;%AG.WH5I5SOVWZZEYV4%X7U785X"B@"4JA1S(&44P"F"580(;]D"9)(-)0 MK#;U5Y?IN0M.^-+2Q*S1Q@YW^C?<0G!:#U3+:W[!%G\#I=+*\HCM&
[#I,]YU M*KYIIMA#4OO_SZW_C_L-;'!+8?;=ZKG]RSWGNQ2$/8OJ&&T'IO]2;V@3R?B[3=. MZSF!=T+DE'='&89(FL8\A3Y!

40L$RJ"$T"/^B3#G,>8:>5LC-"9^]97409[MTJ"EK6<'QR :MFP.!3>S55=D=G@LTQ1MR&K()7H60_[K8"W&5E]$_S5%[#1: M]W&75PJ>N)YF+'IPWD-
N9K;B>P/JZWV3(*?I =3GYFJGUV,[S5] M%9JQX*4!-O0B+P\"!AV#S83"'HNU7]DRJ29,-8:$5!W');QI5?^$' MZC< ;P'AC_E&G6]5[C8TS$S>M)
<2,3\CB(70\Q,*49AA2+@7P9 @D@0\(8*G M[4MYN]&\;5GXE71\.7HA7(U[?(E7H;<-+0:N8;A1$KH!-;)O^X >6 '-(PKW
MDQ_V/^%N0W("E*.=:1HOBVY13F [W:O<+&H9-JTWPM?-Z-9;(HE@NEW%6)!(MOB:(HAA#1' .228(I,C/@BPD(@[-PJ"7J,Q]K=&.H\4U[;\9AC
OPJ(9DIPJ MK&&(L3W&=O+^T9%TF:\Z))*KZ-]%&LM&\X;$/(O.#3YLIXU_+PKV9[Y>KU"2 M1"),?!A2H9KMXPBF/I='D
QG(?,Q9L*H&KQ;>&:=Z\B8*=M>:CW]LI'%3*5& MQ3!6H%.>'>G,?ME%U>14F%/-./N];;H4X^+Z**Q?\3^+\O5:FG9E:Q T?7QK[=@)HM4/-53XNR
M,!M]\P(THT7SPFH8+)H%48MD)&M,G*4>F7.P<**1-43G:47V2]F9,Y4[7*<. MWXEW^09O:*
[:.,EC0UU7T,:B5HR0C&8D@RC$"6S"V3%"4,0LH3R3*R.C7N): M5&*7(.D)GQTS45-C!$,IT;% M[,/FM2SOI%3%AG?M+-_L^$/Q)J_^MFJ4QJR;8
IVPIS5&YQAUGYMV6K8 =MB]+8&IH:N:"TZA490HF5C4K5@07 M*UZ9 D>_BF72.N99T?=EH9*O]]L-^\S+KSGE5>L A+$?^,)C,/$%AXB'$4PI
M0]!//=]+F2=?C582T""5F0U/2[>.QK>$#5VH88R&+8[4?%/3W/CW]@X39; M3<5QSZ6H1_\^?,&;AKOJ=UYM533COKZ?_P=7;2PYNY5'
OS(ZT)F5<>\]U-6 ML<_\%"441BA*(IP E,>1) AFD1QE*(XUFJ8\<-)-K.E:KBI2R18L5[CLE(I M$4VYA&&UQ \#V=RMP%
[R%=M;9*N.8C==;X">M.TD]*V4M[7HTK-JOT>JO7\M M] WHQ :MW)?,#_P 7ITOW>S,N5P_0IKWR[U.9ZW79F-P8CA?>MET7:@>
MMY5AHLC0HMG'MT9TD;T1'0=2CY$]F7B2 /"'TU<#ST&8L6:7?R4"+U:_/X MH:BJU[@LOXNB5,HDW4Y)"J_7Q9_UY1>7!+=M&;T\%,9AX",.4S]6*2=
(0!*(M#&9^X.&8!D)$6G=0]BS,?'I[*+:J&J#C#$C$*T![O-5!$+;G3N[/#7M=,Q&# MIF5VKV#8@"P#K)E9V:,#%#^@SQ"0'($#2Z#CJ>O\,3N:!EWB9D?
5KI'<'.B: M]9N;!,Q@2S]E9?K6C=)\J/&=M-6LHPUT"^<[=;\3DPL)Z[[EJWB%%,B< P9 M]Q.5&R)#"<=F-;Y.V9MYW^B8K.>ON:GL;QOEF_;]=OM2-1W_
M%WM59CO1I3?S_>;P8M[>?Y8&=$W5Z+PZKCKR!LQ=ZEF =V%F#/ M/-1YJ-B9[WOYUGE9$^2?W,X[KS."\1F/LDU9($'4*37ELQN%,>I
M!"Y'<>S77GX4QZE8%T=QG#WTH^4T?"PV7^NKG4_%6K7D5A]:^6&$4YXQ&&>J M0!*C&*:QAV%,HPA'@H>)T-K_7H;]N7?
7Q>ZO]\+)O^ZGE[0'TS^4P*"5>*G! M9G;?H?.?)CZ'?E1TQL%;$/_+M*N,BBJ,HA(+5S8EXJ ;&4'L XN, $!;! MG7$)G45V!D@M'-89%_H\IJ/Q&3O-
_I!CDJ_K>/(J"F*/! &1ZDM"B+(X@1D) M, R3+/(8];. 9JNMREG04^3>VD9ZNZ=@F$BQ/M ST]8^"'K*:2F:F2Y^T)#'
M6.DN<.Y(Q_HK+ZI2%T0ZU:!+CUCD,;W?T)++#?D-;_[[?G.X2E?__J1R_>[$ M;U53OK\B4IHL9AARGA*(?)+-
$(93$C$.4+$4VGM[12B!\U$)D,>M+Z>Q_.0 M'LPWSD->R%KQ $K%!"P$W,E_X+9YA?8N:H7UL.+.!IUEJX^& ?!3Q\K/*O>Z
MEUU3_[,F1TUME!PU+4!FQ,\@.6E&'.W2DMSC:9:49 G(8#]2Z9K+)Q2)92GN4 M@F2[AMTHYODV0Q%E#1^V^22B= 7?IBE'@Q2[$O/!3%(B
@@$EG*."$LR)") MYW*9S,P^RR&@479DP4[1-3L#78%([S@T77 S^WF0>4\1_#8HL_$Y.5@D1T>F M*T06/3T-"WIZD!IYVK)C=?'T5&S]"^M[7-Z5G[?
J&%(GHGMY"U"::2/JJC7[#05LZLD]@=-B26%]B5XV'-2@NVUY8'X*S)L(&'YW< M>>CMMV?Y?6G3WMX_/:LZE9PVKEYO=(1=ZR&]Q6,F;=
M;$@3RV&KL0B,9C,$&$'PA]/&9I,A<=%M2)/B2[4,;@-DH-^0X4*6F3KT7[N\ MY.S=];Z-)U6?THT1N_6'7/"5%\:^'V<)I'&824_#(Q#'7@(S1+V842^+ J-S
MS!1F9K9=9R7DG[CJ+%,?UFL>@&("_/0?7!YU3&<[3GD'>B>?I9 U,V<=5^#= M2*O8,_1[F#M,6W(DJLLIRFL+)L4Y0"TLQPJ%VM.+>T:O=2NKMUJ-
P5 W%.E MO6D$><)4&QA*($E9"ADEF'M$^GA^;%?5-9&SN1.E>@5=.EDQU6!:S-1:KJEO M4<^\OLB[,:.U"[^6"05>CB!T7MLUE:\7*NMR!.?
UBBY7!,P]Z(>223+RG)R7 M-4W5BT370;[TV9DMXX%8W7I(W[N]*.>X\SI51#,#\U#BNI:LG_"H*[&1 SHD MEI5_>7'!Q=S'(7'ZWN'@*ED
@_2$7(PB1.C:Z9C%F8.Y*MQL.) M=?%GU52;YQTG .]9,1Q\90&SYE75K. 97F/Q;3-:K^-&G1]^4@Q)"'\&>Y[
M@:E9^B/98^+J'LR<@67OR*P!.KL_LU_)SE[5V<&-_[?7%)%AWPNC$/J<^](@ M4=58*>/RO; ,!3RAB=F]]P4:,UN<)LG?9O;T)3ST+,=$*>QU\YOE
MBVL%@N,Y=WJT7V08GA$LUR;FF2UBF?2AIEK=B7]@Y?ML[\HZXZM++SET.7F- MUVNU3[[%],OQLZLDC) @!$&,?
95=BS!,$XZ@".*4ICQ+O<2H!]1DCA;+].KW M(:E3;;L&)=9-2::_#3T3MBC&9F:MF:HGT6T)JER3FN11T>"APU;#HSJR*R[/
M/N4P(<459J[252;SLVPRBROXSE)=G"UL48KPIFWS\H"_=<4$6&^E3[*0+ M(LV'S1F)JQCH9Z;M6>BKG\^L+'OS#D+4 9E!+, 9E= X
@XLZH!8_D'ZP7T M5UNN4L!8PJ,: ?-/6X9(CBH/]J3:D>JK-.4\%$$*XP@CB#R20A+Y#*813T6" M/<\SF^4\3&[N4&U#I=]TNBZ-L:Z='ˈ%/,
[3B#!+#*,MQ@=!-7_5;X@XC+EI" MN@J^#!-;-@ZC)?A92$;O4Q8WH*I8N+Y<_5*LY4<^;3<&\TDO?WIFK6WJFWM4
MP2>^W94;XP&C5V37N!>=++;AS:BEQ&:WHH-"V=V+7EYRN9O109&.[D:'GYQ< MR=.TUWE?53O.5BQ)]1]$$10HB"'*/ 2S6/XMQH@(DGFI]% LJW?
Z=.;>/(\J M=MJ02UY3GA!YN0*99CQE.A"&49*CDIR&Y@UHJ,Y2@W-)+/=U-T=47JK6YI*H M_4U%Q^W"""7<*F#NGC8YV57O)<\;U6=:]1II)U:FE%/.2 Q%
(AA$<9;"E'L^ MY&'BHR3P$A'K!Q!=&B,VLP8HX.*F#/?FZUXV!-SP&F$:PP"$,9OH[@,#X9$]S M*'S^EE@!OLL"V'PYS#Q^31$'_?RQ-9;S[C6E.2
+I=3]CF9RU;WTF_RQSNCUJ M@]WF5GRO4R@/%6V8ISCE*()EB80)2*!."(^C#!-F/ 9C;%GE)YEP<3,9J^? MR'S@JAUO7*>5FG8+F%:[T0S-
WQFYG+/S3EN;?_(CJ,VO1LX+1YT 8JK'"T; M%I;-TIH TEF>UI2US'OKOY5VDPU(TE)! D.,QAPYH-Q!21S!1?5QJC;OF76+?JDG^TT&+= M\2^QW^^*?
'W%@[))[Y630/N<2E5K,2;2]41%YO;S6:'UTT J+H3=\(^7U5 M9:1W&[Y*LXRS!#$8\B"#*)"*1%)!88(18A[.(C_24I_IK,RL<"UOJG6("EAC
M11E\YZI+QH8#7+,(M@?6 #:(%CIX$1INT&+PFBE_AVS-%^B1OP$-:VT8LE+- MQ'J_!C5[0/$')(.+(6W@92V&N)T/-C?R9OZ:$[
&O;EI%);S]9P@<>0)NEG1 M_/KG[;^VWV__E!(/+?QOEJXUNQDY@K'Y_[;-7TN6J<-2!)[ZIM729]X5Q793 MF)3&74-@_!;
(@?"&I[!QN6=HUS(BIM7%T+4U%[L9&A&]?S4T]JC%D>Y!].(O MN726UOSYBSR?-'ER;90PR3*4I$$ L52W1?KG.:\NB\+>LN*9WED M>;?
&C[K'A=&%9C9(+7W059IW7-2U.XH5SG9U%+/A2/\0,8[0^''"*3AFMLH0 M%_"'8L?1\4);;*N#QOCJBQTYM 7M'S[T/V2NUFI,(WO[C=-ZE/*=$#F5*F7A
M!8PN-+-:U_3!G@'0<6#C#HR#,J[)3O$PO*$9A6(&#T%;7BL5'E]],176%K2O MPOH?E&EV MH#6SCE_,-L-
[Z@XSSGKP#:NZ8U#,%/U2YADX$)XQ^>Q&K795O>%7QZB/?W@G50*-K=[BB4899++4\SD(" M41"E4M5Y @5BA-'(]T7(#4;LV/"@]96?/&*GIE;E7=?
B>]5(I.2?OM5S==1/ MJ.HD@UN>#,?5F2"N9R*< V@WSJ[E FP+T%(#!T,J>78*NKH)S^T8=.8#[BPP M<#?PSH3TL@/P+$ Y&XAGLX:>,3IIFMJ5]
[[)USN5$U);OKM#.?XJRQ*1I2B" MA&3R_!$&ZN@1,9A1K&:W!SC*F,GYPY#^S&>2EJS]V<,4SC!#(0I2 F/A48A\ M*LT[YAE,<)(P07Q$
F0RDW!..,WG%K:'F%W3\0NP%EU:/#WOFC#CZQ4W=0*>5Q0ZA&8,8])>Z]:^6<\ACBC H6^/(* MK>:.$_F8V>ZW/"@]4R?-GF<*>,L*V':\&%SR3
!>XQYL&3@-O=CK769:SE1F MR[&OV[$"I:%V."2;1FH[6[@9H;<[+9N.E"#5WD3EE_NGF\Z!D>7@ Z6,[]* M^'7SG*N>:_Y$V?OBE+U\?X=KTWN!@>6F-
F<__KQ_GV_3U_- 1!2+XY:V]=3 MN_0O$H8@&;]"<(2&F34V <+I':"&M%97!T/K+G9IH"%<_[I YW$[Y_U\RNQ]
MR9]QKEK*\&J5!%Z8ABR&U/>DKT[5V#A.T"!0: M'M,:8M*7E$2)31,V\QA'$])Q$!RBX'*O=H?(P"(>Q!Z@GI2.';X38HOZ=
MGN"G[ISFIRQ'$*GMO>EC434YHZN0A]SW10]#+.(0!6D&B2\0]$26,9PD/A+< M)')T3F+FX%#3 J4Z=.BH_CO@-6'#P3[GV+ LC"/*
BAP)IW6Q*,0>SR!":=Q M& >^{F}DSU9E7K#/6UQNET#HE)PV3J_X8[ZII\H1+']!-4\L _#$&4DHBSE, M4$8@BB(?ICSET \#&B" M=-F]PJXVUK?
KLCC2MPL$%M6WZP*>ZMO DW;ZUK75?%\["?+T];:I MF_N*,[C(MRL21BC-.(,^#U0Q!L4P53U_4!9EC,>IR]R4;X1>G/?6':=7>U] MHC'
]-33(0QFNKI'H*%K@#T4?U P8CD0=ADX[%N(&$.-0B#46-I&0<1G=!4(& M:"T=!QD7^T(81.-#MH/I:5TV_8E3GG]5OI :-]9V8@XSFE$_"V#*U!B +,Q@
M&G@99R)(I]XOE&4PB'B,VLZ!UI.YIWX UKRI0SP10OFX=PZ?2J.9;L"Y4 M8IBZ /QO:5H7^/RW(EOY*>K9ZXZ^?"UX1E]$&@]N^ */C.SL$?
N4P^YIG'(M[1%TKQOH/DCH9FB%K2.\LZGP Z06GOH^+O3Y5'>-SU@:"VE^ZH0S^?T_#"MY
M^XVN=XRS=Y+]UX#*W;DJ_$W.@YQL^5@73%UK+&U#&89X;7]?KF&2;WFVISR_Y9W9?EYZ_T M=;5MHX&:V257/CZS5;R7CFO=CNG0J@7%[]3AX9
c MCN0WLSYZHCL,EFI(:95#BO--FV/X+]\H7M_7%V_O MY,^J58 Q9VDD72;,A J,QC#S0@Y%XK-
(4)%&H5:CX$$J%LNKR>7W5Q5I^C@K6[_\Y_K#Y+BC=TGTE M^6N\Y8]%*3=BLZUP:(VYO83UNM>;X$!&L
MML#!A1?,!W7$ZV^&6L]/R*2L4^_7;4)U4_/=R[MX*.J?O<*5NJVL"S1O54;V M8_VY:L6HQP@.&$PSA"&*$((DI0A23E/A):$G/*-
QS=-9FEGWNP8.ASE!=7K* M[EG^4#475ZDYT@$M#XWEFXH:ZY(_!RJ)^U)C0>B-;SXZWO8U'6VOB),DH3==
MJ."M$)QN]Z6#L&8:M%R#/MN.LT>=0.@RPW0:0\MGH3H!\&*FJIN5S<\[K[^H M5=@]Y^7?RV+W;-&<+:F")N2U>0QDHTJ"F;=.0:@B"\0./(^G-
C,Z0X#.TG]*0 MT>K8,[3N8]<>#>'ZAQZ=QRUO2*J*;ZM;(K=G3+>K(*.^0&$*PT2$$(G4AX01 M!I/4\P060<9\873/<;3\W'[(Y\]O'SX,WB\U;--
MCO'[C62G#B[T:_Z;G@"K*)8N11)2*%B00I2F"234YS 07I3%24:RV"BU80FF M9];WLZ((>Z]BD5>8A'$8>8)!ADFHJG42F/$PA%%,2>I%H<^1>C-
G6TW<2C\J$>P(\OVR,ZFDN %2#M@(MH1!SU1,HY;UWQT MU"S\)5G0-A/% D /YS11%3_09 MPD$CDEHG@5Q:<]$DD &A3I- AAXU5[VZ]O[SH?
3^TW;S>[4/,1FKHN9R,ZMF MTU"@QP,XQ+>[<@-^KWJ!2WW5U 5I7%5GP,=,=?6@F4%U#26W4F5=&HNIMJ'0 M?54W_>C"4:OS@_'V"R\?
ON#VX%S]7@^5?K]IDF-6GDB*$,("IH2B&(J(/%\ M#A/B9W$@DMC'1KGS2S$^LZ5JB+U J,/X_3$N&$H#F'$60432$&(>QJI\,D)) M',
<\]BRZS_]0KW%RY_K_-&]SYN#5C#JV> #K/&H%:FG 5HH#6GEN0/OJ51.N M6J8?((IE^19>.I)ERO9_CFB6Y2T]P^*)E_5M MV^V&?
<@QR=>2F8$810A#Y*(&8^BE,4>0%C&1I@HWNMBQX MF'FS_TR_<+9;UYVE][TJ/O&O?*/;?'0*OGHV?V;4S,QWQPSX4W(#.G9NP/[G M-6>]?
^\YO*FKGP_%I-*AJ?_CU*UQ@)FS\4KF'"P\=LD:HO-Q3/9+V:8$R\-O MOLFW_$/^5=G(K?R2YI) DT#0U,KEF\>_%P7[,U^O5S2,_"!#*>2(8>GL>/+8
M',K#LL_BU/>E5?/T6N7?;C"S'3NP]>*'WGJZ1@R;L)JBFP4T2CT4]ARK"%* MD]QY$4P]EB88APG?IBLOO*2%#!"MGU&_C.@J[=%S(F8V?[0@ZIF!1QX
6W: MU$]]=D#'C\,64+90.,MD-B2_<-ZR'3CG6VSRTM/6-Q+O:P%9@DC)EZ MMV06'>LHH_W50Q//U%M&PJV)TJG/] BW.;_I^T!<*J!
M*^JSD&32:XNXJ'/:.,1R@X8XB$B0H$!P:M9Q:9#I\ROP-N8D-J]$<3 M3:JJW5,=%'J3"\%++F6RR,HP6W5FI6ZCN'MNP($=<.#')FW#$+SQ*^+Y<#,S
M!*0S7!G; >%U=6Q(:G%;I#M(.A?)%NN8'=0>'?]G/T21;U=)YJ=^YG,8TX3* M$W5 (1$)@SCAB,KC-
@^H4;OS87(SVY1W3IST$<3T#@ON<#"S$>\&G>]ZZK2[MXX*>D(Z."R/$%CTNZ E^>ES0_)3U!<]7+D\CQ9X MS*-Q E-/W5Z'
9:V&"(O00A+TE)&ECUSS\F,[<9[?]_/S=4[=K>GR"C:?,F MRVMHKCI16X(SMK&_+)+C!O8G1%ZD=?UE0:\UK;_RM)E6UA.^FX-:]25_[E); MN@:
(09PQ$E,$$P]G4BL%AQE%($'?<43*1F[4%F/7FL8#\1_3F>>W:QDE/JL8XJ6=KB^,'H5]; MG9%/+V)U]"3HK([FTY/. O+D<5^L6@(S[!%(
MHS!+4QKX7L(MS@,72"US)E"Y0!UEG;9*IG@9G1(FHF!U4C %P/:X,"";VR/# M)4(O<6P8$/C*T6'H$^8-)=H#2-.5^C\X+M]NV!N\Y2N2Q &F
D'A!0&4AX48 MDC1-8>9'.. !PY1A6.'B,P=@VW(=IW-%6$@*0-%6K_OQ%6$AI76E=R&X58; MD8W:4XS)9-6JXNJBB[6M&!.KW\)B]-GILYX?
2KRII&:KV]>GVF&X$[V?K:*$ MLS")!!1J&"V*: AQ)O=;$ODBHD3^U#?]%VU >V:E[:8G/]?3D[<'NC==9I7A
M;:D)K'K[\$Q@F6GZ\93IASY.+2,J%:OW\WD&&O*\-DZC'*+S:R6A.2H5G6 MNDM,Z=WZ44K6&+)#%U>:9K'P"4RQNH(EB0\S2B/H>]PG(4LQ-
;N"O49H9A-R M(APS<'?;'J[7L!'\YCN0&K#0WJ7.W$0?+[>K]<%<]H%]@*9%^@'>UW8RYUA M!YXW+RWXI"ITZYLSS#,NTM2'?H 3B"A%D'
J8$("1K$(L9K.?: M,;MV/=;:-9;KJ7;,]%$/M9-?F7]CY;[P:;?FOB<=M-NR?"B?-EOV;HT?=;_# M5Q>8_RP%%6&@*$/_J O* R^?\HTZM.I_YZ\#,:X%3C PTPL]\
<$?B@M'&>RC M4EJIT_55%U.P4<'Z*C?^L/6LKN*)]'M31J%BJ?N\LWCW3,OZQNJZA471G"M.N6IE@+%6E)Z?+^1>L4KE06!0N9'%*:)1R'R
M:093@A(8H,#W?"]#@J2KK6K2IN<^S> 6=.PZG?XU-Z;NQH+-QNG2\|+FAOS"(+'925IDT[2]E3J> M3KO&- W<[\3A3OW7@O%UM20]=(8AR;P
IG$5W5UXSM $]I3@Q25&RA'K;,2P%H&JUOL'O7&=NZ]]0_ MCGM4-6R!.P%ZV2\-9PO :I 7M "\=EE#L\%LEFT9_!_"/;M9?+3IHH_5'N MTM2U%FYQW
S#?%]5NU[G5#\,4^+Y%/)$S?,E.(09"M24/)$RYB,:$*/9>$ZY MFSL(?)CO*]WDW49U#V\&>^;]5G^:$7Z(%[\77I'?Q?["481]NG=[-M7V"#
M\0_5K78(RI=N27N1M_\'8'767':0B%5\505I>7'[];%N@Z_8N7W:&H17 M+WY^@>AJ"7J7_[O]*AV?1^EF%^UT[IZRUCD 1D'6RVAHQ5@G V$>8IV.@6F(
M=5!(VPCKY467#+ .BG427QU^UN[DI%I"2T^*=!_,NS'&8&IP*ETB<,(9C1(M(0F9ASPOH=BL0+>W]LQ]V5*R*J#M(Z!WE+"4RTS+-
$4RWKPO,.]HZ^VOO.C& M>4&DTVWOTB,SN1K5M1VT_D--4;O=L'OYKM4-Y9OB">>;519'D9>&&0Q(+*3' MP7V(,
<>0XP@'"4_")';K<5@P.;,*UX3KJ7S@CX:@H1[/\F(<^18SPVUF64R0 M=N\;3(!B*1?!AL4?RU.8 +*QPS"%ED6\?^[I&)+98R?G'SQ__*)^T1QU_RX)
M;57QP#N/(M<';C MK)[ET$:=5%R)%>LU+BMU7]'$F#1#3#\HACIW(#\>UR\? F[0=D>[E+NA]0^$OW?S\PF^9!ZKO=MMK*@TF^>?S$:2$I2 :922;[
M]17F#E0;);8/"#H>@78CH]GYH4<3=$1OI#UE^=><[?#:86[\N'A6T>>!91>+ M/X^+UH] :SQM%U)DU?
X\;%4(UGK]FAM#L&'?,/KI+%5R$60R3\@#OT HE@@ MF"8IAWXB0I%PE(3"J'AZC.#,NGE,7E7]=FDP?R@60,V#8?1K%$.]2)9+9,PT
M>B(HQH$J74D=!9U&R2T:0-(5_C08I/TY\[VVOLZB6VF[U]_O<>/78N6)Z"8 E^KO]:>!]Y(+Z/EKJM4U-_"C? ;W]3G M@L[,*%BB-
L.8"AL\K,X%1H06.RG8B-_.UA]WJ(6_H(\NQ?.Q7]/C>,!"?$ MHU!X+(0()ZD\0@0$1LR+ W793?1NM"^L/7_N=E-Z(S?">^GGE&VDP+P:^P22 M8=6?

**B9=MO*:%::?5F:*07:)RLN5Z9]692C8NTKCUC>=;?#K,\G44DWO!O% M>#*"FA+L8=\+(%T?#\/HA!U'LP[UGH")J[MH"PZ6O6JVA^CL)GG"4I:!
MA78^QKXD[3!S"2,)ET 2<0_&/N9IZDG7 M.]0:YW.5PLRZ7M-LG,']#:YIH.LR,N/AKLGRFBEU(ZIR<>^+JNG)X#+<-2C- MA#*Y747"WT-BM4/@ T_:-
E^E['Z1>&U"EV_W[S&S_D6K[LQJ$E&$(M\&#.I M@(B'B?0DO0S&@OE9B'SF8ZVA/5K49M;#_^WZD@6^WX"6O&%#WD'$]/9>9SB8
MZ>@AG&GVK)Z*I+[R"M95OUZHA]UJ]7ZT,6%0729>4;-7A/%2DHV-JO M:4+]U.-)!*,$(@$@8C!%F?PG3L,P#1"5O]5.Z[]"9&9]5H3 GC10M V2F:\!
M,ZR_KL0U4]MC(4$MN,44KFLB&R11.Q#=+I/9Y&6;Y0N/B#28M'OML\MESHYP M?Y2^.O:L>0RKJ8)Z>KPO.=N63QNC)K(7/SSW&: I#\R?ZA%2DC#?
UGU339K& M7A9Z/,@U65[#O?ZJJ$X;Q Y*917]NKSB8C&P08'ZD;#A!R=5_W6YXX?,\K?- MM!F5DU96>'TGVA^HGH.X^K)*$\:2F H)I>]!%/
8D)\F'A>)D3FLU!XJXW* M;>/LP;A:SY@?K.]UUGRMS[@RR;&HJ2OGNNGC1.H2EGXW)ZOZ)G/\-8X-<\,Y MN59M7_G3*PYJ^0 _[;&^$]T/?
V[:KTK^%@+9JMIK5K"GEV7- +IMO90U4IJ% M3>;KOT0%DC4*5TJ%[->S"^BT]*H[\49%B?B&5:^+IZ=B\UE9R%449Z$79RD4 M)$P@0CR%.
H]&$:Q1](XB&B$NHU"+Z8S3-!B)S#;!/9$P;-TGM([".B/$%HWKZ E^&MC1_)2= MJK]>XTJN7"_U85\.$\2(,$80)%&*(5(3U#*$".1)'/ P#/W8UQK/-
$AE9C^M MIJF^V#75":5#ER'24^S)@IOILXW,QNH[*),CK;U,8U%E'13S5$>''S:_QCSD M C9UO[_R[9>"O=]\Y=6VWO_/?
LJYJC2L[_123GP_10',8A%#Y#$",0Y32),L M)I2E(=;KSSN5D9D5_,#$35W.:GPC.@GD8?U?$CK30+ 9:D:WJRY$GG).XG\ M8G>U+D#J7^DZ6<_R]-
"V+:]'O:HF!%_RYZJ]$N'QG"']88%_GLQ*Q$3NE_LC_O*54-2?.-X_W9;&1?Z5-*[O[M8IW3[\V?AP*;).%"-7B#:>!+;P&1!)(XY3 D,?%0Y OA>R::;LK
S.K_B=,Z MNK9G"1SS9*;]QNCJF80Y,3.S$Y*3ZUC=@(8/\$?[WUGJEFS!<&16C,DO:FML MP3DU0-;K6-9:\C+GU>U]V192U*Y6NVL&
(@RHE\:0IRR"B(6A-$ (PX D<2PM M4Q2GOE%-Y75:,]N:AC*X!7O:(\$W8ZSTS(DC! POD]X(/\,90T,^5Q6, Y26 MK50<%_FL(E'C(S:Q#;[!95Z*TI.
<;5MOYA^E&2)'\50R%,#1,)3KD(80.J% M(@E]D?F)5HG&=1(SZVY'S"0 <1$)G=#"5/G,-+.CXU 3Q\68% BXN/""+OZ0
M8,?.^^"3=GOE6UQNY*9H3.SGK54)K5!'D-*;Y=T(+^9'G8$52.0IN/J#6B)NML;1Z1R MM"]>H[+HGC@BZNE^./:XY2)(0&9UKKU%:^"K.8@K-=9 T#
[0N1)]V&>=X4,VH1*X.L%?I+'M\'1/W M[/ Z^@'7]<;5J^^_XG\694VPF1@5RHU5)5*B*$LA"H0/4R_FJHM&(I78BUEL M=
(]N0'ONP^Y0[6VE)C#6[(!&"6PTW@1G/1LP$WJ&1VF7P#DL7[X*P>Q5S.>4 M?Y!BYJN0Z-12)D6.NT;T%[9N-
SL1S::"B6#9[C;OF,*)D9F4M%U,Y&64V0U&6! M]0C%ERN]UH-BL"A,:0906/^D\TU!GZ4 \X(0 ;GG+&5[$Q5VS_]G93I=;'9EIANE6GLQ#[/$$)A'BF-
,P)B(V<;?,R,\=]NSNQ%]NS(R1(9)Z MAF@^?,R,4#<)07WW0<<)^%.R O992[,F'-@!X(7F._7 MAE_ZM=DWFO%\U?@-_,M!\T877D05=<7K=%/[>;LC[_L-
+:7F\S>\^>_[S:4M[T.. M2;Z6/*S\T$M%'(0PYK']PN35G4TYC$,DDI1P1)!8?>4E*71/O88 B^ 7N.W)U]+:%P=/@UI;[H MZ=<2FM/CK^TRYN??WGB4-
P6O/A;;3_Q?N[SDW4!#XQ%C^BO.?$CH,0*8Y 1L MBJVT*#4O^Q&9^I=K Z3&3]_S@&3J0Q_P44P R07X=(+/#(/#S&6W.N$;D%G, M 3 7O>\?
6'S:,C])I3J1\9'%Y'1D;?)OC-7BL9YD_[\FV/:B* MC?J9*,HG++]+8(O+1_.!2;.\/+U#THN_$C,+]#7IG@Q.NF\:YK6<@X;U&W!@ MWF"VUYS8NLH$Z_SS)N?
&":7 M#V"G9T#=(&)F!4]JKVX:!A][#)E"CLKEJ '6=T++-GT8%/FO\-/X)\RRR M)AVM]1F;[$D6I(0+3&!":011P'R8!MB#&:=1Q+PLS
33310[7WYFY3U<\!EV M?[D Q+!63A?/3!-U)3-*W+HNP(3[\RJ%W[7](@)CR*YE=)-56QAYD&2I#IT4"S\ MA&'Y:ZV"CXE\S&P4)&-J@D0 .M9
P]NQVWS@KJV ,ARO,>$U#%N2!<$U,S(3 M<+49YC$!8(,VVLL ;==%>XXOLEGK[.GH#';,GK#\B/[^OY<.VYG<(3\U0M&.4#"/+TP&R+P_6D-AUI?
0R9W05 MO%"Y_K1+I6TF.8CPKDGCP'8 MJ/[?@/82ZCWT76_Y 9(A%RI_&=\I=F R:HZ-0P^P.1K>F6,PJ]FX3/D'L"6# MD.@9F.$EK-."BR?^@+^U>\2_7\-
S& Y0,+,. M#4$@*1XF=[5$KU\ZVZ3]#HGE+B7W(I6E4V^'1+V08COXN&4G[6)3//,2]R, MAD[_-Y[#;(@X41$,%3WKRAF'DQ#]<->+&
(J,$5)8]2^HQ1G5N2[[1?>]>W? M#!MCCX*EI[M.(3#3XCYIT*KT3]W0O5F\?&UA7;6V'J6W;"]K72'/FE=K?]!5 M%8_/N-KG=,&CS5L4/^/Y.D5YZ'
M"8N)/("D.)3^0Q+"U!<^Q#"U&,)"W#HL&7&)1YF-C\?^194R@0Y;9AQ$4S? M3P-/L 1ZC#&(4A'#C$<4ACS-
_!1S']6&M9@SPVE5C]GXLZHM%1!8D0X@LTZ'D(@<_4IN2(8@.>Y4, M+N78RUPE'&>1/$)*[]*3QTKFRV,EQQC&*2<\S.3_I=EJ6VSQ>J)W:63"]_3T
MTS341T#1\RT=N9937DF>',(9!QE7&,$=1K#6T]2J%F8]9#4F@:*J4*F20AW81 MCV'-="*EF4:>"FB3<7=14H-B3GMG2[!GI70\!29K?="74AC-
@]#'5.R[,@Y29M3J MU+M:4FS4O1PV-%_G-0O[ZF2'\V..Q7S7[6M< M?:GO8QEGK[[_5]E>K\W8:.6U*"[R:6"A-(5I&F40QPQA M%%&=I3"
(CYT*;],S>A@H8U6E:.^6*YQOY_RT+ .]Y,!WZJ@VKID0&WXZA9C'@U!<#9<%=MP@N/=34%Y'R@J_$*=D;F
M[MBC^E!4U>KIFAFA7V45VB8Z;)'TX@>3L,@K$B MZTKF2*M'R2VJXKK"G^J[]N%!G\H#ESU8AP4SZ[OXN4E ME^NQ,"C243_%X2?-
E>QVO;YE_WPH5&IX&^K55+#S3\ZL7)(@D!1WU59]O2JP M+8XJH/4UZX+,XUHU35PSC1J1U&'EQ;!D5LIT8;G%%.FZ*'TE&GC*72(E?\8Y
MZ[]"=WF;;3I5,XUH15'BQS"!D :9NOE.!,0D2" 6B.,D"5!"43>P3._H:L>(MUA?Y>%Z9F>:V3 #>4&^.;\U-.6WZT0-<WTM*[S>O\7,N MO=(5%6&<$$]
X1/I:E/BPY2G&+(X*GGQXAY114@5^C.?9#8#P4*2"C5B#:$ MS>S/-93T#(P#V0U/%0>Q%<5Z L.
(V,9&8D0H1U:@&I5%U7Q$U%,]'GOD5F1V>^35%F]!]B?:$UW\P"O6@ M,-.$>($F:9Y/OU5X=*.[\:BL!D!Z(LX9RQ90F:]$9U965CX>TOHD)S?I^C[\
MGDLRO/R0EG23]PEJP/I!T)H+_ECW;%2>YP$CUIZ31 "3>L;0& TH.]XK=5F\@V MZ(]A&WK$--0D?YN\W![D>7<3P+_R[1W#4>
G@:?:J5#B"ZL7BT+3>K"A95Q8 :EEN1T8T/SR@.:"6I$<5QQ4?7NVO$P9^1' M'^YL<1X-DBM'=?2%4WI"S5F-X/^0-)LSM,W,CQ0H(B
M7T@3H8IK(Y4TX48Q)6$0A(X'*N8'TE_86M3M9E05'"#,W\4@2;'D-9S&2%H-17-4B&HCFV3:;+&)24#30B M.QD=]?YX=%2=2O(YD\>-
JC*HK)L2_"#9]6.5N:C&2G$F3RKUY)G/V0TOTIS= M)5%HTRBBR&$1D58.AXCX+$2,AE$B&/==&KF4W:+>:96NKHS"XGKN%F\R:>'6* M-QTI]4H?
>=RJON%OMMP P/>C P";]O$=5&W[%HG+:H!=6,TOOF)KYFK)-ZP: MWIO^/0!*%=_T[*L#O)M_SY@Q9>O]GE&*SO7YV]]LM%7D_A!3>KK<0%/H/LU
M8\7FY?X[IT^%I/W+O[/T$NPF9C&_8\XH#MKEJ2F+&>E1]M$;)>!-+KY:8IP>QFZ2G M^0;\VOR[_'!$*OVO6?G(;2I2SIKC>>0ZA+N!FGKB.
B3.$2)8V/D!$0DB0BH M[1#=2_-!*@OKR*;ZZ=+<'P_?6ORNH26FV1VX!]?T'F<."7I=T-*9[?IN MF'VC3>IH]=4VI7X(W4UHX F#V-<-
;99W9#P\K[@E1>K6J[])O]RN\M)2GR7 M,!+&R F%CW#DARAR A<%'L=QX@?&B;N/=T.5NS&P4Q&I$M: 8)80D MR'%MGOA^(J PEK5=I>'_'2-
>M"VQ%)>&N4K="2A=W-HB@[J4#14+JRO(Z , MT@Q.N9\MG:"S],H Z>@3M,#>SZ!'VQOBIP]T>UU\9T7S_*H7/FA 0D=EM@$ MA9S;"(<\1C$7#O)P:
(>VDW":*4"#1%8VG^H25;74@U54'+=H%RFC]3GH@7Z M!'"@H&/M&)HS3K2]RZYVF!T#U3W'CCX'3UIMDOD8D]^SK"9P7A=50R+)\!UV M$X?;4L-
"GL@]R\?;U27FLU^)KOI56H;X*^IQ=LF>B?IH"$YO;88)HX$4($R(U MF84$B=AS8^][(]!:6Z,-2=:IZL;9[I]2S6K&E!D%G%6,J9ZGD3)4,
MDIHWP,'42/@:I_BE10HS&*TT*W:LVZXT:XZL:V'5/#67Y,JZ_'(=:0),_4M+ MU30(L(1T82&!T]@1R(^Q-/=VX*(XB)4?9_L,1XPPH15[A9->
M_$JP9D29\R:UI^;%ZC!C_:'8L2I^@%G0 !GKA3&6D1S,G,\H-/@89##^N:8@ MZQ->=P@R6" G,Y#A*\"O-C\6A7/NH5 M19[Q_*D\RA=LV-"_AW$/Z[V?
(KWB+E]GJ97]N/;]H&_L1,O4;X M9]_>)PF_TO:N*Y#A[5U[A3.[PC=%G.6N;T= '<$]-T1.&!*$?9^Z$)\I>5NT.T3V6Q>5..MW\]JOWIG6_RVS<">.FS5A37V
MT']MN*I;O#7V_[#]?O(=UJQO?/M4 /KE F4X[>TO)SZ8WAM*;H&S@9ECX, M0%*KG2/,1-]71BN8.8)_%;/FVDRY$/F)@2'"2(>$_6<*2)"(=RT-
OBC='!U%L;&'@G[P4PT^Y]N/:].W8OK.-=NO\A MPX/[8H5^7_,]ML?9/WEZ_T/5_#U+Y^*>_RR7WGX@6_Z)I,5O9//$[TB4R(,_
M"U$@/(IP$KLHHEZ$;)Y@'HN$A<2_JR] OV])L=4,#+P!:!#5.@:HK662'53S M8R7\/LTRI7()V:C;FZ]' ,LW&R*/UD)"W4] LYW 6Y+D711Z3H1]@I*8]%14
MEJ HP!$*DT3ETWEA3$CS(_F8:79K?PO X#^1%I[)#X1G[#_RUZ$9^'H#K"X8 M4M-I/)"8-1[8'C0>V*&]L%]\5@/8]A!;"K*E,%L5Z!EC=V_H$\X5%7P+D-
:-_M-[X%Q$.1S+?$VS(#^W;QP#!A3L1<5>-&8H0]UT7$B2D*/$?X/B<>]D+(H4F7 M\,+GJ2^?+]]__O+YJO/'[];EUP_6]_^Z_/;QOZZ_?/CX/[?
O_8WW\W[]^OOU] MWM%@[P CK$G*"[17]H_P6":I"P:XTW>]U0K)084"G_9T9L*VRQ"Z5+*?]LC1Y M*F_DKZ8I7(P\&@4.P\AUG 3AV*-08B M
NDX[P!@1F'ALS,PTQZF3^CJ.UPO=6JV7IA=,O8 M^A\P&*PKCP'2WU?&[0/?-E-:I9%3AP#M\;HC:RRL#!W2U@'MZM@/&+-[)H;I M2\RY) #3($/PL
F[&LC,YNR.+;S>M%T->?U/MD*LC?5]K5)XXODO= M",4L"!#&CH>2@/B(VH'M84:XXVI9@%?B?V'#TI!]RSV0![^LQDG@;7^O!8+--MLW2Y;7\4;[8-
\N!/XDWT09[CI_'6&R$;_43>2B?DJ0_T2JV0!]GZ3^B%/"7S ME9HA3])AWN?NILCO"]*>/YGCBI@$%'$U,1@+ST618#[R$Q>[-8^)&VA-=1ND
ML+!CT)"T&IKPIFR'XM#8J\%"=M-C_"=T7WNZ+N#F\T9 S;;(W0_K%'ON%XL M,]WB#E]#Z'X3'(VX+)LW9)0]N)S?/CU4QDZYV
MM,\OOCN^6,\E\G=%7CQ4B5W[&;'Z.K)@-ZT9)L"@.^(([8Z<*+4_V,P1]JP M6V2UW_\QV]U?_V3WGQ@0M>%)Q]XKS\ MQBE7P_CN7)\XQ'="A+$=
(!SX"4I88"/;%PP'=F03KM5(\&Q.%MX^6I+60^5' MJN["I25XDQF4]S-K:14-+X 3R5G"USBBK252F,EIN:(46U;+E[5C[,)]6;.D M;]9.^(H[Z]O*4@:
<#]>2MMDYV M'?BB:'Q3^;O7XM>RGM-ZYPB7^%@XR+<#@K#GVR@.]7H675+IVX<15]I<5K4 M%MX-
I]7XFTI="D4=Y0()R7\AU5A:PW8$O:+3\R!G$PC,EN]E4=&]L+ZUPI"T MZRG,"S0G&,,X=X."7EJOTZ1@#/9@HX+1EPP%C8+'2FC^^\PL8<-$8KG"-
C#8]P>7SG"6?4US-<>CTO[SSL!_[=F4L9]XN4/F+^ MS(L74&RW[]V%;?"N8^+FI4Z0.$ZL:)D!=XP\E,!T_/=<\#-S]HU[WKCP&,AS
M6D4>+KAVF\A>.#TM(ON?FSL&=U5K][=\LY$'-_5M[WAL,XX="P4BH0C3B"!B M,Q_%04"$:@/-HVB>I-LI\845N#]*<=$-4S0\67\HKJR&+4@>
%3#>M9\XT$P(;1ZL>\1M8P"W-5HUY* M^1-24;3*=F*I\TEI?E3)ED1H79#.<=-^.;^E GBF\-4IJU>B6#NCCX);6.P:-.'JD]Y^S3ZK#
MQ&5Y+7XKM]G]A^VUN"F*WXN/_V?[;(LT+ZW=.BC;QO#IME-6#O!J^=*5\ M8OE'I1"@?Z>IZ*=/8FM('>BD+2;P&:M6YQ"=6?-
/4Z+KM0$J4RP'#4'/743 NMBF6UND9H1B]<*]E#/T$GWO !]'UW1:OI!"P@,9]ZZLFIX&)XW-*,W M! 0^EV>D2W9=+PDHC!./"?
J^01CKEUURE$HK:/9GET6![WH4Q4[D(VS;\D]^ M&",H&8,;X/HBVC#*/7'45X%\%E8XNU;Y9 M.GQKZ3NEOWA!4WGDKXCI'VF.H$T?5,Q1-6,$SE5E/I>
L'Q1'U$1.8VP[W M CLB$,=[D-+"ZJ/2"MZIT-E/*L$T^>EA4>H[T+ * :5I+<@]Y MYKD/"%N^KD*%Y$ M?=]6WKE.$(6!YZ!
@EAXM@H(0E#=L@H45YP"MFN='I%;8RO)]\K>Z#J(=-M\J9)WR<"T]O/YA$#3/,ZZ=X*_0'5)?*\AY#-GN1]0NB5,KR' ^G=P^^83CN
M9KAS=^"'L>LE'(4.DWH<8Z&J_6+$8\%I$K,XB+5".=.D%M;CPX&S==@7.$'R M[_;GK]'2O*9S85UNMT6:/&VK^;';7-
7^5@E!"]3[KM;,_*VT+X#]K_>#+*%#57; MM>UM#R&"_AHT#>1:X7[S>.*(:LLH6]$'_)TTE,OR<;WXT$137?\A\(L// MN=Z0(E,&S3;Q;L((X1$"LH9*Z',\
((AX)D.W&G'C4CCWA0K;1]=(M?DFS MO%"&*I7[F7QNVTFO4%;I-[XMY5_=C1X+L4JZ1*+)$,LE^_P:BD-
&ED+YR."]^+O*GQZJ%;%%^@@]3'UEBZ40E2=FJ2%L-[0OK4YYOLQS2W&],!--Q MW9G0P]1H#/@"T\TU,)IU/1M9=[U&:-/@#GJC:3P.5\-?
ML7FEA8>GM2V[H14HV5D5=Y>7V7$'H:^.()*:5<1XAP'11"_\"2CF-U4@G1Y9= M326GH74U4N-
I@]R;S>9SQM+GE#V139NWI9N!T_/NTI>9FXW5H0E(Q,G#.:UH MYT*$J=@1NID3^<>PF*7G]"VX7I+.")R#5)VQYPPR7 <:,7[GQ7-*>3/3PO-)
M2!WA(3L2!.$(8Q3SD*E.\B()W<1C5&AGO.I07%COV@ZACU6'T.V>B0NKK-FP M']&C1K0$.;ZBBX@'IK.#O5,OK(8#^! 6+NHM^6O?
1AUX]3^RPI+QQBJK5E(]Z/^^P&6^ M!KS9@I+#E%8.4DY"/@U:3K]BFFTJO=FOY $X>Z1Y:6%+]TA CO8 M?,AABK?K2KG/KVWVM7<-
[1G[K.B!G"O'=)S8NGFF6L!/[ML+HT=FSB4)1P(O6;VA@1]CH1D-AW8FK'L9#ZG6_)1D^_=8B"M'Q'&N"UM2P
MPVMH"4S779U7#%;"_==^7MM."]MUI#]H951\"=>39?5H/DRDZMOA!.O5O NS/U MPOS&,_XGV33!+Q+;-*&NC1POB1 6#D=QD/CR7Z4I\!T>,SL\J_OE
;FE+S6R M3/F5^[DR]5B9HF8!'EB=%I]&5'56H<",PE"_Q88\/)XZ+9 SVU,;"V:>AI2: M CJ_&64O7G#[R<-57K?A9"^BR1;3_6\9=D HKS9YR6_S7[+'5(4-
JI;"X/P(MC:66-F=U<[**!977=YL^5!4FOWR]^=R)3LFMOF(+V$QA0DK34829!00S;;JR M;5IT6[-G4P#0F[=LF%A_W3X.>F!/FCMHOF;@W;R71D.D-
"6;ZS^S>L._E;(N M5?F/M"14;0?W_,[%B>+4*M>AD S84-PYX) M*V^YL+8M&\K/;?@ ;.V:PM1P>.87$BHN&HT@1@2; OO3<<()/>XY
M0BM496&)BBTK;?BJ*IKKYX!ES/"/ MH&>L%A4M- 962?5[+=6&F[H(6,TEZ$BUYLAJ69K/9!E+8R:S!:>_JNDR%L^Q M^3)?"!HVO48KUN+9^Q:
[/]+_UQD]L%X]3?EIPVKVI?YDK/Q3R#P:S#N:A MMK#!ZG;7SUBW&W\NCOKMMZT8I-VZS%ZZ??FW\A6O;JI@CF<2^_B\7&3TBJ(
MT_;S5^C2]GQ8=2]K_XO)G(29/N)TJ&S]]P#.QL%JD M;UZ1=8.!,Z]LYG5V.[<_Y \DS>XBQZ=^3%P4V9Z#L.LG*(D90X$OW"3@ON A M*-
WIE,3"=O>P'."FJ9FR_$1N>AY>N>AA5FI%J@:"/TUSXH,[E1%^J>0@QVW M87 S>68]!%9UO88!'OM6(T\:IRKQ(N/:>C&5U=@6$U(5^$-
J@#I>#E!;6RY.NQ2K"5]8H@].3!H2DIYVS0(%QD[]P?B._>_-K]"+7 M9FI 8QQ&D9I+XB(2)A&*G)C%S,&Q#9A+,D!D86U51*V6]J7(FZ'AN2B<5LV M
UJ8@IX"-1E3,H08< $V W*S&R_IX;=;$T@&KW*&GIWO;NK">X/+JNFGC7(MW+F_WS:CP"\?MMI).@=O+9V/51/4TYU>.8QK MS[GH8/H#*:M*E,
(1I1%OE8KB_S#7EEZ%UM%7<9@M MS^LP\E3$_%WE9GI9Z MB##O'8=]4>NK_'E3YL(A!W(H<02J- D'-J8_K)@M3L%:MC!HF2?1:=613@
M@^EQA4S%PLHU,N.P%ZJ2&2#ZJG4RXX*8JI29>/LL__KOOU='IRYW-$>THPS M>.JXQEJO[:M*QJS?59AFQYJ1WSHL*Y W.XN89O9Q3R6T0%,^B
S.=8F"';R& MHSP)=\!]GGYOIB'>GYONRI^S[T]E;*4%"DO+S-V*42Z2>4OI[Q+(C]2V4>(MNU&
,;>BF@D_06/A;$7V$%@>W=9]3.3C)K/I=;@14M3XEI33CC2ORF6__T' M*;N+X8=+2]P.'8MA7+'.!0?3]0K7M; N9\ %N.TZ Y]I
ME]!'E31>>1C'G_(?,UUX#8 :O>@Z?F>]"ZX';@\NMH;>,2RWHC\X>]KP:]%? M6O%-;OQ%2]4K7F4M_YJEV[+*L[RDV_19NM9'1=DNI:[C>RX2+B7RN!%

[B/BA MW+TI%X[CNHZ78%!!UKS\+6R16F[53_G;]U^ME@E@<=;,WT3/:7A%2[#[&(@7W"TMQKO*PF;E;MX!L&=&>E)@M1,:X26W!)0L?>/W/
MS]G.&VP]2'8]:V/;\6SAQLAAPD,X$@Z*>.2A*) .741%& <@TZM/>F&K^]E MY">+-;RH\,/^=$6]@'L5@DB;1ZUW[:,_'3XK#ZR)/+6]?%S@#&# 1]"];UI"
MP- [IU9>'[KRVA_KVGJTA1H, P4P7[]A7<)KMQ\&"J2G&S%T!:/V[U6 Y@* M=?3:PE9#M5.OPS!G94 =8YV^-#H#)C
^;X00VD&^#XMI'_F#M=;L)M\'XJBG M?.\C\.RGKWG35/K[RT.2;SYMR/U=8@_G&GWGVQ+]QFM]GZ7]SMLNYD#M?)O_QGFRJQ@"!
ME]C,E6J7\""0JA@*1-3()N*%D>,&V'5<_4CG+"PMK+@?N."%*ES=MQLMVWZC M%8.5QYRK=L_J/[7,GMEM$_YA-&*OJXL;9C]V73K_/.S2N6-
1!25JD>^YO+#V M:5T-HU;#Z>]?X,RFJ(M^BC,;IR[]24937NY[@>Y#MC1P>!SC"#%7[548]PI3'R/A12X1@KA, M)-!.0OKD%]Z7.LQ4.] !._#V0
"QZL5EEA,6=%<9D=/!*=%0MEF8IBQ(Q" M^.KM@.""Z>L%9+"*81CYX9&DA2)V+;[DV?V7]}FS.D_YQ_A&]1WZM91> &&V M8(E "4NDU?&((YUCXB-
IC;#MAG9$(U"C"2VJ"QN;/0_J4FZ35R%@U5"K#AH# M0\!:8M2,_LXM'&#@=T=>^D22/*KHUX4'%Y;B (F\0)*'&>.]$,ASA7]U;*X; MY86(X23 "WKY[,Z';
<<+&I.$>#8*<.B;CA>VQY'M.U'L4L\/F%:'ZD$**[@< M;8\]XP:$H.869R&$^PDMN 7Z6 PBF;_YWVOTK1B$-J*\[^Q:\E\XJ09%_I66
MNKH&EY=/VQ]YH8[7=R**A>/A -FAF\BCK0K(TL1&-%)] MD^+(]C'(R1PGM_0E8TN\;8K;-,,E.P;,6]].R%%O&YI/.C#UVPNFZ6O;]+/=
MTYZQ1$0+XUS%(./$UBW[T)^4N"A]Y9!QUF)(\^J4-HS+UX^//';O$E9OQ8? M,WF<&*UK%CLJ1KGTW!3M2'=\W,!SC. "&]ZBUU(;C ;
M,+/(8(U5X0(PZYX*H+->BU0X^(,^J :OPQ,E/F;;=/OR\8$7]ZH^OLC_W/Y0 MZ1\ZS.S=N_)@2G/C([\9ZA*ZO>NACQ$(ASY^^ZA]CY2-,T%G89-24K9;T5=.V
M&N+Z"11CDAHW!3/BAZF^(7108H4&,*,$B[%U5TNTT #73;C0>=PT 9EQD6;I MEE>1IN,N%^]??B'_RHNK#2G+ZOA'0L*",(B0[T>N5-
W(1PE3L]E]3)S0Q3QV M0)$B(/VEH\D[;HXZ4G/EJD#YRQ"UHPP+R4D M8R/1G&8:FRUC9H;:_CF7V0FEXW^_R34]SK9[_5+-D_=" M1Q
M5]V:N0*1Q%5>D><0EWEV2+5,T""%=0XP#5&KHFI)LM"CR[%<= \M9Z U.]H M S4X] R .>.(3 4"GQY*A!V%]5A;:N^];L]U"#]\ISTB1YI4W' CL
M435_(:1*N2)5V:!21,NW3Q M:2O5)(:QG5*^W-DEY;_M56MXW554:Q)6]UK3#*#]U_S[&>Y:S;7@!]X28OT
M465<@WM+3]^TL#Y)!M#/EY2]]R^LP0TYZ8A10"G,B0C&]-L8#!U[& R&6=R @Y0LG,.2+/] M&YT/""N<&<(P6@-
S\M)ZY2Q@_!Y4I@P^9+1_W_#*\!OG^^K*F:Z?2*;S\TM70?DT7ZN]8IA8S:5G/,CW\@WRGJ^[==\R_N*FA*:".'@ M /$8,X1MWT=)Z#G(B;GGQ"&)$E]KO
J8\L+&X,J':NE55IV&59)2P]+__7]% MKA/^KV;H+["SFK90]8+=BX@*&+]J9Q\O4P(&QC=7GS)MNNMV((.*XZ2W&'@! M@S$1JA?9[:S MJG\L4Z9&
<0,&08Q+8WK'GT\0,+V>E,$2HQZTL)H->1A?>KWQ#EH0#P8[Z+UA MMLO71D!Y#WDF#UG-8&O/%D357*
(P3%R$11RCB+$$L3#B09)XS/9MR([>2V7I MNZ-Z7]H1-1S[W2\@O=WY;-A&.S$,7@_'D4TT][;3V/5?784YO&>.O[P"4L M-Z2X+]IX,_N-;)
[X#2\]A_2.11&CW!,(M M1W9AQ3TI:7DDA?6L&*A*65B^Y9"BM!YY49>UG%75,BA:/0V??V PE3^I8$>LP9K6EY$VQ7HP]?+[K>1L,S+&L0X&
L52%OLL&V^]P7O-.-<4PMM'288T?? MD@R\>_ZIT].)$.&8%(=&D&-.20#C""-"6"+$H8O4+,HQN?IZ@0Y=H >Q#NV7
MS'RA2_:OIWKZHAHOMR.F;DP^9TU_\LJ.)*=3%^0QKTRW_#LOGE.JG+,T9TW7 M/O5 Y;+=!=ACS)?>4>"II(>J^LB)
^DVQ3;'21P)'Y3TOS3#"UN8NB5,Q9OT MGCJWA>]4!]BB))N?#$?3+?XE]9RJM_1[@';OYO-5TQ5A;);-;CZ#D,?*][S< M6AT6Y_,OUI+C3 [8XNRNZJ&M)?
QC%VXUNF:;Q=&@G2;MR6=^2)A+4AA#"/ M(D1<3I"12+BR F8\" 6OI?*PF;Y>$ 5S/3VRT7/7IZ-%F;D3B9QS=^=;!31 M3.:FG\:J-
F(4YK%BCS]L6MWT_0??;-J^ SP2PO,90R'UI!H*UT]\C,"+* @\@T]F/A1GE#$=++=R M#5,?E-,"IMZG3-5(>G1Y\9@7U49:A9NO5*Y>\7*5,WX7^H23P"D
88+A)E/ M42RHB^(PMF,>.C9G6EG;FO364;0#%B[]VQ&K\FP)V[Z-/?&&S($E;5Z0H7E1KH,]H +VP E KV)..A(H6;W;3R5I>?EIH8&,<"G,=]<"
(+WR!0I<**>W)09KP*]& M;@MV612?,W:;;C=:@<[3MQ;6_8]&_NW&$:+IJPQS,#!5;>?%'47K6/JR ML<9Q@NXL^B$975 <+;7:;40_A.[5P\
3,TV+.YSRH[;V.F1U9S,_$$D<(]\+ M?81=+T&);W-YHN7<(1[&Q-7*K@!37CS$5,^V*Q9T5FRX*3ZM@=^)'C1+9 (F04X8@01)(@1*'/N1MSCL-(
MN^%1=^&ED\[485S1 D8B#K!/AQQ,$0'-FQX84/B@CW.C.,'!0]L%!/K8[Y[\ M>__>[(C?SA5,>7GU5!2]2W)[$'48=HGO413[KH&% '8&"T)5G23M,
M4,*PM&";QK&(@\B),*RMR3"QA???'>FJ8D82MRKJ.LXC7&YZ*CB7-& :>88@ M#'J73".U)41QS>E39KI?THURC_,5/4WE F MHX%[Z)KKQ>X-
T1Z$[TW7@#=55]G"S0[0M%>)A8,C$CN(!XZ',"$$Q6KX=Q)2 M#AD'!XSE")DH]M0_63UY2\^TWTYP_TR^8<1MZ-ER8D31'"FJT/HCH
MC";KIVNNUF!]$$ZWN?KP0W/TDVFV%.I*QR:.8^GO>%7<0/5MI"$*@S!FG/B>
M:X,..'U$%E8VW7I_?:'HG5[.A0I3M".4"Q2QC.%9I'O+:Y2PC($<[\QR=@'+ MA\9O^KSW?[ZD&?\L5;R\2%XNN7L+@QBEG@D1)31C- 48DQC:R
Q4A%,Q- M7*(='SA=?VGU; FJ2NZ:(N"XVB,.C?/\>2"!ZK?#]VD>?(3]WDXS0[5$+RP ML_(PFM'C<,]KZYUXAWD^.-2./&9X@Z#*T]\?
EZ=W]*GQT3^3\0$#5U/,"^YDPLEN?:U MQ=M""%&L+DYMO6J90>V4@XH=2_%C*89,ZH7>F SO[(APX08^$C95'?M%B))$ M-?!G41*YE(34
66"O3%\2]^F+?]F([V .VDI?^WBJ*OXLVDMP!;E7(K:V$ M;C78+ZP=^@NKQ6^_BS-;_3>UA?4O41\6UPO>&_Y]_[)P>].W^;'G>NZ]HVA
M6_>&^(V!'[J4?J-L&O< SA_X+?FK=WZ/YWLV]BBBMN (X\!!D1VZB$9VQ*G- MB8MC8(/?06(+;\TU:4O2AO:3&Y60WFXT%V[8UK"O%SC2@C"^5K<#I-
:NW_M M).B>YK33[YBI\G5Q3[+TORMSI(;QY)N4U;8I8S?R=](&$]|%IS0C&4W)9I=@ M4^[9D4]_3^^S5*14FIU+2E63B32[;Q-7]S]^[HD@\JA
MJN&@00^0\2.8V3; ME%-B1X$=@PX+:P-8^C3P]/! BA=U"=KAQ]HSM,O@AAFDU;^SGI%[RU\/9CB[M2"ZL RQ-KOT>C?
JZ.SS6'E#7Y*IW)GX!"YGEU_HF,YGZU=E?=?MXK8]SO"6] M&A^&@ZE(D\!?Y ^]H;A)$$?>0$S,/81=+1]*)!!+, MX32B?FQ3K?SJ42]KJ^V[3![S"_4C_
FHL?U2TE/7L[^@%7!;@Z;[[Y4Z(J'ML]R0Q-FFGV@4N?,=W>2>^-!@D7R&9^ MA+!OVR@B/D/4X1YV!6-QY,(.J$^17'A/:!FP>,.!M)WZI,CT5'%>0<#4#
MG5?WKD/>:N@/ST4S:+NN"W:V'NR3!%=NR*XK@-/N[-IO&B3.R=6*)[EX,]5% MGA>K"Y"F8+?3-^-.4))@ETC-#T,78MQ7+2@EF,-R H0(;?(@(S;'W7-
BZN9^*2 M4@4G)3-60N1SE%OE#R[==5;U\A96GFS2^XI"J8XL3U4=@9+U(WE1SON%"CPH M@Z"6E(X\S>J
M2)#R]%E1D0^GFTWUMXEJ*YE50^C_87W\BSP\;G@%;O/$Y&%$7?Y=R'^5VLO+ M[855MY:0%)^VS4?
ZA_6KRI"0:.7>L%&3))7\VI_=8UZT,5_UGSN_0NL=DQ+__M,]W^D,+(,R[YK.?M-OI)/9ZI-&0IAD=U*%0RI2]4'I%286WR[)X7/\U5T@C^
M28YF;^JOMEY2)QCA0:XG_&W3)A(Y_?CP3FU_^HX#8&,;\0XFNDQ952HW;.5$I7 MU.R83\<%R5?4UY*:K -L"[F^G8DKX81]^:D*:EL!K4-
;X,&W2G@(IBM6P6 M],K=*^!".>UF8;"&F>6YVI"RO!85Q:9 V'&Q+Z@\5SMNZ" L8HZ2)(B1L'GD
M"]]Q*&PZV2F)A:U(1;"Z3*]+'4%%TR."T3,,Y\&%]3\4*5C%A\',L@]!%95 MUV& QTHY\J1IG*LZ+]^08OMR6Y"LE-[O094B91R3A*A"#"]$./8)BD4L$*58
MN%X8$ZF0L"C7.,'%8UQU(*>B;W48,*CPU):A;MAK/LE @UYG"<4@Y]6'=+.(MUP2YE>-=>N!/HUV:[QEGUE;S<3_P^I^?L_9LSQ?Y(6*,-
@>\Q+F^\@)8XPP M"Z6[SQ-'^OQNQ+C#8]MV[C)^KSC4LP.C]+1^ZG']4^]2!22;[FA=6!D?;FEH M("L];3\?OVF6;3T&^5U+6%T 6QW:LV;93D.<+\UVA-
;;>;;3L'L2;35>,@AC M(P?)3K3\\D%%BNJ4JCO;QMA5 TF%Z\<(NX&'HM!F*,3,B5TO(".
M6E6_U0QJ0YDPT/];HQ#W[F*G2QT0HP5+5R.FO8BPSIRB5E]2E:;.JNT&^QKB M T2ZEQ2C60HLY@EY%G,"!R5^Y(9$>'80.9"SV 2]A8]B M#?
4J6$@.Z,.\L2FIZ?EC,\H"9F2[8C@D;36TY_/(-$'.Y)--45O5*].$?NR7 MZ;YFX)E]X]6C3;^V('09\Z($"2>2;I>#8WG"DKX7#V/.$I=[2>QK)Q$<++UX
M1*6B995D [K>/H2OX1<9@X(&0VH\[:@ODZ;XA]@ 3HLQ1C./Y/8'MUA:DOO[MHO*B512W:";/I>K2NO-IY[KN[84XZF4"]'+Z8%_T/^$Z;C9[YP^%=5-
M[N7]_>4S23>7#UO8[-G>)9;.%-K]>BJ"*A<#.I:V'_FX39@1-,Q] ZLW?-@ M]4)NVIC9'$5!'*& VBSQJ0JC: UL-"._=$;$LO\7 MUG-#M\JT:BB#-
D6H4+6<@@5%!74Y2OI_E3 M666^S>?:&(IPPOV!KKJFBV2(^,B-,ET%[FI]_#_;E\L_"U9>LG^5C8.NZ6+U MO+]PX6V*A;I^/-
Q8/^2$]G]F/4=K#Z\TX[5F5!AAG,0Y8P-PB= &3E,?>NM MYBB-@.DZ2&./&=?$]NE&-T6N6I"R]R\]!?ESUA3;9_>7=)L^UWGIU,&!<((
M,>I%ZM;81\0G/L*V'W+'9B02,62@GSYID%["I_VI,E*]IFX]]6Q'N:6(E@6+ M['@ %]'JBE4OH+F,L&":K>1432=KN5"]_=
[]6@OM)VO'BW4Y+363F'0@876'BW_E65ACW]'X]"V28;ETSCC4D^DZ$X_#!^Q?3QMR?^=BFQ UU"H6CHTP3C"*8]=#'B8XBK 7Q*'6A?
_)RDM?";2T+$5, M?U[.(?IQG3L+$W"KTX,#&G_3R[K1O)O#E58;<-,+H#O1IO\!N$I\S+;I]N4; MOZ\NW[/M5_+ [TC(6$]@NS$EIHAO 1VPV030-
BML466WFAVP4(5ZY=,H)N/U]97^?'\TP4^Y?DV MR[>->^EQR6@'!TTWKAC)K]R\?' M@M.T^K3?5"O^\OOEM^_Z=QO;BRU]S5S5CW89L&H.K'>2!Z-
R^U'1Z)WI9I4* M3)NG!++ 64\;[9PU]*/TUB^\Z7A\4!U!'9QP MUT]0[&'I%/L>0S&/*&+"<1+/3I*$@@8AZQ!=V"9T6:@SQ<&5)B 1^C9S;>9$ M"
="BI!3'\4,1RC!B1L[S',C'L#FSLTM1*-A<&N+4<^TSBT:F'7M4K^P=O3K M1/Q9"W!,\,YD7[5(KFIB(4(XMK*@=PUK<(J\+&^*7*3;.T^]NQL&(0H<3!!F
M5*#8#RFR0S=T"/.JEPO(_75G[84Q]"M*UF-%"EA-T\&OI\6&]&#*6@.Z&0<$ MKX8XJ6-=[8N],45^XUH"V"TXX#^J\:)G&<3@($I7"&@=;=2/>#
M0H%I'#W(-6*&YX,&1@NK% [87&AX[L8P(O/,C9XUU\W;& 9UDK4Q\BA\?RIW#09P,>3@;O;R)5- M7F[)YO]+'Z]RQN]8D@B&B30.#E9-*T6
$IMBY$;,\W#D$=?5FM U3F:=')&& M\H55T[8D<4M1AR:+] IJW 3,!Q^F\Z;(#3)(QH"=D4?2N^S*V21CT$YS2D:? M-
MO2;^5KUZ)3)G_Y5UK>N0GSJ,TRY"6NW,)#.T%Q0AP4,'; 0[F/!RZ!:.&] M5!96S:M\(UG[FS8I"=KUY4'GW^O@T/8'R;S#E_Y0; (;S?8+5&\;/UM,,!5>
M7D+@/7U4 C/MX?TT5MVS1V$>[]'C#YNI_2631X5M6J;9?=N"B]M.Z!.;(N[[M/L+JBCKAU$&N_*\!<2/7=BA$YT])+*SP'8(PE>T1AIZ^G@<1&
?:TY]_Y]@P MD)ETKH? J@HW#/!8VT:>-(D$E>U8:Q5AJSZL+ZT^'HO6!RP4>TJP) M[\C_K#EO=@BU3KCK+,#0Z-88UMFVM0E;S:YZ1_7_IM%IO;\%
<'$;"BS#BBU ^G\# MW]9HV GT,VCNH\L)=WV/>/;1*H;2F6OG!E)?=ULW$\W)GF^X##P>UI0%OSAN M SAF/(M\H>'/*LRN>LK>^$'-
,!]]%@H,,+4I2B):=6BU_5 MBMZ%]3__8=N.]4B*>M[JA87M"]NN_K^99VB1I^V/O$C_F[/_9;GV1>-'%]@/
MJ_W)=2X<'%T$L=L^G);E4S/]+W_:2I\L4UTQU932\I&K/B/\HZFO@_+7V^'/
MD2IT"Z\$^KT6Z&^U&#]7YH)FI=*5&!5<%_(F:='A#7NKM,BFK7G3Z%Z5G$%GN5UO11.^KP9P-U0-W M\X^6A7GO3V>0Q7P7]^*:B? SI2
:@9YKG]6BN>[F M"Q'#R8X,>AD>SK[ZD=U_SCZI!,EK<2T=2I;=2WJ_9L_EENVZ6/Y<9%OV.;LI
MBM\+8/=68P(+&XG?.2F0R]Y#ZD_65=7A6/64[&0CJSS)@R:I54YIW7KRIDCS MPE+OEM;M#ZE%THQ;UWN/O%(WB9*7VQ$W=<;O,1V.7^53P
S3]E]AYKZV9XO3 MZ*[G.I]-PIG"Z9[]W#^8F;NTZM[4W&*"V:PY M) 3VI2"09W*EM$BNZDE!A'#L2('>->P*HXYRU8&_>]CKG/G?O^P?:4Y[U996
M;V^?,WGNJ]8UE-55E-S/LNO'ZI+B4UX(GF[E0;+\)U<=+CB[E]LFN><]%4\" MAX(2QT>$U.%3@4CH)(@QFP:.EX21
\KT>QNPEC9[-2M2H]])MX*I^S_I4CRJ M*5P*&[0)SIL0F6ZGG3?![#]!N(,2IVXT+GFQ>@-V"N=%ZW]VH'9OBQNT%U8' M[X75(K8:R$L5_+W-
SSA7GZ*W 6K=9DAO_/ /OK&N%MZF,;N,D)Z^8SYMHNH MYW'5IBA$B>V'**"137WB>_+_(;L]G(4UH]9BD_]96NHWV3M;0S-C\ PQZVU9
MRPH/MKT8#-M8Y.['7":KS]]XG3L>Y]'Q! M/=?NS.\"LW?[3[)L$RS#$D_$M(X_.TQ"O:K7W\2^Z>5(_M])_SG/V9;C:[0X;-
F:"NAY&=N.K:)DA0$OH,.>X(U\%QPAGH+ 7YA"BGCHO)QJ8II_[9BQ6FY^6N1\9B:)A3KH31!_U69Z>H*9 MZJNGN8J9O?E(BDRN6M[PH@UVI?
3.Q4$4QH&#/&I")/ 0XDK.,*>:SNN<$+& M0'GKO506MAX5C5GN0/IEI&OKX&N+ JDO-I_RBBF92\G\;J
MNCP*\UAEQQ^&:68UT'RYV'1SYNVY8V.18#AA-J*A31'F,441=C"BMIN0)"(D M%%H]%EX+P,+VY%8UT;;N%5G$U-674)&%9WWOY-
4^[+BE^CM\K@6N2=^;79/> M'ER3-N N@#>B;^-GP7):O5(/7/@[_SP.D/SG_$RTM^;7_D;UKJ^X]+9RQ_6< M:CM_-
;Y6\11>6^JM$_+]?)A&.FC!)3/W/S]DEI6KJ=RG94RT>]Q+F.=2F M/F(L8 C'5#HD"8N0'=J>/(YX//9!Z5^3%!?V(%I]UF--#AK4F)*7;AQC1BE
M0QM=2_PG=?>RD\O-A%P,(A6:6&<+3DS16SD>H0G_- 2A^Z+AR-";\X:% MGKZ^M.KNQV+>YM;-T3C,"]/YH#UBF+YLG4$",+75!;_4,-!AK.9C0'O67'<
MZ#"HD]&?(X\:SM6X?;C_)7M,554O7 &'%EA:!:M9$[?I@PIP__+UYG.GL3]P MN$8O? W%FP,Y4/5&0"^A;E,(S0=N]*ZZ[LB-,6 G0S=&'S:(Z-VH3*N"? M+
M[JUM&]B TX31$"5"! A3&Z.(8$?^;XCCF&'?L;4N[P;67SH)H"4("'/T"$$C M.'4>-)C"[6A=R%,]_<=THH\62$"HY3RP9I&0(] S!22&D8S&"WI>6^\X/\SS
MP6E[Y#'3%A>/Z99LJ]:NK,XERD589=)U?[Q1)Y8=W6XF/.)A@PY+/U MP=-DNW(K#)@P3KMA--\W\/3O[[E5M8.O70^TO[^?@'7@^D\];^#Y7RD6LVU1-
\Q*RW^KBHOO?+O=5('Y&UZD.?N4%])AI=W MF%'.SY&"75"A DCB) @1(*'L?P_N9<-2_%Q49=A[5FQ;EY46;Y5<;.8V GE<7$9W;(F56,L)..
MD21&#T&P%=<['QDA/3@ZF:U@T XL?WB\I-LGLMF*$?]M_IB\Q=.#B=CZS;_ MTEMN:1MZD*;0L%.Y^=9S^8\F]Z#A"="I2U-4T\[2-E*"VE)] 2T0/P7B-
VN; MI4ECO299,-'+;& KQIVLVGFHUZ+]DSC_HV0:VUR-0T8HK=O-8QKR28L-C5?,=/I+2I)T4U6F7ZFH M2;:]HX'K1V',4.A3>7(*,$%Q[%+DNS;Q!
VXG_AW6Y7%]Z^R1 &KPCI/W3 MK3,,:4W+VNS)PQ2W1S1Z^GH>8)B:=FA)9:VIS:>=PTAF4LH> JOJXC# 8Q4< M>1+N5/]6;K/[#]O>.NK+3&!?
^W)J6*P1O/#"F^EOS27$4:KN< L!59"\6]T; MX*B;@+X?#!?NM$>^J&!A*C^C3&<.?!H+R#QZ]>UV-97DV.S(N?@.VNP"+5CF!3+8=(+7Z=5FZ5RU?]
M7ZEKB$=/=^8!#;T=]_%65*OC=4O74H3G'$$Y!6ZV892#A%8>2SD%^'1 Y>0; M;VUV0Q67*3]G]1W]713;#@W"$/$DX@C'+E%^K(,8L;'O,L)9XKZ-
Z0R'C"]L M5.J.>VW#0M5_J/[CFQF\ MFY+\[_PANP"T/V4;B'S['U%OSWF+'P:V@ZTW :-&5$UF&T]4?$/C+?]_PIL? M8"$]G_(B(K^C['>$(H!^H9]C)N)OK?
Y)96$"WY3Y(^\V+[<2/7<2@=&L?.H M'KGS?"=DW%;-PXB#,/4<% M&Y6$A9%YL>XX?.G=9E>#.]/83?>):AB>N#4^7 M!?

VPC_SO/^2GJ%)+'ALV*D^:MSP VPOK"U;/QL\L++/@6,.#M/" MJABYJ(3V<5)H\ ;%8/QS]2W6)[QN.V.P0$ZZ',-7,"B3^,K_O%;/-L'?F-G4
M24(7X=#S0O2$!&7)8@P6PAFAW%$M)K_]*R|\ % $JM10^(*?2(85_@S@<$T M6F&]"W@E73^4V?^ :5_"3^ "U!N8XS8H);G]PBZ4EV95B27-?
|&>>/54S?;/# M3SQ7Q70_RM%"@:-7UJL$Z.?U(-5_X!$#V]!IB9RQRM%IXM1.'$BH,0(*QH!X5-8MLG>C*)6%@_5[LA=6/8)):X@]0$H:AF0.[#"3TNUC
M+EV!^@PV$?$'8 88ESFPFYD9$QG 3.H4ME'C,OCR>F9FBO\#@S/Y.#SC\9/D M.L_X-
TY5^MG+AR=^F_^6YIQJ.U^+_Y);X95JC%:\?"%_7CYL=1,>H>LN[+,T M[%@M/Q:3&YWTWGO=5-1$,@3'V M,RA*
[(SGD3.XEMMJO884HKW\5.0CZ]C)U^!>X[W!;LLBAN M>5%EX4JSH3+?=1V$WI<75L\.M2I+7W]C[X8C=6^+M$&# M=N)18$;;;?^*J^VIHX"Z&^?
X@X;[HRH;O!;_).J[:^+;RJ;]T/^0-),9?.' MC! ;^=QQ$;W8D+T H4:M);>'=N:U8;V%)%54;?^J.D#"WC'
MI*:Y,\XC"^#.:"X&^/8X#7"N[7&$TKK;XS3DD^U1XY5S2_,_\8VZCKLAQ?9% MFNFL5/W_\JQ\_W+P-U7YN4UB[(0V1GX84]GRV$?$<6UD^TE
O83X=@0]X#'B M8F%CT"WG;VA;%7&KR]>%2G8X_.LSB_TAWT'/B"PN79AY&13FDDT"#)#/WCX MPL,K-18P$--PRP&3Q69T3S[^Q0N:EQRF2"G?
_679_&WIW 7,$X'*M(L%43>< M(4:Q9PL4Q23!A-GMKT)*/" M[-FY,M>S;"M*$F;C>C-U.^&9>9NTS2R.F4S;N=RL:N1F$MVQN9MK69CA8SR]
M^YAMT^W+)6/R5UI>R3]>%[?YG]F=\&TO"5R.2*SZ28F((D)5U1OU(AR&/+;) M5IG;"(VEO:^*JM60O; 48>4>*-)Z1FL/N.&9R;4,&-B!%C;>&A
&HGLRK=K M6R#_L#5/N%?Z;;'VVBX8WT>%1B MS3V_"W@<<<EU/W>?&B$E/4WU3YBKL7V%.AKL?47]3MV>?*-6+:C0O M37^U]1+5P @/,M?
@;QLVM=A4'XJS_KJC:AQ)R>_<&',2D!#YE"8(8T\@@MT0 MA81Z@1=$?FQK&5H8V>633_;U@N\2GG&1;G^R>$TS"
M^C@A(G@C#A#BN1IUZ!%=MY$'2! GC3Y@;YN9C*]\^SFCT@I]R#"3?8+,NMQNBS1YVJKK+.7>OE7JJ4UIV\MK#(]&7*;O4-[(ZKS'G8
M8/K2E_CWAR(Y4P?A?AR&>7X'2ZV8X-<'X3"SK_<)@Y#/J:W9%[>&!CU7_3=U!"1("A_BASV+/\Z.[^B#\?4N*K494
MZ6T@@RC2,3YMG7K/[],L4UKUGLB_./-Z_PU)[RY(;->-$XY(&%&$!>O@U.UPD2#'9>>F_6 M>>GVH//20>?MDT;=%>;C&0)_OU\4(,S\-
CA>/H;]]_R%P>+@;^M;C@;9WPBK MZT7PWPC@ONN!-\;;F_+XFR;-EQFK.V^V'<^F;;!P8M_S$H)\U_40IHYJQ,\E MB#H))C%A+@.,6GZ# !
<.%73'J*1UT],W[.^9_TQ>U?E;Y>._54^P_86IWBA- M6]W/;3].C8W[^_;5?R:4TY_L_P;|| M^ZNMY&R>SR?\SN7F^;$J\0)/?
#]Y<6%W2DK2>BZ501%Y\5"%S_8YT1=6Q8O^ M3RMP)SSN!$0P)(3MJ(+(''!%?^/)DAK&+O(LPA**8>HTG(!.-VVP+\]N_[/0\;B=_^QW]6O0R8
MM_:5WOB"S7H_?O3PT/QH@Q-N6&=;7;URAS*S#[MUU-9[XU451)T\\1VC=NMW5Q@N;$?^!# H[R!=*?/^LL*%F8/#&6]JM1.Y3KC M%.;SY&047C
@MUK\P5P4W0#%&:O #=.'9\;*ZT*Z*<7'(KLO;]AUMF/@ZU;] M]S_+;V)#%?7;[4:1EC[,U7/!?B]@EFH&4@N;K@_I<\IXQJH.0?51Y",I5)G M*
<\N*;.D"AVJ8I9OZP?_5)V&OG&QX;11OGK"](Z";GLE6]6+9_XG9-"W\+-_M\9FF3=[*7PAF]?^.#.;R1EE:V0WYZ"_FB&=45A=RSKGL@89/IU8_C!
(CV48QPZ*W$B@*&$TL>.-4%L_W6;*VM*7-9V+BSU] MJV(_D'$P*3.-W),Y)0&\Q!D1@LEXL$EI)(AYI2*66:"=%7EWU9QO\>.H(]]
MH$K%SEP=%G0!CU[03RZRWFVY+IZ#JVOME^9O4_,*5)%]PY[?N(3'R,[I@1A M*AB*B(N1ZWBVP]R(>(&^F=,DNK"U:UK4/#?
4YNN[LA.:AIU;0!0P6(GT]5*5RTW#&HM(K(747FKI# M34D>VFXT[:E?&M;G-'\JK1?IR:[4HN98:.QTYC-O%<]$!PW3ZP
Q:ZITB.*.77F>QE9OHG<(X[9[7\XR!/_*>-ME&EY+6YJ)[.^PJMF%Y7Y)F75O]_(/]&7?0H8\47HNEBHOBT)PHZ'$7%]BJCM
MQE$<>+&T8MJN"9S^TM=IBB&USW19:F=K[9D";T&(M9P9)85'/ JKI+9]93, MK#]JCK2R\V:1(\#;65:>9H[//G-3_2
)I9U]\DY1X'^1ATK$N]3)E*5=^S=2,]+IH^5FY^'7U4T:&"_^]9F3YS;Z=;EQU> M/W_Z]OVG?UB7FS)7D_Q:<^C]D+U8BHN>:IW;N6
M&2FGS2;_LXY],KZMADJUCU4OE4HV%=3=OPBK?$K*E*72+^%5/#6O$"%E?-/: M_U3O[UF6Z^\XEG_NXW$N+]/\QSK]I_N8)%N#X MKKFD6,Q".
(@!/#G00A@F8;U4.PSY:=HDUTUX04JC,,,&/#[\!/MA\9M^"0= M ;)1-VZ?Y'\I[T1(8XI=@CQ?1 ACP5#LQ 3%D0AYS,+(<;0RUT9H+'V-W%"U
M:K+U;6)%6/^<.R2=Z>/N#)B!%[-PN*#3[P0@HT/PT)]KG84G0'6/Q%./FFW= M=;N^[ZW[=IF4E9;?N<(6'(<4$6R["/,D09&GNAL3KLK]Y?]BT+#0
3H+]V#3 M^7%'UQ]C)0Q,'!T2D]Y^/ -XF"Z:X ;OM!.H9MI8AZBLNH].0#W>-]<>/W/T M2O,/+_(,YMQY4F+"C5TD0D^ZU FF*
D816X4!@$3G#M&$JQ9LE,HZD>#=-)+F M#Y:B;5UGFI=$XW+2+I?B=XH4@P;CZ*I0_8^<-8#E9]G7$L?< &![+T/FPZ
M"JY)2+O*'Q[RK+I$OZ/RG"ML[B,W5MV_!:EFKR0(!Y$742?T2!*TA7UZ&V@? M&:T?YF'Q'="%W27;,4XWI.##)5?ZLM';,XWQGI=5>&'5]"8RE SF]
W#F6TX M6@^)E2>>#8,\'6,V\JR9)AYU1ZAOCJY%5;+5[=^EXF-TY\(Y81S'KF\CQ[.5 M@L;2T^6]$)='E$01BYV00SQ=(RX6WF!W35=
(TW0E][B]<@W]GWM=4VOE>_XT MNUF?)WP]6["X2&'&XJ2%S=>=-&N6#OLF5EPMXH&?)9>9K(X9#ZN:I;/$=&RW MSEO,^)!><%+R#[S^Y^?
LDM+B2>[F*4G23759Z6.G]W1\/8 M<>7_(&)[\C3O>@1%B9,@[GF)/#LX4>*"XN[G,K2PN6N8:2<6E=6=8'VWU291 M;?;,@",!YWT+
[9#!:A(&QQ8]CJQW+6]J2HS5RKS#0R7V^D)TQV+W]V<-1QLW9P8Q;A]41!YED77[(V2E9+\,*2))7K_T0VUBAF4%G5."RC2JF!)5&*Y \DS>]D,2A02?
G("U6B]>MY*$D81G'DV4[HASQP M0"[$T?I+>P2*6MUD\H^:(/ "X%@<>KOX&2!A:@;!!Q]"V(]BKFF#1ZNO.U:P M'JK)_,"!Q\RONV_;L2%JU3L<,^&1,$
T<&.$ U>@F"4Q<@@+$_F?2"P"Z&7W M 86UKKIKHI:D6OT8X1?=AW*9#MJ?C188)X0"-;KB[@5SU@7WX8]K7V_W NJ[MW.Y_$.X
5@I[^W#_2_:87F4E*]BG#;G7=0#[WUYEB[I-'I0IZ9>O-Y^KS.*4 M<>VH^PCP:4*D 7G MU7?.[$Y%20(D8@"CK#G>"@).$?"_Q0T(B$A.M/VGW3
M']UXGF[GTR>[T;I)9Y+J&__&<>S:Q'5\Y'#B(AS&(8JE5% L$H*#0 2 J;E_M@R\,GHW;^;Z\5MR_T?N29OSSEC],Y9:,O[QDQDA%TV](=@U$ M:?VA&+
J#F8*^$U#-KZC2R[6N!O&EHW^*?Q-/S7UTEQN[R_WWXL"J4IEP]; MW>#ZX (+'Q@Z="U)N*CRX2U)/L^X:I%UN(=5O;CTP^[#4IE6R5D$ M/(.64!
MTLU)K$;J.;SJ:IHY":RKF-,/&XSOX_DEW3ZIQB6]#3)0*?O?7E@C;SY>6RW5 MNG?S63HX((%I!3P?/$S[SL,-F^DW"LULL%__DNM-]QN%=##B;_Q)L\A?
7Q^$ M-FGQI>F7T/0!^6_[IC-7)<[%'D.B1'V@P#%7AC)?XT9Q21@'N&P0C 8 UJ_MXK-*Q%1,7]W9/E1QU?)'^F@)SG>-*W>IUZ7\3RU7L,,[4.1Z)_
%Q&AD#/J; MHUSL\]1?+]RC]C)C\@,?@,W$,-I%DA\U;.HF6".SY.&JQ@DO+!_W>:5A5/S MK'3S7+HO+9W>LIM6H^[_NAN>9J'9*_MCQ+,0L2](''&1:\J=
J6;@PFI8F&^#!>"=:5?5H;CJ5@H0P?'^"7G5/!G[MB!9/=^O'IMV)X@7 MTYA%*"9"V04_0$0X(0I%P*B3A*Y#?&@^]C&1A0W!+E-Y3[<9"@=/RCZ1S[B]
MSX4:IML&@(V2LX<0G96??;+HZBG:0[#ZLK0'GS57P?_]1 KY*]^\-+\PRA(W MC*)8;L4119@+C @+"+(]YC$G]
(3O:W7@'J&QE@+NR!KKW[%P]-7O#,B&VJ>-MUDCY!O"@.@^C1OZ%.Y/>2$/HU<_4BX^M7VO7?@MFX4NZ3J@SZ6OQ"_I47;?"M*=]E(@EI%(>
(<8H1IGZ"DB3Q$ N$1QSN M1MQ.=$S;*)6%+=J^D3:HHGE<,,.V:S:XP!BY-E)M'=1",G8@EPMT#N/RW_;. MQ?C:JRBD#KQ6#_4>-
FU:VAS3:XY56]2G\HX[#G%=ZB%*/*F!S$VD<^'* M?_4"FXL$>XQH,_ACA!96PJ:#9T/:VA&W:NK0SJ4#PIIV^.<2 4PQ3=$;M"\= MAW9&!].!A5=N8CH.
[[2/Z<3SIG,\MD0-=FD':C?>6^PQREW707ZHHF$\82AR M0XQ"ZM# X6$<)2%L:D8)UQB'F>IAF MFZK12V3E&1IC0$\G9HP^;9#7E979)?M7^?
V97I7;YF>GF]75\^[2]T]]#9* M8MI=B9;6=UX\2W_>NLI+2#I7'_!Q?9L#,TS3IN#,J'A3X,R2N?H67"^5:P3. M02+7V',&H:^K#2G+;_%/HA+1M]?%-
]72\Q=2_)MO?R.;)WXCO_8/4O*;0G[' M;ZH136 S(C;Z2U!9]17UAG:]+GLZ]M/3;$ MU7 Y-85=NXN/H60U@F6+R@MX$E6LJ$;_#3-J"%
[%SH752+'BR&I9LBJ>K&]+ M2Q$08%M4FF8!MR6D"HO&&0ME-#H'7W6]:)TQXH/HG?DJIB>4C4I1O2'%]]6Z
MA22TJ]YZ_]+]FRH[+'8\'KO24(O8$0@SS%%.<(AB3#F.0^P1+X*=6G1)+WZ2 MJ(45!D7<^<3SXC!,D"D^<#""U&4G9I#U2E]%S\(O)FF8D3<9O?
%*\S9F-OLPVF]WOL:0 M\3=;!!Y/^[[]]TU!KXO;LOA8;M.Z!]DO?/LC9_LQRYKQ-9VU%C;@3?>SZCPD
M3TVWW[]9>U:LFA?]F)N6<*9C<'/+!68C=$0R_!I*&BC6)T6@=5B=Q"XW5@>-MZ#V#V-Y7OJW';][PHADMUC3L2.EEQCZDFR=E979S;KE-
8C\BR/43IL9G1BCV M28 "W_6QZWC_?W%7T^,F# 7O^RNX=2^6P'R9RTI5NBM5;]5]DYQZB&PPW4CL M$H5IU?S[8@(I;,#X&4PO493->YZ1;/#8?B-
6IY6%/5ANPR-#V1CK/LN+0MBS M5':P!W$(I/4BHGCP2H=6!57/"%FPX4+P5/OE_A"[OFK[/]&6QKOKLZCR?6D/ MV$%8ASV
FF>.13TI#\;F3,]='@E2Z0X8FSJ(>DZ T@C'G)6S:^*FT-W]'Y,8'EZO&]Y;>*8R[?=N? MBN?UMEY6YQB[7F)3% 6!BSS,"(TB1#Q8I'ADW
MJ@KX3(BAHO>'.MA58NM>D*!0Q%Q#]5: .9O0+\J.H3KCS$L()1QYHG;TQ]T0.3?QD9\X;HI)$-BVTH%6 MS?R&N_R)66[29^:8]_1;.LNEW
=3,HZVI#AT$N88.) 1IG1ZXYK28IH#9-M/]IQL70R4%@GO\4X:XT:*1HMV;_XF(ZIQ106]B47ZAI85:LLKS@FUSX-WW9 M%S'0R586P[3\"/*SE8(=[T-
SX81UI4M6JTHK'I2;_2L7!; J-S/1@O*/]_)^ M0YZW*J#U]>'8=H+'UT.6GSE7.G&JM9@@29,@36-$ M;5%--8DH(A%.D,_[F9N%)*0*[_6Z,?#< <5K,*;9D$=
B>P*^_%"W(&Z^UE MFZPN9>]..<1K5+B80#%C76X9HO36^(S^4_U9GG4[ZW,]ERS>=*>E"X(3PRRT* M3N>@LT X0SCX?&>5KWG&1 MG_,A@P;9?
70@B8T4D1;.YG^B(M-8;2 VG,7^85#?;G-^K?RV\-=\TOYP6C! M'^[^ E!+ P04 " #:B4I:$+-PQ&!O !V304 %0 '!E=',M,C R-#$R M,S%?
<')E+GAM;.R]:7>;27(N^-V_HJ;GZT17[HN/[7M4DLK6N6N6N=621E*Y*K#@+MP@(
.@2O*OGTB0%'<22[YXDVKWHH6DD+$\&1D1&1'Y3__KZ\GLIR^X M7$T7\W_^^)^+/)U__.<_^?)/%\K"'.$__)@___\$__%\#_^>7=;S^]
M6*33$YRO?WJ^Q+#&_,?T_6GGJ:?*>_+19_FWX)V+A759+$_F7SSYXO M/G]3C]^6O\DF-7/W;QW>4 "BU3"#X#:EE_=00,"DH+@?F;4'FR__S\1]#
MUMX@]R Y#Z <|^"8=A"49L%8E]#DS8?.IO._6/]D885_D3LS5>;O_[SGSZM MUY_|>>?__CCCS]_C?_N,__RGU?3D\PPOOO9IB>6?_T3_;D6K
M"L7%V9K_]ID__/ERZ<]+7!%>-JS^1E\X__=UE;W(P*]KG&<\X^YBD=DB7?NA M697MXON_G(6(L\U7)QFGD\VG/HNK]3*D]<1%[J((%E1Q"$JE!$$7!&Y-
!:R/ M0HOK7%>]5T3V1A4K3'_^N/CR,WWPSU42]0\)D6S$<6NY,]'L1_?%WGLUK_MK M(]$/(-H,VB70$6KP6GF0&$*W@M5#',"L7#?
RM>YN:KJ9\OTTV*9 M<4E&Y6+IL$RWU'X=SN<_\?/GL*0/@O1I.LL7_[HL%R-);HF>]([#_] M1!(HN%QB_NU,<_6-GI>#"T#M!SE?
X7BY,PG4^,+UR%H@%]I--6!.*%I$$GLT-F MLR@LMX;-;2K&P4MC]2?:RKH'M"Q.3A;S#0-_P9.(RPE7-B,+^KQ@M(FR1@B1 M*V B,@J%!XFXT+6K9V:
[^O/@Y,FCLK387<"5@^T,].HDN*T"S!"HIXE54> M0@X27$9MD&"$W3'GD$.EXA*R,\U)FG@5K@H4;"W=E(]K!XA#Q=H*0MJB<+O++>7Y!
M3OS$"U.D81:G&F=;1%%J#0<3DB?9LP=,_1.(*R8U4YH?!(Z;*VX%"OUD M0'&00+L PSO\.*UYYOGZ=3C!B8DF:I8Y8'*60O%D(7!'%B^XX'7*V<;#HI*[
M5MT*%.:)@>(P?8!C%?SM%B2@=L(99,N?+XXG;^7WYXO,D](0]+D)B4P/M0L MH2YT1EH))D?,7*IL_$,IU&UQ\B 16\'&/C'8M!-
[%RCZ$+Z^RB2I:9F>70B? MV\GHHF4Z&2AH"GE6FH'7]"=)P5]0J*V3]0%^[EE^*^2X)X:<%J+N C//BNL^">&E4-%W!-. MGM,?
WRP_+/Z83S+72!%\!I=E F6(!8\6OK$2C8K%\>"Q'4HN%]XN@\;>)DCV ME&\]/$-F++]-YP@E'9X25D>12H6Z5 F\+ !4S%R:G$$U#:W)C]>W M\G3RKO*-
G2MP MB8*N4F0FS]]JX@^[M+NYXG9H>#]9U8,D.C(;/BQ#;3%X_^TD+F8$XRB%]@9L MM+DZS;G6.4DZY9S%P"F\"NH@*%Q;;CLT \732I(?
M9.3XN77]"G,/^+F M#VI\755;<#QM/)@AXLV2[BS^>G MRRJ]L[OEBG]2R>EJHE10]1H)!&A"N+<1?'8".HA.V0Q'.A=/K3Z=DAY:CG0 M!I+N
C&OYO1I(:VG7_!%6(=SMB;.J"B\]H"N$/5!42#MBP%O,*(QF9A]<9-[M]^K;U8X]M81H TEW@9A:K[!'\M;X<;'\-G%*DM]D&3!K2"99<(@D!^)&2B:|
M4#JV2)I?6W0[?#RU'.C^6K)S?[EV 8N7)C\2.?CORX7?ZP_/5^M;A"N7/Q[6#R='*@K>3?'\+9 M[()ZP87517BH7CC9P!C U0($(1B/-
OG"=1,C"\7QF4%4Y'&9 MH(@I.E.=/ZRT_;Z5MX/(TTFX-I%P)]TQETS\2E]93;32(?M@9]\H3=X5Q>_1 M<@79L8 Q)!?-88G7>Q;>#B-
/)_?:0KY=0>2L#^R,"18QF"0B:*,BX9P0'VR(MD&U&UAI9'EPY+D-R[]'8P>3J)US8RAHSXB#O.&B7CUAT=;]Q,D7SV0$I97@ MN980G!$^E.)B/NR8N;;
<=EV73R>ONK\LFX'@GWZ^)4OBZV^'C)=[_K%R]?O M7[Z@/[Q_\]NK%\|^O'SQR[/?GKU^_O+]O[U\^>']=2;VG#WW^*GRI)!T-9 <2ADB!2=/=B7N0^7
MURGH9#I5*R37XR9R[AV7X##96M0OP"=/K$7T M6A06M6A^DCU S[CST=H#]IGL.\#1]_D7HGJQ_$8L3+A/*C*?P9K:E8K<+QR
M%GBDO2&84QQ;^WE7UQ]GO,UP.-E;MGOCX@LNXZ+=Q,7/89I??OV,\Q62 7VS M_H3+;U*;A)AEX"$!<[K.!62U2]$YT$Q)] 8M=ZV/L"W(&F<(SG
X;JV)#LS. M.4L?PE=<3:Q$)LDX0C"6:&?)010Z A:A+6IT2CPT3.L %&W6'V<\SN!PV5VV M'>#B,JB+K6Y7EB"UK*/ =(#H4$%DF)Q@.:?\4!+XX.AJG!DY
SHN>TMW?V@L MUF'6$!JO%_T0R(^K1"<;)W(Q8"R#B%87D?U)^+!E93+0U51^Z/D-BT]+H-MP_#A=V!/7F[7'S&Y!
K;VUD@)N:Y!H"?:Y*KNF2%R5!J"HLK0P*2%.UY;CSM M!\6*%X)U=]\/$1/#W'WH1J_=10U$O^(4*JW N3*K\/\XY1"O0OWZXJDSB2'-MZY=?
T^RT%OK\ZV*1_YC.9A.NC8NLU"N:0L&@C*Q6J2LP6M%_0A8AY^L(NWT' M<<#Z/9BC1H@ZEA8ZL%G?Z?8ZXN9:S\1W33L@9 M.!1O;
(OV$FL'<'A#%C347]G?.*SP77WW[$WYG>+_*]2]T\E*]^B0M]*#"DR2 M?^\%H&71. #M#TXGS9.O+P!"E&_&XW)Z%DPVVE
MOQ:!],CK^S,D*"$CSTIKC,T?=KJ?FAZ"\L8X:B3Z#D!T4SP39D.)VCK(K):B MQ/J*8AU);+#PH]+(N7&T+E)0P^Q>F/
'"3F;B+V20H"P8M!69]8%O"L9 M?,B\:&9X?O MP?W!U/\+!&T,3TS ;WTF0':C_MVF(T]ET/<45N>N;EHA/BQD)?57#
MP/6W]Z(QS!57)PT)Q0(H)&R]#.46)R(7)446OLPV](V;@0U>$G.("KJX("Z MPM?-_&D=I8DZ%]#1$R?,./ Q<8@1'1VSW$3YT)"H \'65=G.,-J_'V*'J*(#
M4%U<^[\-W^J=_T4:/4F1%-<()J>-87*R M]0GX"$GC'GP#@:FE&L;,2-/&6)B15'-ZB(A>L[*%0%.?-3;I\)!& H\5/TE MU,L^1>&'-
&38\>:CA_G+K@I&+.4T351SW+BFP M-@I07D1PILZ#E)$;F6-PE] MO3C!Y2V>R)X*[20'KVO:E"<'SA8%N3!?>"F)/?B WGXO/#].U[AIQX'@U5PA
M'8#LMJ@FP:#%K!,P6:>V,*6!/$$$SHUR@B$7QC>&U&TJQDU##@2@ X7=02[J M'@M[);>:D>QH'2,GDJTI>,P05$S 4_!9%T;0)<)XJ*

[)D(7R(D!RY>4J@@!@H#A4ZD&T-5NCF)]D#Y'3C<@^'HU;* MZ,#^/" A9%I;DA+DQ!DHZUT=/\7K8!#+@RTLVH>F-^W7QGW0SY@XRQ>^;;;/AV
M!\=!XNX.,5?FX)W1'Z+5VCL+/M7X,FD-$;VM0X]LXU$SW[S8^B8-8U_F#H*5 M@P3= 5">Y;RYSPZSMV&:?\V?A\]3\K$F(2@IE+5TV
8.2LKZ=K.*4#"F%*,. MQCIRJ<7WJ@3#56!D=P.NVH"9, M"ZZ=-87<0TS\654R0>YDQ M>6#1U)9+'B$RZ\"*HH6V.7/7VA8]1E,W">NC9(D.5TLSF(TQ
^_M1BF?<#U- MY-=$F(9_9WP*U3QK9N1 M1QB5YW+@M&,T,%W(2R237]]K*G5+EN!,-E$.,_:LC\+)YDAX9%3>+N+NP&NZ M>W !3R5X'3-
HBB_(R$8%+]L,5A%33OH4V4,O-O^8H_)VTNQ6H_)V$7,/6)G- M%G_0#L)?%\L7B].X+J>SV_.UOE?"*,4#,0;2&6(NVMILISE$JUTA_OC#S[KN
MA;%="P!6P$&+TX.M3EREQQ.83 MBGZ@#I5#3L)!5-2!W7N(DQB$#)Z!9K4*.3,#T5%(@DE;+Z-5+'=V33=^A\I. MVM_^FFX7570 JNOW1A01O5EN-
FC>W R\Q>7F2;))\3X6P3U8)S70WJ18VJ*' MQ$4R1):WJ;4GMAUE8WOU;7#PX&5>$Z5T![6SIZZ>G:X_+9;3_\8\T;'8[$.! M+%E]"%R2%Q"
(+\T$*\'H8)]W=#Y,T=C'Y!&@=9-2.H74]]7JE#@1Y"]$C FT MV@S9($,?D\] __=:,8.BM#X2[Z>FV_O UE#:0_B=PNCJ(WQ*"*:Y$L"9X#5*
M21!5I%!%)V.8JLAX^ZEO#Y+4[65@:T#MJX;N4/7:E 25-RHZ^P92C$R1ME1) M4-2KT1I01E.=I&R%H.9O?1X;07N(O4?T7/4+BT8OZZ/8JA3B MA3,'=6
G".M3T:X8;'Z!?O KY_;A%7VW62',/1_:!',-BPU*H Y&USY_4P\N)O^#\%'^EC7A7T_SWT=+UII7^5]_8F'C-)5E< M Y M/@2X&DF^
PS]ZW*Q6KU=+LIT/7$F0H2:\ZM1 @^AGHU($))@B?5^E;F MRO+CYLV'0,F^LNV@5/W[W(7O(ZTN!**U%M)Y#:YV&RIA.0139^2C\9G'(EEN
M/<_P7F+&S8P/ 9DV5B/?V"YWQ->)"""(E%.HD%! M8801$+)@*H'7B093(1?,X[A&2QG6!&BG^I@5]J(4.0/4L?\'E>KJZ%-,$F:A3
MSQ$PURR^WLPMHFT7HTR&VZA4\|3D;2K&=7"&@,Z0\,@ MJKD^.L#8+4E-F(_DX:."Q!295)7(Y2..P'NM#?(L6&S]2/(M(L;UBX9!SV&2 M[LFE/O,;?
Z/88**MSLXH \AKFL'5DE25-Z!"I;T*6C;/N.X@8]P2@$'=Z#UE MW0%<7B_FB^M<7#SP_+WG5?&L?3%0B"]0.ND :Q>/<-XMMHG4I
MEM]>D;>Q>8:O7C,N9K.-/,YL^:3H0EO)&- A.O(\G +G:K<%&A31VRB;W\,- MR,ZX=7=#>'>]Z+Z;;4 LGF_C7W".]>:*$*2C (2UM$ZL=9):V8!F;3"]))3
M;EW < \IXQ;M#0>_PV3>PV&,ZRN!-A=&>$>!MMX\<2,"A^#H9#&"'Z-"0A=: M9\"N$3!N3=X@,>C>\NW KER,^[LHB[_,!B:%V09_-
N=/!2XA1L&\!T2,*9YD M\U>![Z-EN[B2/27.-!%[![;E)A^_A-4T3;2S)C!59Y5X!:IX X[H!V]R,#IQ M%VWK*H0[']DW(=%&QX\ 9W>!=XB;%]/9Z1KS!%';
I"+!3@*E01(E<9"M,L ML<*9B*VOB^\A9=Q4PU&0LX_0.\#.7W'Z\1/1_>P+Q0 ?\?7I2<3EFW*K%'ZS M,;X++@3GC8^EEE+$\P>RM.?
T)VULP2@\MO9Z]B)T.XOUI$I]AU?84T/EQ**P M3%L!16]*/3&)VBN6P7BDR()9F47KS.I.!(Y[;AX[,(=-="?M]0O-<_-_NX5(M>S0J%0NI%!
(DB@Q1$8\L:5ZLY:K$UK?>.Y(X[N'<#3R;;+-#@%YI:'LQ_3+- M.,^73@JF&?V6)RH4Z3$H\E)$J5'M4RE"-"1LY0P%JU;AQ3;T+6=I7QBW1.- MU?
&4^PR?/WO_;[_^]N:OP[097G[ZT;H,[V&H_93MYV'UZ=?9XH_+^C*IHD&% MOMXT4:"A6*S#12/P>B/%0[21MYY_\1]#=*]]3/?+A=UD^1?
OOV^POQJ_KVX MZ5E:T_;93#_\/LTU!\%YSL"4)\-L"FU+E!J*8M)'59@+S6N"=J9R[#E^C1!T M1Y9V2'5U<(Y>ST,GH91U+M9W$%)M'O!U@
Y"L*J4E)@DHSUZGG^X8J"!M?W@ M%< NHN]BE/*S_)^GJ[,7-#\LWF%:S--TAM>8^K#859YH="%1%PBUP5+5)V5"
M\9;$6T<;1FE2:#WV;P@^1BXZ.BZ.1P="!V9TJT8(!S.%:K4PX;PW1WLC:W6@ MQ%0?6?Q.2L:UF-V!L(&ZNK"*9\O>5Q-3M*P2"I#-
M9J(1_[L#H8M%=@!'C=B6Y$R[WC<9.)%??3- M%W!.R_KR(#G@L?:>.1:D0R6U:9TL?(B><1O^ND-B,]5U $.2X1+)MK_ L]^O
M2.W\4=XK[94EI.0<.%4?YTTF0;110<"@>)0J"VS]_-'VU(W;9-@=1 =2:Y> MO?TDU,1;$W*I'=[!D6\BD7P3+CC0OC1<6^@=J*#=
M0>?/0#?'CW5]\D"P>S7_0D)?+*>U5]P6'D00H(VLUU621.4H&,-2>):L<%F& MQ]L5@D8?B38.T/952:<(>[O$SV&:-
VTAQ(]!KL#HQR=!J5.KDCD5PAMH_2ND;9!?1U44+WSQO&CK/'G6LP]1ZG-9^E(X^LFU44+93XJA@K84(#\GRM_KW=[6DZ$TA-WK#
MWH3%6DULZA/MJKZWP;&&7 Y8$"I$ZV1*-Q+:M^L=]EEX].DF0R)N<$T/!9(KY@SA>4'%.U.@#4<:-*/91 M39D@BM*@E2S'16L!P@."Z@
M6&]SEG6NS0!C7'8A;%^--]&1[+K4#$KPCN18 L28#3&(M$35GM5U[M%+OD0=?';TV=PBE=3"[XQ[.:A[_=8\@"P5T(A=RJWTF;\20(^*"
MC6"2,8$;K*5PQX'E U2._=S[<3L06JFK@X.;@K?S2_QGZ;].IW4PU\74S/>G M<37-T[\|Y>?E4)G F:-IU/5M2K)9;KBRN!Y.IJN*CL
MLI^A&79NEN@,KW6/WE=#6=UT?'5B3T,QMP_IT\(9Z8UID."%GOW0-J MH V?P,; HF(816Y]B[@+?5WV*AP-HZT4US$V+U)F;V=AOJ;=5Y\5_5Q_9$)^
M40Y%*\C%LOHX7H$0E -I3*[#"B$'UH_W;D]=E_[FT7#91FE=W']O+\]D1%LT MEES#1_*4!-
,0E$U@HK;12..R;IT>VIZZ<>^YCPS(@936;P#TZW0>YNEN049M MHD^&XL?-X()0:LXAU$=$47B#&-J_Z;$[E>/:RV,'0*W4U5$-5(>SG(_N#).
M8R)18AT>"UX% 2I*!]YZ#])&(2.G_S;WB0]3U&50TPP/]QS,#933\V%\A_@F M(J6BM/+-6,IU;F AWDR$+-3WDO[+9.O:B^VIZS)]&0]$
RFM@\,XLE7_7]W; M+V&&FXIUDM@T$>-WP=@\7__"E9]\B\OI(M^^0#A_!OSEU_0IS#_B.]H\+TO! MS8@CE\CY0?"B/HY07XT*(6E(,@;M,!C?/&UT7
['!5$'XQAM;9_8,('K?XLT^(]Z3$O1'[>;,12 ++=0>X M#2EP'[D%HZP$I67-SM6';NB4%=8XCZ:U7SP\;@$KW-AO8BM?>L6=
(];=#H8AH^NT@ZR#E>>/WH;IKF^1*A-EDEP!E*A M!B6*>\< !;-0!6DL*+U]+?;5(P]C>C82+CO^;#]U-(!L*[6N*Y6IR>8^80) MG7*V :2C7Q27"]+A'*1
XP-:F9K'77>0,?:,H9&A=:AB.L#6>>'AIM>.I'E* M*J0-5T_7]Q_@]]/3T["\MNBO)]^G$_+--7[W+-6JNG\X]O%;)]J.O,: M(]M-BM[RDUM-
B=Z'D483HF\O\QV*5F@MT5G0(1A0SOK:CU; 1AM*Y#XYT;J, M^WY]#GY;>?DQS,]'##Y?S%?T\3FT5W;\IYZC?,OQO$JQ?359HM5K2A
MZDY^2$3$UHH+,(W,Y!B-3:X_OV#R.[$^V0>ZM MAY]]!DK'QO@=?L'Y*=9I4<3V9N[D'H;WCD]I960?(]"103U?YN*!W)O=%I>7 M5@%]8-
Z0LI4GC/I4'R!)$(R3446!#EN/!]V2M$--[2/+7"+?*,\5CQ:L+X6B
M+TO"D$(!ETY$E[1%T;HG8UO:QC5M0V#HIT;1$L=VR<*]^OP=SFJ1U?/%:KW:H"%6:O8;K\]S [MW0T,H??/_U2^5=2%#DS$[& EA3P*U'H&'31@3=
<&)]8@XU97=]]A7T)N,*UBI>XJL6:&8*44R"H@,SJG@91&M#]2!!XYJA9KBX M:63:*:%C$_**/F;^<1IG&*[-@ZSWVWL8E8<^KI69V9KD1H;G7Q>+_,=T-
GLV MSY=+GRUY)4%Y@3@AM? Q"S"RD)L?POFP.>>L(/>\"-;<[=J)P,.K,>Y;X ML(E'R05(CS74,07HN#7@,3 IF4E.MGX ?
NRQC53PZ'H=F%&6PUU;+UJ@\OT M[&4%L@4U\491,L[WO:=\Z..;/6&[+5]9[=6.\.W 6^N187@(8.315K M=I+E##R6K$)F+C9_'7TG
EL\QOWH8I?;Q/K@3!$&$E*(H'S2]3))@,Y66RL% MRMPZ=[<;A>/:M.&P==>KW0/IK6?SMFGW6$WGFUCVTV)&ZES5HN3UM[W,VP,?
MU\R\;4MRJ[3[YJ.O7.%8IDG5H$P=.;!]?3FD>"CD\%,+6Q(V<@M\?$[=> M-QQ$'1V;G"M5O?O%?Y?_O%V\=PI)C4S(]\^_X\Q*V1H?
2@$3)1TD,5D(TD_ZI;L_JET1TQ;D-JMDNG.M MRURE\2B3T9HT7RO<(U?@I* 4FNNO&6L^>R6QV@ZO';I[L^_$_TZ^!BR!1_1
MTC'M,@3.'3GNF0*'$@NZUHFS'<@;NX*I(79NERX-HZ2.3=1V%>+#E[R/5/H^
M5@F\M(8K5P)X8^CD%$)"3)%#]EPFEQ.=H*WSPNU+X#>O'OT25M/5FW*U@ODL M+W%9X+Q9[]OEU@E<6LJ.-? Q5>Z[=;67Y+H"X
M]NK4P/+OH('L]Q6^*2]7Z^G)9OIL3D);$1*1*P0H&UC-U1>RJTJ@29;GYE6$ MURD8N26Q+88:"+D#B'R_H+[2//%]3F(YW21*SS;
!%TZ>RA;:T=,*2W!,4N> M0I(L1<-9T:W+PK#LD=KVFX8V9U]"'3)74LU_B>HM.IG! M%<:,28Y[V_J4WXW"\4=/#82\974 01?
G7RFG;69J+&DN.3S8A5F;\IOB_H8 MU1?.9Q?=-WE4"3%K@9"X[..Q.)ES4SLO%'/%2!>]:)TAWX?.<<=$#03'P176 M 2@?*,FX^-:YP8]>^V"XA2C] W
MC&KZQMS-OY\SR*0VH18^,JEJ:D@Q")P1J\EZ\C>D$*QU7G]G(L>=UG1\##90 M50=8?(U_7!'=M._)9,]<1+"FWI$RDJ8/B8'++G&#'MOG?W:E
M<=Q7/P="X]"*ZCC->[M'_4-]?7>OA.Z]GS5<0_U=Q!ZYK=X)B@="JD$J2E F M*'#:U)Z='(I7%F4Z M8(KQ(KS4"H+7M8P[A+.A:*D$S?NNUZ*\+&318?
X+M]=/Q.7KG%(7] MC]*'/F[0P0\#'JCWMOWGQ!@2"D"Z"C(6-(&,W#CZFU.:)YM-\XK4@<8_O$^?
M,)_.ZI?)C17]=5PBX_MB.CNM3\1=WP7)NTP.90*#AKS)P#1X3E&.%U8&DQ6S MHO7<]CU)
[71TQ"X8NE7!>@2E=6RZ[I[7L+_M>O#SAATR,:#U.K"5WR4"I@\< MG*_=:KH>I)PKD)P;6VPHS+>NDAUWU.3KQ>9U.;PR+WZCL\V*J_-';FYYH$(X
MSDR"(!))24A?WV+2H(51.DIG6&S]NNH^=#[IH1*[(/%6EF1HI7805ER>!I?C M,;Z+^1KKO\^G)-P_PC+?
P[YEIB!&!3P*.B5\YA"T+)"]*SP7Q:5O/7>A,0OC MABHCPGU,*/2P$^YDFGRCS1#I><+S;5\Y?G.Z7JW#/%\^8':3>48.DDDF0Y81
M0<5@(3(*^3!)GHJ)AH76@7A3!L8MQAES%XP&@XZ=Y@M>UMBQHBP(56L9LJ402:<,QJ6NRD\:=^)?^
M\:TF\!NPEX6AC4F#"4G2L9\UA'RVUV*Q&'CDK8OSMZ>NJU[\75#Q0,#24B$= MVZ'MNKE>X#I,9P-VJ5TL<-PFM3O9&KY'S6=IE>4&G.7DPG-
'884L$I+U7!I. MCGUIG1>2E6: M/ZN[!5W=-JWM@I!M*A<.4D@F9KEI=XW"[S_#6?YU\7R]Q5.JJ^9ZJ@GYSQ9 M?
LV)'^8M1NVK^T0F+5720WUZ$G%92RT^+Y959)N4 MY,0]JJVA/6)*J-D?6R!]JX%5M\:G#%8T^S,"1RT>UL>2 DZ?O-YE9Y0I9& P@92$/7!43CMT*
MV/"Q@7OKOR;<:>:-3B!J+EKQA. =,K"QB.2B*"A:Q[X/T?.T"D)WPU<3-LZ_3U423HU=<=?^,*A0HHX3H:^6@5QB=56CB5J<:?>H5 M^-#?+J%S;
<'1;_T;Z6]Q]#![0,!?L!ZZ$R(M&NL]^&)5+<$2X'4T8,@ORSES M[[AOA8&S)<=!P0'*NJGN/20WLL+_,IU/3TY/S@G/(3IC1007ZU/",2(XCPJD
M=UX*RPOG6S6*/]+R:XN.K/1]5+9H(;^Q%1^^7B'<:C)QA2'%_%F 4WNN+_<[&\<']6&Y4'I#2Z)JBYUJ$V MIWCR?5R 5./S@B%(O572\5'MWUQY].JG]L?
^@>(=&1ROPPF^*==X>+$X"=/Y M).9"6,X:C!;U;I4Q\%PP2*AY8$IHE[ZM/T\W>I7)A!9F4JEN22ZSPAC;1I;$Z@K'6A:,6%NU%C?,^0N7N7& \&
MC72W:"[(?N#P*^(% UB$T<'088IUZGG1'+SBA6RH4X(KXLKD'9%P^>GC>0Z# M@F!\8VM_W>XD?B%/Z7)C[)9DBWT[+P:$JV'I$30RJ68];,9S-
L?.TYR>R"- M[R^PL57]&O]XKP&HL05#(@R%995(G[O)VNKW_N. /2!E+V M 2(:V1=\NUSDT[1^LWR/RR_3=)8>84XJ51BG0$=P.HX2@X#D&T>5 \&6"
<[!ZGR_%.4Y"R:"*_72KP@'L;ZV]S33H:2D M@FZ1/+R7@/"\Q,-U>AL@!PIX[&.CSG:?XY*8^;@,%RD3YJWA 35HK--NN5$0 MD4Y
*9WP+K/@B]_J\+CKTT=7_Z$:6[04W]B7"K@BV6\&/FTV QV<425OH4AN MZ_-HM7T1!7#K34D9M0HMSI ;RXX[=G68*Z8#!-
L/)LZWA_$HBDD66'V:3[E< M4[(L@[2T0:)'+>Q6[X]LCXJO3XJ#U')JP'I:3Q=LE?IDN3E>S M;V>U/IC/#9TOTA5%ALY%14>G=[H.GJAW*E)RBHE-
]J(!+AZCHPN8[*/>Q4"R M[J D[QZC^MMTCJ](8*L)%R;EQ$E&VE!L+3BY7"DPLWRD2ICO-(T[M;KGY,32(*L;V5R^J#O^ZZ5\Z72'99IV5\RZ06.K\-
K:9C5HXD'UFB1EC&&Z7 MV;[]V5W6ONRIN$4[*8X-@D<*QRZXN]*K_2;.IF=B7US,[(XB!+&XE=E<%S M8\"@LLSY1"& W@HO!Y'1Y?UJ
V@=3S=CHY#8HT-[O3P;2#!=_>UY6'UZC^OU M;..0$(?312VH?Q]FM+\H\I,D4PV1>0HQ93$4;.8"SIG("D,NH]H*=3LMVV5B
MK@'*AI/\V*C:EU%!2'1<0ZJ6G< FTBSPI MQUQTVV4$'UVJ2R>\C<5]*,,^$7.SX^2<,>++8/0&-J-XE*HE.?5E*X5<1\T- M1;7I /#]XCY<<&T<-)-
\CI+XWP%[G\+\QO_R:9]=UWM*;SUAGE_X29M67 MG 2K;'+UE"_U]2J9' 2=+;! UC&PNNH@I;55 MAS;'DFTHJNXS$BFOS=D.$Q2!CH7 8K3=MLP/]GC)
($_<3"T=0.T1I_/]AJ]- MV_2__"%\G:3BS68.LRE"U01.J:>.FGP(C%&)DBD&:HR\/_TS3_NE'5QFNGWHW!H_<7XTHE&=<5/E1,+&) M/(4S$%
(1296"A.7C6H.C]%[2+>;ENO@N?2$Z44O422A[$<8] X1D[MB'?L_,7]'4,"+4NRYEY\H6!7*/(G%9>@$3UF+%P$*YCG_1:KW;2W7.M5[L(
MLH,H[M%H0W+KK"D:N'%8K;F'R*('W5Q3@AM5>M1STU]8,9I^]WG[!E$%6-; MFFTR'N\6L]FOBV4=3C_Q7I MYB0S;U,-,C5$0QLS,9UU=+1-;
[[SO$].]/;" M7?HQ>ZI\Z^SG@?+OP&QME5"3,>C,77UJN'9!)F_ 99D ?1T?+@W%#L=X\+2/ MT:##HV*?G.;>&MBZZ)458B
MR@C(JH.:)4)QR'ZYD7TLG8>D3T;A2.4P_6EWT\3&V[@]*?@7)>/9'SGSW* M$9U2X3%2C,025_5Z-8"WY"^;3"+H(=7.\J%T X,'_EB*$BOO%,.3(GU?7-
&_J$A6T>Q=;ZQW"$8+"/47I9*)V?$B7&NVG_[%T"Y8V>EB:!=M]'""S'$K"V:
MS@U@NEA05D=PH0X",%)H;BU7;*O[]Q_B8F@GC6YU,;2+>,=.U]Z8*66#UDP8 MH'U" 3#66,.8!-H8YK05,=OM"E1W'\)UY
N@G73TP!"N'00VMJIO3)0J03FT M08*TP=69PPD"#PE<45%%'PWR+3M3=Q_"=>09>WLK^P"1C:WM.\<#.IDX*XE! M5%
[2\9<9.*T]6*\Q%I=S2=LU.^P]7?'(L_;VUOS!XNL@/_AX0:GE'C6)PQ@D M?E(H$#(+8*U5V9O@C6V=$7S"5[S[>)&#]*(#:.U33BQK\5[F!9#I3-:3F/5<
M%+"<:573F(6W+G\$C3NJP[&8R@M.+D6:0 PK/,9/(NA^V*5[9)"0.A:"]Y/Q$,7=DA-96.IL[.
MRHH<#!X#^$S11C"F)+*SVDK6$DT[6]<1YR,,C*L]==#Q"Y&OO M5/;>?R)-7%X!O0S+VNNZNOC. 9==>Z[4ZJ*K!;.-+KENKO7]IL(R;Y2T!;BQ
MD]IMU! U!9!DRDS2RG*NMDK)[^#XWD?+P8_9XOL,U%7HWQE4,JDDE -6JYXI M,C(4%SL'UFB+J2#WS3W[.PD9UW=OHO];#]D>+/
.HL5K3$P,F>M2"_Z(^SKW M00>(SE2_T(9BHN.Z>1W2-0+&14D#A3X$D9VDV[!I=W]P_!6G'S^M,3^C#Z43 M^&)FT68+K=ZRBH%+=%G61]?
J*)]0P#,1(3/#?2E,:=;Z2?9= M:1PWVAO$$ VJI@YLU+;_1)6TS0IG"F?*1#1TM1*4:4@)A4I+J'-IW3VUF_U MX.4 &-P0.*Z-&Q8K>P)S=\5U81XW-7A#Z?
KU(?YNH+!,6+R#8^A!& M-!R<$P:0.>EUK./HMGHEIC6B[R=YW,Q=?W!NI-P.L'R/;%],9Z?TU5LBKDZ8 MBB(R2%:2@VZD !\Y0A')%DWRSKIU-F!'$L?-
!O:@/#11WO[87-#6:5'OL_Z> M%KNR$3=^T+-Y/N?QNQBUB<%K'Z#4=^64-D@;4-;H43M5=$DB;G>7L=NZXQK& MIJ'2T%+OP-C=E>94YU0U^XX
SQP-B&QOI=I(WBNZHQ]*9!,>PYLZ%SY.2DC=LN."*9] M]/#4[L%>AV6=S?^E;;77K0\>]);K83:&OM1*F&UPA4 7Z6Q4,I,G1#@#RY %
M+:7'T+IG::A+K8OKPC?EV7P]S74'D%3?8SI=3M=37)T51F$^NT8^^7RZ/K^H MODG0^7-(RJ6,B0$J"F)4=.>Y?%ULB$$PHV\6V1XLF;8<='J-
M@OB;IJY$57< MP6%[(,^_?+O[S;M,\9%$D9"L-7Y4#5DCY(SD%:R0FXSQ4NM9WD.R,ZXT!\3 MI8L^(=/M[JD]!^=-
!E8EI7C*@%]J.EI00\B&0>&1<20'C.=RE"UP2=.X..X& M/%N!>D]-CEU?>):<>K5:G=;-_OOGQ?S?<;6N#QF4^O+G'1NNN*T&;$ MC]]S?"S,WI\6/J;Z>_\-

I33#V]R*L$)F2T/4&P2]0GJ2")4]3_+@3.7B/K6 M-Q;7".@EZWI4$-QT!?;62 =PVE]PEVS/\]M9F%^)EHWU)CNKH+!0&\:] 6_J M"PN9LY1S2MK&UA9U
#Y&=G/WA]5-6SFVCCO_^=UIO1*X"M<2>'*]L#Q%&H5Q;+!D]EN/F=#";^S]3N9 MVP JU4)462R=-TK4R59%R=9U4O>0,G(6]S?4M5!8!
[B[L7E^GT_7]W?O?S]G MQCOEHRT>@K>TB80@/D01($,63BE3\.:):Z]5/E5]?OY5)HS%AX;WUTA*7S/>:1 M:Y'009:6]'=D<6,R"5CD!;6Q3(K6)V5/X>?
^FKP'$GN(=>PS[,.G%(R;ER>? M9XMOB"__Z[0^LG(MT7G-AE96+\9+$Q\Z&6+3Q^HT.K*C]>2.&)1$D8VP;JO3
M;7\;^L#//FI?'%\'8T/M&6E>7#!YA0<=M11%(^C,Z*1/D4&(@>3F(P\Y.G(' M]58XNF>!<0^M5B!I(;VQ$5";5:
<97TR7F.C'M@(Z[0Q]\0^NL"TI,M4R.\5C@;24=C0_-B9VTZV.YC_0IO(CG: M:R6!5-F>S0&@C4BLZE"&TG54*LW)_-1/%U= M88'9I%QQ$BBPI5@S6PIE*?
H-6TMP"*.OINU>M+C[\[?"A>X=%PUDUX7Z*]WS M:=H$HE>X2#P'I-@2T-62R]8)-G_+AMM@12Z.2;X] NY:8BL0F"VBU-
O+98HK0//2^TB*0&\CPH<>E^L54'=[%Y]*+#:BX:MD&1[1]*1 M=#-VU%[-ZX#HZ1<\\]6$NKA--"9FZ6F3]+I=N"?
_BR@"IPCFZFUYMOY*/NP6C';8RYZ+A==]4C M"VV%"-\[(EI*LPMD7!ZF=[&CC4S6^@A!J%)'5!4(,D@H05B-V46FM[NE>GRM M[?)U[$D-I)U0.[@8V-R-
O CKLUPXU\J+0C&[B20.Y1F9/BDT!%1.4\"5#6M] MRW2-@)%OS+NX9MI?(SW!Z7RG\>B-H# =W&8W."U))+43)"A6C+,Z%CD4H']X M:3I
F??!8@_)CGT6_3I=I3#[#PQ+TI8\-Y3<9"$B.5>2.]HC@F4(FGM-2SM$ MLSH[46QU^MSUZ9UH?1]=+5H*KBO-7SC8&A-:D0I@+)&LHXO@M.
0L\K(ZR'. MMGOG[*Y/'[G9>A#-[R.X#@Z#\[D#&],7F?!)NPP^UDQ>*/4]:UY \$Q+YQ)5 M;%V-?&7YD#VW*#HIG8'B4(%*AD-(LDZ[M2%C"M&[UC[% M-
0+&/5OV5N/=<-A#IAT XIY]M-DHM)=HO[V9X[G1S%Z%;+D#EWT&I34'A\E! M"J;H4J*/H7D+Y/;D=0&F?4"P71_P1IY$F#[\,?BG+7@BC52T+ELN+[1,
<&VGT:>!M@(-Q<[26]?0Y&ZSE.N,W:S@.@P M0LI:49R)6>((<+LD<-Q\SE$!MZ=61H3<:KF>O*N.YUEN0GJ/3DD0&&I)?.V_ MX,:#%YEAI,
EB*TF%M&G7H$1_>T20M<6'+=N85R7?'_)]P"7"?A:"-8*,&/Z2@DR45S/I;I4Q[]?S:HB,K?1^5+5K(;VS%3^=7".=*!\Q9 M@['IVRE
M988%N5T?]ZY@>YBL\0ZB!@!X"$X-M3$RT)Y_FF)Y^1739G3AFU*F"9<7DPY< M4EKK"%K7I[."\N!BRE!*,<(+3N:]A>_R D= :BERA?
MY3_ZK>5B>8++#3>_ M3N<4WT_#[#HW%CTMJA&2)):44 J\KU>R3IW00WD/S*.WI-6 M-D[E^X3SL)PN-F>^E4J:D"/D8!4HID/M^G7 9+:Y-
H1]TR))=^?BXW8&C.^& M'ZZ1L2%U3O?O\]5G3-,RQ7R^UR]5H=:YRV!K19%3$+EB@(X5[H2@8WNK:X3' M8'4? >-
Y1@V4NF@MX4Y@0]6N'[C/!OWT?42Y43';JZOCN30*F: M%*L%B]!;/U!U.-7CMC[U44EV9-T_9;1?/L:$^=7\+=*^SY,8)#>L
M:.!6433#2/8^2]KO%"++R)/1L1O@W\5 YQ-=&Z.O%?@/AD*W^V 2G72ER +, M$.*%P5.207<"\F*YXGIUJ_NWDU)YU-?QT#F3LKI%F);"/&LR?O5?
+5>GFX. MP#?K3[C\|"G,WWS>Y!C^E3YBO?J^]4Q@J3#FP"A?Z-S3!:)D=9Q2R"P8GC%N M5;]P#"N\(V^=#Y[MU$ /": ?>F-1)%-PNKYRK-GLDG4V@A!
(P8RT!5R6=+:Q M' N+M9W^. ?"(,QU/G3WJ6ZOPV T]HW1;:8O1?+R:Q44OL,OM%9-2I]_X?5B MGL+]TT3KP@7Q B3W "IR!:'F$[QSQJ<2$L?
M1D0=0,3(J9CC@/JHFML=H?X, MH7A\6)^<V^O $CH):_"&>M\@AX#Y\5"Y$B!FW7$NRLEB5]H79MV'Y9KFIF\C_'F:G>/'LJ\0R)5GVM>TQ^?HD02"O
MC2-DQJ.T3&>S79/(?BB]CZR1)_U \PF>NL BL/%'A34?]F$'Z]/S^846(V<
M82@JG1\K*\=+#QZ60Q;S"WW;;XGTO<8V*H@\WU;+;Y&_U8EMOX;I?;H?/E# ME_SYDMV;@CA?^1:PAV<=OZYQGC'_Z;!3^,5TE6:+%
<6+;\KU5PMFU;H_7ZS6 MJUMYDM6S2&2&M)[PG"B"+!%]}2_#6O[^B M7+M6I!4>LP_U04!3WZT0Y-:5!"FY7&=#2E9:#S]\1L#(9<'C@."N*=U[::0#
M..TON >>\[99F:0$;6S':&.7.@LY\ 014=C0W/S M$",>E:V@=R0=C VU M9U=??+W"0\@:=7U#FJ*C^A@]C 4KH_ A:L.V?%3WG@7&;;9K!9(6TNO
M.6IP_\1YLBH8 ;*$6G*K/?N"A26LH@]N,B.GK!H,Y;B"3R<>(A3?V3=/V6T M;U_&4B_"?CV["M8(10SB4Z#J$DZQ26(7BE((1FMA7>.#U*"?30..T^]_,;O
M\6NB]@73W\=6.Z\82ZP(9[4#$;.H@U(1@LMT[$;G)?.\V]'-V\\P58?=;; C M('RT L5=X+;W/OR]Z61ZOP[+]1,H"7LVSS?&]*B2N'+2@?&V/K0G"T3FR:W6
M+-BHO..L:!5#')_V)SH2YWA;[BE@ZH<^ &^T_'KC7%2:=%ABE8O.X#Q7X)+G M@K-$>^J'[AGOKS;S1SK^#@#;W\/AMLS6$Q]_X8,%5A6NX-
\G5!JC*N3V#$Y M3%F;YA5QQV/OB8[R^9%VY&&0^WO8E#===FZ\2EDQ")R4]9PSX(03X#'6TGD5 M@WLZD^OVB1#[&T/T(VW(0^!V8(3XT.N*KHH
M\C+(= $RCW56N(1@N86L3,XY.9)O-Q_AQ'!$PU#GTQJ=3 X[KVCB9"X>#IG MZZ,"G"CKN$3!P&>T%"N8#%[4*MP8&7JK97:MFUY[X/N'S]D.MW4Z- ,
[H?CO M-=_[N!2Y4"2IH"!&33#(LOI$4D#*.1(Z5&9SXT#0)B'<9L/W=U1WM.%[U>Q. ML/T[RCD_+KC@0G'$(: ATZD4)@A8.)BDI#(V:M'/+,;6S/_P6>L?P
8L_MM"$XSSZ>$]H?EY]+Z#%EDI6NC7>6:_*=,$#Q1FOODZ=?GHP5V(7S'SY-_@.8 M@,&0_$/O_QTBI^R=L,5XR"F0S4SAO!0Z<(%,).N"VNJ5S"YV?
^/X_REGY'^ MO3\0BIMF\|>96O3^]S#/:]___BRMIU_[Z]+#3BRZ;[EC3BO;BN4^)A5IQ8T. MT@-/%(4JY3Q$71Q8XRVS0633_,&X'V524>]I60-:)/H!/"\
X8N%Q-# M8+;Y)?#_3"K:$;/#32K:1?T=.'#7!YAX]XTT(M+1&>NK.<6#DZ@@"Y[I_%2! M1-P8NS_DI**=0/#@I*)=--(!G :94N*RD3)R!,T"2=/$#,Z2CZ1%-
,&*@*;Y M4-L??5+13K ZQJ2B773< 1T@\2TN*<(XJ6]7;(2X.F>CU"<" MI/9@BTV@L+Y-E(T"QD.B>%A%SFUC#-Y#2N?7EL=&7PN%=8"[!I5;Q06MI-*@
M.*_/9^5"QU&59\X].X'T_V[J=G[;J:'_"4SI.L1%;+NGS+:]ZL_EDY:Y-F" MY8]DHP."MW7,!Y-D&"(/,H1>=L;?9T/_3O@=MZ%_%S]Y:U&S)^)X;:83M>K
M=9CGZ?SC>>D\I]2E=@[H5Y*$U_FLDT4HACI:3>KMIFQD![Z>Z+8Z JY;;<&A M0/:4-
]YV=7&K[VUDT:"7AB>0Q5"$I3S)):4,7B5KHW8JWAP@U_'I=IVWSF.= M'V ##@FV45LJ!]Y-/2M$NSWM0$C-T)(/DS0KH(I,$)U4X(ST&>D7[L8NF+Z'
M]!^^_/'0O?8$$/7WT"5\NX];.*^R, 8X1HH@4 >(%'9O.MB2SLY8\>3*%?]. M6_?[/.,/@]P/L"EW<=-]B%Q+,E4YDIN@,KD),10+4J:0K!.%R6[2D*UCP:=<
M'CCZ-AP*9/_3]W]GA:VTD4YJ^W\L^_9]>_:>8 M-1T,CF./8!].=E!!"B')9(+PL*6CUCTP<\/ MGVT=;C\<)T(=#)RC]]\?.XVV1?L"TS8(Z2$40>)#P\"[$
XIQ!3#MD]G2:< M'9E_HN=R1X:@.Y7NA.^:D?^T.#X M=.9"_T_S_8]U[^&Y[_WS-\I:M*1(TK\(3'-0154X.EK8+JX:EK\$\ZQ4$\$WQ1\W\ ME$
:6<=_72SR']/9K$:]-XBXW ??MT"6I7B6+4C.ZZQ9R< [4=]U,,ZK;*W3 MK1^,W(G =@M,\?IW.IVO\;?H%;RU[U@?%LH\]90!3O >E- -G$OD()AD2A.7) M-Y\
OS5UXUK2X3!U__B-IOKJ($?SBO9VN9^G7[[])?SG8OE\%E:K36-^$$$& M%3((%S0HY@MX811PEJOB+$LO6Q>@L-D-H@?K<.P$UX>:B%@B?L 9 M?
OZTF.-9)=UYM[SCS(JD/% <3YS8(B"B#1"LER9P]'92N&073I7C)+-3E16['*^LFB<5KH[VR&(6)6?B_>MW@Y)O,B51
M)&A@]IZ7F<1.@8WO:S2Z&XU&XN3S5*K27R5'\Y:!6I]?K=;UK6O:S]_AV._[M_,>#K5>& # 0)%GP#F]I$ *>X<(\48*[16)WAOG@#C9JMMX-
=@]_HC$20;J M]=[]=(OZ1[BI:+XOZT5]E+H,[!F/^S]YZ>'O947E3(,%:44 %FAP>9S@XCPWGBN])95 M9!/61Z[$5=_)4Q[#",I;Z?
ZY2K4,5@A$=*%15BUF%+ MG"Z=B]TVNX]F7]T^_#*+NU"_%A;\U ^HXM" MB0JB9UPXAIC6%&E #7'A*2Q6(T+R:Y\P+ M'5]U653"_Q'#1B)-
>6C<$5I%P7)3@D97Q]-D3'TX/YV^G%;I,8Z\#)3SP-IN M49T93PM/)0;'ENC0W8F#GTLU(JST3%]E"(F=CSLF4^]S^S=3O]CD9*!L_:"; ME4Z45#.&'-
<>,07.LZ)&@"\-T931ACD:.W_23[+4)_UO:/6B$S5<_>]U6DQM MZ\Z,N;N]:Y\Z/+NMF_7\OUI:9TH(IPGX,H4JP=O%&*RYH@QICFE)G+&D?.,X M>
(^4:=4R88 2A;9\.F[NSNZ+6^]?WL()C[GTL-B$@>6--0*'HT1&%K#]"VNG M*%;O+U_;3,V;1RS1],IBES[1Y=78\Y)8'.[JPVJ#Q8=T!4!2);54%3$.QZ_K
M_"O'*_&T96RT<@IU23OT]UC9@.I,%-PS3L/S[85$S'.'I/,*X5"A:"NNC7C# M_1HDRBM6F4SQ(M*2A04\#ML,>RE-00"?TH=FQ^'):V$*I7!QL.:JD3L>YQ]
MY.HK1IG0TD6F*(/XY.S\^VX.GSVPF';Z:CS/T#-5]7#[LS!E@9@K&9+6%*AB M%588 C[I8UN^,?*F;?8RN7_X9E1F8"V?W;)_7-I4LT][0B%!$.L"G>60A^8
MRGA)>2FYD[&/\CK$Z*5DXB^K9&.!ST!W/K6MD=I*CAGX"!55$*HK$A[AQ1Z@ MD.":8NV8YJP4I(C=Q?;9Y]-&"*.I?+4]#L,U
Y78M*'ZAUM_K^WS:3@M.(?O M(>NZICSOZJ5[:4?[E-IT)<.Y':UY.9GNV M9@PN80D@6_CPE!K 59G"@"LFN>2%Y@Z+$S6FXS-
IMITIR.S6D['()@S+CH"T M]^@!5I+CM$2: E(,8$)*&X(XM@2"3BFKGLVW3_URFEWI[31I OS3'_T<7"VS MLG D/$Z%B"UA+L)HI 6Q2
A)E'!6E(2,,D%IDD6IK,])>$8S/&_:'_!+J(1? MP^X_30/ 5_08>_PU-*TL*O E?;Z^ P59Z%7O4"2:7 B2I)22&>K-[7O%E<.I<,0ELC0"%A(Y82]L).Q+]B-
$OBOU.CO M%,W;W^AO:E83.O:K9OULHMVQ[>N?NK:C27L-C1)765T2I"3$TXR'=B;"<21< M62A&]2YPK^(S$.29YL+?GK1VK(RY=-&
<7(WJ!)PFUMU]\]C>[M:6L2+XM%XH M&UY8!>\66X6T4J4]J<6:]#KE..*=AZ5(HW]OJP7U))2DSGAL+RY^6IK'JY&N MT >S"
(_"$:S@!&EF''*"0(SNC)/:]XHP=D=.IR,QZ:IC89=!7KW'D>13AI!+ MRYSR!&%5:<1*HI#BK$#>A,=B-5,%C>WAGB)?+JVOWFH'G)S#'/3S61;GXE4W
M]YF1E2HL3$09"9ZOIS ;$@X[L!<<8P4K+_8]E,,2):X#/YDF[*IU3I-KQF@L M,S VW>[CQ9_;;@^7KC&!LQLW8QR76C..O%48,>
(YTE89Y+#53(J*61^[N+FW M<&EK_=[,!$U#5@9:N'U]:W5=;['<>Q8O*T\]EZB4F]5%D2RI"R<;F@" L,!B MUS]TE2WM18\WT\%)],I !?=-@V!G:
E;.F$ZW*#B%=(0[R"+PU&),,[["L=^W M&]-@DU6?C9RIQ@&1]9M6Y]]#@Z;5?-F^/?B]7@!MJ\VZ7$U017R LB#6E!UM#U4H)X)UE? MU[7YX]W]LT!
<4&*=#]A))[%WE0/B),VG!S!^_YC MIG&09[_Y?@4"W%->.;RG6B_;KG,AG^Q()05F%7).2,0<+R"TA9T^-);&3DM= MZ=@W<
E,NQT$C:=]4I&@<9-3.'+8I:6@2EBMET.#LRB'DI3$4,(3SV(7-_Z7(Y8H[L34_# M3@9Z]VEI&J=6[KW;_/_39A=_D3FY"N\LULV?]K$S@KTPC'G$+:PM!J
A57&. M"B*H50!P2>.W;SA)Q%SBN;B:\N]BZG2T9:"5KRX=,&1T\;[$]1NA_2A*2_RA^,8F"P#OUPS;RV$-0VZTB._7_>,5?> M=;W'SVQSQ1H M<$O<)
(*.V>&,NBJ4!W$,&ZL U2^%0CIT=-<>?@ZQ/:ED[)3LP'!@ MLD99B<.!4Q@8&0Y\6#XW/V]:91/C9O@IP[]!M=U&Z7A'/P6
M@XS@H<<=@=ZE0;&C2^L)516Q%.B!.AHHTA+=C2T2_CFHTD/UV1:K=BKM M6B,E*YW2' *51N$ED@91Y$@QF!#2URIZ(JT3YA\#Z7';&QQL,]
B9[+OUU> M)4P U]9I"0@I)T3N%18%B)VD?!K*3(I[!Q';_@0<^1^?Q8CJ&<
M*;55&E')0ZFTH4@53"%N<,6+BC*B8I>3=PJ2]F!LXBAL!.89*$XK_97[<=>8 M[^% ^&QIK]PZW'-\?]?,ES>;0^ VX[::55K#FK*A2"
(\1U$(@C0G#.96E*5F M!CL=O4SO!/GR,4X#U:$K0ST%-QGH76<@\N4NV%[T!F8X![,\[E:+)Q]=_]! MF>\Q_^W,.*-
XQ!'2,Q"#;4,KYI25#"O>5DXK*LWR0^<(G1:KSV^AKXMBZFK M2=ZYI?-S,U>+QXX3UZ!9JW 4\:SUA"%2"I-^WTN[N<;3J:D@SL#8O?
0P+U5ST;2AD&TKJF!>K0V?D4)0BKE!3A]# M6%F62,+/4+CPIDHG;*EB'[KTDRQM34I\LS4!'QEH6:PE"I*D:VTD58451F][&F0H&DK6]YHZXS*5NKM
MLG.&6R-^X9\5?3W,^M'2SUQ1518\ T1\%>['88*DU@I!Y%W*HO*DK/H]=S!< MAK2%,)&WU3>B(DN-^X=J_G#KC67?1E+M\KH"@S\CNL".R0)5I"H1
V<3::4M M$EHXZV51:M&O&OCD3Z=]'.HM]"L:\!GLK2\]ADW(?7:W_EXW_]R=E:Y2EH? M>A)XX1 #!Q0I+322!DO!)96^+";UW'8EZJ5=5?[:-0'^&;?
&VA2T7JM?;C7J MU997H\1[G.6P@)$J[1X_T_'N16B?9G#(R9NB0BQ4/4@C.+(*2TZ-*@L:^W+2 M 7$BW%7=#'U>+]?SY8U;FOM-
9EHIYYGP%4S,P#PM=4@3$>Z/.^&X%;(L8Z>W M]@J3_(Y@%&WHN' : ?O$KT1A^C\>";*,H[4.B;"N:G(O^;K[U=NT7+29MCJ#X#5
M^OZAG:H\A\5*]XQ$! 4XI$X1 MV4BL:.??Y\Y#!&GN0BG^A??@[#?:\W1?^8*;RB!=6+E]Z5-; DZ_IYXX =:Z MU^66(TIU0(2,%"@FY75_#.(M\["]9YK^,?
M6M/65]2%>STR=-.MC :A:8'* MRE36*:G9;CIH_(7TYP(DOST><4L;CW &ZM$&@.]V+["?A>S#35M@MGIW__1O MMAV[VQD_37MI+Q=J^>P](%]
(CX4PJ/)$AE=&/9*P:!"WH1V7IMB1V/<6IIA' MXM=(AJO5;O5#:HXST/-+U_BZN55+XS8YCZTUUTP0D-L@SB0.S<4$TLY@9#E8 M BNI-#)ZOJE;E,0%IT
M@'W !I!"(\R]+#3RTMA*;Z(K%KLN]:A0:0U9%.I[J--P'E*?[5VZ]3E >?7K MZ=E%+KQ2BF%4:!'^>7:P\ H$],D1H[X71%=VY@;WG\.
[UV/EIPPCFZG@P)M0" MZ^;SS^Y&+3:Q^FH=<6AAQM6SOS?F_KG M_X.A-S8$_O!D.CH^F+PY3\1=9RR>B57A1<9$5*HB3A;(.\L1,](@;6F%"-A(
M5LE"87,H97E<#])G(D?354? +L--P%L06U&"]&408O(*5+\"PT@DXU0)C0O: MKX(CETU@'$%';TI:&7@2G99O,]/!065*H3## E%"U!_KV
R'J(U*XPO*9>& MQ7Z0\;! R9MO31"3Q&,@W7Z\"LD"]RFVGP]$\P45H('1,*=4U;@$DE9@2^D M!"68&X;I9(KT4I3\#D\'DKU/C48@GX$"=>>;9L977!
OD72R1(PQ@C1XSZC@ MJJBPH*(BL=-QW9+D=U 11WTBX)Z!]GSPWIEP-/<(5"B%W(!U!WA=_'#-YDQP
M1]7GFDJ"5%5@V//#LJI:0?!?.%UX8]2@L:^"])V=,_METPH;Y M0WLCS"2]?'@QA1:>4^XK(6-?7A\F:7YA1!QU?0/>.C"UVTUB>1/Z
M$D/XW=S[3;/:U7X]O.A("G5J.]J^%L:=_/5V]QJ/]LW[%OI[9U%F:8,,:+ M(]2)F(9AH<=E!8(>U-@IVW0G5XJ->CS:>\N3:1>TQ.1\;VFMM8UU-\TZ_OK
M1H'W:<*H(^XX'1DQUGVG4P2/=/=ISR=73R^RS4P#&9XG4BW_>E=_!1]]O:NV!K+3>*N4$(N$))$:-1\I#Z**$J%/IBJO7M&=A+?,-')
[2$P]8%$4!HE06PHKF;+*N@+^*]7A MAD-P$SLW]UJ*/"W=6+X/J-4 \#-3GX?Z9$(K<"P],F$P-F7F2 OND##"-UR1 M4+X\H?KD4'0WEM<#:C(Y,S4Y-
EZ>@J&!.!0RG#EN@C';R+<4RNQ1Z5F):@4 M1AH7NQK\F$RYM$5/O,<-XRAULF+/9%X\1S]3E'C-P%TERH3G1QF&-0Q"V]-
"HA\.&>A_;P4BA%,=V^SG*9*![^>UE*]N6K%8R)353M;+D-K@-OZ M+C3L\\]^\[M3S<72S30NM8:E@XI"A$=R,4=58<&Y*$I"N&>>[:'IZG;40G2
MUFV\N0OIW9G'K[\,%.K)"/.,0KHA&3]D 5DQY5VFG#'7@@/:ND1XF1 MMA C(P4(E[;0 M8A)UG)]D#/3OS)AV$I?J/H1/YW=-0'MF/?
>"0(2."UXAY@N+)"L5\N"E8]*P M*WGLUY.[)4E;6#&I5D6 /OTIY8L;7\[8S?";?@#SV_GRYJG-
W/&3RM0DZ8&C7#PLVUZ()+3H+^1SZ^^UCY'EH\CEI$70,F8V@/YG4__)(?KYH2QPY MG9F^Y?%I]^@@*!F0-4EWW[B<_P]O0+Q/8Z9D)@/%^W#
[8U'?.]<^EG3Q(\SM MJ"D?U#)B[W?^QW4%WJ=1Z'.0!U:VSUOGJ+U,.T[/VB%(Y&1P(OEJ\CDP\EMXO/2] M6KN/:MZT[Y:.IZ9CS%X<97 .N1^.Q&2]7-
GW__ACW:K2^??ES:499_;.#-V+ MNK1'D_W R;4,YT/3GA=,5(+S>O0HY3='A(Y0>A,:?/UTS?V%?_6M5\HP2.]] M?6#$DMV.^O"9\?
Y8CT$2V(C>^56@%T;#X4]8'22OFN\9'P= MQ+WN!<+_ZN.32;R3OJ3\?7#R]\')2=Q\]9=?7!V#E)TK M#H:\G2];S()C;;!O!HXF5$;ZAGT@2FUR;NY66\G-
3K;]*H9 6@0]GJAB(Q M/P\"+=7B?C5?Q:EMVCMHLF+0D;[W7G@2L_=U_<=E8RZ:ZU7S8;6>WZK-T5*\ M*OE>"TA6*3J4U5-

@2\SPQ=T:;#SLX\N;B*9T_ZC)2D>'NE>YAIC /1/4,FJR@=RN)A:/+B[?V= MNZZW/75AGDM?-Z9UK<<:VU.^D^RP.Q+#?4#,D/9O\WK1PGSA_Z.^=>?A
G-S M_UG].07W!S^6[N \I@;TP3-#-8 9__M.+>9^;K;27ZM?VU?(1A=+#/I@NJ/Z MF.K0%]>\5
+,V$(MMP)_NOT1&B'#!#9=_^/X;L.^F*XV()2G(9L/A%83!?O MP+#I"@@B!&%Y^GH= D:.HW>'[45B5KFNXQAE="I0NQ7$A5>N??_I\30PBE$^
MX3.]2,X]74ZAKE6 5W^G*H"Z.7(4:I_#@@;H?+G4MU_6UVZ!J*MV] J,W;A M3Y_Q1ZQK &=\K<_C(,D.7$]@X?F*W)U]Z@.A7\[C2D>X1 MT]&TBW?=
<_*I$\F+Q:YX"IB&3_P.F]KPY249^&2V+]+ET=@:>G45+6E!S' MNCXP\?1%/B#2ERAT[(Z5[B[TB:3L->'O6L6WW&G^KD_\NS[Q-&[L?U[7;3P^
M=GF\'"E9&=6AU=$YV=0$+!:/8L59&KO#I=O6.^&N^\P]-2DW-^OVUM)RM?RF M8/%^O;N]W>2M5NOEM5Y\K)NS'PN]^+V)P=G)7TOIJ>UCK(X
7P:T!YEABJNO M/\WY:AV)W"> M!G"U!Y#46;I_K^_/ FSL*H@8@:JN\=)U6.YE]@Y D LY$[LCIWPG71[O $U= M;/YE?)
7$_OPRRQNP(.Z^M&L[>LIQ%ZA_3Z7[I+FB9R?C&!BZG]O/BSMQ]#N MXL(_3N*W9AD$/__9V-^;<)9NES=G2_O/Y<_5VD90@,$?S6/IG\9O'0_LQ+H2
MPJM/RZW\NY+NS@>8X,W[=:>^PSS@UX]J M'T%-3O!:,J'[N+#MW,[KI5V]:^ /L30GD@C)+I;&T:.X1"36]Q<_K5U= M-!?K[\T'D'!U:2^6C[/YL@X__W-
UY1CI:NV&%=^F=NUD_/Z MJULXLW9VJT.C;YQTCYCN_'\87P=Q25U>!J+8QUJL"^_G!L;]N(RSUHZ/GLX$ M#N.R-UZL;9SS6]-???
CTVIU%Y'10^,F\WV'VM'C&*6VJ-]#[W[[*&@L%@^- MF\SC'&I=CV.4?"W6U_5:+6)'('21LH\9(IG'?E,G:G PD[@@VJ=W.AX+^LY\WT6SC
MWD'3=2@9ZF4>@2W+9/N+V?>Q#&P6QCL7OBI]+U"1E(]S H4X>- M.V:FVZK=1-K'W[[7"T#Y:ATKDCSM4^E:C S.W0V!,CO^O[CUIZ6I;R/ET'M]
M(%VGD6A<[X696PF9,^0O:H5>;_P?C')_#8V+V8S"F5U1.LA)0^ MO$_^Z+A_KE>'ZK6&/_/_).:2P#H(3W)O9\?S'KO\.@?L15=.":A#L*3N
M4!L+KYP21@=-R2'%'^55L^<#]2(HIRQ/%PS)G9!Z=*GDPQB] M^,@I![,S^3S*O$?3<6]]:I%3FB3#,M5Z^1LX+EO!WKN5:>;M,4RD.M7CP_J M?
7FR:4+=='A582<#,/(I@@.?B?(N0=]I1'BDX-6G7]G%P&;_>X<=DX%^'.Y= M>,EF_/,$G0,F[(1[C(L7.><#8*0^*?@4;?1=TIVADG%S$.U.5C*Z77]V6'38
MDCCMC:U_K)W]N% WH^C9-V:R2^ZG\70$DO3I_"DX.S!L MLEOMI]%V')@L#& K5[@$H]8QC."+X9+=:!]B"+N R,@87C>WRW5<6_ALR&1W
MV8>;PM>-Y&4)(Q&V?)1DU]A'V<'L:'L(&)K:>91^$B6<'?$=#?AUC#/7AD MP=6'?S_F34RJ=@9,=R]]"%/=:&1!U/N[C6 1*'H<*MTM\R'D['"*0!2U?
G;EK MYNNY6YW=W)S]5//%Z/L-!\9-=T]\"&$'L?EK' =?UHNY@0E<-K69\#CXQ6/XWHQ\'//_5*1R*<"W>//^K09#N\?3YTK-C[^.B9'!T?Y.WE24M/O)(?
MAG7)^:5>;T6-D^_O_Y5,TO\C>3Z W_06??N+\!^M5N[__Y__!E!+ P04 M" #:B4I:&JF[H0<("R*0 & '!E=',M,C R-#$R,S%X97AX,S$Q+FAT
M;>U;:7,:.1+^?K]"9]I=EDRK #!B_8,=5A)!:JO9LGTUN=S]=:48]H//:%;2 M@+E??]W2#&"#-VR<2XAO4Q7.C%]MEOK1T\^(.9_8-+DXGP
7%W\Y_VN]SMZK MJ]$@ALRS2P"T(5AB9C=G/ LP=]]=+]]I*YU].)Y:UFJT.^UGI.SGEOMU*F\!% MY>?\P%^?'[A!SD,EYA?G0DZ9%&_W9 RB
[Q]VA01')X=W)[-I+"3;M!L_FW/V5VLQ.K,JQ^]HR<*]K?.&CK.NF]^>=U691RI1NKO?=/_J*4>\U0F M\^X/(YF"89@9>P-C?P/^$'X0K#_I_'OSQQN#
[@YO1\..PWQL-KR[9U0=V?3.\[_^O M>S^QP2^#_L?1\)\#O(T6@YOO;G+7'V]N/_8N1VQTQ6X'?3?%=K-%TQS].&"W MO9MWO?
T0MK6:S]3DS_7=AK(SGWPB$PQ][Y9G0G/W:8'V>-MYLK46 2:0F)VPNVK_<[)V=;SRKD02"7U!&+;;1UOG*F_)3.!*>[6R>@;S3UH M5//Z^J,_7*G@M-
&A91BR"9\"TS"5,$->MA-I\"I7VC*5L0]*IRQHUQ_!8J6Q M$=AO!=>X3QC@:@KV'B)(0]"O]H.CYED[J!%S'S(5LVNP?T>#P7VNP6"&AUG4
MP,R>OM#,MG8NL^^XP?7''#9S=I>I60)B#+4'"18*0\@45F4<@P*#P2$35^]Q##*(L;ZCF89=L=(!)M-I'1A)F"/I;]9Z"A=$(32*5)4 B0
MIIA).\$)FAPB%R#YS3$T)7":4^PF6#A?7887C,KV]X-*8+',..\$H66>:PA) M-,=FO=(N,V0C!)Q$/S*+DH*H"+&TDM0:XE#]9,Z(?@C%A.XD6<*T1(AY-#3N
M!"')<8TLB@0-$)L*>2&,RZ>B)L)BQ,U,Q5P-8REL9KC0)QN^K@QRMH*_DP5 MS%JT+QB"ASL'P=&#?
+W;/VD%QV>F!%DI1(A(5!Q+O/0I'S*NP8$&02##!%Q! M!$1JF$@S(7LR2Y%%B4GI6D@3)(U@$(/H\(@;W MT81G8V-]I*Z;
(D&+H,WK0>5(O@*K0J,#Y+"I-(X9T0HRYX?T^I)35WE90\(=-M],H2O(1/K>1L:I3(KQB+48D4[ES %*&10G(M:0+2"P57*3+R5!@]WFZK&E?I M'8\J
QB01=ZF3CD*5!D5"2?ZQVFY()8B 'MX2;&JA/!;"&2(#(W]03R#D7<= MVN'.0/NT<72\CNRM66T-X-OSX=8XQ[TQE8+@RXW*.!$_-PA]4JB$::Y%A2]$
MO.2A3*2=DRS8-"SM-@=%AS*_41Z8KBA<5U_NRPGEA<;G9,P"R9@H4EJX)S6 M'4.&ZB1!L&,+Y+2+R 1UO M O):!KV0C&/T"G) -4%!6:T+!2
M)^.6]&7B=!1=:T^HDN,(:B>Z1=1DX/HR'.Z.@QKSUZB9T.T^.3;TL=E>-\UE/
M>>XT5%3;IK:D,F+65>@N6:WBQ#^@6]8T\2(^CKK8]C(B0!T5*6^<6#U0SX'=5M+P!=Y7;2U1W$5F=3E/KM*=L_M__E#C0T4R 5V-+!@P"?Q6@I>
[(*@0UU:\^*!COQ-D2)D<)7<9,K*L_$4[X4+ M@]U[XNIA_8\U#)MM]UVSAM/MWZV5Z/&ZUV^XN[#3J-(-C.[8%;7[_& MF$:3\^SM7GNOZE#"O-MD@8-
!Y6]A>K1FVLKOR7B5.6B3/$ZZS_?7IPZ7Q0\0 MZH)^1PN:[K?5SF(G/)[?)Y:B7+[*IA]DX_?.EUK2)TVWB^ZS(UDW_1Z2^V[N M!!?;(JOV) MA)@-
[B$JZ%2,7?GG0"=5KS6J:^%>,WS&DAXX4;%!LZR^8XAY^MPR0!NZS>777B('%#8]2Z?>%&Q_/3O3!ZX=S7_"U!+ P04 " #:B4I: M>/H,[/X' "F*0 &
'!E=',M,C R-#$R,S%X97AX,S$R+FAT;>U;:7,:.1+^?K]"9]I=EI0HP :\@OV*5L7T!&7I$/+,S]0@&^LRSYVBUI;8&T5+RLJ=9NSL!&"%Q3NDU%+!7]"\Q
Z_7V86.BQ0RQV(#_MW(%@A979+?M@+UC]7H=:[SF9&W8&\=:S5:'_:3-G9SPT.ZD4W!6^3G="]>G M>WZ0TY$6L[-3(2=,BG<[\B!I0?)8;O5/A/+
[^R+AR?$Q3T0[:A^U>7QT\$NT M@UW1//2Q;J;@W4XJL_H8:/SN?B=W)U,IW+@;-9O_V/%V9Z>)SAP.9K!S^!I\ MK'KBYA:=.9UC=_3DX-
[5N9*W6=?/;R>XJLQCK;3I[C;]OQ-JJ2<\E6K6?3V4 M*5AV!5-VHU.>O:Y9GMFZ!2.38&CE_R_XB^G9?SH1\D.JOE$+9I$_WXL1]*Q
M=M1H/9S!9K"N/)@_O#@#]<&?]Z_&0XN!^>]X>#ZBEU?L@\W@ZOSP8?>#^QR M<-7#K_CM^A(M^C??W>0^_'CS\U9-K]G'_KF?
8KO9HFD._]EG'WLW[WM7 M_8_UZ__\T/^Z9J]Y7D-1:#H7"8 M&W/W:K=S=++QG'(N!-)(74'BN]W#M;,,MV0F,+W=.AE]HWE'C6I>7W_TARL5 M'3X0!
MKJ9@%Q]#.@+S:CB_Q0,E$YH_JFT"D'Z8FI=&.:=(+3(;8;);:989L MA("3Z$=FL2]BA!+2TFM(0ZE43-&]$,H)G0KM8!IB1#[:&C<"4*2XQI9% H-M$)L:
>2'LSZ>F-LQ2Y2>V@]X!FZE=8;C0)QNAK@QRMH2_FP5S$]T+QB"^UL' MP>&#?+W;/6I%AR>V!%DI1(A(=))(O PI'S!NP(,&Q2!'"GQ!!$3]2$D[)GLR
M2Y%%B4GI6D@;*VT+[$?\:K0*KG*C8Q!XV[(W"!8!B+Z B/Y]/.;9+; >4M=- MH= B:O-ZU'D#;WW7]"/"5;B4I%:S@%KRSXC?EL_]"O\R MQ-&"9,,SE-
IA:P/81D??#+;\[=; MMEH[=,Z7(#%E<($^EKX:735]$S'O+"; M=Z%Z.0)$2CE2J,"Z,.@ .6PBK6=&M(+,^R&]ON#495XVH+B'7EF"%_"IE9Q-
MC1+Y%6.Q6DGASP1L,;)22&XD34 #K> K14:>"DO%VV]5ZRN]YU%M 0-RR-O4 M*4>!*N-"-;)_G)8/8B$"L$>0%,M*"+^-@ R1H;$_B&[0UT#YN'!RN
M(GMC5EL!^.9\N#'.<6],I"#XF2PK7UY?]9(\2\8TO'60'K.UOT)5X6G-$HX) F*33G!5-DUHG$N0C:@ MZ'"Y7D=Z"&-'I%
<;U.I(%^[I"#8I(GQN#23%DT_4+%1)?+]KH2P$AB/1R_-M\#)1*+8&A7-B#?E=Q0D]Z)<2T+>L!>/OH%.2-3J."T-H6*]Y:[RFVC]\3T>M
MZ,O&Z*@Z4WKS1)<$88U$]\BZ#!P?QL"?4=#Q15;.XWH;HAIS.QW92_1,Z+UYRFL^ZRG/GX:*;MO4%E1&
MS+H,W06K59SX.W3+BB:>Q\=1%SM=AD,V_@:Z3%/I',!OU([W&L4(M5](C-$[M>8,@1Z]V5-KP+ZGS:F?"KX7$*?A=6&2Q/]QX^]
<#W=>4"#V%@@_72B("Z;&: M'M'C!+\$YB9$ZREP.^H;@4"%;6; 8UF>#O &?POJ'+YH9OVG-BM:U]W&AW]I]L M;C:B)]M^TVWCN/ETZV=
[/6RTVNTO[C;J-*)H,[=[?GW#&F,:;!I6_N>G!BFDKOR?C9>:@3?(XZ2'?7Y\Z?!8O860*^ATM:OK?5COS MG?!X?I]8BG+Y*IM]D$[8,U]]29\TW2RZSXYDU?
1[2.[[F1=<;(.8:ZM_YFY&WXGF<#*FX:+G>^W?'/1A8]P[Q=N MM&CD&?\G)1TS77"#BH]G>WRN;-MC'1"01<'"\EA,V7>9$41B17=?9"?T_W1]*
(GLIH_0B8?NUE&?6C!7V@T8SU^T+3O4L M.24?&_66G$/%XL M_4<]"<]8%8_K%4$,+F<\Y!I\SW9O1[">]Q%FGLEO[OS.O<[W!]/)T>%1KSLY
M&A[#R>EH?-H]GL!D"*\N%'<73NVQW;-A/.B9<%R_Z=1?7R#=,73[PY/)H/^Z M :E@V'-;,#R$R:\#&'='[K'@[$U_..WP2?H]B8%Q7,
<[S'1_357FL>+%UKW M1W48DXQ* I]LZ)$T%ZH.^ *0,!+A(H/^YB#AI Z,1#.
(F"R4XOYC)2S6@=^Z%ZOR%42@0,R/$\2180B31/.!]]X'JVK('/2ZT#^"XC&8DFS+H1J;LW#V_@=6]@*2F9A#IO791 MO?]3M+W_)-H\PP6<$@-
AA%H(2E)\"]>E4(>8<(G%D$NF"MCK!9TD":<>D,2 M+ J58QVHNA&+>4:R]'B/&BDWNHNNA%SSI*P:D3-IC*K5A6^O6P"(I"9APBIR
M*"1ETL*4)B17+*A^M"E7>4(6 -<],8HQ0>ZDL%%]+-"CFPO.B/T8D65:0]9R2 M?#TRVDXY-F]<%36M+"_)MB%M;[I*_=LO]EXD.S8[H.T?
U5K[SD/4Q^M=[0G]ZQ?"_M+(/YA<7O*>3BJ98=;]BR,"Y1(.(7" MQ_9K"KDLZ7<;C9VV,M\K@^P:V?@F)?3TSO$2^7S+WE.RUYMQ%N. BL.JYN<,
MAG',\;!DAI83G%HX-7]-/2FES]IQ7X3UAV[.\&-WYYO_)KSUEJ_)Y5OFGM:5 M#Z\.DS>[\D0RHN:2R2>E=-NE7D"U<.R^_R]F/;W+K\ U!+ 0(4 Q0 (-
J)2EK:2/O<>OD M %U.#0 1 " 0 !P971S+3(P,C0Q,C,Q,T%FAT;5!+ 0(4 M Q0 (-J)2EIL;-.#5PT 'R, 1 " :GY !P971S M+3(P,C0Q,C,Q,T+GAS9%!+ 0(4 Q0 (-
J)2EI_S'RKVQ4 ++(5 M " 2\' 0!P971S+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4 M" #:B4I: CBWK"T_#LQ@(%0 @ $]'0$ <&5T&UL4$L! A0#% @
VHE*6E_OO&);Q0 S]H' !4 M (!G5P!'!E=',M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0 (M -J)2EH0LW#$8&\ '9-!0 5 " 2LB @!P971S+3(P,C0Q
M,C,Q7W!R92YX;6Q02P$"% ,4 " #:B4I:&JF[H0<("R*0 & M @ &^D0(<&5T'@S,3$N:'1M4$L! A0#% M @ VHE*6GCZ#NS^!P IBD !@ (!^YD"
'!E=',M,C R M-#$R,S%X97AX,S$R+FAT;5!+ 0(4 Q0 (-J)2EK4!*YDCP0 'P9 8 M " 2^B @!P971S+3(P,C0Q,C,Q>&5X>#,R,2YH=&U02P4& 2 D "0!<@
]*8" end XML 59 pets-20241231_htm.xml IDEA: XBRL DOCUMENT 0001040130 2024-04-012024-12-31 0001040130 us-gaap:CommonStockMember 2024-04-012024-12-31 0001040130 us-gaap:PreferredStockMember 2024-04-012024-12-31 0001040130 2025-02-10 0001040130 2024-12-31 0001040130 2024-03-31 0001040130 2024-10-012024-12-31 0001040130 2023-10-012023-12-31 0001040130 2023-04-012023-12-31 0001040130 2023-03-31 0001040130 2023-12-31 0001040130 srt:MinimumMember 2024-04-012024-12-31 0001040130 srt:MaximumMember 2024-04-012024-12-31 0001040130 pets:MembershipCustomersMember 2024-12-31 0001040130 pets:MembershipCustomersMember 2024-10-012024-12-31 0001040130 pets:MembershipCustomersMember 2024-04-012024-12-31 0001040130 pets:MembershipCustomersMember 2024-03-31 0001040130 pets:MembershipCustomersMember 2024-04-012024-06-30 0001040130 pets:MembershipCustomersMember 2024-06-30 0001040130 pets:MembershipCustomersMember 2024-07-012024-09-30 0001040130 pets:MembershipCustomersMember 2024-09-30 0001040130 pets:MembershipCustomersMemberpets:PartnerProgramMember 2024-10-012024-12-31 0001040130 pets:MembershipCustomersMemberpets:PartnerProgramMember 2024-04-012024-12-31 0001040130 pets:MembershipCustomersMemberpets:PartnerProgramMember 2023-10-012023-12-31 0001040130 pets:MembershipCustomersMemberpets:PartnerProgramMember 2023-04-012023-12-31 0001040130 pets:ReorderMember 2024-10-012024-12-31 0001040130 pets:ReorderMember 2023-10-012023-12-31 0001040130 pets:NewOrderMember 2024-10-012024-12-31 0001040130 pets:NewOrderMember 2023-10-012023-12-31 0001040130 pets:MembershipFeesMember 2024-10-012024-12-31 0001040130 pets:MembershipFeesMember 2023-10-012023-12-31 0001040130 pets:ReorderMember 2024-04-012024-12-31 0001040130 pets:ReorderMember 2023-04-012023-12-31 0001040130 pets:NewOrderMember 2024-04-012024-12-31 0001040130 pets:NewOrderMember 2023-04-012023-12-31 0001040130 pets:MembershipFeesMember 2024-04-012024-12-31 0001040130 pets:MembershipFeesMember 2023-04-012023-12-31 0001040130 pets:ReorderMembersrt:ScenarioPreviouslyReportedMember 2023-10-012023-12-31 0001040130 pets:NewOrderMembersrt:ScenarioPreviouslyReportedMember 2023-10-012023-12-31 0001040130 pets:ReorderMembersrt:ScenarioPreviouslyReportedMember 2023-04-012023-12-31 0001040130 pets:NewOrderMembersrt:ScenarioPreviouslyReportedMember 2023-04-012023-12-31 0001040130 pets:SharesIssuableUponVestingOfRestrictedStockMember 2024-10-012024-12-31 0001040130 pets:SharesIssuableUponVestingOfRestrictedStockMember 2023-10-012023-12-31 0001040130 us-gaap:ConvertiblePreferredStockMember 2024-10-012024-12-31 0001040130 us-gaap:ConvertiblePreferredStockMember 2023-10-012023-12-31 0001040130 pets:SharesIssuableUponVestingOfRestrictedStockMember 2024-04-012024-12-31 0001040130 pets:SharesIssuableUponVestingOfRestrictedStockMember 2023-04-012023-12-31 0001040130 us-gaap:ConvertiblePreferredStockMember 2024-04-012024-12-31 0001040130 us-gaap:ConvertiblePreferredStockMember 2023-04-012023-12-31 0001040130 us-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember 2024-04-012024-12-31 0001040130 us-gaap:PerformanceSharesMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember 2024-04-

~~012024-12-31 0001040130 pets:EmployeeAndDirectorEquityCompensationPlanMember 2024-10-012024-12-31 0001040130 pets:EmployeeAndDirectorEquityCompensationPlanMember 2023-10-012023-12-31 0001040130 pets:EmployeeAndDirectorEquityCompensationPlanMember 2024-04-012024-12-31 0001040130 pets:EmployeeAndDirectorEquityCompensationPlanMember 2023-04-012023-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMemberpets:A2024OmnibusPlanMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMemberpets:A2024InducementPlanMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember 2024-04-012024-12-31 0001040130 srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-012021-08-31 0001040130 srt:ChiefExecutiveOfficerMemberpets:PerformanceRestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-012021-08-31 0001040130 srt:ChiefExecutiveOfficerMemberpets:PerformanceRestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2024-04-012024-04-30 0001040130 srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2024-04-012024-04-30 0001040130 srt:ChiefExecutiveOfficerMemberus-gaap:PerformanceSharesMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2024-04-012024-04-30 0001040130 srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:The2022EmployeeEquityCompensationRestrictedStockPlanMember 2024-04-292024-04-29 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockMemberpets:IncentivePlan2024Member 2024-04-292024-04-29 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2022-08-012022-08-31 0001040130 pets:FormerChiefFinancialOfficerMemberpets:PerformanceRestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlan 2022-08-012022-08-31 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMember 2023-06-012023-06-30 0001040130 pets:FormerChiefFinancialOfficerMemberpets:FiscalYear2023Memberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMember 2023-06-012023-06-30 0001040130 pets:FormerChiefFinancialOfficerMemberpets:FiscalYear2024Memberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMember 2023-06-012023-06-30 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:PerformanceSharesMemberpets:A2022EmployeePlanMember 2023-06-012023-06-30 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember 2024-05-162024-05-16 0001040130 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-06-302024-06-30 0001040130 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-08-312024-08-31 0001040130 srt:ScenarioForecastMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2025-08-312025-08-31 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0001040130 pets:A2024OmnibusIncentivePlanMember 2024-08-08 0001040130 pets:A2024InducementIncentivePlanMember 2024-09-27 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:IncentivePlan2024Member 2024-09-272024-09-27 0001040130 srt:MinimumMemberus-gaap:RestrictedStockMember 2024-04-012024-12-31 0001040130 srt:MaximumMemberus-gaap:RestrictedStockMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember 2024-03-31 0001040130 us-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2024-03-31 0001040130 us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember 2024-03-31 0001040130 us-gaap:RestrictedStockMember 2024-03-31 0001040130 us-gaap:RestrictedStockMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember 2024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember 2024-12-31 0001040130 us-gaap:RestrictedStockMember 2024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember 2024-12-31 0001040130 us-gaap:RestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember 2023-12-31 0001040130 us-gaap:RestrictedStockMember 2024-10-012024-12-31 0001040130 us-gaap:RestrictedStockMember 2023-10-012023-12-31 0001040130 us-gaap:RestrictedStockMember 2023-04-012023-12-31 0001040130 srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-12-31 0001040130 srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001040130 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMember 2024-10-012024-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMember 2023-10-012023-12-31 0001040130 us-gaap:RestrictedStockUnitsRSUMember 2023-04-012023-12-31 0001040130 us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-012024-12-31 0001040130 us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-012024-12-31 0001040130 us-gaap:PerformanceSharesMember 2024-03-31 0001040130 us-gaap:PerformanceSharesMember 2024-04-012024-12-31 0001040130 us-gaap:PerformanceSharesMember 2024-12-31 0001040130 us-gaap:PerformanceSharesMember 2023-04-012023-12-31 0001040130 us-gaap:PerformanceSharesMember 2024-10-012024-12-31 0001040130 us-gaap:PerformanceSharesMember 2023-10-012023-12-31 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-06-012023-06-30 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-06-012023-06-30 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-06-012023-06-30 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-292024-04-29 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-04-292024-04-29 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-04-292024-04-29 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-08-012022-08-31 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-08-012022-08-31 0001040130 pets:FormerChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2022-08-012022-08-31 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:IncentivePlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-09-272024-09-27 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:IncentivePlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-09-272024-09-27 0001040130 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberpets:IncentivePlan2024Memberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-09-272024-09-27 0001040130 pets:TollFreeTelephoneNumberMember 2024-12-31 0001040130 us-gaap:InternetDomainNamesMember 2024-12-31 0001040130 us-gaap:TradeNamesMember 2024-12-31 0001040130 us-gaap:CustomerRelationshipsMember 2024-12-31 0001040130 us-gaap:CustomerRelationshipsMember 2024-04-012024-12-31 0001040130 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001040130 us-gaap:DevelopedTechnologyRightsMember 2024-04-012024-12-31 0001040130 pets:PartnershipAgreementWithVetsterMember 2024-12-31 0001040130 pets:TollFreeTelephoneNumberMember 2024-03-31 0001040130 us-gaap:InternetDomainNamesMember 2024-03-31 0001040130 us-gaap:TradeNamesMember 2024-03-31 0001040130 us-gaap:CustomerRelationshipsMember 2024-03-31 0001040130 us-gaap:CustomerRelationshipsMember 2023-04-012024-03-31 0001040130 us-gaap:DevelopedTechnologyRightsMember 2024-03-31 0001040130 us-gaap:DevelopedTechnologyRightsMember 2023-04-012024-03-31 0001040130 pets:PartnershipAgreementWithVetsterMember 2024-03-31 0001040130 2022-04-192022-04-19 0001040130 pets:VetsterIncMember 2022-04-19 0001040130 2023-10-032023-10-03 0001040130 2023-10-03 0001040130 pets:VetsterIncMember 2023-10-03 0001040130 us-gaap:CommonStockMember 2024-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001040130 us-gaap:RetainedEarningsMember 2024-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001040130 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001040130 us-gaap:CommonStockMember 2024-06-30 0001040130 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001040130 us-gaap:RetainedEarningsMember 2024-06-30 0001040130 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001040130 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001040130 us-gaap:CommonStockMember 2024-09-30 0001040130 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001040130 us-gaap:RetainedEarningsMember 2024-09-30 0001040130 us-gaap:AdditionalPaidInCapitalMember 2024-10-012024-12-31 0001040130 us-gaap:RetainedEarningsMember 2024-10-012024-12-31 0001040130 us-gaap:CommonStockMember 2024-12-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001040130 us-gaap:RetainedEarningsMember 2024-12-31 0001040130 us-gaap:CommonStockMember 2023-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001040130 us-gaap:RetainedEarningsMember 2023-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001040130 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001040130~~

us-gaap:CommonStockMember 2023-06-30 0001040130 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001040130 us-
gaap:RetainedEarningsMember 2023-06-30 0001040130 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001040130 us-
gaap:RetainedEarningsMember 2023-07-012023-09-30 0001040130 us-gaap:CommonStockMember 2023-09-30 0001040130 us-
gaap:AdditionalPaidInCapitalMember 2023-09-30 0001040130 us-gaap:RetainedEarningsMember 2023-09-30 0001040130 us-
gaap:AdditionalPaidInCapitalMember 2023-10-012023-12-31 0001040130 us-gaap:RetainedEarningsMember 2023-10-012023-12-31 0001040130
us-gaap:CommonStockMember 2023-12-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001040130 us-
gaap:RetainedEarningsMember 2023-12-31 0001040130 2024-12-02 0001040130 us-gaap:SeriesAPreferredStockMember 2024-12-03 0001040130
us-gaap:SeriesAPreferredStockMember 2024-12-03 0001040130 srt:ChiefExecutiveOfficerMemberus-gaap:PerformanceSharesMember 2024-04-
012024-12-31 0001040130 pets:PetCareRxIncMember 2023-04-03 0001040130 pets:PetCareRxIncMember 2023-04-03 0001040130 2024-09-
292024-09-29 0001040130 us-gaap:RelatedPartyMember 2024-12-31 shares iso4217:USD iso4217:USD shares pets:reportingUnit pets:warehouse
pets:performanceObligation pets:model pure0001040130--03-
312025Q3falseP2DP3DP3YP3YP3YP3YP1YP1Y0.33330.33330.33330.33330.33330.33330.33330.33330.33330.33330.33330.333310-Qtrue2024-12-
31false000-28827PETMED EXPRESS, INC.FL65-0680967420 South Congress AvenueDelray BeachFL33445561526-4444Common Stock, par value
$.001 per sharePETSNASDAQPreferred Stock Purchase RightstrueNASDAQYesYesAccelerated
Filerfalsefalsefalse2065645750101000552960008800027300022590003283000117950002855600038880006325000340000188000683830009364860
0.0010.0015100000500000025002500250025004490009000 0.0010.00140000000400000002065645720656457211486922114869221000210001796
450000-3074000449000 0-4327000280001360003080004810001800002930005970001053000208000429000905000 1534000-242000-
26450005395000-2793000465000-61800022000-345000-707000-20270005373000-2448000-0.03-0.100.26-0.12-0.03-0.100.26-
0.12206346512042528220581913203802622063465120425282209872602038026200000.605373000-24480004965000 5161000-71790005196000-
231000-43600032400053000-700000119000-167610001243800015 2000-65000-24370002664000-355000-594000-260780007929000-529000-
19420002756000-1258000-349000-577000-144700075000-2294000-28080000300000035859000272500032600 00-2725000-
39419000176000 12419000-176000-12419000-5195000-
5464600055296000104086000501010004944000047400043000320001498000253900 00Summary of Significant Accounting Policies<div
style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:120%">Organization</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">PetMed Express, Inc. and
subsidiaries, d/b/a PetMeds® and PetCareRx, Inc. d/b/a PetCareRx® (collectively, the “Company”), is a leading nationwide direct-to-consumer pet
pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and
horses. The Company markets and sells directly to consumers through its websites, customer contact center, and mobile application. The Company
offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and
valued customer service.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founded in 1996, the Company’s executive headquarters
offices are currently located in Delray Beach, Florida. The Company’s fiscal year end is March 31, and references herein to fiscal 2025 or fiscal
2024 refer to the Company's fiscal years ending March 31, 2025 and 2024, respectively.</div><div style="margin-top:10pt;text-
align:justify">Basis of
Presentation and Consolidation</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all of the information and
footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements. In the opinion of
management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring
accruals, necessary to present fairly the financial position of the Company at December 31, 2024, the Statements of Operations for the three and
nine months ended December 31, 2024 and 2023, and Cash Flows for the nine months ended December 31, 2024 and 2023. The results of
operations for the three and nine months ended December 31, 2024 are not necessarily indicative of the operating results expected for the fiscal
year ending March 31, 2025. These financial statements should be read in conjunction with the audited financial statements and notes thereto
contained in our 2024 Form 10-K. The unaudited condensed consolidated financial statements include the accounts of PetMed Express, Inc. and its
direct and indirect wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation. </div><div
style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:120%">Use of Estimates </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The preparation of unaudited
condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from
those estimates. </div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments </div><div style="margin-top:10pt;text-
align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair
value due to the short-term nature of these instruments. </div><div style="margin-top:10pt;text-align:justify">Deferred Revenue</div>
<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Deferred revenue is recorded when payments are received or due in advance of performing our
service obligations and revenue is recognized over the service period. Deferred revenue represents prepayments of PetPlus memberships with
PetCareRx, Inc. (“PetCareRx”). The total deferred revenue as of December 31, 2024 and March 31, 2024 for these memberships was $1.2 million and $2.6 million, respectively. Memberships provide discounted pricing,
free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The membership fee is an annual charge
and automatically renews one year from the initial enrollment date. The Company generally recognizes the revenue ratably over the term of the
membership.</div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:700;line-height:120%">Long-lived Assets</div><div style="margin-top:10pt;text-align:justify">Long-lived assets are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is
measured by a comparison of the carrying amount of the asset </div><div style="margin-top:10pt;text-align:justify">to the undiscounted cash flows
expected to be generated from the asset. Management determined that no impairment of long-lived assets existed as of December 31, 2024.
</div><div>
</div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</div><div style="margin-
top:13pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business
combination. The Company is required to assess goodwill and other indefinite-lived intangible assets for impairment annually, or more frequently
if circumstances indicate impairment may have occurred. Goodwill <span style="background-color:#ffffff;color:#222222;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was evaluated for impairment using a qualitative
assessment and the Company concluded that it was not more likely than not that goodwill was impaired as of December 31, 2024. The Company performs its
annual impairment assessment in the fourth fiscal quarter of each year. The Company has concluded that it has one reporting unit and has
assigned the entire balance of goodwill to this reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, an
impairment loss is recognized in an amount equal to that excess.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">
<span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:107%">The Company’s other indefinite-lived intangible assets are primarily made up of a trade name which was evaluated for impairment
using a qualitative assessment and the Company concluded that it was not more likely than not that the other indefinite-lived assets were impaired
as of December 31, 2024.</div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </div><div
style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">The Company does not believe that any recently issued, but not yet effective, accounting standards, if
currently adopted, would have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.
</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Update 2023-07,
"Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". This Update applies to all public entities that are required to
report segment information in accordance with Topic 280. The amendments in this Update revise reportable segment disclosure requirements,
primarily through enhanced disclosures about significant segment expenses. The amendments in this Update do not change how a public entity
identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable
segments. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after

December 15, 2024. Early adoption is permitted. The Update should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this Update.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In December 2023, the FASB issued Update 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This Update applies to all entities that are subject to Topic 740. The amendments in this Update revise income tax disclosures primarily related to the rate reconciliation and income taxes paid information as well as the effectiveness of certain other income tax disclosures. The Update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Update should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the impact of adopting this Update.</div>The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at December 31, 2024, the Statements of Operations for the three and nine months ended December 31, 2024 and 2023, and Cash Flows for the nine months ended December 31, 2024 and 2023. The results of operations for the three and nine months ended December 31, 2024 are not necessarily indicative of the operating results expected for the fiscal year ending March 31, 2025. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in our 2024 Form 10-K. The unaudited condensed consolidated financial statements include the accounts of PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.<div style="margin-top:10pt;text-align:justify;text-indent:18pt">Deferred revenue is recorded when payments are received or due in advance of performing our service obligations and revenue is recognized over the service period. Deferred revenue represents prepayments of PetPlus memberships with PetCareRx, Inc. (“PetCareRx”). The total deferred revenue as of December 31, 2024 and March 31, 2024 for these memberships was $1.2 million and $2.6 million, respectively. Memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The membership fee is an annual charge and automatically renews one year from the initial enrollment date. The Company generally recognizes the revenue ratably over the term of the membership.</div>12000002600000<div style="margin-top:10pt;text-align:justify">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset </div>to the undiscounted cash flows expected to be generated from the asset.0<div style="margin-top:13pt;text-align:justify;text-indent:18pt">Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. The Company is required to assess goodwill and other indefinite-lived intangible assets for impairment annually, or more frequently if circumstances indicate impairment may have occurred. Goodwill was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that goodwill was impaired as of December 31, 2024. The Company performs its annual impairment assessment in the fourth fiscal quarter of each year. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.</div>1<div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company’s other indefinite-lived intangible assets are primarily made up of a trade name which was evaluated for impairment using a qualitative assessment and the Company concluded that it was not more likely than not that the other indefinite-lived assets were impaired as of December 31, 2024.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company's consolidated financial position, results of operations, or cash flows. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Update 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". This Update applies to all public entities that are required to report segment information in accordance with Topic 280. The amendments in this Update revise reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in this Update do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Update should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this Update.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In December 2023, the FASB issued Update 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This Update applies to all entities that are subject to Topic 740. The amendments in this Update revise income tax disclosures primarily related to the rate reconciliation and income taxes paid information as well as the effectiveness of certain other income tax disclosures. The Update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Update should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the impact of adopting this Update.</div>Revenue Recognition<div style="margin-top:10pt;text-align:justify;text-indent:18pt">In accordance with ASC Topic 606 ("Revenue from Contracts with Customers"), the Company primarily generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, and supplies, from one of the Company’s two warehouses. Certain pet supplies offered on the Company’s websites are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product. Customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are based on historical patterns, however this is not considered a key judgment. Revenue is recognized when control transfers to the customer at the point in time at which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time when the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Additionally, the Company has external relationships for telehealth veterinary and insurance services. Virtually all the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">Membership fees represent the amounts recognized from two membership models. The first is the PetPlus membership for PetCareRx customers, and the second is a partner membership, which allows employees in-network to join the PetPlus membership program through their employers. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews one year from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally one year. As shown in the following table, under the PetPlus program, the Company recognized $1.0 million and $3.7 million of previously deferred annual membership fees in the three and nine months ended December 31, 2024, and had $1.2 million of deferred revenue as of December 31, 2024.</div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.294%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div>
</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">(amounts in millions)</div></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>
Deferred revenue, March
31, 2024</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">2.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td
colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred memberships fees and others received
</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px
0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">1.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred membership fee revenue and others recognized </div></td>
<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, June 30, 2024</div></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">2.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred memberships fees and others received</div></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Deferred membership fee revenue and others recognized </div></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, September 30, 2024</div></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0
2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">1.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td
colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred memberships fees and others received
</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px
0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred membership fee revenue and others recognized </div></td>
<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, December 31, 2024</div></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid
#000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt
solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">1.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-
top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In addition to annual
membership fees earned under the PetPlus program, the Company also earns membership fees on a month-to-month basis under its PetCareRx
partner membership program. For the three and nine months ended December 31, 2024, membership fees earned under the partner program were
$0.9 million and $2.8 million, respectively. For the three and nine months ended December 31, 2023, membership fees earned under the partner
program were $0.7 million and $2.1 million, respectively. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company has no material
contract asset or liability balances at December 31, 2024 or March 31, 2024, respectively. </div><div style="margin-top:10pt;text-
align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">The Company disaggregates sales in the following categories: reorder sales vs new order sales vs membership fees. The following
table illustrates sales in those categories:</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-
table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.536%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td
style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">Three Months Ended December 31,</td><td colspan="3" style="padding:0 1pt"></td><td
colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:700;line-height:120%">Increase (Decrease)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">Net Sales (in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid
#000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</td><td colspan="3" style="border-top:1pt solid
#000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td
colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-

```
height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px
1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt">
</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% </span></div></td>
</tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt">
</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid
#000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td>
<td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reorder sales</span></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td
style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,076 </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">54,067 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">82.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span>
</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,991)</span></td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New order
sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">6,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Membership fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,833 </span></td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,447 </span></td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(614)</span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid
#000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid
#000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Total net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,984 </span></td><td style="background-color:#cceeff;border-
```

bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">100.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,317 </td><td style="background-color:#cceeff;border-
bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">100.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,333)</td><td style="background-color:#cceeff;border-
bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(18.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">%</td></tr></table></div><div style="margin-top:10pt;text-align:justify"><table style="border-
collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td
style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended December 31,</td><td
colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-
align:center">Increase
(Decrease)</div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Net Sales (in thousands)
</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt
solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">%</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</td><td colspan="3" style="border-top:1pt
solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div
style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">$ </div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-
top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% </div></td></tr><tr style="height:15pt"><td
colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-
top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0
1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td>
<td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Reorder sales</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">149,367 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">82.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom">$
</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174,250 </td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.3 </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom">(24,883)
</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(14.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New order sales</td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
24,913 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
13.8 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</td><td colspan="3" style="background-color:#ffffff;padding:0
1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,054 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
15.4 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</td><td colspan="3" style="background-color:#ffffff;padding:0
1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8,141)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
(24.6)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Membership fees</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,226 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">3.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">7,256 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">3.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1,030)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(14.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr
style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid
#000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid
#000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
Total net sales
</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double
#000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">180,506 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">214,560 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(34,054)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15.9)</td><td
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>
</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">The Company changed the definition of a new order sale on July 1, 2024, to include sales from customers who have not previously ordered from the Company over the past twelve months compared to the prior definition which was thirty-six months. The reorder and new order sales amounts for the three and nine months ended December 31, 2024, and the reorder and new order sales amounts for the three and nine months ended December 31, 2023 reflect this new customer definition change. </div>Under the previous definition of a new customer, reorder and new order sales were $57.7 million and $5.2 million, respectively, for the three months ended December 31, 2023. Under the previous definition of a new customer, reorder and new order sales were $188.1 million and $19.2 million, respectively, for the nine months ended December 31, 2023.212P1YP1YAs shown in the following table, under the PetPlus program, the Company recognized $1.0 million and $3.7 million of previously deferred annual membership fees in the three and nine months ended December 31, 2024, and had $1.2 million of deferred revenue as of December 31, 2024.<div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-
bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.203%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.203%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:18.294%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div>
</div></td>
<td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">(amounts in millions)</div></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-
align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Deferred revenue, March 31, 2024</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td

style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred memberships fees and others received</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred membership fee revenue and others recognized </div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred revenue, June 30, 2024</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred memberships fees and others received</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred membership fee revenue and others recognized </div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred revenue, September 30, 2024</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred memberships fees and others received</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred membership fee revenue and others recognized </div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Deferred revenue, December 31, 2024</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
</div>1000000.0370000012000002600000110000015000002100000700000120000016000005000001000000.01200000900000280000070000002100
following table illustrates sales in those categories:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended December 31,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Increase (Decrease)</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Net Sales (in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">$ </div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">% </div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reorder sales</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">45,076 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">54,067 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(8,991)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16.6)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">New order sales</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,075 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,803 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,728)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31.0)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Membership fees</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,833 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,447 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(614)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net sales</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">52,984 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">65,317 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">100.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,333)</td><td style="background-color:#cceeff;border-
bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(18.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">%</td></tr></table></div><div style="margin-top:10pt;text-align:justify"><table style="border-
collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td
style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended December 31,</td><td
colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-
align:center">Increase
(Decrease)</div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Net Sales (in thousands)
</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt
solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">%</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</td><td colspan="3" style="border-top:1pt
solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">%</td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div
style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">$ </div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-
top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% </div></td></tr><tr style="height:15pt"><td
colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-
top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0
1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td>
<td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Reorder sales</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">149,367 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">82.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom">$
</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174,250 </td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.3 </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom">(24,883)
</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(14.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New order sales</td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
24,913 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
13.8 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</td><td colspan="3" style="background-color:#ffffff;padding:0
1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,054 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
15.4 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</td><td colspan="3" style="background-color:#ffffff;padding:0
1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8,141)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
(24.6)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Membership fees</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,226 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">3.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">7,256 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">3.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1,030)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(14.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr
style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid
#000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid
#000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
Total net sales
</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double
#000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">180,506 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">214,560 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(34,054)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15.9)</td><td
style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>
</div>450760000.851540670000.828-8991000-0.16660750000.11588030000.135-2728000-0.31018330000.03524470000.037-614000-
0.251529840001.000653170001.000-12333000-0.1891493670000.8271742500000.813-24883000-0.143249130000.138330540000.154-8141000-
0.24662260000.03472560000.034-1030000-0.1421805060001.0002145600001.000-34054000-0.15957700000520000018810000019200000Net
(Loss) Income Per Share<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of ASC Topic 260 (“Earnings Per
Share”) basic net
income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares
outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted and performance stock and
the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock and convertible
preferred shares issued by the Company represent the only dilutive effect reflected in the diluted weighted average shares outstanding.
</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the numerators and denominators of the basic and diluted net
(loss) income per share computations for the periods presented (in thousands, except for share and per share amounts):</div><div
style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-
bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td
style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td
style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.630%"></td><td style="width:0.1%"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">Three Months Ended December 31,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px
1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:120%">Nine Months Ended
December 31,</td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px
1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:120%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</td><td colspan="3" style="padding:0 1pt"></td><td
colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</td><td colspan="3" style="border-top:1pt
solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span

```
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income
(numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>
</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss)
income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td
style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-
align:bottom"><span id="ic87bb918cbb64df083c863a5ddf752ec_3-3-1-1-165177"></span><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">5,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,448)</span></td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td>
<td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr
style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double
#000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Shares (denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of common shares outstanding used in basic
computation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,634,651 </span></td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">20,425,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>
<td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">20,581,913 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">20,380,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px
1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Common shares issuable upon vesting of restricted stock</span></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Common shares issuable upon conversion of preferred shares</span></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,125 </span></td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in diluted computation</span></td><td colspan="2" style="background-
color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
```

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,634,651 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,425,282 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,987,260 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,380,262 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net (loss) income per common share:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Basic</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.03)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.10) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.26 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.12) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Diluted</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.03)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.10)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.26 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.12)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">For the three months ended December 31, 2024 and 2023, 986,378 and 825,825 shares issuable upon vesting of restricted stock and 10,125 and 10,125 shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">For the nine months ended December 31, 2024 and 2023, 519,852 and 837,084 shares issuable upon vesting of restricted stock and zero and 10,125 shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for share and per share amounts):</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"> </td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"> </td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.630%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">Three Months Ended December 31,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px
1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:120%">Nine Months Ended
December 31,</td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px
1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:120%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</td><td colspan="3" style="padding:0 1pt"></td><td
colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</td><td colspan="3" style="border-top:1pt
solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
Net (loss) income
(numerator):</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-
align:bottom">
</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%"> </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-
align:bottom">Net (loss)
income</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(707)</td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,027)</td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">5,373 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(2,448)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td>
<td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr
style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double
#000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Shares (denominator):</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%"> </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of common shares outstanding used in basic
computation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,634,651 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">20,425,282 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>
<td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">20,581,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">20,380,262 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px
1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Common shares issuable upon vesting of restricted stock</td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">395,222 </td><td style="background-color:#ffffff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Common shares issuable upon conversion of preferred shares</td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"

style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,125 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Shares used in diluted computation</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,634,651 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,425,282 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,987,260 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,380,262 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net (loss) income per common share:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Basic</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.03)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.10) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$ </td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.26 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.12) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Diluted</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.03)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.10)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.26 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.12)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> </div>-707000-20270005373000-2448000206346512042528220581913203802620039522200010125020634651204252822098726020380262-0.03-0.100.26-0.12-0.03-0.100.26-0.12986378825825101251012551985283708410125Stock-Based Compensation<div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Compensation - Stock Compensation<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:120%">"). The Company had 423,619 common shares issued, net of forfeitures, under the 2016 Employee Equity Compensation Restricted Stock Plan (the "2016 Employee Plan") (which 2016 Employee Plan was succeeded by the 2022 Employee Plan in April 2023, and no further awards will be granted under the 2016 Employee Plan), 55,074 common shares issued, net of forfeitures, under the 2022 Employee Equity Compensation Plan (as amended) (the "2022 Employee Plan"), and 257,567 common shares issued, net of forfeitures, under the 2015 Outside Director Equity Compensation Plan (as amended) (the "2015 Director Plan"). At December 31, 2024, all outstanding shares under these plans were issued with service-based vesting conditions with the exception of 2,000 performance stock units which vested on July 1, 2024. The Company records stock-based compensation expense for these awards on a straight-line basis over the requisite service period. The Company reverses stock-based compensation expense previously recorded upon forfeiture of unvested awards except for the performance restricted shares with a market condition issued to the former Chief Executive Officer ("CEO") and performance stock units ("PSUs") with a market condition issued to the former Chief Financial Officer ("CFO") as described in the following paragraphs. For the three months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to restricted stock awards of $0.5 million and $1.7 million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded a (reversal) of previously recorded stock-based compensation expense and stock-based compensation expense related to restricted stock awards of $(7.2) million and $5.2 million, respectively. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In June 2023, the Board of Directors amended and restated the 2015 Director Plan and the 2022 Employee Plan (collectively, the "Plans") to include the ability to grant restricted stock units ("RSUs") and performance stock units </div><div style="margin-top:10pt;text-align:justify">("PSUs") under the Plans. The amendments and restatement of the Plans did not increase the maximum number of shares of common stock that could be awarded under the Plans. At December 31, 2024, the Company had 83,500 RSUs outstanding under the 2024 Omnibus Incentive Plan (the "2024 Omnibus Plan"), 290,000 RSUs outstanding under the 2024 Inducement Incentive Plan (the "2024 Inducement Plan"), 569,365 RSUs outstanding under the 2022 Employee Plan and 22,316 RSUs outstanding under the 2015 Director Plan.</div><div style="text-indent:18pt">
</div><div style="text-align:justify;text-indent:18pt">In August 2021, the Company issued 90,000 shares of restricted stock and 510,000 performance restricted shares with a market condition to the Company's former CEO, in accordance with the former CEO's employment agreement, under the 2016 Employee Plan. In April 2024, the Company and former CEO entered into a Transition and Separation Agreement pursuant to which the Company cancelled the 510,000 performance restricted shares and accelerated vesting on 30,000 remaining unvested restricted shares which otherwise would not have vested. Cancellation of the 510,000 shares resulted in an $8.8 million reversal of compensation expense, partially offset by $0.1 million of compensation expense from the accelerated vesting of the 30,000 shares in the nine months ended December 31, 2024.</div><div style="text-align:justify;text-indent:18pt">
</div><div style="text-align:justify;text-indent:18pt"> On April 29, 2024, the Company appointed a new CEO, and in conjunction with her new employment agreement, she received a grant of 483,092 RSUs under the Company's 2022 Employee Equity Compensation Plan. Such RSUs will vest in one-third increments on each of the first three anniversaries of the date of grant so long as the CEO continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In August 2022, the Company issued 13,000 restricted shares and 3,000 performance restricted shares to the Company's former CFO, in accordance with the CFO's employment agreement, under the 2016 Employee Plan. One-third of the restricted shares were scheduled to vest on each of the first three anniversaries of the date of grant, subject to the CFO's continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company. The performance restricted shares were based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue. On June 8, 2023, the Company determined that the performance criteria were not attained over the applicable performance period and accordingly, the performance restricted shares were cancelled.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In June 2023, the Company granted the Company's former CFO 11,750 RSUs under the 2022 Employee Plan, of which 3,750 RSUs were awarded in recognition of the CFO's contributions during fiscal year 2023 and the remaining 8,000 awarded as a part of the equity award cycle for fiscal year 2024. One-third of the RSUs were scheduled to vest on each of the first three anniversaries of the date of grant, subject to the CFO's continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the former CFO ceasing to be an employee of the Company. Also in June 2023, the former CFO was awarded 8,000 PSUs with a market condition. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On May 16, 2024, the Company granted the former CFO 74,850 RSUs of which 14,970 would vest on June 30, 2024, 22,455 would vest August 31, 2024 and 37,425 would vest on August 31, 2025. On May 31, 2024, the Company and the former CFO entered into a Transition and Separation Agreement pursuant to which the former CFO agreed to leave the Company following a transition period. Upon the completion of the transition period and contingent on the former CFO's complying with the terms of the Agreement, the Company accelerated the vesting of all unvested restricted shares and RSUs that were originally scheduled to vest on or before August 3, 2025. Under the Agreement, PSUs with a market condition were cancelled. Acceleration and cancellation of the former CFO's restricted shares, RSUs and PSUs resulted in net additional compensation expense of $0.2 million in the three months ended June 30, 2024. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On August 8, 2024, the Company adopted the 2024 Omnibus Plan pursuant to which the Company reserved 850,000 shares of common stock, par value $.001 per share, of the Company's common stock for the issuance of equity awards granted.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On September 27, 2024, the Company adopted the 2024 Inducement Plan pursuant to which the Company reserved 350,000 shares of common stock, par value $.001 per share, of the Company's common stock (subject to the adjustment provisions of the Inducement Plan) for the issuance of equity awards granted under the Inducement Plan.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On September 27, 2024, the Company's new CFO received a grant of 250,000 RSUs under the Company's 2024 Inducement Plan. Such RSUs will vest in one-third increments on each of the first three anniversaries of the date of grant so long as the CFO continues to be employed by the Company on each vesting date, and such RSUs will otherwise contain the standard provisions for RSU grants by the Company. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">All stock-based compensation expense is recognized as a payroll-related expense and is included within the general and administrative expenses line item within the Company's unaudited Condensed Consolidated Statements of Operations, </div><div style="margin-top:10pt;text-align:justify">with the offset included in the additional paid-in capital line item of the Company's unaudited Condensed Consolidated Balance Sheets. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">Restricted Stock Awards</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The fair value assigned to restricted stock awards ("RSAs") is the market price of the Company's stock at the grant date. The vesting period ranges from one to three years. Restricted stock award activity in the nine months ended December 31, 2024 was as follows:</div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> 2015 Director Plan </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:700;line-height:120%"> 2016 Employee Plan </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> 2022 Employee Plan </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> Total </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> Weighted-Average Grant Date Fair Value </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-vested restricted stock outstanding at March 31, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,707 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">605,343 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,076 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">703,126 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19.39 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted and issued</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,666)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60,540)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46,742)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(120,948)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td> <td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">22.10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(533,641)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,334)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(560,975)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18.71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr> <tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2024</td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,041 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,162 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,203 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0
2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">21.96 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-
indent:18pt">At
December 31, 2024 and 2023, there were 21,203 and 728,446 RSAs subject to restriction and forfeiture outstanding, respectively. For the three
months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSAs of $0.1 million and
$1.6 million, respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded a (reversal) of previously recorded
stock-based compensation expense and stock-based compensation expense related to RSAs of $(8.2) million and $5.0 million, respectively.
</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</div><div style="margin-top:10pt;text-align:justify;text-
indent:18pt">The
Company first granted RSUs in the year ended March 31, 2024. The fair value assigned to RSUs is the market price of the Company’s stock on the
grant date. The vesting period for employees and members of the Board of Directors generally ranges from <span style="-sec-ix-hidden:f-
449">one to three years. For the nine months ended December 31, 2024, RSU activity under the 2022 Employee Plan, 2015 Director Plan,
2024 Omnibus Plan and 2024 Inducement Plan was as follows:</div><div><table style="border-collapse:collapse;display:inline-
table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.687%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">RSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-
align:bottom">Weighted-
Average
 Grant Date
 Fair Value Per RSU</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Balance at March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">85,080</td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0
2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">12.75 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted </td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">1,037,258</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">4.04 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and issued</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-
align:bottom">(66,739)
</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8.38 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(90,418)</td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5.84 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2024</td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid
#000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">965,181</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">4.33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td
colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr></table></div><div>
</div><div style="text-align:justify;text-indent:18pt">The total grant-date fair value of
RSUs granted during the three months ended December 31, 2024 and 2023 was $0.2 million and zero, respectively. The total grant-date fair value
of RSUs granted during the nine months ended December 31, 2024 and 2023 was $4.2 million and $1.1 million, respectively. For the three months
ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs of $0.4 million and $0.1 million,
respectively. For the nine months ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to RSUs
of $1.1 million and $0.2 million, respectively. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">Performance Stock Units
</div><div style="text-indent:36pt">
</div><div style="text-align:justify;text-indent:18pt">The fair value assigned to PSUs
is determined using the market price of the Company’s stock on the grant date for awards with a performance condition, and by using a Monte
Carlo simulation for awards with a market condition. PSUs with a performance condition generally vest over one year. PSUs with a market
condition generally vest over three years. Stock-based compensation expense associated with PSUs with a performance condition are re-assessed
each reporting period based upon the estimated performance attainment on the reporting date until the performance conditions are met.
</div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:115%">The ultimate number of shares of common stock that are issued to an employee is the result of the actual performance of the
Company or individual at the end of the performance period compared to the performance targets. </div><div>

</div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:115%">For the nine months ended December 31, 2024, PSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan
and 2024 Inducement Plan was as follows:</div><div><table style="border-collapse:collapse;display:inline-table;margin-
bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.687%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">PSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-
align:bottom">Weighted-
Average
 Grant Date
 Fair Value Per PSU</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Balance at March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">12,000</td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0
2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">10.48 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted </td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">-</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-
align:bottom">-
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and issued</td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
(2,000)</td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">13.95 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(10,000)</td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">9.79 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Balance at December 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">-</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom">-
</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr></table></div>In the nine months ended December 31, 2024, 10,000 PSUs were forfeited. The total grant-date
fair value of PSUs granted during the nine months ended December 31, 2024 and 2023 was zero and $0.1 million, respectively. There were no
PSU’s granted in the three months ended December 31, 2024 and 2023. For the three months ended December 31, 2024 and 2023, the Company
recorded stock-based compensation expense, net of forfeitures, related to PSUs of zero and $20 thousand, respectively. For the nine months ended
December 31, 2024 and 2023, the Company recorded stock-based compensation (benefit) expense, net of forfeitures, related to PSUs of $(36)
thousand and $44 thousand, respectively.4236195507425756720005000001700000-
7200000520000083500290000569365223169000005100005100000300005100000-
88000001000003000048309213000300011750375080008000748501497022455374252000008500000.0010.0013500000.0010.001250000P3YRestri
stock award activity in the nine months ended December 31, 2024 was as follows:<div style="margin-top:10pt;text-align:justify"><table
style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%">
</td><td style="width:36.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:11.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%"> 2015 Director Plan </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%"> 2016 Employee Plan </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%"> 2022 Employee Plan </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%"> Total </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%"> Weighted-Average Grant Date Fair Value </td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested restricted stock outstanding at March 31, 2024</td><td
colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,707 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0
2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">605,343 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,076 </td><td

style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">703,126 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19.39 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted and issued</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,666)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60,540)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46,742)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(120,948)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">22.10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(533,641)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,334)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(560,975)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">18.71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2024</td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,041 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,162 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,203 </td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">21.96 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
</div>237076053437407670312619.39000000136666054046742120948 22.1005336412733456097518.71100411116202120321.96212037284461000
82000005000000P3YFor the nine months ended December 31, 2024, RSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td

style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">RSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average
 Grant Date
 Fair Value Per RSU</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">85,080</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12.75 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,037,258</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4.04 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested and issued</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(66,739) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8.38 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(90,418)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5.84 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">965,181</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4.33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
</div>8508012.7510372584.04667398.38904185.849651814.3320000004200000110000040000010000011000000200000P1YP3Y<div style="text-indent:18pt">For the nine months ended December 31, 2024, PSU activity under the 2022 Employee Plan, 2015 Director Plan, 2024 Omnibus Plan and 2024 Inducement Plan was as follows:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">PSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average
 Grant Date
 Fair Value Per PSU</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">12,000</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10.48 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested and issued</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">(2,000)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">13.95 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forfeited</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(10,000)</td><td

colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">9.79 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">-</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">- </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>1200010.4800200013.95100009.7900100000100000000020000-3600044000Fair Value<div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company carries cash and cash equivalents at fair value in the unaudited Condensed Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (“Fair Value Measurement”) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</div><div style="margin-top:10pt;text-align:justify">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</div><div style="text-align:justify">Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.</div><div style="text-align:justify">Level 3 - Unobservable inputs which are supported by little or no market activity.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At December 31, 2024 and March 31, 2024, the Company had invested the majority of its $50.1 million and $55.3 million cash and cash equivalents balance in money market funds which are classified within Level 1.</div>5010000055300000Intangible and Other Assets, Net<div style="text-indent:18pt">Intangible assets and other assets, net consisted of the following (in thousands):</div><div>
</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Useful Life</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net Carrying Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Remaining Useful Life (Years)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Intangible Assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Toll-free telephone number</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">- </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internet domain names</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Trade Names - PetCareRx</td><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Indefinite</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,600 </td><td style="background-
color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0
1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">- </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">2,600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Indefinite</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-
align:bottom">Customer
Relationships -PetCareRx</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
7 years</td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">6,700 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1,675)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">5,025 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">5.25 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-
align:bottom">Developed
Technology - PetCareRx</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">
3 years</td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">3,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1,750)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">1.25 years</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,160 </td><td style="background-
color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom">$
</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,425)</td><td
style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
9,735 </td><td
style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td
colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Assets</td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Minority interest investment in Vetster</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">N/A</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">5,300 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,300 </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</td></tr><tr style="height:12pt"><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td

colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance December 31, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,460 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,425)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,035 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Intangible Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Toll-free telephone number</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">- </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internet domain names</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">485 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">- </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">485 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trade Names - PetCareRx</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,600 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,600 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer Relationships -PetCareRx</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">7 years</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(957)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,743 </td><td style="background-color:#cceeff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</td></tr><tr><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Developed Technology - PetCareRx</td><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">3 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000 </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,000)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 years</td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom">$
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,160 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-
align:bottom">(1,957)
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>
<td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid
#000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">11,203 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-
align:bottom">Other
Assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minority interest investment in Vetster</td><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</td><td colspan="3" style="background-color:#cceeff;padding:0
1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,300 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">- </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">5,300 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">N/A</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Balance March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double
#000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,460 </td><td style="background-color:#cceeff;border-bottom:3pt
double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0
2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid
#000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">(1,957)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-
top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0
1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">16,503 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div>
</div><div style="text-align:justify;text-
indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:115%">Amortization expense for intangible assets was $0.5 million for the three months ended December 31, 2024 and 2023. Amortization
expense for intangible assets was $1.5 million for the nine months ended December 31, 2024 and 2023. The indefinite life intangibles are not
being amortized and are subject to an annual review for impairment in accordance with the ASC Topic 350 (“Goodwill and
Other Intangible Assets<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:115%">”).</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2022, the Company engaged in a three-year partnership
agreement with Vetster Inc. (“Vetster”), a Canadian veterinary telehealth company. The Company also purchased a 5% minority interest in Vetster
in the amount of $5.0 million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the
terms of the agreement, Vetster became the exclusive provider of telehealth and telemedicine services to the Company. The minority interest
investment is being valued on the <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:120%">cost basis and the investment will be evaluated periodically for any impairment. On October 3, 2023, the Company
purchased additional shares in Vetster in the amount of $0.3 million, which increased the minority interest investment to $5.3 million. Following
this round, the Company's minority ownership changed to approximately 4.8% of Vetster's outstanding shares.</div><div style="text-
indent:18pt">Intangible
assets and other assets, net consisted of the following (in thousands):</div><div>
</div><div><table style="border-
collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td
style="width:39.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.142%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%">
</td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.203%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.012%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">Useful Life</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">Gross Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"
style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td
colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:700;line-height:120%">Net Carrying Value</td><td colspan="3" style="padding:0 1pt"></td><td
colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Useful Life (Years)</td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</td><td colspan="3" style="background-
color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid
#000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-
color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">Intangible Assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td
colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Toll-free telephone number</td><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </td><td style="background-color:#cceeff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"
style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom">$
</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</td></tr><tr><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Internet domain names</td><td colspan="3" style="background-color:#ffffff;padding:2px
1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"
style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485 </td><td style="background-color:#ffffff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"
style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Trade Names - PetCareRx</td><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Indefinite</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td
colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,600 </td><td style="background-
color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0
1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">2,600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-
align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Indefinite</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-
align:bottom">Customer
Relationships -PetCareRx</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
7 years</td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">6,700 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(1,675)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">5,025 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">5.25 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed Technology - PetCareRx</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">3 years</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,750)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">1.25 years</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,160 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,425)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,735 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Minority interest investment in Vetster</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,300 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,300 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance December 31, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,460 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,425)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">15,035 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Intangible Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3"

style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Toll-free telephone number</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">- </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internet domain names</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">485 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">- </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">485 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trade Names - PetCareRx</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,600 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,600 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer Relationships -PetCareRx</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">7 years</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(957)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5,743 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">6 years</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed Technology - PetCareRx</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">3 years</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,000)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2 years</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,160 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,957) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-

align:right;vertical-align:bottom">11,203 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other Assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Minority interest investment in Vetster</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,300 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">- </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,300 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">N/A</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance March 31, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,460 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,957)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">16,503 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div>37500037500048500048500026000002600000P7Y670000016750005025000P5Y3MP3Y300000017500001250000P1Y3M13160000342500097

and Contingencies<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt">Legal Matters and Routine Proceedings</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On April 18, 2024, Plaintiff Timothy Fitchett (“Plaintiff”) filed an action against the Company in the Court of Common Pleas of Allegheny County, Pennsylvania, on behalf of himself and purportedly on behalf of a class of others similarly situated. Plaintiff alleges that the Company violated Pennsylvania’s Unfair Trade Practices and Consumer </div><div style="margin-top:10pt;text-align:justify">Protection Law by representing “reg.” prices for products which the Company allegedly never charged for those products. On May 13, 2024, the Company removed the matter to the U.S. District Court for the Western District of Pennsylvania in Pittsburgh. The company successfully opposed the Plaintiff's motion to remand the case back to the Court of Common Pleas. On the face of the Complaint, Plaintiff is seeking damages for himself in the amount of the allegedly illusory discounts he allegedly believed he was receiving when purchasing products from the Company or, in the alternative, a complete refund of amounts he paid to the Company, and he is also seeking a liability determination for members of the proposed class. The Company denies liability in this matter and intends to defend the action accordingly. The Company cannot determine materiality or estimate a range of potential liability, if any, at this time if the Company were determined to be liable.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Company may from time to time be involved in various other claims and lawsuits in the ordinary course of business, including claims related to products, product warranties, contracts, employment, intellectual property, consumer protection, pharmacy and other regulatory matters. The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company also intends to vigorously defend its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred. From time to time, the Company may be involved in and subject to disputes and legal proceedings, as well as demands, claims and threatened litigation that arise in the ordinary course of its business. These proceedings may include allegations involving business practices, infringement of intellectual property, employment or other matters. The ultimate outcome of any legal proceeding is often uncertain, there can be no assurance that the Company will be successful in any legal proceeding, and unfavorable outcomes could have a negative impact on our results of operations and financial condition. In accordance with ASC Topic 450-20 ("Loss Contingencies"), the Company records a liability in its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews the status of each significant matter each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the financial statements not misleading. If the loss is not probable and cannot be reasonably estimated, a liability is not recorded in the Company’s financial statements. Gain contingencies are not recorded until they are realized. Legal costs related to any legal matters are expensed as incurred.</div>Changes in Shareholders’ Equity:<div style="margin-top:10pt;text-align:justify;text-indent:18pt">Changes in Shareholders’ Equity for the three and nine months ended December 31, 2024 is summarized below (in thousands):</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional
Paid-In
Capital</td><td
colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained
Earnings
</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0
1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance at March 31, 2024:</td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">21 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,146 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,555 </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Stock based compensation (reversal) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">(8,204)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr>
<td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends forfeited</td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250 </td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
3,754 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at June 30, 2024:</td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,942 </td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">76,559 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">573 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Dividends forfeited</td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

```
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,326 </span></td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at September 30, 2024:</span></td><td style="background-color:#cceeff;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,515 </span></td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,889 </span></td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</span></td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">452 </span></td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Dividends forfeited</span></td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span>
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(707)</span></td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2024:</span></td><td style="background-color:#cceeff;border-
bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-
color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td
style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-
bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-
color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,967 </span></td><td
style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-
bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-
color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,187 </span></td><td
style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Shareholders’ Equity for the three and nine
```

months ended December 31, 2023 is summarized below (in thousands):</div><div style="margin-top:10pt"><table style="border-
collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td
style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional
Paid-In
Capital</td><td
colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained
Earnings
</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0
1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance at March 31, 2023:</td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">21 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">18,277 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,659 </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Stock based compensation expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">1,760 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr>
<td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends declared</td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,346)</td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net loss</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
(1,136)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at June 30, 2023:</td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,037 </td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">84,177 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,728 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Dividends declared</td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,308)</td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
715 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at September 30, 2023:</td><td style="background-color:#cceeff;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,765 </td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">78,584 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,708 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,027)</td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Ending balance at December 31, 2023:</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-
top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">21 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-
top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0
1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">23,473 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-
color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
76,557 </td><td
style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">There were no shares of common stock that were purchased or retired in the nine months ended December 31, 2024 or 2023. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">On December 2, 2024, the Board of Directors (the “Board”) of the Company adopted a rights agreement and declared a dividend of one right (a “Right”) for each outstanding share of Company common stock, to shareholders of record at the close of business on December 16, 2024 (the “Record Date”). The description and terms of the Rights are set forth in a rights agreement, dated as of December 3, 2024 (the “Rights Agreement”), between the Company and Continental Stock Transfer & Trust Company, a federally chartered trust company, as rights agent. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">The Board adopted the Rights Agreement to protect the investment of shareholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of common stock by certain shareholders. The Rights Agreement is intended to enable shareholders to realize the long-term value of their investment in the Company by reducing the likelihood that any entity, person, or group is able to gain a control or control-like position in the Company through open market accumulation without paying all shareholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of all shareholders. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In general terms, the Rights Agreement imposes significant dilution upon any person or group (other than the Company and certain other excluded persons and exempt persons), that is or becomes the beneficial owner of 12.5% or more of the common stock without the prior approval of the Board following the first public announcement by the Company of the adoption of the Rights Agreement. The term “beneficial ownership” is defined in the Rights Agreement and includes, among other things, certain derivative arrangements. </div><div style="text-align:justify;text-indent:18pt">
</div><div style="text-align:justify;text-indent:18pt">In general, each Right entitles its registered holder, subject to the terms of the Rights Agreement, to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share (“Preferred Stock”), of the Company at an exercise price of $27.00 per Right, subject to adjustment under certain circumstances (the “Purchase Price”). The Rights will become exercisable if (among other things) any person or group acquires 12.5% or more of the outstanding common stock, including through derivatives agreements, without the approval of the Board (an “Acquiring Person”). If a person or group becomes an Acquiring Person, all holders of Rights except the Acquiring Person or any associate or affiliate thereof may, upon exercise of a Right, purchase for the Purchase Price shares of Common Stock with a market value of two times the Purchase Price, based on the market price of the Common Stock prior to such acquisition. If the Company is acquired in a merger or similar transaction after an Acquiring Person becomes such, all holders of Rights except the Acquiring Person or any associate or affiliate thereof may, upon exercise of a Right, purchase for the Purchase Price shares of the acquiring company with a market value of two times the Purchase Price, </div><div style="text-align:justify">based on the market price of the acquiring company’s stock prior to such transaction. Any Rights held by an Acquiring Person will be void and may not be exercised.</div><div style="text-align:justify;text-indent:18pt"> </div><div style="text-align:justify;text-indent:18pt">The Rights will expire on the earliest to occur of (a) the close of business on December 2, 2025, (b) the time at which the Rights are redeemed by the Company (as provided in the Rights Agreement), or (c) the time at which the Rights are exchanged by the Company (as provided in the Rights Agreement). There was no impact to the Company’s current period financial statements from adopting this Rights Agreement. </div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">In connection with the adoption of the Rights Agreement, the Board adopted Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company (the “Articles of Amendment”), which designates the rights, preferences, and privileges of 100,000 shares of a new series of the Company’s preferred stock, par value $0.001 per share, designated as Series A Junior Participating Preferred Stock. The Company filed the Articles of Amendment with the Secretary of State of the State of Florida on December 3, 2024.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">Changes in Shareholders’ Equity for the three and nine months ended December 31, 2024 is summarized below (in thousands):</div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Common Stock</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Additional
Paid-In
Capital</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained
Earnings</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance at March 31, 2024:</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,146 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">71,555 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Stock based compensation (reversal) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8,204)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Dividends forfeited</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:120%">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
3,754 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at June 30, 2024:</td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,942 </td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">76,559 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">573 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Dividends forfeited</td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
2,326 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at September 30, 2024:</td><td style="background-color:#cceeff;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,515 </td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">78,889 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">452 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Dividends forfeited</td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px
0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net loss</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
(707)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at December 31, 2024:</td><td style="background-color:#cceeff;border-
bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td
style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-
bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">17,967 </td><td
style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-
bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">78,187 </td><td
style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-
align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Shareholders’ Equity for the three and nine
months ended December 31, 2023 is summarized below (in thousands):</div><div style="margin-top:10pt"><table style="border-
collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td
style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%">
</td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional
Paid-In
Capital</td><td
colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Retained
Earnings
</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0
1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3"
style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance at March 31, 2023:</td><td style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">21 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">18,277 </td><td
style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,659 </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Stock based compensation expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">1,760 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr>
<td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends declared</td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,346)</td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net loss</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
(1,136)</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at June 30, 2023:</td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,037 </td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">84,177 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,728 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">Dividends declared</td><td colspan="2" style="background-
color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-color:#cceeff;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,308)</td><td style="background-color:#cceeff;padding:2px
1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Net income</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom">—
</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
715 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Ending balance at September 30, 2023:</td><td style="background-color:#cceeff;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-
color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,765 </td><td style="background-color:#cceeff;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">
</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">78,584 </td><td
style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation expense</td><td
colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,708 </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
— </td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"
style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"
style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,027)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance at December 31, 2023:</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,473 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">76,557 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>2100025146000071555000-
8204000125000037540002100016942000765590005730004000232600021000175150007888900045200005000-
707000210001796700078187000210001827700091659000176000006346000-
1136000210002003700084177000172800063080007150002100021765000785840001708000-
20270002100023473000765570000010.1250.0010.00127.000.125221000000.001Income Taxes <div style="text-align:justify;text-indent:18pt">For the three months ended December 31, 2024 and 2023, the Company recorded an income tax provision of approximately $0.5 million and an income tax benefit of approximately $0.6 million, respectively, and for the nine months ended December 31, 2024 and 2023, the Company recorded an income tax provision of $22 thousand and an income tax benefit of $0.3 million, respectively. The increase in the income tax provision for the nine months ended December 31, 2024 is related to the cancellation of the former CEO’s performance stock units resulting in additional $8.7 million of increased income during the year. The effective tax rate for the three months ended December 31, 2024 was approximately (192.1)%, compared to approximately 23.4% for the three months ended December 31, 2023, and the effective tax rate for the nine months ended December 31, 2024 was approximately 0.4%, compared to approximately 12.4% for the nine months ended December 31, 2023. The projected full-year effective tax rate used for purposes of the income tax provision for the three and nine months ended December 31, 2024 reflects the $1.8 million impact of a favorable permanent difference associated with the cancellation of the former CEO’s performance restricted shares. No tax benefit was recorded for the original compensation expense due to expected limitation under Internal Revenue Code Section 162 (m) and therefore, there is no tax benefit to reverse upon cancellation of the stock. The impact of this favorable permanent difference is partially offset by the impacts of stock-based compensation recognized for book and tax purposes.</div><div style="margin-top:10pt;text-align:justify;text-indent:18pt">Under Internal Revenue Code Section 382, if a corporation undergoes an “ownership change”, the corporation’s ability to use its pre-change net operating loss and tax credit carryforwards to offset its post-change income and tax liabilities may be limited. Generally, an ownership change occurs when the equity ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation’s stock increases its ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years). On April 3, 2023, 100% of the issued and outstanding stock of PetCareRx was acquired by the Company. The merger triggered an ownership change of PetCareRx within the meaning of Section 382.</div><div>
</div><div style="text-align:justify"> As a result of the acquisition, the Company performed a Section 382 analysis to determine if the net operating losses carried forward would have a utilization limitation. Any limitation could result in the expiration of a portion of the federal net operating loss carryforward before utilization, which would reduce the Company's gross deferred tax assets. As of April 3, 2023, and prior to the acquisition, PetCareRx had approximately $96.0 million of net operating losses and $1.9 million of disallowed interest expense. The results of the Section 382 analysis determined the net operating losses and disallowed interest expense in total, would be limited and reduced to approximately $14.5 million.</div>500000-60000022000-300000-8700000-1.9210.2340.0040.124-1800000-
1800000196000000190000014500000Related Party Transaction<div style="margin-top:10pt;text-align:justify;text-indent:18pt">On September 29, 2024 the Company entered into a master services agreement with Fabric, Inc (“Fabric”), a privately-held company. Under this agreement, Fabric will provide cloud-based product services to the Company with a one-year term with auto-renewal unless either party provides notice at least 90 days in advance. Per the terms of the agreement, the Company will pay Fabric $115,000 the first year and $100,000 for each potential year thereafter with potential changes in the amounts paid based on actual usage of Fabric’s services. There was no expense related to this contract for the three and nine months ended December 31, 2024. There was no amount owed by the Company to Fabric as of December 31, 2024. Sandra Campos, Chief Executive Officer and President of the Company, is an equity-holder in Fabric and serves on the Board of Directors of Fabric. This transaction was

~~***reviewed and approved by the Company’s Audit Committee of the Board of Directors in accordance with the Company’s related party transaction policy.</div>P1YP90D115000100000000falsefalsefalsefalse***~~